<SEC-DOCUMENT>0001062822-20-000067.txt : 20201030
<SEC-HEADER>0001062822-20-000067.hdr.sgml : 20201030
<ACCEPTANCE-DATETIME>20201030163521
ACCESSION NUMBER:		0001062822-20-000067
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201030
DATE AS OF CHANGE:		20201030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		201277822

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lxrx-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:b9120c05-2dcb-454d-ab13-af640022c996,g:c8810420-eb25-4487-a657-7c14820ab259,d:1768c5c1d1b04f5e9a0dc9a726aa65ff--><html xmlns:lxrx="http://www.lexpharma.com/20200930" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N181LTQtMS0xLTA_1470fcab-bda3-4994-822c-407990644a08">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N185LTQtMS0xLTA_9a21778f-f48b-4dd2-a981-7289a7bdeeb8">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N18xMC00LTEtMS0w_b45bc851-570d-4961-95af-5972694590aa">2020</ix:nonNumeric><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N18xMS00LTEtMS0w_61e85acc-ee61-4ca5-a0b4-46d11af65c4c">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N18xNC00LTEtMS0w_a7b86ea5-6d88-432f-8fb0-1de9b3e5b55c">0001062822</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iea929173f03e4cdaac61287b22eed9ce_I20201026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic3dc746618934941bc63c22f6053b48a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39cf4efb3ba498c83f75720de63977b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb255e5708f44e258e296c77abef2148_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ef5ec99dcc48139089e172def809d5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0186178fef405988c9dab2a47db5fa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5003c76dd14af1bb7e8ed41020e64a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69a42b36ef4432baa90bafa0b87bb11_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9306242f52400fb1ec1c48fdb617e8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29409cf569f4995a1b8cd001ef00215_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2f0553a5a443f5aea2354fbbc8b9d7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9180a0741154feab5264fc1b9481852_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6241124cc1d84b06aee3d4a995daa961_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ef45941bee44658e4e342d2743291a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32edc2966d164232b4ab121550c17328_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea93e62cb33048baa2d377777e96a31a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5cd53676cec4b749440e76527ef3861_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354181d4c7a546109de1070307761bf2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab400eacbd9f495eac7d85037d5b894c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea33b9cf6f84275ab78882aff5c053e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53842116e47c4c769795760d6b233005_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb48dd69257444d8e09beb702199378_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98bf3f0537624ef3b1647b80d52ad9f0_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1764073b5f5c4207b578324f9d515f7c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c45f9e1311a4a0bacccdec8642a2255_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332232b87eed4ee0aff6a523ea254baf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b8ebfcf0c04a91bf51a889ee42089b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea1b38341d5b40bfb0ded9fbd0ed8901_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5133b99acae94f1cbb47b475caaef535_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c686e1acee419aaf3b5b0c644d31e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f874d70a3f146138ef4f3c91a8a1390_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i227451f24d98477b8bbc0d386d19ce16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ff9ea196e54e5eb3b7e68af2e1a1dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1f3693c2c8436da37a4d613523cf19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b9122c88b08450aa943128ce8672322_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93b273419a904b9b943ab1c586c82cf2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d9a031b3a643939dc4946a532cd59f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab8293cbb3b949feb1319baf6e0ac30c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61ccbc50ca4646b7a6ca13720db0cd51_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id927be22b9564e918ad8233bbc7d2bca_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232b139d9b954a9f988af16e8e822240_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie771e05af7234472aef6bd918b9dbe61_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89afbb9e0fbb43e182f2150249faef37_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46fdf6eabe5409c982b14a8191c786a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e76433e64224cd28783a0ed1b5ea7b3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9867c02a657c412fa47e3e6fe91bccea_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4615026499f4eaa986552fc1dfbd77a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91fb5ae41331461dac39acd650838e01_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c622449e7a742b49bfa687466d2cb4d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b359f3f2e54a4ca7516f16d229ef6d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i580af670a9ce4ccb936a88ec2d87b2c8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed950d6bbe64a719b452fb582108b70_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0699896381d48e7ad6adc8daae2f1d7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i170f779ba4fd4cdb814e7d6c94490a0b_I20200908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806bb79355704a3d9f9e975c7764b751_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7902597037c2463d85d00a4b46bdb6db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd55aa47b494c508a8707104b290757_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d499c22b144586ab5b1747d70c9923_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b7cb3d54a24978a2f81d13fb5f8bf0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45dc5d23ea3b4654bc9d1ccd692ebca9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6089ded0c145f3a665941d75632fdf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lxrx:RDSeveranceCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f2f211830347d7b962a9ddc24c8919_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lxrx:SGASeveranceCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1258c23791be46e7aa4cc649d072022f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a1a6fc719140c08724cb429ea2062e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a47a08149c54860b477528661d2c215_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ab63a51cfe4a52baceee717c7ac021_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee8595c4e7d498db92de4c18088f054_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i987c8a7c27f2446f9cf494575a39b8e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598b1a29343d4deda20d232162634172_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i338bf2c2e7b6442b8ab5f089399b8061_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16df9c6c19c64790a5837cf1d79351ff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d3c3a225f534e188a9ebe0475319a1b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f83f9e3d794affb390e88fc81fa72e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d7b6895d6da4c09ac7535756e184174_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1772c994ba65403ca45d1f126c089301_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b3093f9ba14f25864a4923a0f67585_I20141120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b46f889feff422fb423fe1a658c6727_I20200928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46df437a0a442c4bead16cb71e6341a_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5c874e6c9e48619cce1b61357c131e_I20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73dd8addd4542a29c4ec9debd3582d1_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb39716de56e4e5a895227f8630d9df3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">lxrx:BioPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5076221df34ff6b100b90bb7f27cf6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91cc58958d74a18bc3bdc7678de13fc_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c565ac789974012b970ac1ab822623b_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813cb4fdefa8444c86cc8630f57e27da_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795f1b1257384f238c4605db9c94d3e7_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd1f447a93c4793b6c6a92f2e209e1e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381201bb0bd34c48a7207b7c78990cd8_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4193bd56cb84f0d9f797512013ed041_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e87a1738c194bf0b536c8857a3ca790_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF84Mg_97ec6ed1-317c-4a0a-8a2e-c5b4a708298a">10-Q</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6MWM1YmY4NGE1MThjNDMzNzliMjVlMGM3Yjc2NjE4NGQvdGFibGVyYW5nZToxYzViZjg0YTUxOGM0MzM3OWIyNWUwYzdiNzY2MTg0ZF8wLTAtMS0xLTA_3067cc6a-89e9-4e8f-9374-466c5a6c4dda">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                       For the Quarterly Period Ended <ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8xNjk_4e572abd-475f-4a60-b452-7bb7f7538a00">September 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6MmE3YjU1NTAyZjhlNDQ3MTg5YzM4YTNhNGYxNzVkMWQvdGFibGVyYW5nZToyYTdiNTU1MDJmOGU0NDcxODljMzhhM2E0ZjE3NWQxZF8wLTAtMS0xLTA_da8593e6-98c2-4525-befb-f8e999632835">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Transition Period from _____________ to _____________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yNjU_9a72cde9-741d-42b3-8e35-619880f6e8d2">000-30111</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yNjg_a31f142a-0ab9-4fec-b641-93e2375e3c3d">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTAyNjgxMWE5MWU0NGJkOGFlMmQ2N2ViMGJjMzc0ZTEvdGFibGVyYW5nZTo1MDI2ODExYTkxZTQ0YmQ4YWUyZDY3ZWIwYmMzNzRlMV8wLTAtMS0xLTA_521e8cc9-adba-4345-a823-9e4459dafbb7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTAyNjgxMWE5MWU0NGJkOGFlMmQ2N2ViMGJjMzc0ZTEvdGFibGVyYW5nZTo1MDI2ODExYTkxZTQ0YmQ4YWUyZDY3ZWIwYmMzNzRlMV8wLTEtMS0xLTA_517eb29e-a281-4e0a-9c27-3a8aa50f4d3f">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMjg_96f47500-7da8-4a5a-b030-06542f8bfa3f">8800 Technology Forest Place</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMzE_94ce2566-7dc9-4b03-a98b-d8aef7cde444">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMzU_5677a01f-5637-46ae-8301-36874b7fee50">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMzg_5b40b80f-2758-470f-b77d-99f26a46dc47">77381</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zOTY_49088fbb-feb4-435a-951f-31bc79d2f882">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF80MDA_e6a041a4-db19-4ca9-b363-4dfba25a0e6b">863-3000</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTdjZjc0MmI3YzE5NGVjNGExNGRjMTI3OWFhNTJkMWMvdGFibGVyYW5nZTo1N2NmNzQyYjdjMTk0ZWM0YTE0ZGMxMjc5YWE1MmQxY18xLTAtMS0xLTA_b95fe50c-962a-42a5-aad9-01c1076d1c6e">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTdjZjc0MmI3YzE5NGVjNGExNGRjMTI3OWFhNTJkMWMvdGFibGVyYW5nZTo1N2NmNzQyYjdjMTk0ZWM0YTE0ZGMxMjc5YWE1MmQxY18xLTEtMS0xLTA_e200a056-a0b2-42e4-bcab-03d399476e49">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTdjZjc0MmI3YzE5NGVjNGExNGRjMTI3OWFhNTJkMWMvdGFibGVyYW5nZTo1N2NmNzQyYjdjMTk0ZWM0YTE0ZGMxMjc5YWE1MmQxY18xLTItMS0xLTA_09b90623-8d08-464d-8ba8-4d384ecd92fa">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6YWUwNDY2ZWQ3OTlhNDllYjhmZTI4NWE1YjE4NDdhMDAvdGFibGVyYW5nZTphZTA0NjZlZDc5OWE0OWViOGZlMjg1YTViMTg0N2EwMF8wLTAtMS0xLTA_663006bb-eecc-4734-b259-b66c23292847">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NWZiYzczYjQ5MWFjNDhkNWI1ZmRjMDQ0NmE0OWFlY2UvdGFibGVyYW5nZTo1ZmJjNzNiNDkxYWM0OGQ1YjVmZGMwNDQ2YTQ5YWVjZV8wLTAtMS0xLTA_3dbcabcf-b276-42f0-8463-89ac05e997f4">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;     <ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8xNTY1_587dc535-2f19-4f8c-a14c-ef3889002cea">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          Non-accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yMTY4_1cac8d3b-1847-498d-98c1-8dd5710f9e8d">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8xNjg0_0cbea6ee-fc4c-404c-a986-ec4f6a934491">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6YWNhYjdkMDk4NGY2NDcxMjk0NWFiMTBmYjc0MjU2YjIvdGFibGVyYW5nZTphY2FiN2QwOTg0ZjY0NzEyOTQ1YWIxMGZiNzQyNTZiMl8wLTEtMS0xLTA_59819a9c-1906-4d54-858e-55fd748f04cc">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;26, 2020, <ix:nonFraction unitRef="shares" contextRef="iea929173f03e4cdaac61287b22eed9ce_I20201026" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yMDc3_472c29c4-76c8-4e50-9d8a-d7de3a4afe64">117,474,808</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, were outstanding.  &#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_10">Factors Affecting Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_10">2</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_13">Part I &#8211; Financial Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_16">Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets - September 30, 2020 (unaudited) and December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - Three and Nine Months Ended September 30, 2020 and 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (unaudited) - Three and Nine Months Ended September 30, 2020 and 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited) - Nine Months Ended September 30, 2020 and 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_28">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_31">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_58">Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_58">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_67">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_67">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_70">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_67">26</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_73">Part II &#8211; Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_73">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_76">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_76">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_79">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_79">27</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_85">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_85">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_88">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1768c5c1d1b04f5e9a0dc9a726aa65ff_88">32</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lexicon name and logo are registered trademarks and Zynquista&#8482; is a trademark of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_10"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Forward Looking Statements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements.  These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Part&#160;II, Item 1A. - Risk Factors&#8221; and in our annual report on Form 10-K for the year ended December&#160;31, 2019, that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part I &#8211; Financial Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_16"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNC0yLTEtMS0w_e21e73e3-3ab6-4ad9-b016-7b50a8429073">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNC00LTEtMS0w_a8ea43cc-cba1-493d-8902-43158cd5b8d1">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNS0yLTEtMS0w_ba0b3d42-1e7b-42c4-9faf-a0186ee51ede">59,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNS00LTEtMS0w_3b67d912-c8d4-4d2b-b6e3-8b384c4a8950">235,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNi0yLTEtMS0w_7cd0f796-5963-472c-a42f-2d4569c0988d">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNi00LTEtMS0w_25acfcd7-f378-4ed8-9578-50a52baac51d">56,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOC0yLTEtMS0w_3f45fe17-b085-4e76-b4aa-af55fb0a85da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOC00LTEtMS0w_600f4f5a-045c-49a4-9d35-9c06b475048c">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOS0yLTEtMS0w_9cddf5ef-5f29-44a9-94bc-554346be305e">9,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOS00LTEtMS0w_7ebc4af8-aa1d-4efb-bdb3-e3be8cce6628">5,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTAtMi0xLTEtMA_d72752ed-3d9c-43b8-9782-ea80d0876953">121,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTAtNC0xLTEtMA_6fb5b4d8-08be-44dd-9649-b2d10123ab57">337,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjI0ODI1ZmJlNmY1NDQ4OGQ4YjliZWI2YmMyOGVkYmUzXzgw_8914c1ee-aae8-483d-a0b5-139f50a776ae">63,795</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjI0ODI1ZmJlNmY1NDQ4OGQ4YjliZWI2YmMyOGVkYmUzXzg3_190fe0cd-1ad3-431d-9561-55ecb3481457">61,741</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtMi0xLTEtMA_293a2c60-8187-42fa-9d6b-9f5008925196">11,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtNC0xLTEtMA_531c2ce8-34da-42c8-9be2-ef218faf85a9">14,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTItMi0xLTEtMA_c0ad677b-492c-43ec-931a-07d72a7e051c">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTItNC0xLTEtMA_44329c34-7bf9-4d03-bbfa-ee23a7b07d4f">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTMtMi0xLTEtMA_dbaef61f-0542-4298-9d31-146f58120ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTMtNC0xLTEtMA_a82c6c96-a84d-40f3-9d36-2cc2916035e0">19,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTQtMi0xLTEtMA_2d27b3e7-7091-4275-8e4c-750eacf069ac">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTQtNC0xLTEtMA_9f101710-09f8-4ec4-99f4-ba67016871b9">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTUtMi0xLTEtMA_5c4bd385-dfd8-452d-9b2b-c84dda0fc965">178,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTUtNC0xLTEtMA_251b333c-eb10-4b7b-9d1e-e6ea655baba4">417,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTgtMi0xLTEtMA_5a16bd69-c625-4530-90af-8a7093c51bc1">11,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTgtNC0xLTEtMA_aa7e0a0f-089c-439d-b4d3-39e04323e679">12,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTktMi0xLTEtMA_ad05b56d-8f07-48ee-9a48-1ab85db39576">58,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTktNC0xLTEtMA_13e8f63b-eaef-4790-9eae-f2c59b52edf6">42,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of deferred issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjEtMi0xLTEtMA_79945f67-4892-4988-a0b1-135a142e88bd">8,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjEtNC0xLTEtMA_abd0224a-1e58-4237-92c7-f202c1364f9a">11,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjItMi0xLTEtMA_f84724bb-a4e1-444d-93ff-c8171cfb8c94">78,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjItNC0xLTEtMA_e0180c46-eecd-41aa-bf85-76bf011a78da">65,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of deferred issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjQtMi0xLTEtMA_d012ebd1-aa5b-42dd-b923-20b663a56c94">11,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjQtNC0xLTEtMA_ada453ba-c2f3-48e7-b50d-161efa673379">234,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjYtMi0xLTEtMA_51f472b3-19b6-482f-8331-cab1701370d1">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjYtNC0xLTEtMA_d14cc743-68b3-42f0-aa0b-3082e2634af4">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjctMi0xLTEtMA_a074f1b3-7c51-4b71-97ac-aeba95f27717">91,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjctNC0xLTEtMA_b0209815-7da9-4cb8-81d8-adfb280c1da7">300,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjgtMi0xLTEtMA_21a972fd-4cf7-4467-b7d5-e6aba1295d14"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjgtNC0xLTEtMA_0bd288eb-fe3c-4bc2-aae6-36757130581c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzIy_3bb12007-94d5-4c69-aba6-37fa2f9272af"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzIy_59eb2b69-1a22-425b-b664-30286394efec">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzM2_535c7e29-4aa5-49ec-ab44-1b972702297c"><ix:nonFraction unitRef="shares" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzM2_733f6893-78c1-4210-8ae4-60ece29fd0a4">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_759d8874-6ad1-43cc-853d-bcea9fe6fee2"><ix:nonFraction unitRef="shares" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_7a25e55e-1f8f-46cc-a0ae-37cabddd1a6e"><ix:nonFraction unitRef="shares" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_a941d534-ca29-4595-a18f-771d47476263"><ix:nonFraction unitRef="shares" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_aa3c743e-080c-4369-b4c3-c2482afe4478">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMi0xLTEtMA_8a08fc1c-ad28-4ed7-812c-785e857171b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtNC0xLTEtMA_094838ea-b2d5-4161-b5fd-fb9dc13568ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzE4_388bf8fe-8fa5-459c-a168-81f2557d53c1"><ix:nonFraction unitRef="usdPerShare" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzE4_558a4074-eb91-4823-b162-3e56abf39098">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzMy_32748e33-276c-473b-92a9-1a963e2fced1"><ix:nonFraction unitRef="shares" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzMy_d570c488-38d6-43ca-a422-7cd743088b7c">225,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzU0_9cf64de2-99cf-4d03-99f8-75dba7c8e6b6">117,231</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzYx_72ea5fd8-4182-4523-914c-da2709b68dad">106,679</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMi0xLTEtMA_3e444cee-b2e6-427c-b8b4-8f4d6dab7f1b">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtNC0xLTEtMA_b766a576-f308-487a-9fbc-7992552c7a7b">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzItMi0xLTEtMA_6fb0b451-b204-4f4d-b071-ca0132b69820">1,486,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzItNC0xLTEtMA_6b3ccc7e-55dd-4e89-9c85-77f98bbbdd71">1,462,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzMtMi0xLTEtMA_1c55bdfd-9502-4e0c-973d-ec9ef809fd01">1,394,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzMtNC0xLTEtMA_4a99d8fb-f624-499f-bfe6-bb4f1f5f3159">1,341,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzQtMi0xLTEtMA_2c6ee8a0-2820-4dd4-b683-ed85375fcf16">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzQtNC0xLTEtMA_c24d9c58-e039-460c-b1c9-442d1e66bb62">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQwOTZlZTkwMWI3NDRmMjk4NzNjYzRkOTdjNjFkNmRlXzI5_4b06dc70-9983-42db-9380-705e890b0361">793</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQwOTZlZTkwMWI3NDRmMjk4NzNjYzRkOTdjNjFkNmRlXzM2_b7f3ad6c-7dcb-4aa1-a4c0-92b3ead9ebf7">407</ix:nonFraction> shares, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtMi0xLTEtMA_903c799d-00a0-4f34-89a9-e315ff102d9e">4,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtNC0xLTEtMA_61aa7a97-3865-4721-a171-ecbb3b7543d6">3,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzYtMi0xLTEtMA_8000c43f-a455-4fb4-9949-04ab2d321324">87,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzYtNC0xLTEtMA_54c5a903-e4d2-4165-9729-b039e1aded68">117,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzctMi0xLTEtMA_348708d3-262a-4f2a-8e40-db0d4f962ca8">178,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzctNC0xLTEtMA_0f706065-084a-4a5d-a495-30d9b92bd3ae">417,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:58.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy0yLTEtMS0w_4b8e5385-a404-4c6f-9d87-5c702428a049">6,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy00LTEtMS0w_9cf6bc9c-d894-4ca6-b484-eaba3e9dfc72">8,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy02LTEtMS0w_f98aeca9-492b-447e-8eb2-6723df08cc4e">23,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Netproductrevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy04LTEtMS0w_ae93a9ab-2dda-4bc1-81cf-ae434d7f83b6">23,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC0yLTEtMS0w_324945af-294e-445e-ac8c-763c888f5b75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC00LTEtMS0w_9393efda-8a4a-435a-bddf-52a93173295b">285,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC02LTEtMS0w_53abb406-d800-480a-bed2-9137055d6042">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC04LTEtMS0w_45103d2d-9862-4646-ac85-6289e26cb9c8">289,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS0yLTEtMS0w_cdac9e7e-a13a-40bb-a1f4-aace188a2558">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS00LTEtMS0w_89357ab4-1f4c-4977-8cec-b4be34296c7a">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS02LTEtMS0w_4fec0ebe-a6d9-49a0-9d33-5f8aba62f786">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS04LTEtMS0w_79dccf7b-495b-4c76-a7ec-1fab0117dfda">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi0yLTEtMS0w_0165a9fd-5f5b-4ac1-8708-678c096cad60">6,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi00LTEtMS0w_094fbbcb-b28b-4f72-b9de-e9c2fdfd2700">294,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi02LTEtMS0w_77cb9f17-9073-42b6-8d8a-02a3b5b482e3">23,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi04LTEtMS0w_becdea60-b889-45c4-af5a-9f87bb22c4b1">313,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible asset amortization)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC0yLTEtMS0w_0fe33069-8b23-49f4-bc84-d9492ce92ffb">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC00LTEtMS0w_0a1bc2d2-7399-4d17-8d61-0d8c968561ac">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC02LTEtMS0w_faba7f25-31ad-4a52-aa7b-1bae8a91049e">1,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC04LTEtMS0w_dc37c513-a0d3-48af-b914-2f85c5d8babe">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfNjg_1d48607e-95c1-426d-be3e-a2164b73243d">1,029</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfNzI_76dfd68f-2e47-4796-b29b-e823ae221f59">1,698</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfNzY_a1e9e7b9-ae04-4ba2-9764-609f4f378aad">5,154</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfODM_2700ab6b-cc89-489a-8225-32a7f4a2a3ea">5,369</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0yLTEtMS0w_a47f1f94-9ebc-4c6a-8496-5f9ff7512da4">40,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS00LTEtMS0w_adfd7646-232a-4b90-aa6b-baab437f448f">26,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS02LTEtMS0w_3f05acde-6dfb-4bdf-b971-7738603442bf">152,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS04LTEtMS0w_02db9d2d-9e1c-4844-8b16-e21f9dc9ee07">51,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzc5_a90f6f6d-70df-4e59-a2a4-1d2c5ab9f49f">875</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzgz_74db910d-ff6f-4f77-aa39-fae06dbfadaf">1,864</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzg3_d9b42675-1d3b-4d54-98f1-3aeaf2a30b13">5,440</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzk0_9e90776b-8113-4c5a-90ea-f116b4e9e93e">5,370</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMi0xLTEtMA_28eedee8-2080-46c9-9d68-ace4776587a9">11,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtNC0xLTEtMA_e32324e1-e075-499d-a5c4-b93ea3886791">13,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtNi0xLTEtMA_98a4131b-4db9-46c5-beeb-9740eb7db5a4">40,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Sellinggeneralandadministrativeexpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtOC0xLTEtMA_1bfc3a9f-651b-4517-a810-00fd3a9857cd">42,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfRealEstate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItMi0xLTEtMA_d6476afe-1d1d-48c5-a520-855527ccfbbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfRealEstate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItNC0xLTEtMA_1934de79-cbb4-4415-a5c4-3df91be899d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItNi0xLTEtMA_e0480255-1bbf-4c30-a623-8d7520dacfdf">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfRealEstate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItOC0xLTEtMA_ddddc0c5-c944-4b70-8f58-99d83da45757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtMi0xLTEtMTcwNw_e17497f0-3c65-4db9-8dd3-68ea554919d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNC0xLTEtMTcwNw_eaf570f1-cea6-49bc-beb3-51ec48513fde">28,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNi0xLTEtMTcwNw_598390ce-b0c6-4e6e-9ab6-9b81997a8411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtOC0xLTEtMTcwNw_bc2c8f47-40e0-4ed0-8315-116ed1cb2e6d">28,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtMi0xLTEtMA_dd08b3ed-1eb0-4712-ae95-c458aeb3050c">52,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtNC0xLTEtMA_f2a23d7c-f90f-4bac-ba27-22cb3ffac0a2">69,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtNi0xLTEtMA_70201ed1-f8a1-491d-96a9-0f7c81cb43ac">196,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtOC0xLTEtMA_f8b9f443-1494-4cc4-be4d-6314c592c1d7">124,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:GainOnSaleOfNonFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctMi0xLTEtMjk3OA_f20283d6-f2c7-4ffc-a9f7-04bd26ed9e13">132,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="lxrx:GainOnSaleOfNonFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNC0xLTEtMjk3OA_1bdd9e76-c08b-4606-8d15-aa2e32937fc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:GainOnSaleOfNonFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNi0xLTEtMjk3OA_f7c0b756-21c1-4edd-8ecc-4ef4b06f4fd0">132,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="lxrx:GainOnSaleOfNonFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctOC0xLTEtMjk3OA_1739192e-c719-4d51-b451-8574e8b4f2d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtMi0xLTEtMA_deef3690-03ee-486a-990e-51377a0bbfb6">86,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNC0xLTEtMA_4e66a982-a0c4-4117-8833-36f5e30c78d2">224,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNi0xLTEtMA_fd3e605f-8918-4953-82bc-33701c0f7840">40,342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtOC0xLTEtMA_2d3092b1-53fd-4655-ad40-08d77b127bbe">188,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtMi0xLTEtMTY5Mw_e001e4fa-40f8-40e5-8131-8e2c13849123">255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNC0xLTEtMTY5Mw_00e71993-74a5-472b-ab43-abcd382c04d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNi0xLTEtMTY5Mw_e3445f6b-fdb8-46d6-8e2c-dfd24aae3332">255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtOC0xLTEtMTcxNQ_03bf7fee-7c11-4eef-8492-47007d0d36a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtMi0xLTEtMA_f210d62f-f91a-43e8-bb9b-7e1823264ab8">4,118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtNC0xLTEtMA_803d5306-159d-43e3-a2b4-e06e8287685e">5,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtNi0xLTEtMA_8da4ecf0-12a6-4125-8903-b7f8ab434069">14,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtOC0xLTEtMA_4c59ac7d-ecbb-41b1-8ca5-02076bd199cd">15,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctMi0xLTEtMA_d34c5b7a-3049-41fc-866d-654d83cc21c7">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNC0xLTEtMA_c67e5b72-f1be-4630-af87-fd631785bf70">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNi0xLTEtMA_2cd3e5ed-32c7-4bdf-a914-befc950c7022">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctOC0xLTEtMA_69a12185-1034-43e7-97eb-b88bd659b24f">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtMi0xLTEtMA_9de479ae-4e40-4e28-b1fa-0f00e993d548">82,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNC0xLTEtMA_63a179d5-7b6a-477c-ae17-c4e1526ebc10">220,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNi0xLTEtMA_1e119b9e-d3fc-4355-b65f-46bb31c946d2">53,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtOC0xLTEtMA_d96f8999-8a83-4ca7-bf95-0bef6a90e9d7">175,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktMi0xLTEtMA_7f6dbffc-b29e-4453-ad62-17b47e2372a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktNC0xLTEtMA_002104d4-4d11-49ab-b017-9d247912ce44">6,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktNi0xLTEtMA_299c18db-1b9d-430f-9877-01116c3e97bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktOC0xLTEtMA_1a411a41-2ac1-4b9e-8272-5838345bea95">6,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtMi0xLTEtMA_a1c75e31-3f36-417c-8a6c-23140eaffbc6">82,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtNC0xLTEtMA_3851af57-ad4c-4c3f-8e05-0e8c7aa29ae4">226,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtNi0xLTEtMA_3ff03380-0278-4351-9a84-7afed8d449ba">53,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtOC0xLTEtMA_b620c131-a373-497b-a262-1d3039e533e7">181,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtMi0xLTEtMA_5bca442a-0ccf-4545-a51d-c587f1acc676">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtNC0xLTEtMA_be182d47-7038-4a7f-bbb1-eef7ae598237">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtNi0xLTEtMA_8ca3446d-b13c-40e8-97dd-d922d6e4c867">0.50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtOC0xLTEtMA_c73e8007-37ad-4369-88c4-909f8450ea07">1.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItMi0xLTEtMA_7ee69594-8118-40ee-b76a-d7648fee5789">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItNC0xLTEtMA_93ab164b-ee97-4ad6-9772-73906f859199">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItNi0xLTEtMA_ca36ba35-5105-49cd-a77b-a85269209543">0.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItOC0xLTEtMA_0ce21719-dc7f-4545-bf9a-c29ce9cae880">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtMi0xLTEtMA_0addcdfb-b806-40ca-ae9e-13e5ade795ff">107,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtNC0xLTEtMA_29e1cf1a-323e-4d22-b313-56fa0a9cd000">106,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtNi0xLTEtMA_3007e813-ebc2-4508-862b-7fa2c14cdd93">106,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtOC0xLTEtMA_d658df1c-b00c-43a2-b0b1-86fdfbc5d5e4">106,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtMi0xLTEtMA_c225fdd3-d455-4d39-ab84-b77aa61e7df4">117,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtNC0xLTEtMA_a449d26a-6dd0-450e-a59f-70303bbc5d35">116,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtNi0xLTEtMA_97ec8eab-80cf-4faf-bffb-2768e5c07825">106,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtOC0xLTEtMA_6d27ce67-3cfb-4001-9796-762b8f7e6e45">116,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtMi0xLTEtMA_8d411e1c-01dd-441e-9386-19cef0ec1f0a">277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtNC0xLTEtMA_286f9c57-ae92-40b7-9c0a-ad1890abb65c">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtNi0xLTEtMA_4e5af950-e766-47ef-af86-0a0f13c888e0">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtOC0xLTEtMA_3bfa3c9f-2c59-4eeb-9ee3-6eb9cef4e87e">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktMi0xLTEtMA_1cf2a1f8-8ea0-4094-8455-83eab6b312b3">82,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktNC0xLTEtMA_cd429bb8-48bc-448f-857e-d3afae0e4054">226,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktNi0xLTEtMA_77044910-639c-4543-8d84-818f76c37048">53,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktOC0xLTEtMA_1f6a319c-4122-4277-96a1-ac657309cfe8">181,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.722%"><tr><td style="width:1.0%"></td><td style="width:37.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3ef5ec99dcc48139089e172def809d5_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0yLTEtMS0w_cdb5e087-0af3-4baf-9db4-b1664b98b1b9">106,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ef5ec99dcc48139089e172def809d5_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi00LTEtMS0w_79dcd2a4-6438-433d-9e30-6ba5def54d99">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0186178fef405988c9dab2a47db5fa_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi02LTEtMS0w_88e5a37f-6a07-4029-ad18-8e825ef87c65">1,447,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a5003c76dd14af1bb7e8ed41020e64a_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi04LTEtMS0w_16f3c264-5ffa-448b-be60-d3a6b7d4df40">1,471,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69a42b36ef4432baa90bafa0b87bb11_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0xMC0xLTEtMA_a3f8fc41-8f6e-4c47-9249-78653720cca5">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide9306242f52400fb1ec1c48fdb617e8_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0xMi0xLTEtMA_fe86a0cf-1a00-48f5-8f3c-9f14fa7a56f1">2,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia29409cf569f4995a1b8cd001ef00215_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0xNC0xLTEtMA_f2f07442-4be2-4d74-b15a-cdba3accbcc7">26,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS00LTEtMS0w_6794f6ce-4250-4b67-a1db-767541a7d384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS02LTEtMS0w_6d02f011-b2f5-4b90-97b5-38bcc7fa4fb6">3,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS04LTEtMS0w_6fc32725-269c-496e-a0c4-abac074a65c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS0xMC0xLTEtMA_eb593f57-65d6-4996-a01a-546a7672597b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS0xMi0xLTEtMA_c72a47a3-fb85-4ded-a617-d0c3dead1a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS0xNC0xLTEtMA_6be7f0b9-0d57-45e5-abf9-cf869f7f03e8">3,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0yLTEtMS0w_93ce7528-06df-4e37-93f8-324187ad2f73">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi00LTEtMS0w_5bd597c0-2a14-47d9-9ddc-fdb6f6c3d156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi02LTEtMS0w_b4f937fb-1fee-47d8-9d45-255926476146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi04LTEtMS0w_26a2ff50-8da0-42cb-99bd-0c55e3fb6e70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0xMC0xLTEtMA_4e205830-6d92-4d71-a08d-96295bc55eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0xMi0xLTEtMA_b3179fcc-f356-4892-aeea-a1dce4faf175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0xNC0xLTEtMA_929e742c-e12a-4012-ab6b-581462e65050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC00LTEtMS0w_53d4a0f0-1819-4054-a772-80b6cac497ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC02LTEtMS0w_7d2c392d-c0e3-4cfe-9462-5a50875acb39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC04LTEtMS0w_bd5f28b3-5e6e-4902-8c48-ce5320bb28de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC0xMC0xLTEtMA_d8110daf-3532-44da-9d5e-922957cbaf82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC0xMi0xLTEtMA_500cc99a-088f-4745-a0e1-0b0a3b7ad422">941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC0xNC0xLTEtMA_2f843bf4-ee0c-4404-b847-10e52770324a">941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS00LTEtMS0w_f1be4066-122a-45ee-a9cb-21643a6346c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS02LTEtMS0w_77ca6b42-5123-4e12-9217-46830b077bfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS04LTEtMS0w_3a001c4f-0a0c-4598-8c1d-731d00f56349">21,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS0xMC0xLTEtMA_5b189190-1d8b-46ba-9bae-fd9fef06b9cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS0xMi0xLTEtMA_6ecf0d14-0f19-44a4-bc11-5aa7e57e4ae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS0xNC0xLTEtMA_bb705df5-35ad-4d5d-bee3-466a692d6f89">21,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtNC0xLTEtMA_0664d2b7-b39c-4c71-a1ea-d86b221844e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtNi0xLTEtMA_16179dfa-02d0-4869-8586-ac2d66136d6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtOC0xLTEtMA_8c28ebec-4d57-4386-87a0-0754887c7e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtMTAtMS0xLTA_4eafc592-bb64-4a75-a016-c287b8899e26">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtMTItMS0xLTA_e3012e0a-7da5-4900-99aa-55fbda9621bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtMTQtMS0xLTA_baa1ffee-d060-4dc3-b922-0b8e51195a9e">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a2f0553a5a443f5aea2354fbbc8b9d7_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMi0xLTEtMA_18338bb5-1368-4ba2-8703-728d62a0c13f">106,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a2f0553a5a443f5aea2354fbbc8b9d7_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItNC0xLTEtMA_9d7b8d22-1566-40a9-bd03-26207c4f0ff0">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9180a0741154feab5264fc1b9481852_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItNi0xLTEtMA_76bfc607-890e-4a93-9627-84b0e1b98bea">1,451,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6241124cc1d84b06aee3d4a995daa961_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItOC0xLTEtMA_2f3dc9f7-5489-4cf6-8c0f-6e5a588cb6aa">1,493,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ef45941bee44658e4e342d2743291a_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMTAtMS0xLTA_151ba1de-68a5-452a-afb2-d9b144953358">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32edc2966d164232b4ab121550c17328_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMTItMS0xLTA_ca269be4-9def-4ef0-80db-78fd062d2576">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea93e62cb33048baa2d377777e96a31a_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMTQtMS0xLTA_aa867f7b-fe91-4c8c-85fb-5702c7042eba">45,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtNC0xLTEtMA_053a33d2-7782-44d0-abd2-2d568d7d5ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtNi0xLTEtMA_0c6b4215-4eaa-4924-83a9-9e394c1807c8">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtOC0xLTEtMA_56a75697-b53b-4fdc-869a-0bbcb1c596ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtMTAtMS0xLTA_29c36266-b7f0-49fb-ac10-cb2a4f28433d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cd53676cec4b749440e76527ef3861_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtMTItMS0xLTA_b6cbde86-717d-4972-9ed1-e8fb526b7bc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354181d4c7a546109de1070307761bf2_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtMTQtMS0xLTA_947274fd-1647-400f-bb3f-b170d5955a6a">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtNC0xLTEtMA_e1e144f5-4a9c-4fff-ac3f-cf3a5b02af8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtNi0xLTEtMA_9fd0b92f-c7eb-4ddd-95c7-f679e27298c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtOC0xLTEtMA_e6d988d7-d327-4d73-9122-34d3dcd31f71">23,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtMTAtMS0xLTA_62fa9612-9586-4a29-8985-26dbf0a12d63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cd53676cec4b749440e76527ef3861_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtMTItMS0xLTA_8537caac-b42e-4dc1-95cb-ec76d19f9ffe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtMTQtMS0xLTA_5a635340-3d63-4581-9004-186989a89fd0">23,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtNC0xLTEtMA_a566bf61-1282-4a57-a455-e19cbfef3a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtNi0xLTEtMA_3b3c4e6b-67af-48bb-892c-a8817b7e2396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtOC0xLTEtMA_362d4a49-13eb-4529-9766-a4986b2911e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtMTAtMS0xLTA_a21383f2-f975-4118-a657-e7befceda3ad">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cd53676cec4b749440e76527ef3861_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtMTItMS0xLTA_136fae3d-7983-4ef5-aad8-5aec1add7ada">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354181d4c7a546109de1070307761bf2_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtMTQtMS0xLTA_f5143c39-af4d-44ca-87ad-b8ffb44051f5">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab400eacbd9f495eac7d85037d5b894c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMi0xLTEtMA_8987ec98-5649-45d8-bea3-0446cef5fd21">106,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab400eacbd9f495eac7d85037d5b894c_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctNC0xLTEtMA_f8b1fbef-8db4-464b-b3b0-933b2f61a86e">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea33b9cf6f84275ab78882aff5c053e_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctNi0xLTEtMA_9b64daa9-a100-4aab-aed6-100fd407c19d">1,455,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53842116e47c4c769795760d6b233005_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctOC0xLTEtMA_009ebc9c-abeb-4a61-b3e6-f97183e8c920">1,516,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb48dd69257444d8e09beb702199378_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMTAtMS0xLTA_eb56e19e-8968-4795-a553-80959243ff8d">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98bf3f0537624ef3b1647b80d52ad9f0_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMTItMS0xLTA_f9cb026f-8d85-4d81-a6b5-82002ac3954d">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1764073b5f5c4207b578324f9d515f7c_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMTQtMS0xLTA_57e75da2-09f7-4b0e-ac9e-01472553e432">64,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtNC0xLTEtMA_04d1ab6b-d8bd-4ec8-b954-c81495be4820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtNi0xLTEtMA_62882e57-58b0-432b-9e5a-e319f817b1e9">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtOC0xLTEtMA_bbbd96b4-a2f0-444a-a895-2eb589aa48eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtMTAtMS0xLTA_b2f613a2-1f34-45f4-b07b-d1226228a423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtMTItMS0xLTA_19d89f95-53ae-408c-89af-2fb043bf4615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtMTQtMS0xLTA_00c95db7-7656-4bde-88a0-3c79e607408e">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtNC0xLTEtMA_30e6bfa3-6743-44d1-b081-0d936e271f45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtNi0xLTEtMA_78522f53-c465-46ee-bd2d-b2a3ae71f167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtOC0xLTEtMA_6d605ba9-a820-48ff-a711-64201ee8feac">226,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtMTAtMS0xLTA_b9923bc8-0777-484a-bab5-028a73eef6b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtMTItMS0xLTA_3e7b8e48-02c9-4d52-9da1-ae79526aa033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtMTQtMS0xLTA_0850bab5-7c11-43ea-8058-27b7e7d93d43">226,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtNC0xLTEtMA_f5bdd64a-3ebe-4e94-a41f-dffa1c5cdc87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtNi0xLTEtMA_62206914-e7af-49de-948c-7b977b1a7245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtOC0xLTEtMA_eaf578df-4312-40c6-9adc-9bb6ca659771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtMTAtMS0xLTA_3d5a7550-1188-44ac-8c75-764a6957e416">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtMTItMS0xLTA_7405b69f-5fc1-41bd-826f-6390a00edc46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtMTQtMS0xLTA_136084d6-1ec2-4a1f-a139-5539a5950570">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c45f9e1311a4a0bacccdec8642a2255_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMi0xLTEtMA_30855ff8-74b5-4009-82f1-9d349ed829f2">106,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c45f9e1311a4a0bacccdec8642a2255_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItNC0xLTEtMA_f20fa67b-7304-463b-8a03-db3690a9d7cf">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332232b87eed4ee0aff6a523ea254baf_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItNi0xLTEtMA_eb0ae887-f436-4498-af53-4e8b8beba142">1,458,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83b8ebfcf0c04a91bf51a889ee42089b_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItOC0xLTEtMA_89d34765-3938-4b5c-8386-d79a35e9ccdf">1,290,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1b38341d5b40bfb0ded9fbd0ed8901_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMTAtMS0xLTA_97162770-e53f-48f6-b33d-5752cc3f4c75">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5133b99acae94f1cbb47b475caaef535_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMTItMS0xLTA_a422a237-595e-4656-a555-f5744353d201">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMTQtMS0xLTA_62fa78d4-cd52-4c6d-b532-97439dd1b60f">164,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.506%"><tr><td style="width:1.0%"></td><td style="width:37.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72c686e1acee419aaf3b5b0c644d31e4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0yLTEtMS0w_d5e68ddd-6263-4243-baad-4480a90f80d7">106,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c686e1acee419aaf3b5b0c644d31e4_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi00LTEtMS0w_ccff8471-d780-4371-8cb0-ac381d8ec0ac">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f874d70a3f146138ef4f3c91a8a1390_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi02LTEtMS0w_153d3930-bcea-4195-806b-1f5b7b4c8d25">1,462,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i227451f24d98477b8bbc0d386d19ce16_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi04LTEtMS0w_ab1d7665-d278-44f6-932f-9a6ff53cee15">1,341,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ff9ea196e54e5eb3b7e68af2e1a1dd_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0xMC0xLTEtMA_98815244-cfe7-48bd-a24d-662f7719e320">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1f3693c2c8436da37a4d613523cf19_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0xMi0xLTEtMA_3ad26917-1032-4e26-b631-b03c666dc314">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0xNC0xLTEtMA_f4f0f92c-0743-4689-8d9d-b4483969e2de">117,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC00LTEtMS0w_c8aea926-8cdb-451e-9dab-b9b6c452c8fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC02LTEtMS0w_4ca5c9d5-f82a-4586-ad63-5d91cdac8de4">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC04LTEtMS0w_2999b551-980a-45bd-80d5-63fa9a79abf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC0xMC0xLTEtMA_73e635a2-5a6e-4bf8-9d40-c77db737c46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC0xMi0xLTEtMA_eff782bb-a9fe-46a0-b3bd-1c0aab054bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC0xNC0xLTEtMA_e9218361-3822-4175-b083-a334206e989a">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0yLTEtMS0w_8abdd2ae-b80e-49b2-9917-d6a33add6720">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS00LTEtMS0w_c251b247-6ecb-4404-bcf2-02cb1a0b8450">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS02LTEtMS0w_93ca2dc2-7c0d-48af-ab63-30c1471cd29d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS04LTEtMS0w_6dc499fa-d154-4bdb-9c3e-1270765c392a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0xMC0xLTEtMA_60b13dd1-e95c-4407-bda8-abbb8cac8b16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0xMi0xLTEtMA_40f70ec4-52b2-4c59-b459-5b320dd2e6bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0xNC0xLTEtMA_2a757f40-faaf-4797-b14c-bdd2825b5a3f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy00LTEtMS0w_e1f9493f-76de-4743-a16c-e3506634f5e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy02LTEtMS0w_68f063a2-3e8d-49d0-8fb5-93f1c022d97f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy04LTEtMS0w_48528953-0898-49a9-93fa-3943a88ad008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy0xMC0xLTEtMA_a9e82da5-b527-4c71-bfbd-957b11de6992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy0xMi0xLTEtMA_abc82305-42c1-4197-8656-24030e4e8d0e">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy0xNC0xLTEtMA_88b493f6-24cb-458f-a46a-d674004dcafc">923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC00LTEtMS0w_c4eb839b-0b76-4852-9d56-b483a375e059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC02LTEtMS0w_f1e2d2ca-94fb-417f-a8ec-c486a42526f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC04LTEtMS0w_a29b21dd-bc0f-42f1-bfd8-5f2cb08ff3e6">66,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC0xMC0xLTEtMA_9f08fcaf-193a-48b7-9381-d2b7ff203edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC0xMi0xLTEtMA_590d5b89-cea4-4332-84cc-877a0bd93de8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC0xNC0xLTEtMA_7ee6a0bd-fa7d-49f9-8c01-588c99051830">66,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtNC0xLTEtMA_4552ed3c-d8b9-43b0-8d01-de4754f5eb41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtNi0xLTEtMA_eded77ed-95fb-4d8c-94ac-ed6e88861467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtOC0xLTEtMA_a9f348d2-56d0-4cf2-aed3-1d733b7c6f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtMTAtMS0xLTA_5eed29a3-f0dd-484c-bc9c-2df805fc105a">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtMTItMS0xLTA_d0389d5d-344f-4818-ae2e-0e6a208902a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtMTQtMS0xLTA_54a61375-4ca0-40b7-a2d2-4f7ed15b48be">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93b273419a904b9b943ab1c586c82cf2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMi0xLTEtMA_cf6fddad-66e6-4258-a0da-7dcc6ca818b1">107,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b273419a904b9b943ab1c586c82cf2_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtNC0xLTEtMA_5f1351a8-9ec0-4e71-853b-1c40ef6083b4">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d9a031b3a643939dc4946a532cd59f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtNi0xLTEtMA_abc28933-dcc8-4b96-8d18-c0c92685fc2c">1,466,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab8293cbb3b949feb1319baf6e0ac30c_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtOC0xLTEtMA_1817d34c-0f13-4acf-b28b-e38d4397846d">1,408,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ccbc50ca4646b7a6ca13720db0cd51_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMTAtMS0xLTA_33cd09f2-1668-4b3f-9d0a-2528cd1bb452">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id927be22b9564e918ad8233bbc7d2bca_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMTItMS0xLTA_ba4a9939-2b44-4502-af66-698d44480791">4,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232b139d9b954a9f988af16e8e822240_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMTQtMS0xLTA_52a43dc4-b682-4dca-b728-3e22d9d32e06">54,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItNC0xLTEtMA_0fbb2a99-520c-4faa-b635-dd8c5c334338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItNi0xLTEtMA_8772e416-d6cc-4194-badc-adf1e9739f11">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItOC0xLTEtMA_fb011d29-e50f-42fb-95d0-627046e73b28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItMTAtMS0xLTA_48056bb7-4565-4828-80d5-45c9e64eb492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItMTItMS0xLTA_1b6703bb-b344-4363-87ea-4e54ebe8d388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItMTQtMS0xLTA_562b4230-df99-4763-93bc-9c68ac01eea8">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMi0xLTEtMA_a3dbfac8-49d9-496a-aa78-28b71e75ae39">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtNC0xLTEtMA_f8a4c866-f110-4689-bfd6-eea88233c64a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtNi0xLTEtMA_3a67abe4-6672-4f17-a504-8b30d3127cb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtOC0xLTEtMA_2b1f903c-9d68-47d0-851a-9eb6cbb09625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMTAtMS0xLTA_be51a4fa-1202-4fd2-a036-626d107cb327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMTItMS0xLTA_a906328c-3f46-4c53-951e-17ee562f36f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMTQtMS0xLTA_8820b4f7-ee29-4368-8c6d-6fee5ed501a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtNC0xLTEtMA_56a26d4e-8425-4f58-a690-0612185f1703">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtNi0xLTEtMA_7db7b200-ad42-457f-a277-d5a2fcc8c799">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtOC0xLTEtMA_a4d10c19-651e-4d54-b0c6-00d3791fe3e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtMTAtMS0xLTA_c1424c04-db88-4b91-aa0b-c01c6ac69fcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtMTItMS0xLTA_14ba84f6-4aa5-46a3-bcd8-adcc12959e6a">103</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtMTQtMS0xLTA_f7803dab-7c0f-4c89-8f76-65cba1e9064e">103</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtNC0xLTEtMA_3a0b2ca8-4ae2-4875-928b-237f3db4b4ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtNi0xLTEtMA_e55688d3-89ae-4214-a674-25085929544b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtOC0xLTEtMA_b41483c1-a2cc-47f5-880b-601063fca3d7">69,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtMTAtMS0xLTA_7fbc3056-f63d-4a0c-bf5f-5705d16d1089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtMTItMS0xLTA_f462248b-47e6-4720-b842-c38db7094866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtMTQtMS0xLTA_029b43bc-cff4-480f-8e95-6a560e82de71">69,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtNC0xLTEtMA_3c0a7051-85e7-46a6-afcc-a0f8cef70185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtNi0xLTEtMA_5e4d62e4-0e43-4b7b-b812-b720fb783e8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtOC0xLTEtMA_f98da19f-4d22-430b-a234-8933f441bfa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtMTAtMS0xLTA_d8882b5a-1db2-48b2-818d-c2a7ab14936e">548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtMTItMS0xLTA_1befca34-5b9d-4bf9-960d-9461e2c92e78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtMTQtMS0xLTA_2aa3c8cc-a3c0-42c2-b68f-f9791e4e6dbd">548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie771e05af7234472aef6bd918b9dbe61_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMi0xLTEtMA_1fb04178-2baa-40fc-a425-056802241e87">107,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie771e05af7234472aef6bd918b9dbe61_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtNC0xLTEtMA_3b485590-0ac8-42eb-8597-ffe8484e6de1">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89afbb9e0fbb43e182f2150249faef37_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtNi0xLTEtMA_d27b09c8-ed55-4c3e-b934-6eef861dde87">1,470,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia46fdf6eabe5409c982b14a8191c786a_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtOC0xLTEtMA_6042d88f-0b72-4ffc-a973-8c5efa73557b">1,477,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e76433e64224cd28783a0ed1b5ea7b3_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMTAtMS0xLTA_a762748e-bc18-424d-be94-374ea9e36696">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9867c02a657c412fa47e3e6fe91bccea_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMTItMS0xLTA_18af184b-15a3-428e-afd9-911ec61df409">4,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4615026499f4eaa986552fc1dfbd77a_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMTQtMS0xLTA_12e35ef3-1132-4aa1-9c66-e3eb6d8141f2">10,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktNC0xLTEtMA_31488d59-16fc-410b-b05b-28dde59e297a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktNi0xLTEtMA_4665d229-2a95-4f07-a326-e152bf4a4abf">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktOC0xLTEtMA_f7e2fdaa-7efe-472d-b9bc-d064ccdc09c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktMTAtMS0xLTA_3ffd0132-5e64-4428-8121-69dd3c8c5aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktMTItMS0xLTA_a302e6c3-8560-411f-942f-21f5965b59b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktMTQtMS0xLTA_a421c2ff-cef2-4e3f-b7f8-46a7525546f6">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net of fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMi0xLTEtMjA2Ng_0009651a-3e2c-4324-b415-95680538761e">9,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNC0xLTEtMjA2Ng_5ffa12ee-37cf-4586-8df2-b652f35105ae">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNi0xLTEtMjA2Ng_4d9e7cb9-bc1f-4ab5-a338-1c71d9da42e8">14,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtOC0xLTEtMjA2Ng_07bc2120-ec40-4196-9b4e-dd63fb8283ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTAtMS0xLTIwNjY_e71c1c6d-0a6c-4ea4-b64f-fd5241ad6eaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTItMS0xLTIwNjY_68a19d7b-e738-430d-a90f-5df593e3058a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTQtMS0xLTIwNjY_034288d0-21d5-4522-8733-1ae659b122e4">14,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNC0xLTEtMA_96a71d52-ce26-4f32-ac6b-7d2089b3c148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNi0xLTEtMA_a945ea8f-05db-40b0-9c77-1e8d9b596926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtOC0xLTEtMA_a96c5788-1237-4da4-8534-855162ebd135">82,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTAtMS0xLTA_cd845e87-304c-45e8-8ccd-7a9cc70cb161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTItMS0xLTA_d80f7009-7f0d-4ebf-a4ef-17d65edd115b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTQtMS0xLTA_dc2b93c4-cfb4-450e-ad07-a1049210c6a7">82,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtNC0xLTEtMA_d117f46c-dad9-420e-9083-a8c52a14bc32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtNi0xLTEtMA_d5a2b672-e432-450c-80e7-b205e4510029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtOC0xLTEtMA_c7cd0fb5-e1ae-4b6d-b3e4-135497b6bddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtMTAtMS0xLTA_c9a6b992-9b31-44a1-80f0-3fabc8a839e9">277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtMTItMS0xLTA_26f00afa-a065-44d1-8e67-1bd788c2866e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtMTQtMS0xLTA_d896dee1-022f-4509-935b-312ad445f80a">277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c622449e7a742b49bfa687466d2cb4d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMi0xLTEtMA_2c79c3bf-8c1f-4d9a-aa3e-40620a12d239">117,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c622449e7a742b49bfa687466d2cb4d_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItNC0xLTEtMA_9d63d6e9-e414-42a9-b2e3-1ac1e64e4764">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b359f3f2e54a4ca7516f16d229ef6d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItNi0xLTEtMA_bad99830-5109-4cda-a76a-38ea77cfb8d7">1,486,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i580af670a9ce4ccb936a88ec2d87b2c8_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItOC0xLTEtMA_fffc8a2e-502c-4d07-98f8-158668dab518">1,394,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed950d6bbe64a719b452fb582108b70_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMTAtMS0xLTA_58fcaae0-56bb-47f5-a509-7c2e82bb056e">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0699896381d48e7ad6adc8daae2f1d7_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMTItMS0xLTA_db1954f6-b0a0-426e-877b-5b9a0c57d596">4,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMTQtMS0xLTA_2de3d6cc-7589-43d8-858f-6093b2953c5d">87,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:73.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMy0yLTEtMS0w_8115fcb3-d29f-4ba7-ac5a-c6ee5189646a">53,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMy00LTEtMS0w_2d53d23e-320b-420b-b7fc-d284c75fc81d">181,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNS0yLTEtMS0w_62ea5057-96d9-4757-91b0-eea732860002">2,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNS00LTEtMS0w_ed0e4354-90fd-4595-a482-1a3f88d54395">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNy0yLTEtMS0w_1a8e6d60-2618-444f-9b6c-2a81046ec4b6">10,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNy00LTEtMS0w_a35ba686-f6d0-4f4a-a556-ddcebfcbf1eb">10,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOC0yLTEtMS0w_305f30ed-01c7-4f24-97f3-1b2be58bee71">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOC00LTEtMS0w_26248526-d7db-4530-87d3-33bc34702555">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOS0yLTEtMS0w_cf2cc1ff-86bb-484e-8805-c36a46a54cd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOS00LTEtMS0w_0cd0cbab-8504-47c2-9446-32a587537d77">6,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of XERMELO assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:GainOnSaleOfNonFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtMi0xLTEtMjAwMg_b86797bf-2f82-404b-a8d4-4f2effb41d69">132,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="lxrx:GainOnSaleOfNonFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtNC0xLTEtMjAwMg_4e3a77f9-acae-44a4-887c-7e3a03316558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfRealEstate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtMi0xLTEtMA_1c6cf545-9e61-47c0-85cc-1871457fc429">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfRealEstate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtNC0xLTEtMA_456e0022-4c3d-4883-8ed3-96106e55ba68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItMi0xLTEtMjAwNg_8532951f-66d6-4618-8192-0dd07e01d4a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItNC0xLTEtMjAwNg_80359697-0704-4377-a2e4-df72ccc868e4">28,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishments, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtMi0xLTEtMjAxMA_0c34e94f-d76c-4134-8797-c9087f69716a">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtNC0xLTEtMjAxMA_479bc0d0-971e-4757-acd5-ca97454675f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItMi0xLTEtMA_993c65e4-0432-4dac-b536-37c215313ebe">52,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItNC0xLTEtMA_ef825b0d-62d3-47e8-b2d1-6808b6db3269">50,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtMi0xLTEtMA_dee2989d-bebd-4c17-85e5-e5cc89346861">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtNC0xLTEtMA_df950a49-82fc-4ab3-9a4e-88058805470b">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTQtMi0xLTEtMA_3f1d7555-f161-402c-9091-d902d64e5768">6,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTQtNC0xLTEtMA_c29c2cd6-ca24-4305-87ae-dfe0ce0f5c03">3,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTUtMi0xLTEtMA_dcfe3f0c-3e2f-47e9-9cd9-f64d91cbdcdc">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTUtNC0xLTEtMA_ec1c256d-23db-41d6-abe5-96a411300064">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTYtMi0xLTEtMA_b3e175c8-6323-49b0-9b03-6d085d8b4fae">14,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTYtNC0xLTEtMA_2ecea822-82e1-444b-b77c-a3ae5f11221d">645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTctMi0xLTEtMA_46fd3386-a325-4e0a-b647-d8d9b0b57b0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTctNC0xLTEtMA_de618d96-48ad-41fc-8cfd-8d57a1adfc61">25,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 47.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTgtMi0xLTEtMA_4cbf90cc-6652-4726-9757-fb21d9d31e2e">108,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTgtNC0xLTEtMA_13c20d51-98d2-4261-bd13-abe72a0adb42">138,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjAtMi0xLTEtMA_3c2896bc-2797-40c4-9837-fba748d4d3bf">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjAtNC0xLTEtMA_3435c997-c5b5-4a91-91cf-38ab6da841ad">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from XERMELO sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjUtMi0xLTEtMjEzOA_7762fb8c-8a74-4eb1-9b50-6c073332881e">160,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjUtNC0xLTEtMjEzOA_9aa91441-041d-45aa-ac87-5a1b4eb20c24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjItMi0xLTEtMA_316e9800-40fa-4d78-8e5e-94e3d21edfe7">53,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjItNC0xLTEtMA_0ac7914c-e0a9-4afa-b9ed-248e2768c6d2">176,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjMtMi0xLTEtMA_271ccf37-7ca6-40bf-ba63-f1db3bb748b3">229,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjMtNC0xLTEtMA_c944656d-50b0-4011-b752-5531a53c1fef">130,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjQtMi0xLTEtMA_6488be25-97f2-4a9c-9bb5-044d718bd920">336,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjQtNC0xLTEtMA_1c383885-8cfe-49e6-a513-e81b325ab289">46,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjctMi0xLTEtMA_74bf752d-a191-457a-af53-18c7fbc144d6">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjctNC0xLTEtMA_a61948b4-d064-4071-bc19-31b9c900e145">941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjktMi0xLTEtMA_c6c3814e-07cb-4470-913a-53432a98b5fb">210,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjktNC0xLTEtMA_153f0abd-c185-4913-88ee-8dc177624273">963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 47.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzEtMi0xLTEtMA_81b88304-4a74-4c08-99f3-ddc286571e6d">211,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzEtNC0xLTEtMA_0fae2db6-78f9-4c82-a667-099b80bdb64d">1,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzItMi0xLTEtMA_1e9355b1-87ef-41d3-9395-d89523f9df4b">16,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzItNC0xLTEtMA_26657c83-3ea0-4219-aff2-bbeb013d1c4a">89,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzMtMi0xLTEtMA_2a335efb-e297-4b62-becd-4e68418c8d4b">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia29409cf569f4995a1b8cd001ef00215_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzMtNC0xLTEtMA_4d96f037-5650-48c9-9d43-db36165eb4a8">80,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzQtMi0xLTEtMA_2bc2182a-01ac-4a7e-9ef7-ca40c8843de8">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzQtNC0xLTEtMA_932d0038-76ba-4aa8-90c7-702778340a7f">170,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzctMi0xLTEtMA_3b8f9a6b-9385-4563-bf0d-1468098a00fc">16,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzctNC0xLTEtMA_17664838-383d-44fe-9589-fab01780432d">13,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed by TerSera from the XERMELO sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i170f779ba4fd4cdb814e7d6c94490a0b_I20200908" decimals="-3" format="ixt:numdotdecimal" name="lxrx:LiabilitiesAssumedByTerSera" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNDYtMi0xLTEtMzU2MA_705668bf-5b5c-4993-862b-686d41ed9cb1">3,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in satisfaction of convertible debt exchanges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNDctMi0xLTEtMzU2MA_d66819d7-5191-4562-9135-f5e6df74d2ed">14,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODg_b004a4bc-94f7-42cc-aa69-0497822082e7" continuedAt="ifb8fd9038bd04973ade29beca10ae75d" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ifb8fd9038bd04973ade29beca10ae75d" continuedAt="i4886cbe46d74429a89b3a6d87c4d3fbe"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyOTk_da4bd51c-237b-4c6e-b5de-563b76201369" escape="true">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2019, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNDc_5a4e0f4a-e538-426c-b7b8-cc76974c13e4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMzMTM_639ab400-b142-4ecd-bed2-c67fe42ae154" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of September&#160;30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMzMTQ_43080a65-dc53-40ca-ae14-fffd7a85ee44" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span></ix:nonNumeric></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNjg_07383640-454d-4343-8826-3ceaa6f68075" continuedAt="i7574eda4a8bc4c659d267aa02c0bf091" escape="true">Inventory: </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7574eda4a8bc4c659d267aa02c0bf091"> Inventory was comprised of supplies of XERMELO supporting the Company&#8217;s commercialization of the product in the United States.  Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method.  As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $<ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxMDc5Mg_82cfad69-7e4d-4757-a74e-bffe846dcfd9">3.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxMDc5OA_57a009a3-0b92-4791-ba41-c96c453b8a4a">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxMDgwNg_b42825cd-2679-4fe0-b284-d16474a7e59d">0.9</ix:nonFraction> million, respectively.</ix:continuation>  See Note 3, Asset Sale, for additional information relating to inventory.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Intangible assets, net consisted of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  During 2017, intangible assets relating to XERMELO of $<ix:nonFraction unitRef="usd" contextRef="i806bb79355704a3d9f9e975c7764b751_I20170331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxOTc5NQ_c18ffd39-7486-4c99-b493-542a615577ef">24.7</ix:nonFraction> million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;).  Intangible assets with finite lives are amortized using the straight-line method over their estimated lives.  As of December 31, 2019, the net carrying value of the finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzI5ODUzNDkxNDEzMw_131b2c98-09c5-4189-b55e-b7419857ecbe">19.7</ix:nonFraction>&#160;million.   During the three and nine months ended September&#160;30, 2020, the remaining net carrying value of $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxOTYxNg_12d4f016-0884-49f7-b8fe-f4912b4a07ad">18.5</ix:nonFraction> million for the intangible assets relating to XERMELO was reduced to <ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzI5ODUzNDkxNDE0NA_c2e86c63-2dd9-4027-843f-477f1b3d9afb">zero</ix:nonFraction> as a result of the Xermelo sale. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODA_80f12ca9-2e2c-4659-ae39-f20f127fe7c2" continuedAt="i9dbcdfca11324fffa87b91e8e0504eb8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i4886cbe46d74429a89b3a6d87c4d3fbe" continuedAt="i287d77c997c94ce99f355b4aefffb7f4"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i9dbcdfca11324fffa87b91e8e0504eb8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"></td><td style="width:52.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfMy0yLTEtMS0w_b93b8f08-416e-444f-b342-37dbf77b7d41">50,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfMy00LTEtMS0w_275a068d-367a-4f2d-bee0-d8266c66155d">29,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedCompensationAndBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNC0yLTEtMS0w_e8cb5ea8-3201-4dcf-aeed-429bdf732afe">6,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedCompensationAndBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNC00LTEtMS0w_ff5f2ebd-58bf-49fd-90e7-fd0b008fd30e">9,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNS0yLTEtMS0w_c74d0975-aa5d-4fa5-8906-fc66bb302d19">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNS00LTEtMS0w_f264b505-af34-4ead-92d0-7685f7eb6266">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNi0yLTEtMS0w_703ef531-cdca-43af-905f-71f4f93243c1">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNi00LTEtMS0w_6f8596ee-6a01-4d4f-9099-b59efb8200bd">2,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNy0yLTEtMS0w_41820e3e-8310-41f7-ae3c-c77a159fd543">58,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNy00LTEtMS0w_ac9366dd-8b12-472d-826f-b2b6d029dd83">42,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMzMDE_e4e74d2d-41f1-48b9-a812-72687371aad4" continuedAt="i7fb578892993423a9200ad8e7256b013" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflected the Company&#8217;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i287d77c997c94ce99f355b4aefffb7f4" continuedAt="ia6d854633b564889be8b3da8d1185cb6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7fb578892993423a9200ad8e7256b013" continuedAt="i5a33b784945246289efebee396c99544">sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</ix:continuation></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5a33b784945246289efebee396c99544">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODE_50286b21-db1f-4f08-b467-240b82ad265f" continuedAt="i55df95757a0f4746b33c14ca623065f7" escape="true">Cost of Sales: </ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55df95757a0f4746b33c14ca623065f7"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.  For the three and nine months ended September&#160;30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxNjI0MQ_a0de9e40-e0ac-4278-8820-7140876eef65">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxNjI0OQ_b7787608-a675-4622-9335-7dcb1e202136">1.2</ix:nonFraction> million, respectively, and for the three and nine months ended September&#160;30, 2019, includes $<ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxNjYwNA_1413e506-6630-47fb-80dc-a4f4ed469659">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcyMTk4OQ_42c44b5e-0eb7-40f2-987d-3a7eaf5b14e9">1.3</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNzc_b906b2a8-abf1-4b33-a175-15809536e5a1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODI_e90f4fd1-b449-4cbc-96b8-dfb177f587d3" continuedAt="i1dda4c452cd14b6ab3541bac4de7bc3c" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1dda4c452cd14b6ab3541bac4de7bc3c">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the nine months ended September&#160;30, 2020 and 2019:</span></div></ix:continuation><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODM_ee45a959-a9b6-470e-82a8-76ac65536f11" continuedAt="i42627b343dd1432994050d12aba94df9" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ia6d854633b564889be8b3da8d1185cb6" continuedAt="i832ef70ef15e4732b66663c5976c6f08"><div style="margin-bottom:6pt"><ix:continuation id="i42627b343dd1432994050d12aba94df9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi0yLTEtMS0w_7fe0d0db-2441-4a3a-8975-3d03d1e53a39">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi00LTEtMS0w_52e71e63-b25b-4067-b852-aaa4233be24e">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi02LTEtMS0w_16dd0465-67f1-4023-b848-0c21dad3e6a4">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi04LTEtMS0w_9fc9aad6-b516-4123-81e2-4aca48862db4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy0yLTEtMS0w_30a82bca-1d24-49de-8000-226a662df797">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy00LTEtMS0w_500c7895-3bab-433b-95be-a72a63f653b7">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy02LTEtMS0w_f570ed05-aa12-4f4f-9fd0-948a57498d50">8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy04LTEtMS0w_ae2b79b9-3ea6-47e9-aeb7-5d0f2571d92e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS0yLTEtMS0w_1e3048b8-49ac-4d31-9298-6ae20b01e7ca">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS00LTEtMS0w_795644d3-5e9d-426e-bd43-29df667644e7">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS02LTEtMS0w_551e6cd4-d475-47f0-ad84-be8d1624a297">4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS04LTEtMS0w_b6f4a45c-633d-460f-a2bd-d10f31a5713e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi0yLTEtMS0w_f144e077-f0f7-4ffd-bf7d-fc4e237149ea">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi00LTEtMS0w_674d1394-22cb-4be1-bfc6-1e67d44d0009">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" format="ixt-sec:duryear" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi02LTEtMS0w_e9aea5a1-872b-4db4-815b-c6687161899b">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930" decimals="2" format="ixt:zerodash" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi04LTEtMS0w_434ffbcb-b4bd-4886-851d-00b0d01746bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the nine months ended September&#160;30, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODQ_ce6ba4c3-6982-4f1e-8be7-e38c341932aa" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7902597037c2463d85d00a4b46bdb6db_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMi0yLTEtMS0w_74a3e785-8ed3-4f1c-8ae4-31dea786079e">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7902597037c2463d85d00a4b46bdb6db_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMi00LTEtMS0w_1b8da3e9-ddec-4947-92c7-2efd2c4142c6">8.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMy0yLTEtMS0w_d74a3d16-e0ef-481a-b540-d9cb837af224">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMy00LTEtMS0w_1bfb2ef9-ebc2-487b-bae2-53e4eee1fb00">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNS0yLTEtMS0w_59528046-5b23-48b6-9cfb-507b51aa01e2">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNS00LTEtMS0w_894df406-a48e-4e3d-9111-e50ce7744ae7">12.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNi0yLTEtMS0w_97ce75f2-e27f-48dd-a2d1-5419a3916553">1,909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNi00LTEtMS0w_2e7b94c2-6dfe-4317-bf08-4640d5f55f4a">5.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dd55aa47b494c508a8707104b290757_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNy0yLTEtMS0w_a0634570-74ec-4d22-823e-ac7a9d8a4ee4">8,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6dd55aa47b494c508a8707104b290757_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNy00LTEtMS0w_90a615b3-367c-4295-a3a3-4b6c98c5ba33">7.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dd55aa47b494c508a8707104b290757_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfOC0yLTEtMS0w_ae06f3fc-3d81-4ade-8c36-80bb01f43b77">5,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6dd55aa47b494c508a8707104b290757_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfOC00LTEtMS0w_ac8d2050-2fed-4d34-91fc-657fc29b623e">9.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) In connection with the reduction in force in September 2020, unvested stock options were forfeited or cancelled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNTc_1bf9a1a7-f578-4f4d-9b60-3852e79aeeb9" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16d499c22b144586ab5b1747d70c9923_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMi0yLTEtMS0w_bdb674d9-b458-4815-b7ae-a0aded021836">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16d499c22b144586ab5b1747d70c9923_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMi00LTEtMS0w_08c4db79-35fd-42f4-87c9-043c06d64170">6.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMy0yLTEtMS0w_9ac29088-8b9a-4e30-9e7e-ce1b5aa22810">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMy00LTEtMS0w_b27ffd18-e41e-463d-b0de-bd13583b8717">3.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNC0yLTEtMS0w_40de4841-fe99-430f-b109-10df88482be2">1,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNC00LTEtMS0w_2cfeb57f-6f28-46bc-9947-9fea35b6a24c">6.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNS0yLTEtMS0w_584c0874-d4fb-427a-b95d-9549d95a4e3a">1,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNS00LTEtMS0w_6a175689-605a-4a77-b925-d7233ac7f47c">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b7cb3d54a24978a2f81d13fb5f8bf0_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNi0yLTEtMS0w_8d05b364-5853-43df-b9a4-dda7feea426f">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b7cb3d54a24978a2f81d13fb5f8bf0_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNi00LTEtMS0w_249d6723-679d-4a75-a6ee-61a1ead78b6a">4.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(1) In connection with the reduction in force in September 2020, unvested restricted stock units were forfeited or cancelled.</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i832ef70ef15e4732b66663c5976c6f08" continuedAt="iff1dc4a18f5d48c7b1016e70e66c58f0"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNTg_f5ed4868-9295-4ab8-bee9-1cddfadf8fc9" continuedAt="ib6f042e7a8d64d42a0e962127ac561b5" escape="true">Net Loss per Common Share:</ix:nonNumeric></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff1dc4a18f5d48c7b1016e70e66c58f0"><ix:continuation id="ib6f042e7a8d64d42a0e962127ac561b5"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_37"></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNy9mcmFnOjNlNzM3MTMxNjE4MzRmMzJhNDFlZTQxZDVjMDQ0OTRlL3RleHRyZWdpb246M2U3MzcxMzE2MTgzNGYzMmE0MWVlNDFkNWMwNDQ5NGVfMTcyMw_2d4070fb-108d-4558-a0a6-db3232befb7f" continuedAt="i0a117d3793bd479590abcb39de82e166" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a117d3793bd479590abcb39de82e166" continuedAt="i39bbcccbdae24394ba5c49fc81e273d2">In November 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39bbcccbdae24394ba5c49fc81e273d2">In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_849"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="lxrx:SaleOfNonFinancialAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzkzNDU4NDg4NDExNTg_ef3e9520-d3dd-4549-a04b-825d8f72cc1e" continuedAt="if57e92d9d8f04940bad010fada8276dd" escape="true">Asset Sale</ix:nonNumeric></span></div><ix:continuation id="if57e92d9d8f04940bad010fada8276dd" continuedAt="i8bc60d22c43546e2b4fc8d628d8ae22d"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company completed the sale of its XERMELO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (telotristat ethyl) product and related assets (the &#8220;XERMELO sale&#8221;) to TerSera Therapeutics LLC (&#8220;TerSera&#8221;) pursuant to an Asset Purchase and Sale Agreement entered into in July 2020.  The upfront consideration paid by TerSera, subject to a working capital adjustment as set forth in the Asset Purchase and Sale Agreement, was $<ix:nonFraction unitRef="usd" contextRef="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzMyOTg1MzQ4ODc4NDk_6fa44998-70a4-4974-847e-c36f7450a361">160.4</ix:nonFraction> million and the net gain recognized in connection with the XERMELO sale was $<ix:nonFraction unitRef="usd" contextRef="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:GainOnSaleOfNonFinancialAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTc2ODY_7269756e-04a4-44e9-b7ef-707bfbe33482">132.8</ix:nonFraction> million.  The gain is reflected on the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzMyOTg1MzQ4ODgzNzI_11462b29-5703-4b72-90d9-cd4982c749cf">65</ix:nonFraction>&#160;million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer.  The Company has determined that these amounts are constrained until the achievement, if any, of specific events.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company&#8217;s operations.  For the three and nine months ended September&#160;30, 2020, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company&#8217;s XERMELO operations is $<ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lxrx:XermeloPretaxNetLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA3MDE2OTc_94fc64c3-9747-45d9-80ca-8419ff14893e">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lxrx:XermeloPretaxNetLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA3MDE3MDA_23e884e0-b139-452c-b676-753e6ca7f154">12.1</ix:nonFraction> million, respectively, and for the three and nine months ended September&#160;30, 2019, the pretax net loss for the Company&#8217;s XERMELO operations is $<ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lxrx:XermeloPretaxNetLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTg4NjA_7143180e-1cd5-4e13-bc95-bc8d439c919f">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lxrx:XermeloPretaxNetLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTg4Njg_0cf88b79-220b-49b4-aa67-ce566590ee49">10.8</ix:nonFraction> million, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8bc60d22c43546e2b4fc8d628d8ae22d">As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company currently expects severance charges to approximate $<ix:nonFraction unitRef="usd" contextRef="i45dc5d23ea3b4654bc9d1ccd692ebca9_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA3MDE2OTI_fedd46cd-e288-4742-9d18-029048b11988">5.7</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTkxMDY_1cf178c5-c0b6-4f01-a248-4e6438a5020d">5.5</ix:nonFraction> million was incurred through September&#160;30, 2020. Of this charge, $<ix:nonFraction unitRef="usd" contextRef="iab6089ded0c145f3a665941d75632fdf_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTkxNTI_9d2d5aaf-7edb-44a3-9fd7-729bca21f714">2.5</ix:nonFraction> million was recorded in research and development expense and $<ix:nonFraction unitRef="usd" contextRef="i90f2f211830347d7b962a9ddc24c8919_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTkyMDk_d95c4b11-ec0b-47a2-aadb-d473c65cbda5">3.0</ix:nonFraction> million was recorded in selling, general and administrative expense in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_40"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMzQz_2ccf2990-e278-4f9e-830e-b695170e5c56" continuedAt="iaf631598af1c4a3692cc716747e5c3fc" escape="true">Cash and Cash Equivalents and Investments</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf631598af1c4a3692cc716747e5c3fc" continuedAt="i7ec647a1ee4f44e488df95b0d79bd0c9">&#160;</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ec647a1ee4f44e488df95b0d79bd0c9"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at September&#160;30, 2020 and December&#160;31, 2019 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMzM5_6bdf185a-9b66-4595-b2b7-1def2f13ca9f" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy0yLTEtMS0w_e36db5ad-df06-486d-acd7-fe044f996d6a">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy00LTEtMS0w_fb00cf66-3e6d-4021-a691-81bf082b5054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy02LTEtMS0w_69dbe730-0cde-47ef-9b44-97e0202f3024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy04LTEtMS0w_aa03b0f1-4256-406e-8cff-bc2d5a38ae75">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS0yLTEtMS0w_91e3196c-baa6-4fae-9225-664d60bed06c">38,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS00LTEtMS0w_1c370c19-0a29-41e3-a43a-5a7e62e2d508">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS02LTEtMS0w_90164a82-dfcd-47f4-9e26-e6c8fdaf0ec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS04LTEtMS0w_b01f1f75-0718-415f-ae33-a8a0a998bf57">38,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi0yLTEtMS0w_0edd56cc-1d1b-42fe-bf35-5e966a481a59">20,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a47a08149c54860b477528661d2c215_I20190930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi00LTEtMS0w_bbe6e701-8f14-4409-a2ae-4f3d1504aafc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi02LTEtMS0w_82da2cd3-ab6f-4080-b729-330cd6a67e8b">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi04LTEtMS0zNzMz_bfe928f8-85b5-466e-b661-48b0e5c1c8ce">20,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy0yLTEtMS0w_c7c2c9a1-6054-46d1-b352-c3855dda578d">59,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy00LTEtMS0w_3b09137b-6653-498b-a96e-fe8d2cd60bfd">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy02LTEtMS0w_609defc9-fac6-4283-b4b5-13837fb1a276">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy04LTEtMS0w_ea58aa2c-ca0c-4a87-8355-e32693cdd303">59,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC0yLTEtMS0w_3f869a0e-7bc9-412a-b7a3-988bfbed6f31">111,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC00LTEtMS0w_bee708d5-9b8a-4649-bccb-4fdfefab0de0">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC02LTEtMS0w_1fb587e0-50a2-4d1e-ba19-633e8cb2a5eb">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC04LTEtMS0w_91a05d4d-22df-4773-b908-915e4e3e9f1f">111,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtMi0xLTEtMA_b7800558-8f89-499d-a47e-384298e14266">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtNC0xLTEtMA_cd8b9d76-9fb8-4fa6-b12f-d46db566dd32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtNi0xLTEtMA_00d4d960-a5d1-47f2-9233-03649b147643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtOC0xLTEtMA_49eb3320-595f-4752-a354-34f5184c41da">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtMi0xLTEtMA_364ed4d9-d532-47e8-a602-ab9164ea90f7">235,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtNC0xLTEtMA_8cff7d04-d503-42bc-8a4b-a740583ea4d1">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtNi0xLTEtMA_f632945c-26f5-4ef1-85b6-b8286f90c362">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtOC0xLTEtMA_5e1e49b5-e9a9-4474-9e9d-ac7a475463f1">235,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598b1a29343d4deda20d232162634172_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctMi0xLTEtMA_b12fbd75-9a94-4b0c-8976-0d237c1567a3">235,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598b1a29343d4deda20d232162634172_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctNC0xLTEtMA_8c5e5de1-b8a3-45c0-bfb3-a4d56454715f">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i598b1a29343d4deda20d232162634172_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctNi0xLTEtMA_56a0bb7c-3590-4c8c-a29a-fb9dac94518b">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598b1a29343d4deda20d232162634172_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctOC0xLTEtMA_4bfaaa3d-59e4-494c-96a1-88359f551226">235,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtMi0xLTEtMA_9e154ce1-2ca0-4e6f-ae55-e310fe713937">271,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtNC0xLTEtMA_00351c43-07ad-48b6-8233-ad57b92b1606">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtNi0xLTEtMA_3468b5a6-3a48-4764-9c33-8efd80c33511">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtOC0xLTEtMA_11e0dfc4-cdc0-45b6-ade4-2b0efe454e9c">271,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMTcx_350a0f8f-899d-49e3-9447-e69ccdda06da"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMTcx_d5618df9-9b64-43f6-a2b2-cf85de167405">no</ix:nonFraction></ix:nonFraction> realized losses during either of the nine months ended September&#160;30, 2020 and 2019, respectively.  The cost of securities sold is based on the specific identification method.</span></div></ix:continuation><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_43"></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RleHRyZWdpb246YWJiMjM0NGEzZjAyNDJhM2IzMzc3ODRjNzhjNjQ1MjNfMjE1Mw_2c27baf3-3b6c-4877-8c22-049882c889b5" continuedAt="id31e6fa2309a404f9955a88e63a37687" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="id31e6fa2309a404f9955a88e63a37687" continuedAt="i6a8975a226f942fa84e692718fba0884"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6a8975a226f942fa84e692718fba0884"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RleHRyZWdpb246YWJiMjM0NGEzZjAyNDJhM2IzMzc3ODRjNzhjNjQ1MjNfMjEzNw_f8747973-bd36-4e93-bf91-dd30ffe129f4" escape="true"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16df9c6c19c64790a5837cf1d79351ff_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC0yLTEtMS0w_20404609-1f81-4c5c-95f0-802976ca9e90">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3c3a225f534e188a9ebe0475319a1b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC00LTEtMS0w_7b8f6835-dc39-4c0d-90aa-e4d4595d559d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC02LTEtMS0w_a8d2c754-b62c-4d2f-a034-394542ad6152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC04LTEtMS0w_bc3132dc-b8d3-4b3b-b710-f68270c11997">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16df9c6c19c64790a5837cf1d79351ff_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS0yLTEtMS0w_3a964375-c29e-44e1-a736-8c845e72ea20">38,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3c3a225f534e188a9ebe0475319a1b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS00LTEtMS0w_84c17c8d-f3a1-4574-ae21-69049cea989d">20,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS02LTEtMS0w_ef2f85e7-9780-4dce-84a7-17d92328fa76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS04LTEtMS0w_73c09ac8-88f9-4fb4-9abb-7a1498b20778">59,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16df9c6c19c64790a5837cf1d79351ff_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi0yLTEtMS0w_dc1f1de4-06aa-44a7-aabf-abf94da9d07a">91,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3c3a225f534e188a9ebe0475319a1b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi00LTEtMS0w_01594086-6570-4fc0-b4fb-59601de6ae2a">20,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi02LTEtMS0w_c612c1a4-5c24-4937-bafb-7e770114f55f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi04LTEtMS0w_bc4b647b-2269-4160-a126-7a7c36f81310">111,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f83f9e3d794affb390e88fc81fa72e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC0yLTEtMS0w_61ad6364-6bbd-4ccb-8de3-ba0c54f10011">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7b6895d6da4c09ac7535756e184174_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC00LTEtMS0w_042ba9a8-c25c-4b86-85d4-3832d94407bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC02LTEtMS0w_540fc905-32c2-4562-b5f7-07600b57cbd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC04LTEtMS0w_130c9cbb-ed4b-41d3-843e-7380aac82fd4">36,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f83f9e3d794affb390e88fc81fa72e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS0yLTEtMS0w_3c35e70c-6bdf-4be6-a67b-0f17be061ecf">235,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7b6895d6da4c09ac7535756e184174_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS00LTEtMS0w_7a2e5d1d-1e64-4d7d-9e8d-14eb5924aec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS02LTEtMS0w_a6a4a0c8-e022-48f4-8fb5-3dd7c35155f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS04LTEtMS0w_331ac7be-21b6-4e09-9058-e74a54018aec">235,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f83f9e3d794affb390e88fc81fa72e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi0yLTEtMS0w_2c40c3b4-a4f4-4c1c-af39-c2d1f0154de3">271,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d7b6895d6da4c09ac7535756e184174_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi00LTEtMS0w_eed58b6a-e1f3-4782-b14b-e18127702bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi02LTEtMS0w_4f9db557-6861-4540-88fb-f47e46694be9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi04LTEtMS0w_4159570f-4ec4-4b82-9f64-700547c5acfc">271,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of September&#160;30, 2020 or December&#160;31, 2019. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.  These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon, Inc. in 2010, and intangible assets associated with the acquisition of Symphony Icon, Inc. in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, Debt Obligations, for fair value measurements of debt obligations.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, Impairment Loss on Buildings, for fair value measurement of fixed assets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_46"></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzI5ODUzNDg5NjA3Ng_c60f85c1-9d4c-4dc5-af05-0b96ca85b308" continuedAt="ieedde49c02e649c58351a9d0c243bb90" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="ieedde49c02e649c58351a9d0c243bb90" continuedAt="i84c21a72e1664b9797dfd39213858df6"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="i1772c994ba65403ca45d1f126c089301_D20141101-20141130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTAz_b2c70142-13cc-4657-8ba8-7bc6338d5723">87.5</ix:nonFraction> million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i17b3093f9ba14f25864a4923a0f67585_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTQz_564a6717-10f9-4da3-85a5-f7aa6b17374d">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $<ix:nonFraction unitRef="usd" contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchangeTotalPrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTI0Mw_05a6154d-a938-451f-9921-fa957d3425c1">75.8</ix:nonFraction> million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes.  In September 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928" decimals="0" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchangeSeptemberSharePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNjg3OA_4dbb2ee0-076f-405b-b561-9b7581a329e2">9,332,471</ix:nonFraction> shares of the Company&#8217;s common stock and paid $<ix:nonFraction unitRef="usd" contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchangeSeptemberCashPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNjg4Nw_33cb50e4-d689-4396-b57f-05ae9c64b7c1">44.0</ix:nonFraction> million in cash, which included $<ix:nonFraction unitRef="usd" contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedInterestOnConvertible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTA2Mw_133e6651-5e9e-4fe4-bd30-a0c674ff2df8">1.1</ix:nonFraction> million of accrued interest, to exchange $<ix:nonFraction unitRef="usd" contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchangeSeptemberPrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTA1Ng_d3a3726c-898d-4b81-b8bd-62554e3914ad">67.1</ix:nonFraction> million aggregate principal amount of such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchange" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNzI2NA_c305451d-a138-42f2-8b41-cdedb2f75921">8.4</ix:nonFraction> million was recorded and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.  As of September&#160;30, 2020, the carrying value of the remaining Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:ConvertibleDebtExchangeRemainingNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNTY0MA_cf5e22c9-5fbe-4192-9e8b-8a44bd448d14">20.0</ix:nonFraction> million. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001" decimals="0" format="ixt:numdotdecimal" name="lxrx:FutureConvertibleDebtExchangeShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNjk0MA_5f7b9b6d-fd4e-4d7d-8523-f4aa7232fcdc">1,036,484</ix:nonFraction> shares of the Company&#8217;s common stock and paid $<ix:nonFraction unitRef="usd" contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001" decimals="-3" format="ixt:numdotdecimal" name="lxrx:FutureConvertibleDebtExchange" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNzAzNA_d77c9930-cbf3-4bf0-b0c0-1f9a8cf5be2a">6.0</ix:nonFraction> million in cash, which included $<ix:nonFraction unitRef="usd" contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AccruedInterestOnConvertible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTE1MA_4026e60e-36fa-4c39-85fb-a4b66a203007">0.2</ix:nonFraction> million of accrued interest, to exchange an additional $<ix:nonFraction unitRef="usd" contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001" decimals="-3" sign="-" format="ixt:numdotdecimal" name="lxrx:PrincipalAmountOfConvertibleNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTExMQ_f78fcfd4-646c-4eba-b2da-150c99dedbeb">8.8</ix:nonFraction> million aggregate principal amount of such Convertible Notes.  As of September 30, 2020, these notes are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i84c21a72e1664b9797dfd39213858df6" continuedAt="i00dca95652f94bc78cc25d01245d3814"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="i17b3093f9ba14f25864a4923a0f67585_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNjYx_564a6717-10f9-4da3-85a5-f7aa6b17374d">5.25</ix:nonFraction>%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially <ix:nonFraction unitRef="number" contextRef="i1772c994ba65403ca45d1f126c089301_D20141101-20141130" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTM4OA_e05f531c-32f1-4e9c-b054-8595caa07770">118.4553</ix:nonFraction> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i17b3093f9ba14f25864a4923a0f67585_I20141120" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTUwOQ_2be99744-5a55-4ef9-9873-87f96987e72d">8.442</ix:nonFraction> per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Convertible Notes, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i1772c994ba65403ca45d1f126c089301_D20141101-20141130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMjM2Mg_1b71a52a-80bc-4a94-907d-552ee127d073">3.4</ix:nonFraction> million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of September&#160;30, 2020, the balance of unamortized debt issuance costs was $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMjcwOA_34ae451e-1cee-47fb-b304-7f3e8a568c04">0.13</ix:nonFraction>&#160;million, which was adjusted in September 2020 upon execution of the exchange agreements and offsets long-term debt on the condensed consolidated balance sheets.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMjg5NA_d4c7ec07-43dd-40a1-a7a2-4e675a550232">15.4</ix:nonFraction>&#160;million as of September&#160;30, 2020 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The loan agreement provided for a $<ix:nonFraction unitRef="usd" contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtInstrument_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzQyMw_e37c3224-9541-4cbc-a6f5-ceb58ed4b0b7">12.9</ix:nonFraction> million mortgage on the Property and had a two-year term with a 10-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRate_Base_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzYxMw_19d78de7-cb19-45ac-ba6e-380f39b13115">5.5</ix:nonFraction>% and (b) <ix:nonFraction unitRef="number" contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830" decimals="INF" name="lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzYyNA_0a49335b-0cd2-4e2a-869d-0fa96cbfda05">7.5</ix:nonFraction>% and provided for a balloon payment of $<ix:nonFraction unitRef="usd" contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtBalloonPayment_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzY2NQ_115ee0d8-76bf-4ab4-a39c-7e4468d332c5">10.3</ix:nonFraction> million, which was paid in full in August 2020.  At December&#160;31, 2019, the condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:MortgageDebtInstrument_Revere_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNDExOA_b4c547ff-4fef-4782-a6f7-cd2b561e554e">11.0</ix:nonFraction> million and is included in current portion of long-term debt.  The fair value of the loan agreement approximated its carrying value.&#160;&#160;The fair value of the loan agreement was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioPharma Term Loan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma under which $<ix:nonFraction unitRef="usd" contextRef="if73dd8addd4542a29c4ec9debd3582d1_I20171218" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNDc3Ng_fa3bb6a5-a51d-4a1f-ba88-7e9c2e6a0744">150.0</ix:nonFraction> million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;). The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at <ix:nonFraction unitRef="number" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNDkwNA_2372ffc1-143f-42fe-a0ba-fc4d127356ce">9</ix:nonFraction>% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO sale in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $<ix:nonFraction unitRef="usd" contextRef="ifb39716de56e4e5a895227f8630d9df3_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwODA0Mw_dbea2c19-4f54-4618-8e0e-e5a388c868f5">8.6</ix:nonFraction> million was recognized and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the BioPharma Term Loan were secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contained certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i00dca95652f94bc78cc25d01245d3814" continuedAt="ica9a1d7062b3422382933c8dfa90b9df"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments, transactions with affiliates and subordinated debt.  If an event of default occurred and was continuing, all amounts outstanding under the BioPharma Term Loan may have been declared immediately due and payable.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the BioPharma Term Loan, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="if73dd8addd4542a29c4ec9debd3582d1_I20171218" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNjMwMA_93fae6f1-ef73-48dc-9a44-cc870a26d6e8">4.1</ix:nonFraction> million of debt issuance costs.  The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. The remaining balance of the debt issuance costs were written off and included as part of the debt extinguishment loss.</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ica9a1d7062b3422382933c8dfa90b9df">At December&#160;31, 2019, the fair value of the BioPharma Term Loan approximated its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_49"></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMTgyMw_98a63505-2eae-439a-8c1d-a62bc9ff6c5c" continuedAt="i73cb95d379414e0f93e3399ea9abe08e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i73cb95d379414e0f93e3399ea9abe08e" continuedAt="i39e9458a93894965a9db747720e826ca"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  The Company&#8217;s motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#8217;s securities during the period from March&#160;11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (&#8220;Sanofi&#8221;) seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the &#8220;Termination Agreement&#8221;).  In September 2020, Sanofi withheld approximately $<ix:nonFraction unitRef="usd" contextRef="icb5076221df34ff6b100b90bb7f27cf6_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMzI5ODUzNDg4NzE2NQ_1157e003-4d92-47a6-8bc7-37a67e7c0e10">23.2</ix:nonFraction>&#160;million from the final $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMzI5ODUzNDg4NzE5NA_4a6601d5-c460-4bc5-87e7-7c5cbdcf1d1f"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMzI5ODUzNDg4NzE5NA_df1fcd92-f589-4d70-968a-b9ac024d08e6">26</ix:nonFraction></ix:nonFraction>&#160;million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement.  The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement.  The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys&#8217; fees and costs.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39e9458a93894965a9db747720e826ca">In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</ix:continuation>&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_52"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfOTcyNQ_595741d7-5955-4a15-831a-b7be4ef1d77c" continuedAt="if6d22ded78854196ac66f4dd95346aca" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="if6d22ded78854196ac66f4dd95346aca" continuedAt="ic6e003bf5e814142ac5d6808251b2f92"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic6e003bf5e814142ac5d6808251b2f92" continuedAt="icebcabf343b84b13879de3e1ac01bcdc"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTcxMQ_0c26df95-b570-4428-a515-45f9091fa098">47.2</ix:nonFraction> million through September&#160;30, 2020, consisting of $<ix:nonFraction unitRef="usd" contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTc0MA_0d08fddf-e42f-4211-8038-c5e334c941ef">24.5</ix:nonFraction> million in upfront payments and a $<ix:nonFraction unitRef="usd" contextRef="ia91cc58958d74a18bc3bdc7678de13fc_D20170101-20170331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTc2OQ_0c9bc2a6-80db-4df8-a712-f55d852a7138">6.4</ix:nonFraction> million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $<ix:nonFraction unitRef="usd" contextRef="i0c565ac789974012b970ac1ab822623b_D20180101-20180331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTk4Ng_e80bf66d-2288-4aef-9285-d404018c3054">5.1</ix:nonFraction> million milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $<ix:nonFraction unitRef="usd" contextRef="i813cb4fdefa8444c86cc8630f57e27da_D20171001-20171031" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjE1Ng_3b2b83b9-c959-474a-8184-97aac52d9c95">3.8</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in Germany, a $<ix:nonFraction unitRef="usd" contextRef="i795f1b1257384f238c4605db9c94d3e7_D20171101-20171130" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjIxOA_cf81e919-2a72-4a8f-9784-e13537df386b">3.8</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom, a $<ix:nonFraction unitRef="usd" contextRef="i2fd1f447a93c4793b6c6a92f2e209e1e_D20191001-20191231" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjI5MQ_a168d3cd-abc6-4e2f-92db-08df4a58da75">1.3</ix:nonFraction> million milestone upon Ipsen&#8217;s receipt of approval from Health Canada and a $<ix:nonFraction unitRef="usd" contextRef="i381201bb0bd34c48a7207b7c78990cd8_D20190201-20190228" decimals="-4" format="ixt:numdotdecimal" name="lxrx:IpsenMilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjM2Mg_d3ae68bf-10b0-4c9f-a43a-c75847439f86">2.3</ix:nonFraction> million milestone upon Ipsen&#8217;s first commercial sale in Canada.  In addition, Lexicon was eligible to receive from Ipsen (a) up to an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenMaximumRegulatoryAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjUxNw_9f253b42-8794-484a-b75b-327592e1ffde">9.6</ix:nonFraction>&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#8364;<ix:nonFraction unitRef="eur" contextRef="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031" decimals="-6" format="ixt:numdotdecimal" name="lxrx:IpsenMaximumSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjYyOA_0d64f031-31aa-4f65-a75a-a74bf4d4f7e6">72</ix:nonFraction>&#160;million upon the achievement of specified sales milestones. Milestone payments that were contingent upon the achievement of a substantive milestone were deemed constrained.  Lexicon was also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen had entered into a commercial supply agreement pursuant to which Lexicon supplied Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen paid an agreed upon transfer price for such commercial supply.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the following as its performance obligations with respect to the revenue recognition of the $<ix:nonFraction unitRef="usd" contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzQxOQ_0d08fddf-e42f-4211-8038-c5e334c941ef">24.5</ix:nonFraction>&#160;million upfront payments: </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The development services Lexicon was performing for XERMELO;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The obligation to participate in committees which governed the development of XERMELO until commercialization; and</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The obligation to supply commercial supply of XERMELO under a commercial supply agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the license had stand-alone value because it was an exclusive license that gave Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considered the license and the development services under the Ipsen Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the commercial supply agreement was a contingent deliverable at its onset.  There was inherent uncertainty in obtaining regulatory approval at the time of entry into the commercial supply agreement, thus making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen.  As a result, the Company determined the commercial supply agreement did not meet the definition of a performance obligation that needed to be accounted for at the inception of the arrangement.  The Company also determined that there was no significant and incremental discount related to the commercial supply agreement that should have been accounted for at the inception of the arrangement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the initial transaction price was the $<ix:nonFraction unitRef="usd" contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNTUwNA_0d08fddf-e42f-4211-8038-c5e334c941ef">24.5</ix:nonFraction>&#160;million in upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the allocation, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ia4193bd56cb84f0d9f797512013ed041_D20150101-20151231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoLicenseDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNjg3Nw_c60aaec7-39aa-424e-904e-8bd50e1c74ec">21.2</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenTotalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNjg4Nw_0d08fddf-e42f-4211-8038-c5e334c941ef">24.5</ix:nonFraction>&#160;million in upfront payments for the license in 2014, and an additional $<ix:nonFraction unitRef="usd" contextRef="i2e87a1738c194bf0b536c8857a3ca790_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoLicenseDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNjk1MA_62b0922a-3cc1-4d18-acdf-83c1f89fd3b8">1.4</ix:nonFraction>&#160;million in 2015 upon entering into the amendment.  The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNzAyMw_d607dc30-73ad-4d59-9646-9c33a69fa3cb">1.7</ix:nonFraction>&#160;million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $<ix:nonFraction unitRef="usd" contextRef="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNzE2Mg_4f26616f-e0be-4eef-8091-7c0537a89941">0.1</ix:nonFraction>&#160;million allocated to the committee participation performance obligation ratably over the period of performance.  Milestone payments that were contingent upon the achievement of a substantive milestone were </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icebcabf343b84b13879de3e1ac01bcdc" continuedAt="idd3cceff27404c58bbd963ad15cab4de"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed constrained.  If or when the constraint was determined to be resolved, the Company would re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  Revenue recognized under the Ipsen Agreement was $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfOTM0NTg0ODg1NTY1NQ_47325532-c5d0-468e-9024-319bafa5b141">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzg0ODI5MDcwNzkxNg_6d570a73-0196-4e18-9791-c65038887772">3.5</ix:nonFraction> million for the nine months ended September&#160;30, 2020 and 2019, respectively.   Royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:IpsenRoyaltyIncome_LXRX" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNzcyOQ_17c8d65a-2a4b-4707-b509-2829bec1ce45">0.3</ix:nonFraction> million was recognized for each of the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd3cceff27404c58bbd963ad15cab4de">Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzI5ODUzNDkwMjg1MQ_073b209e-3b46-4ad6-8d04-fbe65a9592eb"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="lxrx:Lxrx_Sanofiterminationcashpayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfODcwNw_7bb0700e-0cd8-42f3-9a96-5e2b6dca01d6">208</ix:nonFraction></ix:nonFraction> million in September 2019 and $<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:Lxrx_sanofiInitialCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzI5ODUzNDkwMjg1Mg_91c657e3-5ad1-41c2-bf70-4c4e25db4339"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="lxrx:Lxrx_sanofiInitialCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfODcyOQ_86f3ff65-3c2a-48fb-a797-aa121ef67b2e">26</ix:nonFraction></ix:nonFraction> million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  See Note 7, Commitments and Contingencies, for additional information.  In March 2020, Lexicon announced its plan to close out the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Revenue relating to the Termination Agreement was recognized in the third quarter of 2019.  Revenue recognized under the Sanofi Agreement was $<ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzI5ODUzNDkwMjg1MA_4f86f877-5bef-4430-9f53-428d83959324"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="lxrx:SanofiRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzg0ODI5MDcwNzkzNw_165aa31d-8610-48ab-a0e9-5381cc8f6fed">286.0</ix:nonFraction></ix:nonFraction> million for the nine months ended September&#160;30, 2019.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_55"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:AssetImpairmentChargesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81NS9mcmFnOmQ2YWExMjc1MDhiODRmYzNhMTM4MjJiNmFjNTlhMDIzL3RleHRyZWdpb246ZDZhYTEyNzUwOGI4NGZjM2ExMzgyMmI2YWM1OWEwMjNfOTM0NTg0ODg0MDUxOQ_db70a6bc-b7e3-4283-a5b3-ab7b85b0db94" continuedAt="if84f91568ef54e75b8a17b2ba93bbc41" escape="true">Impairment Loss on Buildings</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if84f91568ef54e75b8a17b2ba93bbc41" continuedAt="i5bb421d660e5475780a7a4de6ffc02c8">&#160;</ix:continuation></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5bb421d660e5475780a7a4de6ffc02c8">In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which the Company agreed to sell its facilities in The Woodlands, Texas for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="lxrx:AssetSalePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81NS9mcmFnOmQ2YWExMjc1MDhiODRmYzNhMTM4MjJiNmFjNTlhMDIzL3RleHRyZWdpb246ZDZhYTEyNzUwOGI4NGZjM2ExMzgyMmI2YWM1OWEwMjNfMzg0ODI5MDcwMTI3MA_5d615499-0d7c-4400-ac44-26275d70faa9">11.9</ix:nonFraction> million.  The sale agreement is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement at its discretion.  The property did not meet the criteria for classification as held for sale at September&#160;30, 2020.  Due to the negotiations to sell the property in 2020, the Company evaluated for impairment and recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81NS9mcmFnOmQ2YWExMjc1MDhiODRmYzNhMTM4MjJiNmFjNTlhMDIzL3RleHRyZWdpb246ZDZhYTEyNzUwOGI4NGZjM2ExMzgyMmI2YWM1OWEwMjNfMzg0ODI5MDcwMTI1Mg_e0480255-1bbf-4c30-a623-8d7520dacfdf">1.6</ix:nonFraction> million in the second quarter of 2020 in order to reduce the carrying value of the property to its estimated fair value, less estimated selling costs.</ix:continuation>    </span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_835"></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzMyOTg1MzQ4ODQ2MDE_a4de345e-f26a-4f8d-8af2-97b1e77bccba" continuedAt="ibd843337d5ab4292bc28489f7cfc9af3" escape="true">Earnings (Loss) Per Share</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd843337d5ab4292bc28489f7cfc9af3" continuedAt="i86044eb7d3bd4cd7bd580010fecf9fda"><ix:nonNumeric contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzMyOTg1MzQ4ODQ2MDI_0b221511-3dfa-4f66-a063-94b3af08a0da" continuedAt="ib7d9f83c8d214cba88bbe19d15facb99" escape="true">The following is a summary of Lexicon&#8217;s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.</ix:nonNumeric></ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i86044eb7d3bd4cd7bd580010fecf9fda"><div style="margin-bottom:6pt"><ix:continuation id="ib7d9f83c8d214cba88bbe19d15facb99"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:40.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtMi0xLTEtMzI5MQ_425b85f9-0116-47d4-ab48-48042bd8e952">82,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtNC0xLTEtMjI1Mw_c9d9818a-e741-4ebf-8cd6-ac8cbe031a6d">226,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtNi0xLTEtMzI5MQ_396ef072-5a89-43ff-aed9-4b245e7dd33b">53,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtOC0xLTEtMjI1Mw_25a713f0-c676-44c8-8f9b-9e8ba47a90ae">181,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Add interest on Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtMi0xLTEtMzI5MQ_5a646368-ec09-48e3-ae7a-76ee9be5c273">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtNC0xLTEtMjI1Nw_f9b11fe0-e17b-40bf-b72a-a4d7c0a6e9cd">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtNi0xLTEtMzI5MQ_6fcdbef0-491e-4820-bb39-caa8a09173f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtOC0xLTEtMjI1Nw_feea6e8f-2e65-4989-a2e0-2be75a95cf0f">3,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtMi0xLTEtMjI1Nw_8a30e523-699a-43fe-9564-c599c4611b57">83,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtNC0xLTEtMjI1Nw_6a1e560c-4a6b-4042-b7d7-68b3e6212fcf">227,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtNi0xLTEtMjI1Nw_987b3ded-6ba1-4bb5-a77f-267c45b1bacf">53,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtOC0xLTEtMjI1Nw_3d43fcee-f52e-42d3-a594-04ac4a1c8251">185,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtMi0xLTEtMzI5Nw_d33b6b37-9956-4d0b-b1fb-f2faf3021788">107,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtNC0xLTEtMjI2MQ_c3992a27-06a8-4a48-8412-4884a09d14ad">106,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtNi0xLTEtMzI5Nw_882fee00-4e9f-498b-b663-dbc4406b9ea2">106,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtOC0xLTEtMjI2MQ_14c5f326-ca42-48b1-ba26-1eb9616e6ce1">106,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Share based compensation awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTItMS0xLTMzMDM_42b51dd8-d580-455b-b00d-b0f120c6fa4e">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTQtMS0xLTIyNjE_a2f7a9e1-fb36-4e07-b174-7c949bbe15f1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTYtMS0xLTMzMDM_1a73fc2a-6bca-41f1-b5fb-5bec2d9b028f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTgtMS0xLTIyNjE_5f75f1d0-0327-4aed-916d-fc6e5eaa38f2">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTItMS0xLTMzMDM_be07ca49-2447-42f2-9611-90f44d450ffc">10,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTQtMS0xLTIyNjE_02549bcd-72ca-4c58-b1ab-b111c1f49b49">10,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTYtMS0xLTMzMDM_497a41cf-2e9b-4324-a21d-00b86d633e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTgtMS0xLTIyNjE_b1fc2375-15f8-42b8-a985-e17559d251a8">10,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTItMS0xLTIyNjE_09136aea-bfe9-4f08-a9f4-79eaf685515b">117,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTQtMS0xLTIyNjE_1db5074f-16ea-4cf7-8c9f-37e06d3c48cf">116,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTYtMS0xLTIyNjE_0ee67a10-8fd8-42a4-9e96-bf0868b49a48">106,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTgtMS0xLTIyNjE_ffd94489-6403-4b27-a721-29652f0254e6">116,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTItMS0xLTMzMDk_51dfbb44-dd46-448b-b44b-e02ad996c322">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTQtMS0xLTIyNjE_eb5d5cc3-79eb-46da-aa13-e19cea6cfa1b">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTYtMS0xLTMzMDk_ab184d89-81c8-4030-9fed-7b7eabef7363">0.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTgtMS0xLTIyNjE_3bbbc317-0e21-4591-9e24-e88eb1ceabff">1.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTItMS0xLTMzMDk_94f4fd1c-d3f2-47ab-ab77-54e885719df8">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTQtMS0xLTIyNjE_f11a0708-7344-4ad4-9c09-35ba659d73fc">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTYtMS0xLTMzMDk_1112a1a1-43f4-410d-acdd-39ce9584eda1">0.50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTgtMS0xLTIyNjE_2486a32e-5c28-40eb-8857-85614f854c20">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was <ix:nonFraction unitRef="shares" contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0NTA_6533cabf-1c73-49a4-83b3-c87b6d13906c">11,773</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0MTQ_e56d22fb-e1d9-4051-a18a-6f225c6aa75e">10,576</ix:nonFraction>, respectively, for the three months ended September 30, 2020 and 2019, and <ix:nonFraction unitRef="shares" contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0Njk_6a29fa30-1cf2-4e95-9caa-8d513e2f77a3">11,859</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0Mjg_0b5e4004-7f00-4d61-a9bf-c7ab08d99c31">8,452</ix:nonFraction>, respectively, for the nine months ended September 30, 2020 and 2019. For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. We are devoting most of our resources to the research and development of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.  We identified the target of LX9211, adapter-associated kinase 1, or AAK1, in our target discovery efforts as a promising approach for the treatment of neuropathic pain, and identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb from which we hold exclusive development and commercialization rights.  In preclinical studies, LX9211 demonstrated central nervous system penetration and reduction in pain behavior in multiple models of neuropathic pain, and has been demonstrated not to affect opiate pathways.  We have reported top-line results from two Phase 1 clinical trials of LX9211, and are now conducting a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain and preparing to initiate a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing Zynquista&#8482; (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type&#160;1 diabetes, in support of which we completed a Phase 3 program involving approximately 3,000 patients with type 1 diabetes.  The FDA has issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States and has confirmed that position in denying two appeals of the complete response letter.  Zynquista has been approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 kg/m</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have recently completed a Phase 3 development program for sotagliflozin in type 2 diabetes involving approximately 5,000 patients across nine studies (exclusive of outcomes studies), and are completing the close-out of two outcomes studies involving approximately 10,500 and 1,200 patients, respectively, with primary endpoints evaluating a composite of total cardiovascular death, hospitalizations for heart failure and urgent visits for heart failure.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug discovery and development programs.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we completed the sale of our XERMELO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (telotristat ethyl) product and related assets to TerSera Therapeutics LLC, or TerSera.  We commercially launched XERMELO following regulatory approval in the United States in February 2017 for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults inadequately controlled by SSA therapy.  In connection with the sale, TerSera assumed responsibility for the continued development of XERMELO as a treatment for biliary tract cancer, currently in a Phase 2 clinical trial.  We are eligible to receive development, regulatory and sales milestone payments from TerSera of up to an aggregate of $65 million for the development and commercialization of XERMELO in patients with biliary tract cancer and mid-teens percentage royalty payments from TerSera on net sales of XERMELO in biliary tract cancer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sotagliflozin, XERMELO and compounds from a number of additional drug discovery and development programs originated from our own internal drug discovery efforts, and LX9211 and other compounds targeting AAK1 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb. These efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working both independently and through strategic collaborations and alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs.  We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians.  We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the launch of XERMELO, we derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses.  To date, we have generated a substantial portion of our revenues from a limited number of sources.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our ability to effectively close out the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease in a timely manner; TerSera&#8217;s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts; our success in establishing new collaborations and licenses; and general and industry-specific economic conditions which may affect research and development expenditures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future revenues from our sale of XERMELO to TerSera are uncertain because they depend on the achievement of milestones and payment of royalties we earn from TerSera&#8217;s development and commercialization of XERMELO in biliary tract cancer.  Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.&#160;&#160;We may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.&#160;&#160;Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and, as of September&#160;30, 2020, we had an accumulated deficit of $1.4&#160;billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants. Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities. We expect to continue to incur significant research and development costs in connection with the continuing development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our condensed consolidated financial statements and accompanying notes.&#160;&#160;Actual results could differ from those estimates.&#160;&#160;We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recent accounting pronouncements that have a material impact to our condensed consolidated financial statements.   </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Net product revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Net product revenue recognized from the sale of XERMELO in the United States for the three months ended September&#160;30, 2020 decreased 22% to $6.5 million as compared to the corresponding period in 2019, due to the Xermelo sale on September 8, 2020.  Net product revenue for the nine months ended September&#160;30, 2020 increased 4% to $23.4 million as compared to the corresponding period in 2019.  Revenue from sales of bulk tablets of XERMELO to Ipsen were $1.3 million for the nine months ended September&#160;30, 2019.  Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance.  Revenue recognition policies require estimates of the aforementioned sales allowances each period.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborative agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Revenue from collaborative agreements for the three and nine months ended September&#160;30, 2019 was $285.9 million and $289.2 million.  Revenue from collaborative agreements for the three and nine months ended September&#160;30, 2019 included $260 million from the Termination Agreement with Sanofi and recognition of amounts allocated to the performance obligation for development activities of sotagliflozin in the Sanofi Agreement.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of sales and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:43.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO.  Cost of sales for the nine months ended September&#160;30, 2019 included costs related to the bulk tablet sales to Ipsen.  Cost of sales for the three and nine months ended September&#160;30, 2020 includes $0.3 million and $1.2 million, respectively, and for the three and nine months ended September&#160;30, 2019 includes $0.4 million and $1.3 million, respectively, of amortization of intangible assets relating to XERMELO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:42.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar increase</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, stock-based compensation expense, and facility and equipment costs.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party and other services &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Third-party and other services for the three months ended September&#160;30, 2020 increased to $31.7 million from $18.5 million, and for the nine months ended September&#160;30, 2020 increased to $125.9 million from $24.0 million as compared to the corresponding periods in 2019 primarily due to increases in external clinical development costs relating to sotagliflozin subsequent to the termination of our collaboration with Sanofi.  Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel costs for the three months ended September&#160;30, 2020 increased 18% to $5.6 million as compared to the corresponding period in 2019, primarily due to the severance costs related to the reduction in force of our personnel in September 2020, partially offset by the lower costs related to employee salaries and management bonuses.  For the nine months ended September&#160;30, 2020, personnel costs decreased 3% to $15.6 million as compared to the corresponding period in 2019, primarily due to lower headcount as a result of the reduction in force, partially offset by the severance costs.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expense for the three months ended September&#160;30, 2020 decreased 39% to $1.0 million, and for the nine months ended September&#160;30, 2020 decreased 4% to $5.2 million as compared to the corresponding periods in 2019, primarily due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and equipment costs for each of the three months ended September&#160;30, 2020 and 2019 was $0.7 million, and for each of the nine months ended September&#160;30, 2020 and 2019 was $2.0 million.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended September&#160;30, 2020 increased 14% to $1.2 million, and for the nine months ended September&#160;30, 2020 increased 4% to $4.0 million as compared to the corresponding periods in 2019, primarily due to increases in our insurance costs, partially offset by lower costs of travel.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar decrease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage decrease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel costs to sell XERMELO and to support our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Personnel costs for the three months ended September&#160;30, 2020 increased 17% to $7.7 million, and for the  nine months ended September&#160;30, 2020 increased 2% to $21.9 million as compared to the corresponding periods in 2019, primarily due to the severance costs related to the reduction in force of our personnel in September 2020, partially offset by the lower costs related to employee salaries and management bonuses.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Professional and consulting fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Professional and consulting fees for the three months ended September&#160;30, 2020 decreased 38% to $2.0 million, and for the nine months ended September&#160;30, 2020 decreased 8% to $8.1 million as compared to the corresponding periods in 2019, primarily due to lower marketing expenses and legal fees.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expense for the three months ended September&#160;30, 2020 decreased 53% to $0.9 million as compared to the corresponding period in 2019, and for each of the nine months ended September&#160;30, 2020 and 2019 was $5.4 million.  The decrease was due to cancellation of unvested share-based awards as a result of the reduction in force of our personnel in September 2020. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Facilities and equipment costs for each of the three months ended September&#160;30, 2020 and 2019 were $0.5 million and for each of the nine months ended September&#160;30, 2020 and 2019 were $1.4 million. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended September&#160;30, 2020 decreased 45% to $1.0 million, and for the nine months ended September&#160;30, 2020 decreased 26% to $3.9 million as compared to the corresponding periods in 2019, primarily due to decreases in travel expenses due to the COVID-19 pandemic. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on the sale of XERMELO</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, a gain of $132.8 million was recognized in connection with the sale of XERMELO and related assets to TerSera.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Loss on Buildings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, we began negotiations to sell our facilities in the Woodlands, Texas.  We recognized an impairment loss of $1.6 million as a result of writing down the buildings to the estimated net selling price. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Loss on Intangible Asset</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, an impairment loss of $28.6 million was recognized to an indefinite lived intangible asset associated with the 2010 acquisition of Symphony Icon, due to the decision to terminate research and development activities related to a program for irritable bowel syndrome that was among the assets acquired.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Debt Extinguishments, Net</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the closing of the sale of XERMELO and related assets to TerSera in September 2020, we repaid term borrowings of $150.0 million to BioPharma Credit PLC and BioPharma Credit Investments IV Sub LP.  A debt extinguishment loss of $8.6 million was recognized.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into separate, privately negotiated exchange agreements to exchange $67.1 million aggregate principal amount of its 5.25% Convertible Senior Notes due 2021, or the Convertible Notes.  As a result, a debt extinguishment gain of $8.4 million was recognized.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Interest and Other Income, Net</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Interest expense for the three months ended September&#160;30, 2020 and 2019 was $4.1 million and $5.2 million, and for the nine months ended September&#160;30, 2020 and 2019 was $14.4 million and $15.5 million. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Interest and other income, net for the three months ended September&#160;30, 2020 and 2019 was $0.3 million and $0.6 million, respectively, and for the nine months ended September&#160;30, 2020 and 2019 was $1.9 million and $2.1 million, respectively. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) and Net Income (Loss) per Common Share</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income (loss) and Net income (loss) per Common Share.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income was $82.6 million, or $0.71 per diluted share, in the three months ended September&#160;30, 2020 as compared to $226.1 million, or $1.95 per diluted share, in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corresponding period in 2019.  Net loss was $53.1 million, or $0.50 per share, in the nine months ended September&#160;30, 2020 as compared to net income of $181.3 million, or $1.59 per diluted share, in the corresponding period in 2019.    </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our strategic and other collaborations, target validation, database subscription and technology license agreements, product sales, government grants and contracts, third party financing arrangements and financing under debt and lease arrangements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had $111.4&#160;million in cash, cash equivalents and short-term investments.  As of December&#160;31, 2019, we had $271.7&#160;million in cash, cash equivalents and short-term investments.  We used cash of $108.7&#160;million from operations in the nine months ended September&#160;30, 2020.  This consisted primarily of the net loss for the period of $53.1 million and gain from the sale of XERMELO and related assets to TerSera of $132.8 million, partially offset by a net decrease in operating assets net of liabilities of $61.1 million, non-cash charges of $10.6&#160;million related to stock-based compensation expense, $3.6 million related to depreciation and amortization expense, including amortization of debt issuance costs, $1.6 million related to the impairment loss and $0.3 million related to the net loss of debt extinguishments. Investing activities provided cash of $336.7&#160;million in the nine&#160;months ended September&#160;30, 2020, primarily due to $176.3&#160;million of net maturities of investments and $160.4&#160;million of proceeds from the sale of XERMELO.  Financing activities used cash of $211.8 million, primarily to repay $210.8 million of debt borrowings and to repurchase $1.0 million of common stock. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Zynquista was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 kg/m</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, who could not achieve adequate glycemic control despite optimal insulin therapy.  Upon the achievement of certain European regulatory pricing approvals, we will be required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we initiated a Phase 2 clinical trial of LX9211 in diabetic peripheral pain. As a result of the commencement of the Phase 2 trial, we were required to make a royalty payment of $2.5 million, which was paid in October 2020. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which we agreed to sell our facilities in The Woodlands, Texas for a purchase price of $11.9 million.  Such sale is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement in its discretion.  Such sale is also subject to the negotiation and execution by the parties of a month-to-month leaseback agreement for up to six months with respect to a portion of the property concurrently with closing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June&#160;1, 2015 through December&#160;31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will be substantial and will depend on many factors, including the success of our ongoing nonclinical and clinical development efforts and ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our ability to effectively close out the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease in a timely manner; TerSera&#8217;s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts; our success in establishing new collaborations and licenses; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to successfully complete our nonclinical and clinical development efforts with respect to sotagliflozin, LX9211 and our other drug candidates and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may authorize us to repurchase shares of our common stock, repurchase, in cash or common stock, our outstanding convertible notes, or make a cash payment to holders of our convertible notes to induce conversion pursuant to the terms of the convertible notes, in each case, in privately negotiated transactions, publicly announced programs or otherwise.  If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure about Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $111.4&#160;million in cash and cash equivalents and short-term investments as of September&#160;30, 2020.  We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are not subject to interest rate sensitivity on our outstanding Convertible Notes as they generally have a fixed rate of 5.25% per annum.  The Convertible Notes interest is payable in cash semi-annually in arrears and matures in December 2021, unless earlier converted or repurchased in accordance with their terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_67"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_70"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the three months ended September&#160;30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II -- Other Information&#160;</span></div><div style="text-align:center"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_76"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Securities Class Action Litigation.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against us and certain of our officers in the U.S. District Court for the Southern District of Texas, Houston Division.  Our motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020.  The lawsuit purports to be a class action brought on behalf of purchasers of our securities during the period from March 11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from our Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On October 16, 2020, we initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH, or Sanofi, seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019.  In September 2020, Sanofi withheld approximately $23.2 million from the final $26 million payment due to us under the termination and settlement agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by us under the terms of the termination and settlement agreement.  We dispute that at least a significant portion of such costs are properly reimbursable by us under the terms of the termination and settlement agreement and assert that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the termination and settlement agreement.  We are seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys&#8217; fees and costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Normal Course Legal Proceedings.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_79"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.  The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face business disruption and related risks resulting from the outbreak of the novel coronavirus, or COVID-19, including delays in the enrollment of ongoing clinical trials and the initiation of planned clinical trials and other operational impacts, each of which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our ability to obtain regulatory approval in the United States for sotagliflozin in type 1 diabetes.  If we fail to obtain such regulatory approval or fail to successfully commercialize sotagliflozin for type 1 diabetes in the United States upon regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our ability to effectively close out two outcomes studies evaluating the effect of sotagliflozin on cardiovascular death and heart failure and involving approximately 10,500 and 1,200 patients, respectively.  If we fail to effectively close out such clinical trials on the anticipated timelines, our cash position will suffer and our stock price will likely decline.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on TerSera&#8217;s ability to successfully develop and commercialize XERMELO for biliary tract cancer and our receipt of milestone payments and royalties from such efforts.  If TerSera does not successfully complete such development and commercialization activities, we will not receive milestone payment and royalties relating to such efforts, our cash position will suffer and our stock price will likely decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical community.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish an effective and specialized sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies.  These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Capital Requirements and Financial Results </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs.  If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are significantly dependent upon our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of pharmaceutical products.  If we are unable to establish such collaborations or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from pharmaceutical products we develop will be greatly reduced.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We lack the capability to manufacture materials for nonclinical studies and clinical trials and rely on third parties to manufacture our drug candidates, which may harm or delay our research and development efforts.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development activities.  We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Employees and Facilities Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to manage any future growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Environmental and Product Liability </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have used hazardous chemicals and radioactive and biological materials in our business.  Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Common Stock</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Invus, L.P., Invus C.V. and their affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Invus has additional rights under our stockholders&#8217; agreement with Invus, L.P. relating to the membership of our board of directors, which provides Invus with substantial influence over significant corporate matters.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price may be extremely volatile.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to securities litigation, which is expensive and could divert management attention. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future sales of our common stock, or the perception that such sales may occur, may depress our stock price.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conversion of the Convertible Senior Notes may dilute the ownership interest of our existing stockholders, including holders who had previously converted their notes, or may otherwise depress the price of our common stock.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may engage in future acquisitions, which may be expensive and time consuming and from which we may not realize anticipated benefits.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the risks and uncertainties that affect our business, see &#8220;Item&#160;1A. Risk Factors&#8221; included in our annual report on Form 10-K for the year ended December&#160;31, 2019 as filed with the Securities and Exchange Commission. </span></div><div><span><br/></span></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_864"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Other Information</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Entry into a Material Definitive Agreement</span></div><div style="text-indent:48.95pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 30, 2020, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) with Jefferies LLC, as sales agent (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Jefferies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;), pursuant to which we may offer and sell, from time to time, through Jefferies, shares of our common stock, par value $0.001, having an aggregate sales price of up to $50,000,000 (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not obligated to sell any Shares under the Agreement.  Subject to the terms and conditions of the Agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations to sell Shares from time to time based upon our instructions, including any price, time or size limits specified by us, subject to certain limitations.  Under the Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including block transactions, sales made directly on the Nasdaq Global Select Market or sales made into any other existing trading market of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Shares will be issued pursuant to our shelf registration statement on Form S-3 (Registration No. 333-234568), filed November 7, 2019 and effective as of November 18, 2019.  We will file a prospectus supplement with the SEC on October&#160;30, 2020 in connection with the offer and sale of the Shares pursuant to the Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of Shares, reimburse legal fees and disbursements and provide Jefferies with customary indemnification and contribution rights.  The Agreement will terminate as set forth in the Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing description of the Agreement in this quarterly report on Form 10-Q does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 1.1 hereto and is incorporated herein by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vinson &amp; Elkins L.L.P., our counsel, has issued a legal opinion relating to the validity of the Shares being offered pursuant to the Agreement.  A copy of such legal opinion, including the consent included therein, is filed as Exhibit 5.1 to this quarterly report on Form 10-Q and is incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This quarterly report on Form 10-Q shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Agreement nor shall there be any sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh11openmarketsaleagr.htm">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="exh11openmarketsaleagr.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh11openmarketsaleagr.htm">, dated October 30, 2020, with Jefferies LLC</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*5.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh51veopinion10-30x20.htm">Opinion of Vinson &amp; Elkins L.L.P</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset Purchase and Sale Agreement, dated July 29, 2020, with TerSera Therapeutics LLC (filed as Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K dated September 8, 2020 and incorporated by reference herein).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to Asset Purchase and Sale Agreement, dated August 10, 2020, with TerSera Therapeutics LLC (filed as Exhibit 2.2 to the Company&#8217;s Current Report on Form 8-K dated September 8, 2020 and incorporated by reference herein).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Vinson &amp; Elkins L.L.P (included in Exhibit 5.1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh311certificationofp.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh312certificationofp.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*32.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofp.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension  Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by &#8220;[**]&#8221;) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i1768c5c1d1b04f5e9a0dc9a726aa65ff_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exh11openmarketsaleagr.htm
<DESCRIPTION>EX-1.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3b817b0b453b457f968eb5350d154c3f_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 1.1</font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPEN MARKET SALE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">SM</font><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;October 30, 2020</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">JEFFERIES LLC </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">520 Madison Avenue</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York 10022 </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and&#47;or principal (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agency Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Floor Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#8217;s sole discretion.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;Open Market Sale Agreement&#8221; is a service mark of Jefferies LLC</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached hereto as Exhibit A that is executed by its Chief Executive Officer, President or Chief Financial Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Sales Price less the Selling Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Maximum Program Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Common Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable), or (d) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or other entity of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principal Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means The Nasdaq Global Select Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selling Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means three percent (3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Settlement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the second business day following each Trading Day during the period set forth in the Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Company&#8217;s Common Shares issued or issuable pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day on which the Principal Market is open for trading.</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">REPRESENTATIONS AND WARRANTIES OF THE COMPANY </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company represents and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each Settlement Date, (4) each Triggering Event Date and (5) as of each Time of Sale (each of the times referenced above is referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company has prepared and filed with the Commission a shelf registration statement on Form S-3 (File No. 333- 234568) that contains a base prospectus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Base Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act.  The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares. Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act as from time to time amended or supplemented, is herein referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Registration Statement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prospectus,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use.  The Registration Statement at the time it originally became effective is herein called the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original Registration Statement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;  As used in this Agreement, the terms &#8220;amendment&#8221; or &#8220;supplement&#8221; when applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date&#59; and all references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At the time the Original Registration Statement was declared effective and at the time the Company&#8217;s most recent annual report on Form 10-K was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form S-3 under the Securities Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Compliance with Registration Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Original Registration Statement and any Rule 462(b) Registration Statement have been declared effective by the Commission under the Securities Act.  The Company has complied to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental information.  No stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Prospectus when filed complied or will comply in all material respects with the Securities Act and, if filed with the Commission through its Electronic Data Gathering, Analysis and Retrieval system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EDGAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (except as may be permitted by Regulation S T under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares.  Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.  As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Time of Sale Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The Prospectus, as amended or supplemented, as of its date and at each Representation Date, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below.  There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Ineligible Issuer Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not an &#8220;ineligible issuer&#8221; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act.  Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">requirements of the Securities Act.  Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein.  Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the Agent&#8217;s prior consent, prepare, use or refer to, any Free Writing Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Incorporated Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Exchange Act Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Statistical and Market-Related Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All statistical, demographic and market-related data included in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects or represent the Company&#8217;s good faith estimates that are made on the basis thereof.  To the extent required, the Company has obtained the written consent for the use of such data from such sources.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Disclosure Controls and Procedures&#59; Deficiencies in or Changes to Internal Control Over Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, the Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#8217;s principal executive officer and its principal financial officer by others within those entities, within the time periods specified in the Commission's rules and forms&#59; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company&#8217;s most recent fiscal quarter&#59; and (iii) are effective in all material respects to perform the functions for which they were established.  Since the end of the Company&#8217;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#8217;s internal control over financial reporting (whether or not remediated) and no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.  The Company is not aware of any change in its internal control over financial reporting that has occurred during its </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">This Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement has been duly authorized, executed and delivered by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Authorization of the Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and, except as described in the Registration Statement and the Prospectus, the issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">No Applicable Registration or Other Similar Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except otherwise disclosed in the Prospectus, there are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">No Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus&#58; (i) there has been no material adverse change, or any development that could be reasonably expected to result in a material adverse change, in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business&#59; and (iii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#8217;s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Independent Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Ernst &#38; Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PCAOB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) in compliance with the applicable requirements relating to the qualification of </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The financial statements filed with the Commission as a part of the Registration Statement and the Prospectus present fairly in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#8217; equity and cash flows for the periods specified.  Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto.  The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto in all material respects.  No other financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus. The financial data set forth in each of the Registration Statement and the Prospectus under the caption &#8220;Selected Financial Data&#8221; fairly present in all material respects the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement and the Prospectus. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Company&#8217;s Accounting System</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, the Company and each of its subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that&#58;  (i) transactions are executed in accordance with management&#8217;s general or specific authorization&#59; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets&#59; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization&#59; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences&#59; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission's rules and guidelines applicable thereto.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Incorporation and Good Standing of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and perform its obligations under this Agreement.  The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of the Company&#8217;s &#8220;subsidiaries&#8221; (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus.  Each of the Company&#8217;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#8217;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the Prospectus, are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim.  The Company does not own or control, directly or indirectly, any corporation, association or other entity that would constitute a significant subsidiary as defined under Rule 1-02 of Regulation S-X other than the subsidiaries listed in Exhibit 21 to the Company&#8217;s most recent Annual Report on Form 10-K.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Capitalization and Other Capital Stock Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement and the Prospectus under the caption &#8220;Capitalization&#8221; (other than for subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement and the Prospectus).  The Common Shares (including the Shares) conform in all material respects to the description thereof contained in the Prospectus.  All of the issued and outstanding Common Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws.  None of the outstanding Common Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement and the Prospectus.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Stock Exchange Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Common Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are listed on the Principal Market, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Principal Market, nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration or listing.  To the Company&#8217;s knowledge, it is in compliance in all material respects with all applicable listing requirements of the Principal Market.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.36pt;text-decoration:underline">Non-Contravention of Existing Instruments&#59; No Further Authorizations or Approvals Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither the Company nor any of its subsidiaries is in violation of its charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject, except for such Defaults as could not be expected, individually or in the aggregate, to  result in a Material Adverse Change.  The Company&#8217;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and the issuance and sale of the Shares will not contravene (i) the provisions of the charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary, (ii) any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, and (iii) any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries&#59; except, in the case of clauses (ii) and (iii), as would not reasonably be expected to result in a Material Adverse Change.  No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#8217;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby, except such as (i) have been obtained or made by the Company and are in full force and effect under the Securities Act, (ii) as may be required under applicable state securities or blue sky laws or FINRA (as defined below) and (iii) if not obtained, have not or would not reasonably be expected to result in a Material Adverse Change. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">No Material Actions or Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, there is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change.  No material labor dispute with the employees of the Company exists, except as described in the Prospectus, or, to the knowledge of the Company, is imminent&#59; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could result in a Material Adverse Change. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Registration Statement or the Prospectus, the Company and its subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the Prospectus as being owned or licensed by them or which are used in and necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and, to the Company&#8217;s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material respect any such rights of others.  The Intellectual Property owned by the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication.  To the Company&#8217;s knowledge&#58; (i) except as otherwise disclosed in the Prospectus and with respect to LX9211 (to which the Company owns an exclusive license), there </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are no third parties who have ownership, royalty, or exclusive license rights to any Intellectual Property owned by the Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement and the Prospectus as licensed to the Company or one or more of its subsidiaries&#59; and (ii) there is no material infringement by third parties of any Intellectual Property owned by the Company.  There is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others&#58; (A) challenging the Company&#8217;s rights in or to any Intellectual Property licensed to the Company&#59; (B) challenging the validity, enforceability or scope of any Intellectual Property owned by the Company&#59; or (C) asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other intellectual rights of others.  The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are, to the Company&#8217;s knowledge, in full force and effect.  To the Company&#8217;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken reasonable steps to protect, maintain and safeguard Intellectual Property owned by the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company&#8217;s knowledge, no employee of the Company is in or has been in violation of any term of any such agreement.  The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property owned by the Company have been materially complied with&#59; and in all foreign offices having similar requirements, all such requirements have been materially complied with. The product candidates described in the Registration Statement and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">All Necessary Permits, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, the Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement or the Prospectus (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), except as would not reasonably be expected to result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt;text-decoration:underline">Title to Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets owned by them which is material to the business of the Company, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects except as do not materially affect the value of such property and do not interfere in any material respect with the use made and currently proposed to be made of such property by </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Company.  Except as otherwise disclosed in the Prospectus, the real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Tax Law Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the Company and its subsidiaries (i) have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and (ii) have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings and for which adequate reserves are maintained in accordance with generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Company Not an &#8220;Investment Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  The Company is not, and will not be, either after receipt of payment for the Shares or after the application of the proceeds therefrom as described under &#8220;Use of Proceeds&#8221; in the Registration Statement or the Prospectus, required to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change, except as described in the Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.38pt;text-decoration:underline">No Price Stabilization or Manipulation&#59; Compliance with Regulation M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that reasonably would be expected to cause or result in stabilization or manipulation of the price of the Common Shares or of any &#8220;reference security&#8221; (as defined in Rule 100 of Regulation M under the Exchange Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulation M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) with respect to the Common Shares, whether to facilitate the sale or resale of the Shares or otherwise. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Related Party Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement or the Prospectus which have not been described as required. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ac)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.38pt;text-decoration:underline">FINRA Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete and correct. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ad)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">No Unlawful Contributions or Other Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, neither the Company nor any of its subsidiaries nor, to the best of the Company&#8217;s </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement and the Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ae)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.38pt;text-decoration:underline">Compliance with Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as described in the Prospectus and except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change, (i) neither the Company nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law (including fundamental principles of common law), rule, regulation or ordinance, including any judicial or administrative interpretation thereof, relating to pollution or protection of human health (to the extent relating to exposure to Hazardous Materials, defined below), the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release of pollutants, contaminants, or hazardous or toxic wastes or substances that are subject to regulation by any governmental authority  (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required of them under Environmental Laws for their operations has currently conducted and are each in compliance with the terms and conditions of such permits, authorizations and approvals, and (iii) the Company and its subsidiaries has not received written notice of any pending or threatened liability under any Environmental Law and, to the knowledge of the Company, there is no event or occurrence that would reasonably be expected to result in the receipt of any such notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(af)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.71pt;text-decoration:underline">ERISA Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as would not, individually or in the aggregate, result in a Material Adverse Change&#58; (i) the Company and its subsidiaries and any &#8220;employee benefit plan&#8221; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) established or maintained by the Company, its subsidiaries or their &#8220;ERISA Affiliates&#8221; (as defined below) are in compliance in all material respects with ERISA&#59; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of which the Company or such subsidiary is a member&#59; (ii) no &#8220;reportable event&#8221; (as defined under ERISA), other than an event for which the 30-day notice period is waived, has occurred or is reasonably expected to occur with respect to any &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates&#59; (iii) no &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would have any &#8220;amount of unfunded benefit liabilities&#8221; (as defined under ERISA)&#59; (iv) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a) Title IV of ERISA with respect to termination of, or withdrawal from, any &#8220;employee benefit plan&#8221; or (b) Sections 412, 4971, 4975 or 4980B of the Code&#59; and (v) each &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by action or failure to act, which would reasonably be expected to cause the loss of such qualification.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ag)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ah)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ai)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.37pt;text-decoration:underline">Anti-Corruption and Anti-Bribery Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity&#59; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office&#59; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law&#59; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit.  The Company and its subsidiaries and, to the knowledge of the Company, the Company&#8217;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(aj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.37pt;text-decoration:underline">Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ak)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Clinical Data and Regulatory Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The preclinical tests and clinical trials, and other studies (collectively, &#8220;studies&#8221;) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are, to the Company&#8217;s knowledge, being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">scientific standards for products or product candidates comparable to those being developed by the Company&#59; the descriptions of the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and the Company and its subsidiaries have no knowledge of any other studies the results of which reasonably call into question the results described or referred to in the Registration Statement or the Prospectus&#59; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) except where failure to do so would not result in a Material Adverse Change&#59; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration Statement or  the Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(al)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.37pt;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria&#59; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions.  For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(am)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.37pt;text-decoration:underline">Sarbanes-Oxley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(an)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Duties, Transfer Taxes, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No stamp or other issuance or transfer taxes or duties are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ao)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Cybersecurity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company&#8217;s and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, and databases (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IT </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are reasonably adequate for  the operation of the business of the Company and its subsidiaries as currently conducted. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, operation, redundancy and security of all IT Systems and data, including &#8220;Personal Data,&#8221; used in connection with their businesses.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) a natural person&#8217;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card number, or bank account information&#59; (ii) any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended&#59; (iii) &#8220;personal data&#8221; as defined by GDPR (as defined below)&#59; (iv) any information which would qualify as &#8220;protected health information&#8221; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. In the past three (3) years, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person under Privacy Laws (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ap)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Compliance with Data Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in material compliance with, the European Union General Data Protection Regulation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GDPR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (EU 2016&#47;679) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with the Company&#8217;s policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Company further certifies that neither it nor any subsidiary&#58; (i) has received written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws&#59; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any Privacy Law&#59; or (iii) is a party to any order, decree, or settlement agreement issued by a governmental authority that imposes any obligation or liability under any Privacy Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(aq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Other Underwriting Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not a party to any agreement with an agent or underwriter for any other &#8220;at the market&#8221; or continuous equity transaction.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ar)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.71pt;text-decoration:underline">Compliance with Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company and its subsidiaries are, and at all times have been, in compliance with all applicable Health Care Laws, except to the extent that any non-compliance would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public Health </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder&#59; (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare programs&#59; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.)&#59; (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010&#59; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies&#59; and (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof.  Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.  The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission).  Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.  Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">ISSUANCE AND SALE OF COMMON SHARES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Sale of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Mechanics of Issuances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions set forth in &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice&#59; provided, however, that (A) in no event may the Company deliver an Issuance Notice to the extent that (I) the sum of (x) the aggregate Sales Price of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount&#59; and (B) prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e mail to the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:21.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement.  For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both agree in writing to any such modification.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Method of Offer and Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Shares may be offered and sold (A) in negotiated transactions with the consent of the Company or (B) by any other method permitted by law deemed to be an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">at the market offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as defined in Rule 415(a)(4) under the Securities Act, including block transactions, sales made directly on the Principal Market or sales made into any other existing trading market of the Common Shares.  Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clause (A) above) the method of placement of any Shares by the Agent shall be at the Agent&#8217;s discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confirmation to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions of &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or its designee&#8217;s account at The Depository Trust Company through its Deposit&#47;Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date.  The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Time of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Suspension or Termination of Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period set forth in an Issuance Notice shall immediately terminate&#59; provided, however, that (A) such suspension and termination shall not affect or impair either party&#8217;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice&#59; (B) if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to such Shares&#59; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v) above, and may use the Shares to settle or close out such borrowings.  The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:15.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Guarantee of Placement, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in placing Shares&#59; (B) the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares&#59; and (C) the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:12.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Material Non-Public Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material non-public information.</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) by the Agent deducting the Selling Commission from the applicable Issuance Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs)&#59; (ii) all fees and expenses of the registrar and transfer agent of the Shares&#59; (iii) all necessary issue, transfer and other stamp taxes in connection with the original issuance of the Shares&#59; (iv) all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors&#59; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement&#59; (vi) all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and printing a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Blue Sky Survey</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or memorandum and a &#8220;Canadian wrapper&#8221;, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions&#59; (vii) the reasonable fees and disbursements of the Agent&#8217;s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#8217;s participation in the offering and distribution of the Shares&#59; (viii) the filing fees incident to FINRA review, if any&#59; (ix) the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with the road show&#59; and (x) the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#8217;s counsel pursuant to subsections (vi) and (vii) above shall not exceed (A) $50,000 in connection with execution of this Agreement and (B) $15,000 in connection with each Triggering Event Date (as defined below) on which the Company is required to provide a certificate pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">ADDITIONAL COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement&#58;</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Exchange Act Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Agency Period, the Company shall  file, on a timely basis, with the Commission all reports and documents required to be filed under Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act&#59; and  either  include in its quarterly reports on Form 10-Q and its annual reports on Form 10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to this Agreement and (2) the net proceeds received by the Company from such sales or, in the Company&#8217;s sole discretion,  prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interim Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such summary information and, at least once a quarter and subject to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Securities Act Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission&#59; (ii) of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, any Free Writing Prospectus&#59; (iii) of the time and date that any post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective&#59; and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.  If the Commission shall enter any such stop order at any time, the Company will use its commercially reasonable efforts to obtain the lifting of such order as soon as practicable.  Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Amendments and Supplements to the Prospectus and Other Securities Act Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with applicable law including the Securities Act.  Neither the Agent&#8217;s consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, the Company shall not be required to file such amendment or supplement if there is no pending Issuance Notice and the Company believes that it is in its best interest not to file such amendment or supplement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Agent&#8217;s Review of Proposed Amendments and Supplements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule 462(b) under the Securities Act), insofar as such proposed amendment or supplement relates to the Shares, or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent&#8217;s prior consent, and the Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Use of Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#8217;s prior written consent, any &#8220;written communication&#8221; that constitutes a &#8220;free writing prospectus&#8221; as such terms are defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Free Writing Prospectuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company insofar as such proposed amendment or supplement relates to the Shares or the transactions contemplated hereby, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Agent&#8217;s consent, which shall not be unreasonably withheld, conditioned or delayed.  The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus prepared by or on behalf of, or used by the Company insofar as such proposed amendment or supplement relates to the Shares or the transactions contemplated hereby, as the Agent may reasonably request.  If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be&#59; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Agent&#8217;s consent, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Filing of Agent Free Writing Prospectuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall not take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Copies of Registration Statement and Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  After the date of this Agreement through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment thereto, and with copies (which may be electronic copies) of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule 424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time&#59; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable)&#59; and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance&#59; provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Blue Sky Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares.  The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.  The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its commercially reasonable efforts to obtain the withdrawal thereof as soon as practicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Earnings Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act&#59; provided that the Company will be deemed to have furnished such statement to its security holders and the Agent to the extent such statement is filed with the Commission on EDGAR or any successor system.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Listing&#59; Reservation of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company will use commercially reasonable efforts to (a)  maintain the listing of the Shares on the Principal Market&#59; and (b) reserve and keep available at all times, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt;text-decoration:underline">Due Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and, upon reasonable notice, making available documents and senior corporate officers, during normal business hours and at the Company&#8217;s principal offices, as the Agent may reasonably request from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto)&#59; and (ii) an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Deliverables at Triggering Event Dates&#59; Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(a)(ii)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the filing with the Commission of an annual report on Form 10-K or a quarterly report on Form 10-Q (including any Form 10-K&#47;A or Form 10-Q&#47;A containing amended financial information or a material amendment to the previously filed annual report on Form 10-K or quarterly report on Form 10-Q), in each case, of the Company&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other than information &#8220;furnished&#8221; pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) that is material to the offering of securities of the Company in the Agent&#8217;s reasonable discretion&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(any such event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Triggering Event Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company shall furnish the Agent (but in the case of clause (C) above only if the Agent reasonably determines that the information contained in such current report on Form 8-K of the Company is material to a holder of Common Shares and informs the Company in writing of such determination) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A) confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B) confirming that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof, and (C) containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> dated as of the date that the instructions for the sale of Shares are issued.</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Legal Opinions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for which no waiver is applicable and excluding the date of this Agreement, a negative assurances letter and the written legal opinion of Vinson &#38; Elkins LLP, counsel to the Company, Brian T. Crum, Vice President and General Counsel of the Company and Max Bachrach, Ph.D., Vice President, Intellectual Property, of the Company, each dated the date of delivery, in form and substance reasonably satisfactory to Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event Date). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Comfort Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause Ernst &#38; Young LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel&#59; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus.  If requested by the Agent, the Company shall also cause a comfort letter to be furnished to the Agent within ten (10) Trading Days of the date of occurrence of any material transaction or event requiring the filing of a current report on Form 8-K containing material amended financial information of the Company, including the restatement of the Company&#8217;s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per each filing of an annual report on Form 10-K or a quarterly report on Form 10-Q. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Secretary&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i) certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii) certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii) containing any other certification that the Agent shall reasonably request.</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.36pt;text-decoration:underline">Agent&#8217;s Own Account&#59; Clients&#8217; Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#8217;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Investment Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Market Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.  If the limitations of Rule 102 of Regulation M (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d) of Rule 102.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Notice of Other Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, or effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice&#59; and will not directly or indirectly enter into any other &#8220;at the market&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement&#59; provided, however, that such restrictions will not be required in connection with the Company&#8217;s (i) issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii) issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii) issuance or sale of Common Shares or securities convertible into or exchangeable for Common Shares as consideration for mergers, </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">acquisitions, other business combinations, joint ventures or strategic alliances occurring after the date of this Agreement which are not used for capital raising purposes&#59; provided, that the aggregate number of Common Shares or securities convertible into or exchangeable for Common Shares issued in connection with all such acquisitions and other transactions does not exceed 5% of the aggregate number of Common Shares outstanding immediately following the offering of Shares pursuant to this Agreement and (vi) modification of any outstanding options, warrants of any rights to purchase or acquire Common Shares. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Accuracy of the Company&#8217;s Representations and Warranties&#59; Performance by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall have delivered the certificate required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> on or before the date on which delivery of such certificate is required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 4(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">No Injunction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Material Adverse Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change&#59; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating organization&#8221; as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">No Suspension of Trading in or Delisting of Common Shares&#59; Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall not have been delisted from the Nasdaq Stock Market, the New York Stock Exchange or any of their constituent markets.  There shall not have occurred (and be continuing in the case of occurrences under clauses (i) and (ii) below) any of the following&#58;  (i) trading or quotation in any of the Company&#8217;s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally on either the Principal Market shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or the FINRA&#59; (ii) a general banking moratorium shall have been declared by any of federal or New York, authorities&#59; or (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities. Additionally, the Company shall meet the then-applicable requirements for use of Form S-3 under the Securities Act, which, for the avoidance of doubt, will consist of the Registrant Requirements under General Instructions I. A of Form S-3 and one or more of the Transaction Requirements under General Instructions I.B of Form S-3 pursuant to which the Shares may be issued and sold.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Documents Required to be Delivered on each Issuance Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Agent&#8217;s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">No Misstatement or Material Omission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Agent shall not have advised the Company that the Registration Statement, the Prospectus or the Times of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s reasonable opinion is material, or omits to state a fact that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Agent Counsel Legal Opinion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Agent shall have received from Cooley LLP, counsel for Agent, such opinion or opinions, on or before the date on which the delivery of the Company counsel legal opinion is required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with respect to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they request for enabling them to pass upon such matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">INDEMNIFICATION AND CONTRIBUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Indemnification of the Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading and to reimburse the Agent and each such officer, employee and controlling person for any and all expenses (including the fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action&#59; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection (b) below.  The indemnity agreement set forth in this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be in addition to any liabilities that the Company may otherwise have.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Indemnification of the Company, its Directors and Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">circumstances under which they were made, not misleading&#59; but, for each of (i) and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information set forth in the first sentence of the ninth paragraph under the caption &#8220;Plan of Distribution&#8221; in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all reasonable and documented expenses (including the reasonable and documented fees and disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be in addition to any liabilities that the Agent or the Company may otherwise have.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Notifications and Other Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Promptly after receipt by an indemnified party under this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or to the extent it is not prejudiced as a proximate result of such failure.  In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party&#59; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and&#47;or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties.  Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for any reasonable and documented legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">indemnified party (in the case of counsel for the indemnified parties referred to in &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above), (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Settlements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The indemnifying party under this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment.  Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request&#59; and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the indemnification provided for in this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement&#59; or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.  The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent.  The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, any reasonable and documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.  The provisions set forth in &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; provided, however, that no additional notice shall be required with respect to any action for which notice has been given under &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for purposes of indemnification.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the provisions of this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Agent shall not be required to contribute any amount in excess of the Selling Commission received by the Agent in connection with the offering contemplated hereby.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.  For purposes of this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">TERMINATION &#38; SURVIVAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the provisions of this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the term of this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination&#59; Survival Following Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement, upon ten (10) Trading Days&#8217; notice to the other party&#59; provided that, (A) if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to such Shares and (B) &#8206;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive termination of this Agreement.  If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:21.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)In addition to the survival provision of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8206;Section 7(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Press Releases and Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may issue a press release describing the material terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form 8 K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (except  any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">No Advisory or Fiduciary Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company acknowledges and agrees that (i) the transactions contemplated by this Agreement, including the determination of any fees, are arm&#8217;s-length commercial transactions between the Company and the Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Agent and its affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (v) the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Research Analyst Independence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company acknowledges that the Agent&#8217;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">policies, and as such the Agent&#8217;s research analysts may hold views and make statements or investment recommendations and&#47;or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions.  The Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to the Agent&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jefferies LLC</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">520 Madison Avenue</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10022</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58;  (646) 786-5719</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  General Counsel</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy (which shall not constitute notice) to&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cooley LLP</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55 Hudson Yards</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10001</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Daniel I. Goldberg, Esq.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (212) 479-6275</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to the Company&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8800 Technology Forest Place </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Woodlands, Texas 77381</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Brian T. Crum</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; 281-863-8010</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy (which shall not constitute notice) to&#58;</font></div><div style="padding-left:18pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vinson &#38; Elkins LLP </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1001 Fannin Street, Suite 2500</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Houston, Texas 77002</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; David Oelman</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (713) 615-5861</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and in each case their respective successors, and no other person will have any right or obligation hereunder.  The term &#8220;successors&#8221; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Partial Unenforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof.  If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Governing Law Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.  Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Specified Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.  Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.  The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.  </font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.  This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.  The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</font></div><div style="text-align:center"><font><br></font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Immediately Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div><font><br></font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><div id="i3b817b0b453b457f968eb5350d154c3f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms</font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jeffrey L. Wade           </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58; Jeffrey L. Wade</font></div><div style="margin-bottom:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;   CFO &#38; EVP Corp &#38; Admin Affairs&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JEFFERIES LLC</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Dustin Tyner            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;  Dustin Tyner</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58; Managing Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i3b817b0b453b457f968eb5350d154c3f_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ISSUANCE NOTICE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jefferies LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">520 Madison Avenue</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York 10022</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; &#91;__________&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to the Open Market Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> between Lexicon Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Jefferies LLC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) dated as of October &#91;&#9679;&#93;,  2020.  The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Delivery of Issuance Notice (determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________________</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Issuance Amount (equal to the total Sales Price for such Shares)&#58;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of days in selling period&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First date of selling period&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Last date of selling period&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement Date(s) if other than standard T+2 settlement&#58;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&#8217;s sole discretion)&#58; $ ____ per share</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Comments&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;  </font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notice Parties</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Company</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Jeff Wade &#8211; Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer </font></div><div style="padding-left:0.36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Brian Crum &#8211; Vice President and General Counsel</font></div><div style="padding-left:0.36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Jim Tessmer &#8211; Vice President, Finance and Accounting</font></div><div style="padding-left:0.36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Agent</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Donald Lynaugh - Managing Director</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Michael Magarro - Managing Director</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Dustin Tyner - Managing Director</font></div><div style="padding-left:0.36pt"><font><br></font></div><div><font><br></font></div><div style="height:60.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>exh51veopinion10-30x20.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie99d03a6177343b49660abcf7d249fa8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vinson &#38; Elkins LLP Letterhead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 5.1</font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">October 30, 2020</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.730%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Lexicon Pharmaceuticals, Inc.<br>800 Technology Forest Place<br>The Woodlands, TX 77381<br></font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), with respect to certain legal matters in connection with the proposed issuance and sale from time to time by the Company of common stock, par value $0.001 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), having an aggregate offering price of up to $50,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), pursuant to that certain Open Market Sale Agreement, dated October 30, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Sales Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) between the Company and Jefferies LLC. We have participated in the preparation of a Prospectus Supplement dated October 30, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), forming part of the Registration Statement on Form S-3, effective as of November 18, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), that also contains a base prospectus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Base Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and, together with the Prospectus Supplement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). The Prospectus Supplement has been filed pursuant to Rule 424(b) promulgated under the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In rendering the opinions set forth below, we have examined and relied upon (i) the Registration Statement and the Prospectus&#59; (ii) the Amended and Restated Certificate of Incorporation of the Company, as amended to the date hereof&#59; (iii) the Second Amended and Restated Bylaws of the Company, as amended to the date hereof&#59; (iv) the Sales Agreement&#59; (v) resolutions of the Board of Directors of the Company dated October 23 and 24, 2019 and October 22, 2020&#59; and (vi) such other certificates and other instruments and documents as we consider appropriate for purposes of the opinions hereafter expressed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In connection with this opinion, we have assumed that all Shares will be issued and sold in the manner stated in the Prospectus and the Sales Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth below, we are of the opinion that the Shares, when issued and delivered against payment therefore in accordance with the Sales Agreement, will be validly issued, fully paid and non-assessable, except as described in the Registration Statement and the Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The opinions expressed herein are qualified in the following respects&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">A.    We have assumed that (i) each document submitted to us for review is accurate and complete, each such document that is an original is authentic, each such document that is a copy conforms to an authentic original and all signatures on each such document are genuine, and (ii) each certificate from governmental officials reviewed by us is accurate, complete and authentic, and all official public records are accurate and complete.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:14.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.456%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">B.    This opinion is limited in all respects to the federal laws of the United States, the Delaware General Corporation Law and the Constitution of the State of Delaware, as interpreted by the courts of the State of Delaware and of the United States. We are expressing no opinion as to the effect of the laws of any other jurisdiction.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Very truly yours,</font></div><div style="margin-bottom:12pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#47;s&#47; Vinson &#38; Elkins L.L.P.</font></div><div style="margin-bottom:12pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Vinson &#38; Elkins L.L.P.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exh311certificationofp.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i06b9e8177bed4a38bae499a8c5cde793_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lonnel Coats, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; October&#160;30, 2020 </font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:46.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exh312certificationofp.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ifed4a092e843472ca0d9049c146e4a69_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey L. Wade, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; October&#160;30, 2020 </font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:51.023%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exh321certificationofp.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="icc27dbcc1e754b93978fd39fe72f8fac_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Lexicon's Quarterly Report on Form 10-Q for the period ended September&#160;30, 2020, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 30th day of October, 2020.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:7.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:8.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President, Corporate and Administrative</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Affairs and Chief Financial Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lxrx-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b9120c05-2dcb-454d-ab13-af640022c996,g:c8810420-eb25-4487-a657-7c14820ab259-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNotes" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables">
        <link:definition>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
        <link:definition>2408405 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>2409406 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsLevel1Notes" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes">
        <link:definition>2110102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsDetails" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails">
        <link:definition>0402407 - Document - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSaleNotes" roleURI="http://www.lexpharma.com/role/AssetSaleNotes">
        <link:definition>2111103 - Disclosure - Asset Sale (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetSaleDetails" roleURI="http://www.lexpharma.com/role/AssetSaleDetails">
        <link:definition>2412408 - Disclosure - Asset Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>2113104 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>2314302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails1" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1">
        <link:definition>2415409 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails2" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2">
        <link:definition>2416410 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2117105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2318303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2419411 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2120106 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsTables">
        <link:definition>2321304 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails">
        <link:definition>2422412 - Disclosure - Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>2123107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2424413 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>2125108 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>2326305 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>2427414 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentLossonBuildings" roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildings">
        <link:definition>2128109 - Disclosure - Impairment Loss on Buildings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentLossonBuildingsTables" roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsTables">
        <link:definition>2329306 - Disclosure - Impairment Loss on Buildings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpairmentLossonBuildingsDetails" roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails">
        <link:definition>2430415 - Disclosure - Impairment Loss on Buildings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComprehensiveTextBlockListPolicies" roleURI="http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies">
        <link:definition>2231202 - Disclosure - Comprehensive Text Block List (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.lexpharma.com/role/EarningsPerShare">
        <link:definition>2132110 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.lexpharma.com/role/EarningsPerShareTables">
        <link:definition>2333307 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails">
        <link:definition>2434416 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesLineItems" abstract="true" name="AccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_AccruedCompensationAndBenefitsCurrent" abstract="false" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberCashPortion" abstract="false" name="ConvertibleDebtExchangeSeptemberCashPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMilestonePayment" abstract="false" name="IpsenMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SGASeveranceCostsMember" abstract="true" name="SGASeveranceCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lxrx_PrincipalAmountOfConvertibleNotes" abstract="false" name="PrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesTable" abstract="true" name="AccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Netproductrevenue" abstract="false" name="Netproductrevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_Sellinggeneralandadministrativeexpenses" abstract="false" name="Sellinggeneralandadministrativeexpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberSharePayment" abstract="false" name="ConvertibleDebtExchangeSeptemberSharePayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_Lxrx_sanofiInitialCashPayment" abstract="false" name="Lxrx_sanofiInitialCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" abstract="false" name="Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" abstract="false" name="MortgageDebtInterestRateBasePlus_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_LiabilitiesAssumedByTerSera" abstract="false" name="LiabilitiesAssumedByTerSera" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_BioPharmaMember" abstract="true" name="BioPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lxrx_XermeloPretaxNetLoss" abstract="false" name="XermeloPretaxNetLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" abstract="false" name="ConvertibleDebtExchangeTotalPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeRemainingNotes" abstract="false" name="ConvertibleDebtExchangeRemainingNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_AccruedResearchAndDevelopmentServicesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenTotalUpfrontPayments" abstract="false" name="IpsenTotalUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInstrument_Revere_LXRX" abstract="false" name="MortgageDebtInstrument_Revere_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_InventoryAbstract" abstract="true" name="InventoryAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenRoyaltyIncome_LXRX" abstract="false" name="IpsenRoyaltyIncome_LXRX" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AssetSalePrice" abstract="false" name="AssetSalePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_RDSeveranceCostsMember" abstract="true" name="RDSeveranceCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" abstract="true" name="ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" abstract="false" name="TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" abstract="false" name="IpsenMaximumRegulatoryAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchangeShares" abstract="false" name="FutureConvertibleDebtExchangeShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_IpsenTotalPayments" abstract="false" name="IpsenTotalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesDomain" abstract="true" name="AccruedLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesAxis" abstract="true" name="AccruedLiabilitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchange" abstract="false" name="ConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" abstract="false" name="MortgageDebtInterestRate_Base_Revere_LXRX" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="lxrx_SaleOfNonFinancialAssetsTextBlock" abstract="false" name="SaleOfNonFinancialAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_GainOnSaleOfNonFinancialAssets" abstract="false" name="GainOnSaleOfNonFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchange" abstract="false" name="FutureConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" abstract="false" name="IpsenRevenueAllocatedtoCommitteeDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount" abstract="false" name="ConvertibleDebtExchangeSeptemberPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedInterestOnConvertible" abstract="false" name="AccruedInterestOnConvertible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_MortgageDebtBalloonPayment_LXRX" abstract="false" name="MortgageDebtBalloonPayment_LXRX" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" abstract="false" name="IpsenRevenueAllocatedtoLicenseDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>lxrx-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b9120c05-2dcb-454d-ab13-af640022c996,g:c8810420-eb25-4487-a657-7c14820ab259-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e31f9334-9df0-4a6c-b208-158a30f6b365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1cf0b0b6-b205-42e1-93ef-26e37765d260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e31f9334-9df0-4a6c-b208-158a30f6b365" xlink:to="loc_us-gaap_AccountsPayableCurrent_1cf0b0b6-b205-42e1-93ef-26e37765d260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b3b11229-1dc9-4213-8581-017e58ecf7ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e31f9334-9df0-4a6c-b208-158a30f6b365" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b3b11229-1dc9-4213-8581-017e58ecf7ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_138102e9-963b-40bf-86fd-b960d28a60b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e31f9334-9df0-4a6c-b208-158a30f6b365" xlink:to="loc_us-gaap_LongTermDebtCurrent_138102e9-963b-40bf-86fd-b960d28a60b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ae82def-d7d8-4fa2-9b19-a75f74b4315f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eca19704-62df-4599-bd70-6c72ffd2a458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ae82def-d7d8-4fa2-9b19-a75f74b4315f" xlink:to="loc_us-gaap_PreferredStockValue_eca19704-62df-4599-bd70-6c72ffd2a458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_746c9e4e-c031-44c6-8945-afa083324adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ae82def-d7d8-4fa2-9b19-a75f74b4315f" xlink:to="loc_us-gaap_CommonStockValue_746c9e4e-c031-44c6-8945-afa083324adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c8612385-336b-4a45-88e2-3f93b81ee174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ae82def-d7d8-4fa2-9b19-a75f74b4315f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c8612385-336b-4a45-88e2-3f93b81ee174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baab470d-9ffe-41ee-ad23-c9a970bddd9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ae82def-d7d8-4fa2-9b19-a75f74b4315f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baab470d-9ffe-41ee-ad23-c9a970bddd9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_870323b7-6aa8-4d9b-894e-3613aa2813b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ae82def-d7d8-4fa2-9b19-a75f74b4315f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_870323b7-6aa8-4d9b-894e-3613aa2813b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e5fb5a1a-2431-4e7d-af2a-d56919ffe978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8ae82def-d7d8-4fa2-9b19-a75f74b4315f" xlink:to="loc_us-gaap_TreasuryStockValue_e5fb5a1a-2431-4e7d-af2a-d56919ffe978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a69c7bdf-e1b3-4aa7-9afa-f1c41fbc3aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e09e3605-7dcf-499d-9788-77207cdac455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a69c7bdf-e1b3-4aa7-9afa-f1c41fbc3aac" xlink:to="loc_us-gaap_LiabilitiesCurrent_e09e3605-7dcf-499d-9788-77207cdac455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2badcc42-db72-4198-8e76-ee86faf57827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a69c7bdf-e1b3-4aa7-9afa-f1c41fbc3aac" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2badcc42-db72-4198-8e76-ee86faf57827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_017680b0-b683-4fc5-bd71-1edb3f4d58d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a69c7bdf-e1b3-4aa7-9afa-f1c41fbc3aac" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_017680b0-b683-4fc5-bd71-1edb3f4d58d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_20c7f81f-08b0-497f-a5f7-7a90c3482a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52e15fd4-476e-4717-b705-f1f3402ccc0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_20c7f81f-08b0-497f-a5f7-7a90c3482a8c" xlink:to="loc_us-gaap_Liabilities_52e15fd4-476e-4717-b705-f1f3402ccc0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_75a3386d-875b-4d68-8534-b51fefc8a1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_20c7f81f-08b0-497f-a5f7-7a90c3482a8c" xlink:to="loc_us-gaap_StockholdersEquity_75a3386d-875b-4d68-8534-b51fefc8a1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_34b715f2-ad71-4181-b7e7-b95af6197056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7af8a823-3c4a-41b6-9f9d-51aeee9f20bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34b715f2-ad71-4181-b7e7-b95af6197056" xlink:to="loc_us-gaap_AssetsCurrent_7af8a823-3c4a-41b6-9f9d-51aeee9f20bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_64a2c1db-16c3-40aa-a1e5-d42981fa04a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34b715f2-ad71-4181-b7e7-b95af6197056" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_64a2c1db-16c3-40aa-a1e5-d42981fa04a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b9b6f1fa-f2a0-45ab-b118-5cab306545ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34b715f2-ad71-4181-b7e7-b95af6197056" xlink:to="loc_us-gaap_Goodwill_b9b6f1fa-f2a0-45ab-b118-5cab306545ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ecbb9ab4-89b2-4c84-b73a-7a2af2535f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34b715f2-ad71-4181-b7e7-b95af6197056" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ecbb9ab4-89b2-4c84-b73a-7a2af2535f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_10b1b849-4c1b-498a-9d24-69bcbd45572c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_34b715f2-ad71-4181-b7e7-b95af6197056" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_10b1b849-4c1b-498a-9d24-69bcbd45572c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e907e810-fee5-4e94-8d9c-b7a6563c5308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc995898-57b4-472f-ac43-554e3d49413a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e907e810-fee5-4e94-8d9c-b7a6563c5308" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc995898-57b4-472f-ac43-554e3d49413a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_096924db-3b46-40f4-9f4e-70eee96b53c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e907e810-fee5-4e94-8d9c-b7a6563c5308" xlink:to="loc_us-gaap_ShortTermInvestments_096924db-3b46-40f4-9f4e-70eee96b53c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc4adb20-c029-47c2-b896-0e89f030a69b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e907e810-fee5-4e94-8d9c-b7a6563c5308" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc4adb20-c029-47c2-b896-0e89f030a69b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_89f5d948-dd5b-4edc-8044-191d00f6dde3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e907e810-fee5-4e94-8d9c-b7a6563c5308" xlink:to="loc_us-gaap_InventoryNet_89f5d948-dd5b-4edc-8044-191d00f6dde3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_38aa71dd-b34f-48f5-9329-2417ec2549ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e907e810-fee5-4e94-8d9c-b7a6563c5308" xlink:to="loc_us-gaap_OtherAssetsCurrent_38aa71dd-b34f-48f5-9329-2417ec2549ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a6d3b484-9cf6-4a33-8e36-a5eb199e24e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f60bdda7-e019-40e6-ac3d-7e69ee7342e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a6d3b484-9cf6-4a33-8e36-a5eb199e24e0" xlink:to="loc_us-gaap_NetIncomeLoss_f60bdda7-e019-40e6-ac3d-7e69ee7342e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0ec52967-7050-4fb5-a0cd-58c1fdb18677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a6d3b484-9cf6-4a33-8e36-a5eb199e24e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0ec52967-7050-4fb5-a0cd-58c1fdb18677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1b496bff-c83c-42fc-a087-acc6ba35104a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c685cc2-98b1-4c6e-af6a-c2cf17987a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1b496bff-c83c-42fc-a087-acc6ba35104a" xlink:to="loc_us-gaap_Revenues_4c685cc2-98b1-4c6e-af6a-c2cf17987a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_63ac474e-37f0-472b-9c51-80d0b3a7539d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1b496bff-c83c-42fc-a087-acc6ba35104a" xlink:to="loc_us-gaap_OperatingExpenses_63ac474e-37f0-472b-9c51-80d0b3a7539d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_861c0b5c-6b3d-41ee-8002-e96591278987" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1b496bff-c83c-42fc-a087-acc6ba35104a" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_861c0b5c-6b3d-41ee-8002-e96591278987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c8bb1e50-a46b-409c-b842-ba692834edfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87ed174b-8604-40d3-8a54-9b35a4e41acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c8bb1e50-a46b-409c-b842-ba692834edfe" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87ed174b-8604-40d3-8a54-9b35a4e41acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6e75597f-f63c-4a58-b3fa-07f824fda89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c8bb1e50-a46b-409c-b842-ba692834edfe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6e75597f-f63c-4a58-b3fa-07f824fda89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_73ea350e-edc2-46ec-ac7a-217426177b01" xlink:href="lxrx-20200930.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c8bb1e50-a46b-409c-b842-ba692834edfe" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_73ea350e-edc2-46ec-ac7a-217426177b01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_922c30ba-c33e-493d-b7bb-9e95206c069d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c8bb1e50-a46b-409c-b842-ba692834edfe" xlink:to="loc_us-gaap_AssetImpairmentCharges_922c30ba-c33e-493d-b7bb-9e95206c069d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0503d3b0-965b-4271-ae10-661956ba5afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_e7f14a01-d4e0-4785-9ae6-7568a53fb27b" xlink:href="lxrx-20200930.xsd#lxrx_Netproductrevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0503d3b0-965b-4271-ae10-661956ba5afe" xlink:to="loc_lxrx_Netproductrevenue_e7f14a01-d4e0-4785-9ae6-7568a53fb27b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62b7b923-e331-4435-aaca-f3fa4ba5e208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0503d3b0-965b-4271-ae10-661956ba5afe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62b7b923-e331-4435-aaca-f3fa4ba5e208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_e97dcf38-1fae-448f-b149-6f35c5eef231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0503d3b0-965b-4271-ae10-661956ba5afe" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_e97dcf38-1fae-448f-b149-6f35c5eef231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87512272-765b-4ee7-a3c4-a19dd6b5524a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6b672178-1708-429d-96f4-02d2fb4e382e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b503f64d-d296-440f-b726-8cdd8279fb5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6b672178-1708-429d-96f4-02d2fb4e382e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b503f64d-d296-440f-b726-8cdd8279fb5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3513af72-3545-4c7e-b64c-e2d7c7d55774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6b672178-1708-429d-96f4-02d2fb4e382e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3513af72-3545-4c7e-b64c-e2d7c7d55774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_453bd123-a5a9-4654-bdd6-ea21a9f2b818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6b672178-1708-429d-96f4-02d2fb4e382e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_453bd123-a5a9-4654-bdd6-ea21a9f2b818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a696914d-eaa9-4c7a-bc78-82f3a8658d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_NetIncomeLoss_a696914d-eaa9-4c7a-bc78-82f3a8658d3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b7f5488a-6275-4096-8876-6b0bfa0b3bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b7f5488a-6275-4096-8876-6b0bfa0b3bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_999aab23-559d-41b5-a122-991996695e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_ShareBasedCompensation_999aab23-559d-41b5-a122-991996695e10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_91531389-99e4-44db-83e2-82c604fe540e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_91531389-99e4-44db-83e2-82c604fe540e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b1c325e-4620-4269-a4d6-be5b3cf9781b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7b1c325e-4620-4269-a4d6-be5b3cf9781b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cb452e71-3c8e-4b0f-82b3-15aae767411f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cb452e71-3c8e-4b0f-82b3-15aae767411f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aeb0fe40-ba49-41e7-9f71-23347d5f05ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aeb0fe40-ba49-41e7-9f71-23347d5f05ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aeffd266-1da3-4faf-9b0d-add3f9ebbfe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aeffd266-1da3-4faf-9b0d-add3f9ebbfe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2e3ef2bb-ebda-4e68-8e4f-6fd6d19333ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2e3ef2bb-ebda-4e68-8e4f-6fd6d19333ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_c8fcf7a7-05eb-499e-aa45-91bb42c80b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_c8fcf7a7-05eb-499e-aa45-91bb42c80b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_94a0a7be-df0a-4fd3-be9f-235bb718db29" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eaa46ccc-7c98-459d-8532-4c24c2e0f4cc" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_94a0a7be-df0a-4fd3-be9f-235bb718db29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54ee1930-86e0-486a-8e1f-ec2f186d7b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5cae4641-9c7b-4c84-b722-57c7913d2957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54ee1930-86e0-486a-8e1f-ec2f186d7b0f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5cae4641-9c7b-4c84-b722-57c7913d2957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_c1821e81-e742-4fb6-9ab6-c59db91964ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54ee1930-86e0-486a-8e1f-ec2f186d7b0f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_c1821e81-e742-4fb6-9ab6-c59db91964ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9d55f47e-7c56-4956-b630-a6f921e6c9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54ee1930-86e0-486a-8e1f-ec2f186d7b0f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9d55f47e-7c56-4956-b630-a6f921e6c9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_935c0a49-1148-4b2c-b0c5-c34e845a7e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54ee1930-86e0-486a-8e1f-ec2f186d7b0f" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_935c0a49-1148-4b2c-b0c5-c34e845a7e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5a6f67a-3817-4a01-b698-fb0dc40b6e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_30458295-5724-4e43-9f0b-c491bf98820e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5a6f67a-3817-4a01-b698-fb0dc40b6e14" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_30458295-5724-4e43-9f0b-c491bf98820e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_86149a2e-a378-4a40-96de-dadf8710a9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5a6f67a-3817-4a01-b698-fb0dc40b6e14" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_86149a2e-a378-4a40-96de-dadf8710a9d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#RecentAccountingPronouncementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleNotes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#AssetSaleNotes"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/AssetSaleNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#AssetSaleDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestments"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurementsDetails1"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligations"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligationsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildings" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildings"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildingsTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildingsDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ComprehensiveTextBlockListPolicies"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>lxrx-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b9120c05-2dcb-454d-ab13-af640022c996,g:c8810420-eb25-4487-a657-7c14820ab259-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended" id="i803e6b8a003f44dd8d1867ba27043c8d_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i5d8cb0f4361a4e5694b759340cc7e7bf_ConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b701bb35-911e-42b6-baa0-dac839060bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b701bb35-911e-42b6-baa0-dac839060bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_24a88dba-8b9d-4ecb-bf9c-27ffb667cb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_ShortTermInvestments_24a88dba-8b9d-4ecb-bf9c-27ffb667cb0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fdceb773-24f4-4e2c-b88a-d3fa99edbe2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fdceb773-24f4-4e2c-b88a-d3fa99edbe2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e742e3fe-a574-4fd7-9609-7b8b75b7b9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_InventoryNet_e742e3fe-a574-4fd7-9609-7b8b75b7b9ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0f1db1b3-9418-42e1-9db0-aebff8cb3b66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_OtherAssetsCurrent_0f1db1b3-9418-42e1-9db0-aebff8cb3b66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e0da45c8-fc5a-482c-bf18-fa5b2fbb6f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_AssetsCurrent_e0da45c8-fc5a-482c-bf18-fa5b2fbb6f14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27d4ea8a-c35b-439c-be00-c65d807e2ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_27d4ea8a-c35b-439c-be00-c65d807e2ffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab76e6e4-ed31-4fe7-980a-80345a0dc130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_Goodwill_ab76e6e4-ed31-4fe7-980a-80345a0dc130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c267683-3d42-4bb9-9187-0c6f838dcb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c267683-3d42-4bb9-9187-0c6f838dcb8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d43a18e7-be9e-49b1-819d-7fe996b1a96b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d43a18e7-be9e-49b1-819d-7fe996b1a96b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b439a5ba-8d25-48da-8cec-3fc41f699b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_Assets_b439a5ba-8d25-48da-8cec-3fc41f699b89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dbcfde7e-9a5f-4e0a-ada7-4993b6c22011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_AccountsPayableCurrent_dbcfde7e-9a5f-4e0a-ada7-4993b6c22011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_131e3608-f7b6-4f90-89b2-d496305382d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_131e3608-f7b6-4f90-89b2-d496305382d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b04e21b9-6a3e-493c-a61f-513ffad763bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_LongTermDebtCurrent_b04e21b9-6a3e-493c-a61f-513ffad763bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e1925dc4-bffc-4b1a-9606-515073d89480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_LiabilitiesCurrent_e1925dc4-bffc-4b1a-9606-515073d89480" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_824004d2-5590-4250-8f00-310e4d98a52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_824004d2-5590-4250-8f00-310e4d98a52f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c4d4262a-60cb-444b-bf3f-e56a5312c408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c4d4262a-60cb-444b-bf3f-e56a5312c408" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b8d3b48b-7a9e-4134-bdcb-80e501bff8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_Liabilities_b8d3b48b-7a9e-4134-bdcb-80e501bff8c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5e577080-e56e-40ba-98e3-5916beb228d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5e577080-e56e-40ba-98e3-5916beb228d7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_30161834-9d9f-4c90-a594-13d76ad394e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_PreferredStockValue_30161834-9d9f-4c90-a594-13d76ad394e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8c96af4e-3316-4bea-9cb0-629885554a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_CommonStockValue_8c96af4e-3316-4bea-9cb0-629885554a7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ea3a839e-6ae8-423f-b097-b118d1906065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ea3a839e-6ae8-423f-b097-b118d1906065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cdb85691-0734-4b68-8534-f348a7c26041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cdb85691-0734-4b68-8534-f348a7c26041" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9ae9e46a-fa54-4105-a7d1-b0b3ce93136e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9ae9e46a-fa54-4105-a7d1-b0b3ce93136e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d0b63475-f858-46dd-9887-733758470fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_TreasuryStockValue_d0b63475-f858-46dd-9887-733758470fcb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c7804a36-5302-467e-971b-423e52ba214f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_StockholdersEquity_c7804a36-5302-467e-971b-423e52ba214f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_89e88590-94bb-4c2c-a50d-d19b3d7f6f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_89e88590-94bb-4c2c-a50d-d19b3d7f6f6b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:to="loc_srt_StatementScenarioAxis_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7db7385c-79da-49b0-abd5-97a05c6c47c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7db7385c-79da-49b0-abd5-97a05c6c47c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8265f830-9316-4005-8de8-433992787db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8265f830-9316-4005-8de8-433992787db9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8265f830-9316-4005-8de8-433992787db9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8265f830-9316-4005-8de8-433992787db9" xlink:to="loc_us-gaap_ClassOfStockDomain_8265f830-9316-4005-8de8-433992787db9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0ab8d73d-0f14-4a8e-8aeb-1a82f7455abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8265f830-9316-4005-8de8-433992787db9" xlink:to="loc_us-gaap_ClassOfStockDomain_0ab8d73d-0f14-4a8e-8aeb-1a82f7455abc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended" id="ie3da3448572d4415a846f0516f2fa6d8_ConsolidatedBalanceSheetsParentheticals"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended" id="i0f37960e8373468e942942293b2bb879_ConsolidatedStatementsofComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_434373e2-efaa-4851-a19e-c9d5da677172" xlink:href="lxrx-20200930.xsd#lxrx_Netproductrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_lxrx_Netproductrevenue_434373e2-efaa-4851-a19e-c9d5da677172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8719f322-1b3f-4f64-af9c-a0fb55c5461f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8719f322-1b3f-4f64-af9c-a0fb55c5461f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_ee85d971-0084-428d-a1eb-ff7a452a2b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_ee85d971-0084-428d-a1eb-ff7a452a2b02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_68a3b695-6a4f-49aa-9383-ddcf95b22e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_us-gaap_Revenues_68a3b695-6a4f-49aa-9383-ddcf95b22e2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_efad347a-495d-40d7-a5d8-da5d4d32d74a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_efad347a-495d-40d7-a5d8-da5d4d32d74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_07e54b80-9aef-469d-afd9-df22fdd4bf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_07e54b80-9aef-469d-afd9-df22fdd4bf2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_ef2b445f-0779-4093-b6b6-6372ddfa16a8" xlink:href="lxrx-20200930.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_ef2b445f-0779-4093-b6b6-6372ddfa16a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e6cf4b13-63fe-4040-92ec-2aa1a51b0944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_AssetImpairmentCharges_e6cf4b13-63fe-4040-92ec-2aa1a51b0944" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e792c86e-3d82-4abc-9eed-e2a6bba00829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_OperatingExpenses_e792c86e-3d82-4abc-9eed-e2a6bba00829" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_5cdd807b-b352-4f49-bd2e-af777ede95da" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_5cdd807b-b352-4f49-bd2e-af777ede95da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79bbc0a6-4f3f-408f-b63f-4a4b450d1883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OperatingIncomeLoss_79bbc0a6-4f3f-408f-b63f-4a4b450d1883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_487efee0-86cd-40d0-bc91-f68b168f5784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_487efee0-86cd-40d0-bc91-f68b168f5784" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5f9cc374-0a2d-4b69-9dcc-527733ef8b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_InterestExpense_5f9cc374-0a2d-4b69-9dcc-527733ef8b23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_79e46a42-7e2b-481f-94ab-b1b71eeb9272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_79e46a42-7e2b-481f-94ab-b1b71eeb9272" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba7a3544-6093-434c-9a64-0e3a4f8390fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba7a3544-6093-434c-9a64-0e3a4f8390fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_77579bd4-434e-4768-85ef-68c368b473db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_77579bd4-434e-4768-85ef-68c368b473db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf0e9979-0055-4996-a8a3-0f607a26af2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_NetIncomeLoss_bf0e9979-0055-4996-a8a3-0f607a26af2b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_061759f8-2f52-4df0-87ae-584faf460cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_EarningsPerShareBasic_061759f8-2f52-4df0-87ae-584faf460cf3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4a20ed2c-2902-4ea0-b085-0447ac46af5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4a20ed2c-2902-4ea0-b085-0447ac46af5c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa684fe5-1f15-4bb5-8628-29a6ede9dc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa684fe5-1f15-4bb5-8628-29a6ede9dc3a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bb598f04-5788-4b0c-bead-d3a299e7c8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bb598f04-5788-4b0c-bead-d3a299e7c8fa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bcb5264-9f95-4146-b85c-4c6943360cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bcb5264-9f95-4146-b85c-4c6943360cb3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_33936aee-2dab-40b3-b672-12378f8c9a48" xlink:href="lxrx-20200930.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_33936aee-2dab-40b3-b672-12378f8c9a48" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0a58c4e9-54db-4142-ab1a-ff7576cf3db6" xlink:href="lxrx-20200930.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0a58c4e9-54db-4142-ab1a-ff7576cf3db6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_c08eb61a-05a1-41c7-bbe3-c46d50391610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_c08eb61a-05a1-41c7-bbe3-c46d50391610" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6ce923cd-7923-4d6a-b555-672cfdf82a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6ce923cd-7923-4d6a-b555-672cfdf82a86" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5fef88ce-43aa-4f2c-baf7-abe05d59288f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_StatementTable_5fef88ce-43aa-4f2c-baf7-abe05d59288f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_944f6ff8-5498-4691-b43b-8fa2f871d97d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5fef88ce-43aa-4f2c-baf7-abe05d59288f" xlink:to="loc_srt_StatementScenarioAxis_944f6ff8-5498-4691-b43b-8fa2f871d97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_944f6ff8-5498-4691-b43b-8fa2f871d97d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_944f6ff8-5498-4691-b43b-8fa2f871d97d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_944f6ff8-5498-4691-b43b-8fa2f871d97d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_490e1e76-11e0-476d-a2c9-75de4636be10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_944f6ff8-5498-4691-b43b-8fa2f871d97d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_490e1e76-11e0-476d-a2c9-75de4636be10" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended" id="id6346cfd3ec04418a264ab4ad2e7ec7f_ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="iabed17e8e05d47c7a2d8f8bc0a0fa8d9_ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f01176c6-4784-4657-9cd1-37986df6f21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_CommonStockSharesIssued_f01176c6-4784-4657-9cd1-37986df6f21d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f25c4248-33ae-4a53-a0b5-7918031853d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f25c4248-33ae-4a53-a0b5-7918031853d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9e41037f-8b7a-4b0d-b5e6-0481f3ef6533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9e41037f-8b7a-4b0d-b5e6-0481f3ef6533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e36dd79d-7d34-459a-b234-8f385ea4bf96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e36dd79d-7d34-459a-b234-8f385ea4bf96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_87615dfc-7d22-4f36-93bb-67455a3609d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_87615dfc-7d22-4f36-93bb-67455a3609d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2b2358c-74ef-45a5-80a1-00e62dad9407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2b2358c-74ef-45a5-80a1-00e62dad9407" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ecd05302-ec3a-4231-ae2d-60c58af717fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_NetIncomeLoss_ecd05302-ec3a-4231-ae2d-60c58af717fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_af4a84e7-85be-4392-91fc-da1509ba1f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_af4a84e7-85be-4392-91fc-da1509ba1f65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bc98067f-91bb-44f0-8734-480c316bd14e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7fa4d447-b348-4f00-a1e4-9f0c78ae9891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3e7c95a7-7f49-410e-88e1-e956a188fba0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:to="loc_srt_StatementScenarioAxis_3e7c95a7-7f49-410e-88e1-e956a188fba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3e7c95a7-7f49-410e-88e1-e956a188fba0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3e7c95a7-7f49-410e-88e1-e956a188fba0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3e7c95a7-7f49-410e-88e1-e956a188fba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4a97b20d-84ed-4757-a48c-1a500251e749" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3e7c95a7-7f49-410e-88e1-e956a188fba0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4a97b20d-84ed-4757-a48c-1a500251e749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ade0ea57-7ad3-4ce0-bdd6-889629c646ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ade0ea57-7ad3-4ce0-bdd6-889629c646ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ade0ea57-7ad3-4ce0-bdd6-889629c646ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ade0ea57-7ad3-4ce0-bdd6-889629c646ca" xlink:to="loc_us-gaap_EquityComponentDomain_ade0ea57-7ad3-4ce0-bdd6-889629c646ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ade0ea57-7ad3-4ce0-bdd6-889629c646ca" xlink:to="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a0fb6e3d-59d8-4d15-90cc-3949f1cba7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_CommonStockMember_a0fb6e3d-59d8-4d15-90cc-3949f1cba7b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_56aa85a7-a2c7-4894-b115-60b3d5bfd36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_56aa85a7-a2c7-4894-b115-60b3d5bfd36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cb5a48ec-029a-45f1-b65d-2cca4af1754f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_RetainedEarningsMember_cb5a48ec-029a-45f1-b65d-2cca4af1754f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4a4ca96-cad0-46db-bb10-6554fecb6e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4a4ca96-cad0-46db-bb10-6554fecb6e42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_7f1816b1-505d-4836-95d9-c0c4e6ed249d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_TreasuryStockMember_7f1816b1-505d-4836-95d9-c0c4e6ed249d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0964870c-d46c-41de-9efd-75726e76a303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0964870c-d46c-41de-9efd-75726e76a303" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0964870c-d46c-41de-9efd-75726e76a303_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0964870c-d46c-41de-9efd-75726e76a303" xlink:to="loc_us-gaap_ClassOfStockDomain_0964870c-d46c-41de-9efd-75726e76a303_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a041e1cd-22d1-40f2-8dbb-77dedc81cba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0964870c-d46c-41de-9efd-75726e76a303" xlink:to="loc_us-gaap_ClassOfStockDomain_a041e1cd-22d1-40f2-8dbb-77dedc81cba2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="iba972a2618534d15875a0cc9950c5138_ConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2b81200-3727-4933-8439-44b65c0e48e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:to="loc_us-gaap_NetIncomeLoss_c2b81200-3727-4933-8439-44b65c0e48e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e03324c8-37aa-45a5-98fd-f156abd108cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e03324c8-37aa-45a5-98fd-f156abd108cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2640155c-d63c-4f7d-a854-5d58fb267378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_ShareBasedCompensation_2640155c-d63c-4f7d-a854-5d58fb267378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c39805ce-2946-4c03-a244-40922ac83490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c39805ce-2946-4c03-a244-40922ac83490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f2d36530-8f54-46ac-a4be-fb445bf35665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f2d36530-8f54-46ac-a4be-fb445bf35665" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_9d0b2306-2f5f-4963-a424-e4beed89e96c" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_9d0b2306-2f5f-4963-a424-e4beed89e96c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_45319304-cf5e-42d1-8f5b-98448807b54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_AssetImpairmentCharges_45319304-cf5e-42d1-8f5b-98448807b54b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e19935cd-fd5b-433e-ba64-139d396c3067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e19935cd-fd5b-433e-ba64-139d396c3067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_817d6ee0-09c7-4173-902b-283767381776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_817d6ee0-09c7-4173-902b-283767381776" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3653100b-902d-4cbb-8bf0-966d2740a639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3653100b-902d-4cbb-8bf0-966d2740a639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de4d787a-ff23-4f7b-a897-41eeb16271c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de4d787a-ff23-4f7b-a897-41eeb16271c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_61055746-9fc3-4d19-84d8-28e9a313e47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_61055746-9fc3-4d19-84d8-28e9a313e47d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_421e0d85-453a-4e6e-a75b-52a9af5a2b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_421e0d85-453a-4e6e-a75b-52a9af5a2b9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4620ed31-e085-402b-9009-8bd0b4cb639f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4620ed31-e085-402b-9009-8bd0b4cb639f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c31652fd-f10e-4fd4-8ee7-5b292cd283f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c31652fd-f10e-4fd4-8ee7-5b292cd283f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_61ddfb9a-4032-406a-83f4-04eb53531471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_61ddfb9a-4032-406a-83f4-04eb53531471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8aaffff4-8c0d-4565-bb91-cf442d7baa54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8aaffff4-8c0d-4565-bb91-cf442d7baa54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4b1b3d64-82b5-41db-b73b-1ac7fc9843bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4b1b3d64-82b5-41db-b73b-1ac7fc9843bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac8f84f1-3f4d-4538-b8d1-d243669e5a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac8f84f1-3f4d-4538-b8d1-d243669e5a36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8dd8176d-917a-471a-a2b6-079b66282188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8dd8176d-917a-471a-a2b6-079b66282188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_79e6c776-a49f-428a-a014-783cdde883ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_79e6c776-a49f-428a-a014-783cdde883ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c726c521-ac81-4360-8009-02a923a288ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c726c521-ac81-4360-8009-02a923a288ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb4bc4c9-857e-4fbb-a529-32990086cf58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb4bc4c9-857e-4fbb-a529-32990086cf58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_079590e6-7134-48eb-8c56-f5e55f80a28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_079590e6-7134-48eb-8c56-f5e55f80a28d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7b43eeb-20a3-4c12-9575-d05258fe17a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_df5e8b9c-0ae9-41fc-a134-451ddc9b6455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:to="loc_us-gaap_InterestPaidNet_df5e8b9c-0ae9-41fc-a134-451ddc9b6455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera_c7316b26-7c64-4b08-b8e4-0b8998ee9f39" xlink:href="lxrx-20200930.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:to="loc_lxrx_LiabilitiesAssumedByTerSera_c7316b26-7c64-4b08-b8e4-0b8998ee9f39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a61707f8-d7d1-4906-9910-80ccbc6cb2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a61707f8-d7d1-4906-9910-80ccbc6cb2bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_9833518e-f5d0-49d9-b7b9-76900ac55cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_9833518e-f5d0-49d9-b7b9-76900ac55cda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5886f434-6e8f-4fd3-806d-618854bb69dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5886f434-6e8f-4fd3-806d-618854bb69dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70800449-8737-4451-891d-190466b02778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70800449-8737-4451-891d-190466b02778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_70800449-8737-4451-891d-190466b02778_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70800449-8737-4451-891d-190466b02778" xlink:to="loc_us-gaap_EquityComponentDomain_70800449-8737-4451-891d-190466b02778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_29880ae2-04e7-43ca-a4a4-fb1fd8b8a955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70800449-8737-4451-891d-190466b02778" xlink:to="loc_us-gaap_EquityComponentDomain_29880ae2-04e7-43ca-a4a4-fb1fd8b8a955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9a927be3-ca18-4ffc-a18e-043e74e44034" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:to="loc_srt_StatementScenarioAxis_9a927be3-ca18-4ffc-a18e-043e74e44034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9a927be3-ca18-4ffc-a18e-043e74e44034_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9a927be3-ca18-4ffc-a18e-043e74e44034" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9a927be3-ca18-4ffc-a18e-043e74e44034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_79300054-f7e6-4b0b-869d-b779d19472e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9a927be3-ca18-4ffc-a18e-043e74e44034" xlink:to="loc_srt_ScenarioUnspecifiedDomain_79300054-f7e6-4b0b-869d-b779d19472e1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended" id="ia9ad36c3644448478821d02134834669_SummaryofSignificantAccountingPoliciesNotes"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i4aed66e0a641488c9c57684c7bea3f03_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended" id="i9d1ca708b50f4516b8149b4238dfa1a6_SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" id="iab10b7dd4f534e5c968b6b1127987113_SummaryofSignificantAccountingPoliciesInventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_2e809705-107d-4db6-b0ae-3f019e0fdf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_InventoryRawMaterials_2e809705-107d-4db6-b0ae-3f019e0fdf3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_9ce93afe-288a-40fd-9a9e-0f95aaa30e36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_InventoryFinishedGoods_9ce93afe-288a-40fd-9a9e-0f95aaa30e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_ee0c39f3-00da-4df6-afdd-eb246d714c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_InventoryWorkInProcess_ee0c39f3-00da-4df6-afdd-eb246d714c7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4ab01633-587a-4411-a60b-b3879d6dd6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4ab01633-587a-4411-a60b-b3879d6dd6ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_3c109fe1-a5a0-4f36-a1bc-374c52add47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_InventoryCurrentTable_3c109fe1-a5a0-4f36-a1bc-374c52add47d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_21bf6ed9-5238-4f0d-92aa-06ed628a1836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_3c109fe1-a5a0-4f36-a1bc-374c52add47d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_21bf6ed9-5238-4f0d-92aa-06ed628a1836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_21bf6ed9-5238-4f0d-92aa-06ed628a1836_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_21bf6ed9-5238-4f0d-92aa-06ed628a1836" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_21bf6ed9-5238-4f0d-92aa-06ed628a1836_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_77be632c-85fc-4719-a286-52c8e7d84c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_21bf6ed9-5238-4f0d-92aa-06ed628a1836" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_77be632c-85fc-4719-a286-52c8e7d84c1c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended" id="i45fe0bc85937499eb35e0eb11943b653_SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_675a1dc2-6297-406f-ada1-76d1689ac66f" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_675a1dc2-6297-406f-ada1-76d1689ac66f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_e0299a03-8e36-4987-a2be-be882033f41b" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_e0299a03-8e36-4987-a2be-be882033f41b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_5f1dd2a2-df9e-4783-bf61-5155f8c6aaf5" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_5f1dd2a2-df9e-4783-bf61-5155f8c6aaf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_129bf153-f4dc-4da5-aeba-7aa754f494f9" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_129bf153-f4dc-4da5-aeba-7aa754f494f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_48979847-22ec-4dc0-8519-f7a465e1e8f3" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_48979847-22ec-4dc0-8519-f7a465e1e8f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_ec1e6766-4efb-48ed-9323-8de3cc9b4f36" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_ec1e6766-4efb-48ed-9323-8de3cc9b4f36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_48e91d59-42d9-483e-bd71-c7eb5228dbb9" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_48e91d59-42d9-483e-bd71-c7eb5228dbb9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_1c7f9b94-f2c8-4035-8153-cb3dc8b06376" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_1c7f9b94-f2c8-4035-8153-cb3dc8b06376" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a097acef-18fe-475f-a989-7cbaeaec30c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_PlanNameAxis_a097acef-18fe-475f-a989-7cbaeaec30c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a097acef-18fe-475f-a989-7cbaeaec30c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a097acef-18fe-475f-a989-7cbaeaec30c4" xlink:to="loc_us-gaap_PlanNameDomain_a097acef-18fe-475f-a989-7cbaeaec30c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_82338ea1-8390-43df-b453-8d84a9db5cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a097acef-18fe-475f-a989-7cbaeaec30c4" xlink:to="loc_us-gaap_PlanNameDomain_82338ea1-8390-43df-b453-8d84a9db5cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_4fff338c-a337-4998-863b-ceb6ded15669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_AwardDateAxis_4fff338c-a337-4998-863b-ceb6ded15669" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_4fff338c-a337-4998-863b-ceb6ded15669_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_4fff338c-a337-4998-863b-ceb6ded15669" xlink:to="loc_us-gaap_AwardDateDomain_4fff338c-a337-4998-863b-ceb6ded15669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_26ece069-988b-4004-92e2-541dbd32175b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_4fff338c-a337-4998-863b-ceb6ded15669" xlink:to="loc_us-gaap_AwardDateDomain_26ece069-988b-4004-92e2-541dbd32175b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97153b40-9232-4beb-bd5a-9e064b1bcefc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_AwardTypeAxis_97153b40-9232-4beb-bd5a-9e064b1bcefc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97153b40-9232-4beb-bd5a-9e064b1bcefc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_97153b40-9232-4beb-bd5a-9e064b1bcefc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97153b40-9232-4beb-bd5a-9e064b1bcefc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_940e2b81-c8f4-4f16-9a19-c1bb9983b225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_97153b40-9232-4beb-bd5a-9e064b1bcefc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_940e2b81-c8f4-4f16-9a19-c1bb9983b225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_5f9e1579-3b98-4b93-b39b-f5f92b0de419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_940e2b81-c8f4-4f16-9a19-c1bb9983b225" xlink:to="loc_us-gaap_StockOptionMember_5f9e1579-3b98-4b93-b39b-f5f92b0de419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df" xlink:to="loc_us-gaap_ClassOfStockDomain_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69c655f9-ce86-4575-b0f8-aa457d38a267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df" xlink:to="loc_us-gaap_ClassOfStockDomain_69c655f9-ce86-4575-b0f8-aa457d38a267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77195c0f-ae05-470a-ad21-d98ca4a96ce1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_srt_RangeAxis_77195c0f-ae05-470a-ad21-d98ca4a96ce1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77195c0f-ae05-470a-ad21-d98ca4a96ce1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77195c0f-ae05-470a-ad21-d98ca4a96ce1" xlink:to="loc_srt_RangeMember_77195c0f-ae05-470a-ad21-d98ca4a96ce1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ded3802-2181-4472-83fb-57d38ba62f42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77195c0f-ae05-470a-ad21-d98ca4a96ce1" xlink:to="loc_srt_RangeMember_1ded3802-2181-4472-83fb-57d38ba62f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0522bb23-62e9-40e3-aa7a-777d4532c1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_VestingAxis_0522bb23-62e9-40e3-aa7a-777d4532c1ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0522bb23-62e9-40e3-aa7a-777d4532c1ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_0522bb23-62e9-40e3-aa7a-777d4532c1ef" xlink:to="loc_us-gaap_VestingDomain_0522bb23-62e9-40e3-aa7a-777d4532c1ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_809f2477-1d32-4767-8bbb-69710b76dba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_0522bb23-62e9-40e3-aa7a-777d4532c1ef" xlink:to="loc_us-gaap_VestingDomain_809f2477-1d32-4767-8bbb-69710b76dba0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended" id="ic4f3f9fcde0c418ca24621341e6ce8e9_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d24d2f68-8f6c-4fb3-a5a3-979095d0c824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d24d2f68-8f6c-4fb3-a5a3-979095d0c824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20a2773d-79ee-4c78-ad05-2778230ce315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20a2773d-79ee-4c78-ad05-2778230ce315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_75853f12-fb49-4967-9458-cd8443203367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_75853f12-fb49-4967-9458-cd8443203367" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_351c7143-40cb-40ee-8156-e2387cd2e6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_351c7143-40cb-40ee-8156-e2387cd2e6ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_778c8ab4-9f43-44c5-b360-17f0ceee9c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_778c8ab4-9f43-44c5-b360-17f0ceee9c6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_11793b29-c5ac-4ff8-8eee-ad1187434bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_11793b29-c5ac-4ff8-8eee-ad1187434bd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_94b1ed03-8def-4ae7-8273-ff2876a6ae17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_94b1ed03-8def-4ae7-8273-ff2876a6ae17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6fa54418-48aa-4091-80aa-cfa14f3b279c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6fa54418-48aa-4091-80aa-cfa14f3b279c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e90a7534-bab8-4374-9403-7d808a4607e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e90a7534-bab8-4374-9403-7d808a4607e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61f0141b-f265-48a6-a965-ef483723d79d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61f0141b-f265-48a6-a965-ef483723d79d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc664d32-6abd-4930-9df8-7f5a209fc972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc664d32-6abd-4930-9df8-7f5a209fc972" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c94c59e-74b2-475f-8b79-d0d905500ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c94c59e-74b2-475f-8b79-d0d905500ae0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_03e11768-b21e-4f4f-a502-9a0bfcdcf095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_03e11768-b21e-4f4f-a502-9a0bfcdcf095" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd0ad112-aa3e-4e91-8ded-0b8db8ac01bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd0ad112-aa3e-4e91-8ded-0b8db8ac01bb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_993e095a-9de5-4e05-935a-e4d68f9bdcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_993e095a-9de5-4e05-935a-e4d68f9bdcd6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff2a6189-41a2-4d78-9c09-d88b4a84cb5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff2a6189-41a2-4d78-9c09-d88b4a84cb5c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6f775536-cd97-4968-85f6-fc35d06bc07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6f775536-cd97-4968-85f6-fc35d06bc07c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6dcd987f-54f6-4b96-8b73-27c8b2dde4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6dcd987f-54f6-4b96-8b73-27c8b2dde4ec" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_PlanNameAxis_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0" xlink:to="loc_us-gaap_PlanNameDomain_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_af554f1d-5fe8-4d8d-9b6c-ec00f8b06da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0" xlink:to="loc_us-gaap_PlanNameDomain_af554f1d-5fe8-4d8d-9b6c-ec00f8b06da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_3466d636-aadc-4328-a105-bee2c325d4c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_AwardDateAxis_3466d636-aadc-4328-a105-bee2c325d4c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_3466d636-aadc-4328-a105-bee2c325d4c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_3466d636-aadc-4328-a105-bee2c325d4c7" xlink:to="loc_us-gaap_AwardDateDomain_3466d636-aadc-4328-a105-bee2c325d4c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_75b09875-aff0-4218-9610-f49109a4e1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_3466d636-aadc-4328-a105-bee2c325d4c7" xlink:to="loc_us-gaap_AwardDateDomain_75b09875-aff0-4218-9610-f49109a4e1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c0d38e2-0d3a-418e-9681-5c9160c9d262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_AwardTypeAxis_7c0d38e2-0d3a-418e-9681-5c9160c9d262" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c0d38e2-0d3a-418e-9681-5c9160c9d262_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c0d38e2-0d3a-418e-9681-5c9160c9d262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c0d38e2-0d3a-418e-9681-5c9160c9d262_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c0d38e2-0d3a-418e-9681-5c9160c9d262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15e559b3-63da-4ee9-a10a-f5e955900315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15e559b3-63da-4ee9-a10a-f5e955900315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9a9bd377-ae6e-48f7-b0dc-9cddaed45393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9a9bd377-ae6e-48f7-b0dc-9cddaed45393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db29367f-38fb-4f9f-a483-ea7c4dfa15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db29367f-38fb-4f9f-a483-ea7c4dfa15e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_db29367f-38fb-4f9f-a483-ea7c4dfa15e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db29367f-38fb-4f9f-a483-ea7c4dfa15e6" xlink:to="loc_us-gaap_ClassOfStockDomain_db29367f-38fb-4f9f-a483-ea7c4dfa15e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac03a5d4-5650-4468-9cb5-42ad84553b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db29367f-38fb-4f9f-a483-ea7c4dfa15e6" xlink:to="loc_us-gaap_ClassOfStockDomain_ac03a5d4-5650-4468-9cb5-42ad84553b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_21b697aa-1e9a-4805-92f5-07fc509ccc3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_srt_RangeAxis_21b697aa-1e9a-4805-92f5-07fc509ccc3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_21b697aa-1e9a-4805-92f5-07fc509ccc3f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_21b697aa-1e9a-4805-92f5-07fc509ccc3f" xlink:to="loc_srt_RangeMember_21b697aa-1e9a-4805-92f5-07fc509ccc3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b27e667f-7fa9-42d3-a156-477807bd3b91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_21b697aa-1e9a-4805-92f5-07fc509ccc3f" xlink:to="loc_srt_RangeMember_b27e667f-7fa9-42d3-a156-477807bd3b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_VestingAxis_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac" xlink:to="loc_us-gaap_VestingDomain_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_43bdea9e-2214-41e9-939a-b86f33162d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac" xlink:to="loc_us-gaap_VestingDomain_43bdea9e-2214-41e9-939a-b86f33162d46" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended" id="ieb06aef358bb4c2ebec3e51e3dde7477_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839bc157-14d9-40b9-8f7e-58d79b80ef44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839bc157-14d9-40b9-8f7e-58d79b80ef44" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_af8502d2-df08-4a28-98c0-e77c4c7bf8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_us-gaap_PlanNameAxis_af8502d2-df08-4a28-98c0-e77c4c7bf8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_af8502d2-df08-4a28-98c0-e77c4c7bf8f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_af8502d2-df08-4a28-98c0-e77c4c7bf8f5" xlink:to="loc_us-gaap_PlanNameDomain_af8502d2-df08-4a28-98c0-e77c4c7bf8f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_94b4e2c2-b85f-4fbc-a6c5-e5207dcb6020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_af8502d2-df08-4a28-98c0-e77c4c7bf8f5" xlink:to="loc_us-gaap_PlanNameDomain_94b4e2c2-b85f-4fbc-a6c5-e5207dcb6020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ecdb796-d717-4866-920d-516347486535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_us-gaap_AwardTypeAxis_9ecdb796-d717-4866-920d-516347486535" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ecdb796-d717-4866-920d-516347486535_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9ecdb796-d717-4866-920d-516347486535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ecdb796-d717-4866-920d-516347486535_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c58581f-0609-40d9-9a34-e09b91fd4b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9ecdb796-d717-4866-920d-516347486535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c58581f-0609-40d9-9a34-e09b91fd4b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e932603d-befd-423e-a05a-829585866de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e932603d-befd-423e-a05a-829585866de4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e932603d-befd-423e-a05a-829585866de4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e932603d-befd-423e-a05a-829585866de4" xlink:to="loc_us-gaap_ClassOfStockDomain_e932603d-befd-423e-a05a-829585866de4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79f17016-49fa-47df-9a0c-09ad699eee30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e932603d-befd-423e-a05a-829585866de4" xlink:to="loc_us-gaap_ClassOfStockDomain_79f17016-49fa-47df-9a0c-09ad699eee30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_408aa1bd-0f96-4e54-b104-02554400905f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_srt_RangeAxis_408aa1bd-0f96-4e54-b104-02554400905f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_408aa1bd-0f96-4e54-b104-02554400905f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_408aa1bd-0f96-4e54-b104-02554400905f" xlink:to="loc_srt_RangeMember_408aa1bd-0f96-4e54-b104-02554400905f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aae9c4f8-626b-42bc-a14c-f3903a892a21" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_408aa1bd-0f96-4e54-b104-02554400905f" xlink:to="loc_srt_RangeMember_aae9c4f8-626b-42bc-a14c-f3903a892a21" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended" id="ie6f7d43ea418488cbcd9fd9914baf570_SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_9b260e9c-ca4a-47b2-963f-522b383eedb9" xlink:href="lxrx-20200930.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_9b260e9c-ca4a-47b2-963f-522b383eedb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_f2135aa3-a765-42ef-a78f-330d6c9e75e9" xlink:href="lxrx-20200930.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_f2135aa3-a765-42ef-a78f-330d6c9e75e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cb989945-1f73-4d0b-b178-a6dc31ac2e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cb989945-1f73-4d0b-b178-a6dc31ac2e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4d6d987a-75c2-496e-b3b6-bf8e2bbddd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4d6d987a-75c2-496e-b3b6-bf8e2bbddd4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5e332f19-18b3-48fb-a41f-0922cf29b30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5e332f19-18b3-48fb-a41f-0922cf29b30a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_d1123c49-c11d-463f-b0a2-76736e5f2625" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_lxrx_AccruedLiabilitiesTable_d1123c49-c11d-463f-b0a2-76736e5f2625" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_6b84df51-14fe-40bf-ac3d-7a9c63989083" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lxrx_AccruedLiabilitiesTable_d1123c49-c11d-463f-b0a2-76736e5f2625" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_6b84df51-14fe-40bf-ac3d-7a9c63989083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_6b84df51-14fe-40bf-ac3d-7a9c63989083_default" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_6b84df51-14fe-40bf-ac3d-7a9c63989083" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_6b84df51-14fe-40bf-ac3d-7a9c63989083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_9befc763-7239-46dd-8ddf-7976ea34d8af" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_6b84df51-14fe-40bf-ac3d-7a9c63989083" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_9befc763-7239-46dd-8ddf-7976ea34d8af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" id="ie971df4598aa46a9942f1f40f505eb78_SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended" id="i2ec88eb8c73545c28f305cb54567444f_RecentAccountingPronouncementsLevel1Notes"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#RecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended" id="i16e40df4218c418a9ef412e88a48a72e_RecentAccountingPronouncementsDetails"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleNotes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#AssetSaleNotes"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/AssetSaleNotes" xlink:type="extended" id="ic02d2bea32f548b4859d14a8e0d933cb_AssetSaleNotes"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#AssetSaleDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="extended" id="i67cd017d4b9443e1983d06f9bf9ae668_AssetSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5504e054-dad0-401a-9c4c-1051a9f4f8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5504e054-dad0-401a-9c4c-1051a9f4f8ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7179a24f-c76e-49ce-82aa-2df813b21db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:to="loc_us-gaap_SeveranceCosts1_7179a24f-c76e-49ce-82aa-2df813b21db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:to="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_5f640dc9-fc48-4b0f-afee-d75210b4e850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_5f640dc9-fc48-4b0f-afee-d75210b4e850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_5f640dc9-fc48-4b0f-afee-d75210b4e850_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_5f640dc9-fc48-4b0f-afee-d75210b4e850" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_5f640dc9-fc48-4b0f-afee-d75210b4e850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b8d1650d-579c-4c78-8168-9ab0fd5d76d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_5f640dc9-fc48-4b0f-afee-d75210b4e850" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b8d1650d-579c-4c78-8168-9ab0fd5d76d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BioPharmaMember_3e177a76-c6c7-477e-b0d0-15055069f42e" xlink:href="lxrx-20200930.xsd#lxrx_BioPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b8d1650d-579c-4c78-8168-9ab0fd5d76d5" xlink:to="loc_lxrx_BioPharmaMember_3e177a76-c6c7-477e-b0d0-15055069f42e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b6458ce4-a32f-40b4-9465-69786d77e3a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:to="loc_srt_StatementScenarioAxis_b6458ce4-a32f-40b4-9465-69786d77e3a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b6458ce4-a32f-40b4-9465-69786d77e3a2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b6458ce4-a32f-40b4-9465-69786d77e3a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b6458ce4-a32f-40b4-9465-69786d77e3a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_25a03991-9eaa-46a3-823a-5edc9f23f1d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b6458ce4-a32f-40b4-9465-69786d77e3a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_25a03991-9eaa-46a3-823a-5edc9f23f1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_27064a18-80b3-4d7b-be21-3a6ac6b78874" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_25a03991-9eaa-46a3-823a-5edc9f23f1d4" xlink:to="loc_srt_ScenarioForecastMember_27064a18-80b3-4d7b-be21-3a6ac6b78874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember_44faf3b6-9c5a-458d-85d3-7da918e6e955" xlink:href="lxrx-20200930.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:to="loc_lxrx_RDSeveranceCostsMember_44faf3b6-9c5a-458d-85d3-7da918e6e955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SGASeveranceCostsMember_1d785382-cd76-4607-9ae8-a69a67f7efa5" xlink:href="lxrx-20200930.xsd#lxrx_SGASeveranceCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:to="loc_lxrx_SGASeveranceCostsMember_1d785382-cd76-4607-9ae8-a69a67f7efa5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestments"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended" id="i150aedc75c074c60a3c976dcd745295b_CashandCashEquivalentsandInvestments"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended" id="i01ae009bceaa46b3bf84265abeab32eb_CashandCashEquivalentsandInvestmentsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended" id="id9d6e45387de4d2396207534d5b203c6_CashandCashEquivalentsandInvestmentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_a9e1f538-d1af-4645-b2ce-5f4be182ac47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_a9e1f538-d1af-4645-b2ce-5f4be182ac47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5fa8e221-ee22-42e2-99a9-ac99e48ea761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5fa8e221-ee22-42e2-99a9-ac99e48ea761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29f83663-841a-4c1d-bff0-1720dda0b5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29f83663-841a-4c1d-bff0-1720dda0b5e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_01d3034a-2d41-4c59-b35d-8323f0f88937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_01d3034a-2d41-4c59-b35d-8323f0f88937" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_4bf5e4ca-a30d-4298-9ee9-bd7071117f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_4bf5e4ca-a30d-4298-9ee9-bd7071117f20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d3c005fc-6617-4339-9a28-010d1fa6f820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_4bf5e4ca-a30d-4298-9ee9-bd7071117f20" xlink:to="loc_us-gaap_InvestmentTypeAxis_d3c005fc-6617-4339-9a28-010d1fa6f820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d3c005fc-6617-4339-9a28-010d1fa6f820_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_d3c005fc-6617-4339-9a28-010d1fa6f820" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d3c005fc-6617-4339-9a28-010d1fa6f820_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_d3c005fc-6617-4339-9a28-010d1fa6f820" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_8766feae-c927-4d62-b852-9196c9dfc63a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_CashMember_8766feae-c927-4d62-b852-9196c9dfc63a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_93d22b58-2e2b-45ff-b021-0f1172690c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_93d22b58-2e2b-45ff-b021-0f1172690c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_e498e002-c64e-417d-96a3-2db4708a548a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_e498e002-c64e-417d-96a3-2db4708a548a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_1ea531ea-5229-455a-a851-a22b740c8868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_InvestmentsMember_1ea531ea-5229-455a-a851-a22b740c8868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2d5eca5a-0ac1-4682-99a2-222a5dc69d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2d5eca5a-0ac1-4682-99a2-222a5dc69d73" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended" id="i4fcc2306ba0c4227a0735d98ed0e8789_CashandCashEquivalentsandInvestmentsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_56aa812c-ee01-401f-b2b7-65081e65e15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_74395092-9f46-47b2-a573-c4f4616d9dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_56aa812c-ee01-401f-b2b7-65081e65e15f" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_74395092-9f46-47b2-a573-c4f4616d9dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_d4c0385b-9c80-435d-a6b5-e7610f25cba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_56aa812c-ee01-401f-b2b7-65081e65e15f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_d4c0385b-9c80-435d-a6b5-e7610f25cba6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_2ffbc766-d580-440a-93c7-c8eba58e8b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_d4c0385b-9c80-435d-a6b5-e7610f25cba6" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_2ffbc766-d580-440a-93c7-c8eba58e8b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_2ffbc766-d580-440a-93c7-c8eba58e8b06_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_2ffbc766-d580-440a-93c7-c8eba58e8b06" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_2ffbc766-d580-440a-93c7-c8eba58e8b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_2e641a09-64b5-4b41-bb71-55bc5516a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_2ffbc766-d580-440a-93c7-c8eba58e8b06" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_2e641a09-64b5-4b41-bb71-55bc5516a9fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended" id="i6197833a0bb74852a897ab23c034df1f_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i2e53957ebc45401f97ccc50465e07db1_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="ib0fe2078d9984f98adba01d4ffab3c79_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_04fe263d-c85b-4e79-ade6-7d2231b726c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_04fe263d-c85b-4e79-ade6-7d2231b726c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_039e3daa-4562-4da0-bd3a-1b45b4db68f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_039e3daa-4562-4da0-bd3a-1b45b4db68f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_57d9cc54-bda1-4714-89ad-5b566765e82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_57d9cc54-bda1-4714-89ad-5b566765e82f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_49b01283-37d2-4bff-9934-cec365679de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_49b01283-37d2-4bff-9934-cec365679de7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_49b01283-37d2-4bff-9934-cec365679de7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bcacf46a-c126-4a12-a968-923c46028eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bcacf46a-c126-4a12-a968-923c46028eaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c6144f5a-2bf7-4f2d-8a5c-46d4026db629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c6144f5a-2bf7-4f2d-8a5c-46d4026db629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e2449e1e-49cb-4f48-8904-d54b0d8442f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e2449e1e-49cb-4f48-8904-d54b0d8442f9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligations"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended" id="i15b44e094eec48408253b5b23391d308_DebtObligations"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligationsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended" id="ifbc9ab4ab693434ea0318033b811aca2_DebtObligationsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended" id="i2c294f2fa24943a996c457158cb274ba_DebtObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d3bd5905-9719-4303-8415-5a7572aa44e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d3bd5905-9719-4303-8415-5a7572aa44e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_69581f9c-0577-4b7c-a887-5a952055d7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_69581f9c-0577-4b7c-a887-5a952055d7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_ae4f87d9-d4f7-4504-923c-0c3fd9781f40" xlink:href="lxrx-20200930.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_ae4f87d9-d4f7-4504-923c-0c3fd9781f40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c0d885d-8f06-438c-9b12-14133944eb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c0d885d-8f06-438c-9b12-14133944eb2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b8fc5a5f-0cef-4c38-bf16-89bb6185a221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b8fc5a5f-0cef-4c38-bf16-89bb6185a221" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_c2d7de8a-6b7d-4a8e-bde1-cd91afd6cb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_c2d7de8a-6b7d-4a8e-bde1-cd91afd6cb65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_360122ee-5f70-4051-9c77-c1ccdee83079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_360122ee-5f70-4051-9c77-c1ccdee83079" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_25e27949-297e-446c-a2f0-a78129956b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_25e27949-297e-446c-a2f0-a78129956b04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_3965ddca-0b80-48be-877f-6ae9169b11b2" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_3965ddca-0b80-48be-877f-6ae9169b11b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_89b2a004-be50-4aaf-afd6-6e7e3ae75ab7" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_89b2a004-be50-4aaf-afd6-6e7e3ae75ab7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_774114de-0249-400c-a568-4a2c6fc89ee2" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_774114de-0249-400c-a568-4a2c6fc89ee2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_73f3bb59-bda3-464d-9161-90eb0aa7397a" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_73f3bb59-bda3-464d-9161-90eb0aa7397a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_650be34a-438e-4a78-8982-ddadf4914a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_650be34a-438e-4a78-8982-ddadf4914a8a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c336af03-e344-4754-ad35-1808f2799bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c336af03-e344-4754-ad35-1808f2799bae" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b6613d12-7fc6-4be1-b595-73aec4465e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_b6613d12-7fc6-4be1-b595-73aec4465e8f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_534d25bf-ab7b-4001-8363-3478322d846e" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchange_534d25bf-ab7b-4001-8363-3478322d846e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_841af6b3-55f1-4534-a304-f4c6f1250735" xlink:href="lxrx-20200930.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_AccruedInterestOnConvertible_841af6b3-55f1-4534-a304-f4c6f1250735" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a68c17f-53fe-487b-8d7d-cb64a216c78d" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a68c17f-53fe-487b-8d7d-cb64a216c78d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_83e7dc5c-4dc7-4f20-b701-8a5b818b1e78" xlink:href="lxrx-20200930.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_83e7dc5c-4dc7-4f20-b701-8a5b818b1e78" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_209f33cc-a7f9-4162-84a8-769a38997491" xlink:href="lxrx-20200930.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_209f33cc-a7f9-4162-84a8-769a38997491" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_33e07875-b6cf-44ef-bc74-76617ebcc9ff" xlink:href="lxrx-20200930.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_33e07875-b6cf-44ef-bc74-76617ebcc9ff" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_d8da276d-0285-4f7c-965a-d900cff44462" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_d8da276d-0285-4f7c-965a-d900cff44462" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount_7a70d4af-76b7-4f50-8538-f08cb97a4faf" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount_7a70d4af-76b7-4f50-8538-f08cb97a4faf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_0163f877-6192-4f6a-ba28-8385953f44ae" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_0163f877-6192-4f6a-ba28-8385953f44ae" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_b1d59009-a7a0-4db0-9ce5-6d43402c2794" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_b1d59009-a7a0-4db0-9ce5-6d43402c2794" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_24d303f5-77a0-4f23-995e-c305cffc20c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_24d303f5-77a0-4f23-995e-c305cffc20c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_24d303f5-77a0-4f23-995e-c305cffc20c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_24d303f5-77a0-4f23-995e-c305cffc20c6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_24d303f5-77a0-4f23-995e-c305cffc20c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c1fbc8e5-44b5-4a7a-960d-1f4fabe5255c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_24d303f5-77a0-4f23-995e-c305cffc20c6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c1fbc8e5-44b5-4a7a-960d-1f4fabe5255c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a05b251e-f43f-4109-acf1-33b62cfbbc9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c1fbc8e5-44b5-4a7a-960d-1f4fabe5255c" xlink:to="loc_us-gaap_SubsequentEventMember_a05b251e-f43f-4109-acf1-33b62cfbbc9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ec4b0f3d-5264-42a9-9a12-75f672f479f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ec4b0f3d-5264-42a9-9a12-75f672f479f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ec4b0f3d-5264-42a9-9a12-75f672f479f3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ec4b0f3d-5264-42a9-9a12-75f672f479f3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ec4b0f3d-5264-42a9-9a12-75f672f479f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ad927d3-789d-485c-ab35-3cb02e7714cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ec4b0f3d-5264-42a9-9a12-75f672f479f3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ad927d3-789d-485c-ab35-3cb02e7714cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_782616ba-4be3-4165-a6ec-bb78cc66d75a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_782616ba-4be3-4165-a6ec-bb78cc66d75a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_782616ba-4be3-4165-a6ec-bb78cc66d75a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_782616ba-4be3-4165-a6ec-bb78cc66d75a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_782616ba-4be3-4165-a6ec-bb78cc66d75a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe32d339-8504-4adb-a0f7-7fcd822403f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_782616ba-4be3-4165-a6ec-bb78cc66d75a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe32d339-8504-4adb-a0f7-7fcd822403f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended" id="i6287da98d62b4a27991df1c2824f896a_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i3a81853545c14e63b070ecb291ae11e6_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f13b1ffd-347b-4d8e-bf87-bae56892f5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d344b168-3b55-43ae-b7e2-704d6d909bec" xlink:href="lxrx-20200930.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f13b1ffd-347b-4d8e-bf87-bae56892f5e4" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d344b168-3b55-43ae-b7e2-704d6d909bec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_0f382649-46e4-463a-89e5-d35ab17adc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f13b1ffd-347b-4d8e-bf87-bae56892f5e4" xlink:to="loc_us-gaap_OtherCommitmentsTable_0f382649-46e4-463a-89e5-d35ab17adc7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86977555-1675-431c-8f95-74eed3f5cf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_0f382649-46e4-463a-89e5-d35ab17adc7a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86977555-1675-431c-8f95-74eed3f5cf6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_86977555-1675-431c-8f95-74eed3f5cf6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86977555-1675-431c-8f95-74eed3f5cf6f" xlink:to="loc_us-gaap_ReceivableTypeDomain_86977555-1675-431c-8f95-74eed3f5cf6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4512042b-e53e-4154-ad59-9aa594cb7844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86977555-1675-431c-8f95-74eed3f5cf6f" xlink:to="loc_us-gaap_ReceivableTypeDomain_4512042b-e53e-4154-ad59-9aa594cb7844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_17fb03a6-bdeb-439f-af67-5fd24d8c5cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_4512042b-e53e-4154-ad59-9aa594cb7844" xlink:to="loc_us-gaap_AccountsReceivableMember_17fb03a6-bdeb-439f-af67-5fd24d8c5cc8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended" id="i45b747c45ba6464ab818b40ee6c5b976_CollaborationandLicenseAgreements"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended" id="i55f24c2c4cf04c658a555b83026d4234_CollaborationandLicenseAgreementsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended" id="i87787c6b1c7143f58cbbce2d027b1a6c_CollaborationandLicenseAgreementsDetails"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildings" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildings"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildings" xlink:type="extended" id="ib57b2cc898814fc2b1ead45352cf4d5e_ImpairmentLossonBuildings"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildingsTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildingsTables" xlink:type="extended" id="id3738024e11c466ebef35ee1757f322f_ImpairmentLossonBuildingsTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildingsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails" xlink:type="extended" id="ie442698a41b546a09e2db109ee310369_ImpairmentLossonBuildingsDetails"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ComprehensiveTextBlockListPolicies"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies" xlink:type="extended" id="i95de3c395db844a3a49070160fe412f1_ComprehensiveTextBlockListPolicies"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended" id="i4bb9ba0127784baba20b299f9303a9d7_EarningsPerShare"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended" id="i5f4351d3fd8e4c7cade776231941c8ef_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended" id="i4c3996eafed142bba3593d4ae5118c37_EarningsPerShareDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lxrx-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b9120c05-2dcb-454d-ab13-af640022c996,g:c8810420-eb25-4487-a657-7c14820ab259-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7f7af92-2ff4-496c-b650-dee89831ae75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_24c51a7c-7e1f-4bb3-ba08-fca6eaeb4526_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_68f91126-c44d-4627-8123-b01c1d2cd4af_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_378ee69c-f9f1-4f80-8ab7-81e68ca38dc7_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchange" xlink:to="lab_lxrx_ConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3120b244-6730-4cde-8ef5-839f3223e65f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_44da8918-8184-4359-9505-23e8e10ba2c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_de5884ba-0d24-4256-bff1-d4c21460e089_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_139d7aa8-74f7-40e7-9e83-90dbeeb5b8da_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_5964325e-5e56-484a-a2ed-73210747d3d7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8d617888-da70-477b-916b-8ac1a58f6876_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_33f0c082-b39a-4955-9fa4-570ddef78b19_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:href="lxrx-20200930.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:to="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_e3164a8b-3323-4867-9e8d-656407760f2b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_32a428e4-7c58-426e-9a44-73ae3c9125a3_terseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_1d39a87d-b7af-46e5-a224-4273a1e37e63_negatedTerseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_label_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_documentation_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:to="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c64869e0-de02-4696-b104-7d9fb1f9d1d8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_8d5a3849-aa6f-41a0-84b1-5046f922258e_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SGASeveranceCostsMember_e9d7a463-e020-4384-8aa5-e6bc99d2797c_terseLabel_en-US" xlink:label="lab_lxrx_SGASeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SG&amp;A severance costs [Member]</link:label>
    <link:label id="lab_lxrx_SGASeveranceCostsMember_label_en-US" xlink:label="lab_lxrx_SGASeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SG&amp;A severance costs [Member]</link:label>
    <link:label id="lab_lxrx_SGASeveranceCostsMember_documentation_en-US" xlink:label="lab_lxrx_SGASeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SG&amp;A severance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SGASeveranceCostsMember" xlink:href="lxrx-20200930.xsd#lxrx_SGASeveranceCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SGASeveranceCostsMember" xlink:to="lab_lxrx_SGASeveranceCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e17e1792-fcd9-44f2-8991-4d8a8f89f083_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8b926784-b5a0-4183-8d96-23999e7503cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d504bc45-7729-44a2-8b63-be8a10f5de60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_854b8034-7feb-4bc9-b8b0-11a338fe1ee0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_193dcf38-919f-4ff4-b690-be348325a571_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_7538e8c3-9e93-489b-b43a-cc6c7ba2e58c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b10e20d2-d6cb-4021-a734-78f8bd96a564_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcc64286-462d-4885-aae3-f01b8fe66d2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_157db92c-2eb8-4c04-be6a-c90cfba479f0_terseLabel_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_label_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_documentation_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:href="lxrx-20200930.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:to="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3be446d3-1ff3-440c-82fc-ca1613b7c58a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_18a3aadb-8842-44e4-a325-b29672540f86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9c2c0cc4-bc95-44ac-8f23-468d68d865c5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_594bde90-5b42-4d1a-b799-fa3fd8a9daf6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9ce51217-964f-44a5-9cce-afabb39b7e56_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8378ca6c-de09-4c46-bdb4-f2ab552ec2b1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1d099cb8-c5b5-4549-9858-2103764dfc81_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ca69625f-6b86-4015-89a1-0bea608386e6_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7d9d977b-0ad6-4ceb-a00e-97c52f1b7f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_223acdcf-33a8-4445-ba0a-8e1f667235fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_8b1fd778-76c2-4109-a183-3c068715cee0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_211247f1-2de5-478c-a7cd-8726929ffbca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_a1a5577c-44d6-4c18-a194-59c6779cf4e5_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4f18902a-0388-4516-b700-449f87aba5aa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_721b444f-b179-480a-b612-5981ecc43e7c_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_126fa3ed-31ca-430f-a3e2-ca77fee7b3df_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_9742a5a6-915a-40ca-aafd-95e43ba749a5_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_382c768f-8f7d-4411-8ad5-1b46e5b1dbd1_terseLabel_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses, included stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_label_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_documentation_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:href="lxrx-20200930.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:to="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_06c3bc44-2c45-4be4-99f0-c0180b9a0e89_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_5c1a16f2-f6ff-4398-a544-222c03496b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5f6bfeb5-0939-44d5-96d9-b9c95f4615e5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_752c00f5-3268-4953-a83c-3cbf793d00e5_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9744aee0-e229-465e-befe-a25fd0983f17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_043dd1f6-088b-43c1-841f-2ba47a4a3d2c_terseLabel_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_label_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current - due within 1 year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:href="lxrx-20200930.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:to="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_4f7b496b-9964-4c91-8b5d-cca462d030e7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_088c4cde-3e46-4dae-8b0d-82ef1877719d_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_bbf44f58-cdee-4ba2-af97-6b09e9921aa9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_cf6fd09a-cc9d-4865-990e-106b80960222_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_be622e2b-ae18-4185-8252-6018a1bcfcd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_25eadabe-f9e9-408c-840a-cd6b02a4c3fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_67479049-7552-42e7-82f9-037e18b57487_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fc58f07b-5721-417a-849b-4fa3b9e93919_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_50d9647b-c883-45c3-8fba-6c003e46376c_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_e8e82b77-345c-458f-99a7-e31e40d23d04_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6acfffd7-4251-4ed9-8d9e-7b7eb437dd6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_348d54ca-d4f7-4b22-bf8c-103c616dad15_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange" xlink:href="lxrx-20200930.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchange" xlink:to="lab_lxrx_FutureConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_9d7c890e-e06e-40ec-b167-c8e17c0b9b19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_ff294310-9bdf-4b66-9a1b-26e4815b3333_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0076828d-2651-4b59-9022-426226793e79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_55e22b3e-c67c-4e00-88ae-c52d91a13a94_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_1230990e-90c7-44e5-942b-0203b208a855_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesAxis" xlink:to="lab_lxrx_AccruedLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bbba04c6-233c-4a03-88f2-88e6f2b17dba_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_447a0630-2cbe-45b0-aab1-8378c3c57f96_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:to="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_152ae7c6-768d-407e-b4d8-1c2ef08b8178_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_6116d8c4-07d0-4567-9d75-2c38f9d68f0e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_81f95360-74a1-4cb4-a2d9-8fb009704c09_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ccc641fd-e9e2-4b68-ad19-0087f410e71e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_112ca4f0-109d-4939-9dbf-b7a10d1a4c42_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_7c4df4ea-258e-4569-9ba8-52524d9d3b7e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_0236533d-462a-4f3f-8333-16afed898650_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_78d8c459-01e4-45ad-9cfb-762390c6494d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d0b5eeea-961f-4be1-bdae-ab6d49e220cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_3cc10864-23a3-4d16-b993-054c64750920_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_a5d66ad2-35ad-43a2-b09d-6861b160cbc9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_276016d9-e895-407b-840a-4a6a8d6103be_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InventoryAbstract_fe855288-08cd-4d85-b4b5-d88a339da026_terseLabel_en-US" xlink:label="lab_lxrx_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_lxrx_InventoryAbstract_label_en-US" xlink:label="lab_lxrx_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_lxrx_InventoryAbstract_documentation_en-US" xlink:label="lab_lxrx_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InventoryAbstract" xlink:href="lxrx-20200930.xsd#lxrx_InventoryAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InventoryAbstract" xlink:to="lab_lxrx_InventoryAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_42672679-19cd-4332-93e5-cfeefa3c839e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_6559b409-814c-4968-a80e-c9d4ee8c312a_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d8b5e7ec-2514-4b9d-a4ef-6428ba4be66f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c29c55eb-b42b-4e34-8307-eb61d4b3fc83_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6ce78123-9add-45ed-9aec-f8df7e121569_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ffeb9897-ce14-473b-a47a-32cc75a15ae7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_655dfc09-b5b7-4874-bfc2-f2026873a1fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_9f7355e9-d62a-4ebd-8fac-c7942c4609d2_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to License Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_332ca0c6-fa7a-4998-8d61-236b30221dab_terseLabel_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_label_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_documentation_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_fda8b7d2-a13b-4819-81d4-f606031cfd78_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesDomain" xlink:to="lab_lxrx_AccruedLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_77bdcfd5-d311-4f0a-be93-34094f2ca2b2_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20200930.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_90e2d205-482e-49b9-9931-9c2d472b1b2d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_30f38b57-50dc-4c14-9119-a1bda9000b3d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0974cb99-56bd-413a-9ce6-10a00fbe4369_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_a47954da-46ad-4e9f-86ee-577a01009022_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_830939ea-8b32-46da-9d98-08bb24ce9521_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fac5d324-36a4-4cd7-bed9-0fde20fc3312_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_99be1145-3edf-48d5-b072-fc5520cbd2fd_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e94bffc6-7efc-4cde-8eaa-9f71a1215615_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43a7647c-fdf6-4fe5-9942-abd50dc71630_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_dded773e-aa6d-403b-93d7-65e25ea46d37_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_865f161f-07ba-4c29-bb20-3660bd05cd31_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_95cc3f42-6330-495b-b826-699b74221116_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e0b2665c-0265-4971-8443-1ec8767f6b9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_d438a46e-ee5f-47fb-9d6e-a3b70f334a84_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_06e40e48-e13f-4ba0-8e1a-953343c9596c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_182aa160-8efb-4503-8692-25b6f2411a91_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0e97de2c-231f-43a9-8942-fc264aeae250_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_156b0ae2-c9b5-4641-9792-ec8415a56eb2_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_1ca1e725-93ab-49fc-a784-46b3c0f0efb5_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5597e84a-c79a-4954-95f2-4e0b0c3d920a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2cbdd499-8784-4640-b523-5db5c2c53535_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePayment_fd3b103b-6407-4511-aa40-b18fe55cb9b6_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePayment" xlink:to="lab_lxrx_IpsenMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e35aa4ce-00ba-41bb-9020-ae48bb9e333b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_13557e2a-4a89-4ac2-a4e9-8d90573c8882_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f89f875e-516a-463d-9e30-381a0d06536f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_d017502b-7d34-4ebc-a850-9066bafb9176_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_83cbf5db-1774-4e38-97e9-01170f7fd270_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_7f41c4a2-d3e5-4d41-b061-d0454bccfbd3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5bb81b06-4922-4688-beb9-7585af2c599c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_bdc5d7fe-7a1f-4d57-a9f3-556c53f8bb6b_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_877c03e7-e788-4a64-a9fe-7d832d2d9869_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_51ec62a9-4dd0-4ef5-b1f0-18a73700b4de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_61514a15-d037-4af7-9013-6cb54b8db399_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3cc2553-3ab0-46fb-b011-ac5f23800f86_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_29e473d7-2eea-4b06-81ae-cb2ab6ad8b63_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_78e36736-db95-4b81-8e18-3e953ac5b0c0_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d26b49a3-6278-401f-a23c-60c8c26a4db8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_5b1d7454-4c67-478c-84bf-c302abcaf362_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="lab_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_2087fa4e-e4d6-46f0-9427-468b23c4355e_terseLabel_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:label id="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TerSera Maximum Development, Regulatory and Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:href="lxrx-20200930.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ed71e06b-573a-4273-9b0d-06d948a939ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.001 par value; 225,000 shares authorized; 117,231 and 106,679 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5af393a1-fb69-4cad-8e18-aabdb3c003b2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7a2225bf-3f04-4552-a850-e179e9208036_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_54b52d78-3805-48ea-a197-eb6ae33fb195_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:to="lab_us-gaap_AssetRetirementObligationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_5c715866-a51d-4765-aa89-c27c633c50a1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfRealEstate_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfRealEstate" xlink:to="lab_us-gaap_ImpairmentOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_013be1e6-5db6-48bf-9ce2-55067f2d0b9f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f1b41a63-f28f-4995-a927-e57e94ee8d6a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_736645dd-547a-41cd-a079-a108ec897da8_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6264b101-6e26-4fa0-a5e1-9e289ced2b1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_29a1f8f7-1367-45e3-983b-d655cbfc0b27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_d1c91d67-f389-43f0-a3fc-5dfd805f88d8_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_b38439ef-80ad-40af-b551-45145a22b029_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_90a5e482-e18f-4ecd-aa88-3f0b333eff66_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b77ba92d-580f-460b-ad95-a8167b6c888e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_87c6bb28-41cd-4017-a71c-1c4c489792e3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a4c0f6f6-e803-4270-a23d-5e133eb9d7d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_599694f3-6cc7-4780-a57d-ff3ee1ad37fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_308a2e8e-f8e1-4998-9b4c-95e6ef4f53d7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_600b30e7-447b-4e4a-a438-3eddc20097af_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeDomain" xlink:to="lab_us-gaap_TradingActivityByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4ce84f8d-942f-40f5-a600-83fa2b88d35d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a21bffae-eb42-4066-990f-31d769ccfe92_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ee7cc2f0-ee30-45ca-ad35-0721414159f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e5d404c3-728e-4873-9fb2-0d3abefc16e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c727ebe0-3787-4a12-bd89-80851aa9a10b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_38fb38af-f73e-445c-b3d1-533c08daf03d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_07837aba-a3fe-466d-a56e-e61ff2416a43_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_03302a98-2b42-4c90-b239-6a803f13b52f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_afe09384-3e00-4924-8587-b8bd08cbefb9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_f1aad80e-80a8-4b2f-818e-cfbca2724faa_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_927a2ba0-cdac-4d9f-87ee-18093064eedb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_cfda5350-12f1-4566-8477-951ada88b467_terseLabel_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_label_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_documentation_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:href="lxrx-20200930.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:to="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b984b0e1-9b58-4e38-af9a-66fd75794fce_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_35798b4e-70f1-42d4-9e91-aced768cd78a_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6205ecba-c855-4aa6-84a8-44caa6360654_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_XermeloPretaxNetLoss_8f5784fb-dbda-476a-a239-bcbfdbdb7dd5_terseLabel_en-US" xlink:label="lab_lxrx_XermeloPretaxNetLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xermelo Pretax Net Loss</link:label>
    <link:label id="lab_lxrx_XermeloPretaxNetLoss_label_en-US" xlink:label="lab_lxrx_XermeloPretaxNetLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xermelo Pretax Net Loss</link:label>
    <link:label id="lab_lxrx_XermeloPretaxNetLoss_documentation_en-US" xlink:label="lab_lxrx_XermeloPretaxNetLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xermelo Pretax Net Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_XermeloPretaxNetLoss" xlink:href="lxrx-20200930.xsd#lxrx_XermeloPretaxNetLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_XermeloPretaxNetLoss" xlink:to="lab_lxrx_XermeloPretaxNetLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3f86b694-39f0-4055-88ac-9fd74121a701_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_384d8068-1daa-435a-8236-87cfb616688a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e746d31c-192d-410b-b1e6-c94873903e15_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholder's equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_678bc057-b199-4d5c-b5e8-6e62f76fb440_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8d23d063-f10c-4986-b860-4006795871af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_a4c35204-5138-45c5-8004-850f60df01af_terseLabel_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets</link:label>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_label_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets [Text Block]</link:label>
    <link:label id="lab_lxrx_SaleOfNonFinancialAssetsTextBlock_documentation_en-US" xlink:label="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Non-Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:href="lxrx-20200930.xsd#lxrx_SaleOfNonFinancialAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:to="lab_lxrx_SaleOfNonFinancialAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8f8c92e7-4197-4941-9c44-9198a6456880_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90f2acf5-be93-4010-ad12-37d385acf362_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_70864a8e-c32a-43d3-99bb-e552fd9ff9a5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f30ffa5f-c695-4b48-b53d-8caaf8d2f71b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba0b7fb7-15e7-4add-87e9-d879468b50bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_65ce2fa0-a74e-4f3f-9aed-af40d8dcaa68_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5e9a7a4-d039-45d9-b096-01e2ad20b0eb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_29278272-9946-477f-b5b7-46d18518565d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_fe087396-1f2a-4802-98fe-2c1fae158e58_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:to="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b6f40efb-20eb-475a-8815-5cd96307507d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPayments_517e3631-8322-4de0-beb2-e7b7ab2b5d44_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments" xlink:href="lxrx-20200930.xsd#lxrx_IpsenTotalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPayments" xlink:to="lab_lxrx_IpsenTotalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a7192585-30ab-4969-a7b9-f8c9d4699967_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_30c744e3-53bb-4360-92ef-d2f22dedbef7_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_58a165c2-20ac-4d91-81a2-c95825399c4b_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_5bd64c97-ee96-4f07-bc52-464919aaa39f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d14a9725-5edc-4a4a-88fb-331bb5e9e29d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3f8f2fa6-0c66-4905-acc1-fd63686edbda_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $63,795 and $61,741, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_32c2a130-40ee-457a-8667-d0b16c3c8c37_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8593b90b-4b82-4588-807d-b73be7df096e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ebd3a8cf-45a0-4557-a693-e9117db39de9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_64bbd363-4603-47cb-981a-4be660ca7fc8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e392b802-e318-404e-aeee-ca0b33f7731b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_6e6bb296-ecdd-4ca4-a84e-455f1784a6af_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0434a893-c42a-4548-8bf4-6ee7443b3460_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6882de46-f035-439e-b743-377388b2b9ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8cb2c990-720a-4ab6-bffe-9127cebc3393_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_7cc90866-9903-497c-ae5f-d6f23caa5f04_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_39653157-28be-4898-92ae-8916d99af2a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_30a1e97d-50f9-4674-8aa7-fe63513a9ee3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d097ebcd-7bef-4aca-9d24-acd96789a60d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount_5a43c1f0-59fb-4fdd-ae17-cb3f8aae96e9_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September principal amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September principal amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September principal amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4ec0ffc7-5912-4e37-933d-4a09a266d25a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d3095403-9c31-4baa-bcf9-06fbe3a7b71d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_8fae31c3-1776-4d81-95e8-e8fe94497d64_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d978dc4f-0094-49c5-a0f7-6cba4c072eb2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b3ddad74-2ef3-484d-97e0-9148965eb031_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5a32dde4-e85b-42d7-94a5-d1decebd2594_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_247027d2-a446-4428-8515-5646508655b5_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInstrument_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInstrument_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8ced4c91-3f06-451d-92ab-d6fe5a420f69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fd8ee076-9e15-4053-bcc7-410d02d81eeb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f6e64e87-84da-4109-8a24-70f53e2385ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_a743edd0-dbd0-4043-9f67-7bd469ae25a4_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeAxis" xlink:to="lab_us-gaap_TradingActivityByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_40920c88-5770-4bc9-aa6b-0cd676f6e23c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_32578f3d-b7dd-4dc6-951c-d20564376aad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_c90fe7b8-cc4d-430d-ac23-a9271223dedd_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fec2f618-efaf-4d0c-afa1-320c2b3404cf_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_fc0a95e3-9d55-4e45-b4a0-1e83d4aaac1d_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_32294cd6-2611-48af-9c44-3f3d207c0473_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Upfront Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalUpfrontPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments" xlink:href="lxrx-20200930.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalUpfrontPayments" xlink:to="lab_lxrx_IpsenTotalUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_40a4df67-532b-4db2-a459-c413d1c43f9a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_0685a6e0-800f-4d4a-b18c-f78e15391023_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_ab514a0a-71e2-4b74-a5f4-06c8207a850c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_3b4fa4d8-a426-4cc5-9a81-f1a3c02c3ec6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f4b2780a-9f9b-4919-8a86-7f72346ca182_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_451cc956-0d33-4120-b512-bc861fdf3608_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_21e964cb-e230-45d1-b2ca-46f2870bdab3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_03b228ba-29f4-45ad-bd29-15428f2b7cc8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_241ddc2b-9dd9-4d93-a8d0-774e643851df_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_40029e4b-761c-45f7-bc2d-421e674ff151_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6e3ee9d7-4e09-4a80-bf24-df84508a2a49_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bec08c6f-f451-47fc-9ebf-8762d509e88f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_0b02e23e-7cb3-4870-90d0-895efc231365_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20200930.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c0623a0b-1579-43d9-bbc5-006edff5bf9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_0d5d755d-7f7c-488f-b65c-cba6e17c9071_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_88da0cd2-a2ac-41eb-ae5e-9447ad6795b0_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_88ddd5ef-9f3b-473d-bf04-81ff123d6acd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_eb8e56db-3556-4c67-8b20-0109dfa6f0a8_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_fe5cec25-0386-43cb-b58d-9fb414870fe0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_2b48b514-8c8f-4015-b991-0b7b4f03ee05_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6a2566f-9b37-462c-a077-a1c233c99148_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_65acb844-8cbe-4109-812a-93de547d79b1_terseLabel_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:href="lxrx-20200930.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:to="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7cfbdf08-3b0b-44b4-8e30-427d79fefaea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4792b1cb-ad57-4baf-8097-17a756ab03a4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a002410e-fb46-40d0-9c50-b58f45f56c0f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_99e652cc-5bde-43ed-b088-a44bbfb07287_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_afb5c00d-34a8-4a19-ac8f-3f84a3a39889_terseLabel_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_label_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:href="lxrx-20200930.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_6b00930f-b697-4d85-9280-7420816152a4_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:to="lab_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_118fb2ad-7501-4099-87ba-bc9895eade4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_97ee08ce-2709-4d40-9588-d4f3191b57e0_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesTable" xlink:to="lab_lxrx_AccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_47ec443c-c3ff-4360-9f98-23a54a84772c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_BioPharmaMember_13bf1892-11f7-47da-85d5-a7d38cc06e5b_terseLabel_en-US" xlink:label="lab_lxrx_BioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioPharma [Member]</link:label>
    <link:label id="lab_lxrx_BioPharmaMember_label_en-US" xlink:label="lab_lxrx_BioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioPharma [Member]</link:label>
    <link:label id="lab_lxrx_BioPharmaMember_documentation_en-US" xlink:label="lab_lxrx_BioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioPharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BioPharmaMember" xlink:href="lxrx-20200930.xsd#lxrx_BioPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_BioPharmaMember" xlink:to="lab_lxrx_BioPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_feeefc3c-3eda-4de5-9973-e93d9b304f2e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_11e41b5b-7ecf-4592-b0d8-3eb7d8ada455_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_30f3d0d9-39e2-4f4e-8784-478b05bfc690_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_297e1c3f-b275-4c62-bbf8-7d9a8d8d9a3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3d4eafab-9927-4eb7-a2dc-2151e20648c1_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_921c1f4a-b84b-43c3-acb7-f739c76be483_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_ae248f72-ace9-4de3-b644-e5b01b5ace05_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_34648554-c376-47cc-b874-8773d87f579b_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3a48e3f-105a-4d7f-af49-c6111c4cbcb6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_97b4d835-6279-4447-82df-bc98b354fc4e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $1,029 $1,698, $5,154 and $5,369, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_269b5dd2-c37c-406e-bb77-7142e6fb377d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_d9a36e81-ce72-4b32-88a2-80dd44fbdbb6_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_1ea53194-ca9c-46ff-bcde-97d502e4db96_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_2610a9e5-f53d-4ae9-a113-7b8279f4a461_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fb0605b6-e125-4453-a96c-0d95d3b1427f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8b8f2c11-f70a-4690-aabf-a66c6289f60e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8e87f71b-38e5-467e-9037-bf3ee52822e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e5f9668-1840-4084-b296-d17f494a3276_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_37388b9d-e32b-4c2e-9c93-8c20aa8a881d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_996973a1-5d37-4545-8724-5556e80b8d67_terseLabel_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs [Member]</link:label>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_label_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs [Member]</link:label>
    <link:label id="lab_lxrx_RDSeveranceCostsMember_documentation_en-US" xlink:label="lab_lxrx_RDSeveranceCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D severance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember" xlink:href="lxrx-20200930.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RDSeveranceCostsMember" xlink:to="lab_lxrx_RDSeveranceCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_81fd1e09-e280-4d52-9e65-2263294f6908_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ed725884-6a74-48a5-99a5-4661ae64d482_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_f252ca95-3d00-4a38-9186-0c838db23cbe_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_6a931e9f-7d97-4966-8c84-4eb05a417de4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e632a37-dcbe-4657-a9ef-7f2216a215f0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2392e578-2db9-4e5e-86a0-e2608c51e7df_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_5f30f298-b899-4647-b732-1567d2dfc1b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_4e8baf9b-235b-40b2-971d-d9a286ecd66f_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20200930.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4e5bb175-1f90-4411-a543-16edcdd5ebeb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_3521235f-c13f-4210-983c-bf7ff219e8e5_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_784a96ad-3b2f-4d62-a1d0-ea2ef255bf8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_94dda81f-8a1a-4a9e-9215-d537fd552904_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_e3384d10-b6dd-4b45-be49-0acc417d160a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_55ab5877-756f-48c3-b0dd-ef261dc3c348_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_169eba4b-0d72-4412-8d8b-ac136b522f75_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_22e68d3f-1d77-48ad-b6b1-40e40f9f4bab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_876e344a-d58b-40d4-b68c-cbe85fb7c6fc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share, diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2b81df0d-0ca7-4ed7-b335-9efbca8c17f4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9aa0eddd-231d-43c1-ab72-f32a28f46b69_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_08ddeaca-93ac-4e66-98a8-37802816ea9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6b076bbc-0aa0-497e-8db6-7c10072efcf9_terseLabel_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="lxrx-20200930.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_47100f23-4e52-4d7f-9c83-ea12082eaf76_terseLabel_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20200930.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8df96c0-6d57-4b30-870e-c34c96b1488c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fa8ef170-64b9-495b-9b07-fd91bdf830c0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_198392e9-e858-488f-a8b2-4abebcbd0d9f_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_label_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:href="lxrx-20200930.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:to="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_d8df30d9-fe8d-4d6e-a89d-638d5b2f272c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5fc212df-6114-42e5-b593-f2d255a6f7d4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_13bc91aa-20d9-4319-8953-abb5e195701c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_17e8f5ba-4fd0-47d4-b6ac-2b4289913e73_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_e0b658b8-1948-4b0f-b6bf-aefcf2d0db39_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Regulatory And Commercial Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:to="lab_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_57a585da-de55-4fff-b865-0950b1cacbf5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_eb0f880a-b51a-4430-b4b4-0a84ce7f770c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_96b04b0e-dad8-4af0-8858-5580ecde1e8d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_311e697d-bd93-4b87-9a09-5f5eb7f72900_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_057cd9a1-8d20-40b1-83be-b50df6239971_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a2a40f66-4ded-4e6e-94ca-029437d60c74_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_05238ce3-0205-49e8-a36b-e7665a7a3f0a_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_c04a8a03-cf2f-4079-9a5b-d7c5bbf830eb_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ddf83e15-8334-4ff5-b506-2375a2914375_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_88dc7ef4-710e-452e-9548-d7ba303dd8da_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_87787bbf-aa6a-4fdd-b42c-d5b3e8b12ae6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Netproductrevenue_26a3afd8-09ec-4ebd-9914-8e3b82bef42f_terseLabel_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_label_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_documentation_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue" xlink:href="lxrx-20200930.xsd#lxrx_Netproductrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Netproductrevenue" xlink:to="lab_lxrx_Netproductrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AssetSalePrice_07980a05-0e04-4263-9f53-cd5869b010d8_terseLabel_en-US" xlink:label="lab_lxrx_AssetSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">asset sale price</link:label>
    <link:label id="lab_lxrx_AssetSalePrice_label_en-US" xlink:label="lab_lxrx_AssetSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">asset sale price</link:label>
    <link:label id="lab_lxrx_AssetSalePrice_documentation_en-US" xlink:label="lab_lxrx_AssetSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">asset sale price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AssetSalePrice" xlink:href="lxrx-20200930.xsd#lxrx_AssetSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AssetSalePrice" xlink:to="lab_lxrx_AssetSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ee8e5675-130e-4be6-a22f-e2f4acec0997_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_1b4bb3e2-b1ef-49db-81ae-414ac1140e72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f88acdaf-9505-48c5-8671-d06305f902cb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d96b9ca1-019c-4a11-91d5-4d69ede88341_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_445776a1-0daf-479f-8432-f0cefbb43e3a_terseLabel_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_label_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_documentation_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible" xlink:href="lxrx-20200930.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedInterestOnConvertible" xlink:to="lab_lxrx_AccruedInterestOnConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_551a1b81-54bb-41fe-be6e-cd5845fb4baf_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_85f79c83-7ba4-4769-8c54-36e0611bafde_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_c233248d-1ec0-4344-a9a3-d335550bbc07_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_686916ff-9bc7-42ad-9751-6239d093ecab_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20200930.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7f9591e7-1a2d-42ce-9962-791b43a02a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62083a69-232b-4e76-b63e-7b4600e43439_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a1b6d1df-da08-46ce-9e74-5ac7050b4bba_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e60d8d7d-c4ef-4513-97bb-051483674333_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_47f3e26d-6c85-4e8d-8026-5df35c2dc424_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_4156a714-b402-4fca-9839-1badbc35ee79_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems" xlink:to="lab_lxrx_AccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ab04f7de-24da-4d24-adef-cb75c82c1c93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c13ada4a-d347-4d91-8dcc-8d9ac15129cf_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c9c30291-6620-4344-b676-0dcdcb812c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_a07fc39b-d097-40a8-852f-e5d673533509_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_efa1811f-93f7-49ce-9298-e83bcd99f902_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_cd62392c-0b56-4521-8fc2-05878846e88d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 793 and 407 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_066d7612-cb51-4c09-84bb-08e377f2e6db_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_a189abe9-7b0d-42e4-805f-11da686b3d81_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0d277006-a176-43be-8a96-8988d136cb90_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRoyaltyIncome_LXRX_c73a9a97-e0c4-47a2-9a19-990d4a4a93d4_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Royalty Income_LXRX</link:label>
    <link:label id="lab_lxrx_IpsenRoyaltyIncome_LXRX_label_en-US" xlink:label="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Royalty Income_LXRX</link:label>
    <link:label id="lab_lxrx_IpsenRoyaltyIncome_LXRX_documentation_en-US" xlink:label="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRoyaltyIncome_LXRX" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRoyaltyIncome_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRoyaltyIncome_LXRX" xlink:to="lab_lxrx_IpsenRoyaltyIncome_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_92dc881c-0778-4b63-8cfe-a1976c853917_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2abe3f97-98af-44c3-8ee8-12cd6a51b1a2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_1f3c26a3-3315-4b40-b99e-a83383d462b3_terseLabel_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_label_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX</link:label>
    <link:label id="lab_lxrx_MortgageDebtBalloonPayment_LXRX_documentation_en-US" xlink:label="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:to="lab_lxrx_MortgageDebtBalloonPayment_LXRX" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9c4b526b-640f-418d-968c-1ad3e1595333_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_8d5f3adb-0e2c-49dc-b6b7-d05d71077ea2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:to="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b8d423a2-3ddb-4093-aca0-80c5374238e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_37d5bb45-a9be-4d84-b9b4-5b5afb5e038b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_757d0947-604b-452e-94f2-5ed63cc4fff9_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Committee Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_d5ddc72c-7d17-4ba0-8960-64eac2251bbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lxrx-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b9120c05-2dcb-454d-ab13-af640022c996,g:c8810420-eb25-4487-a657-7c14820ab259-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dd9ae1f5-cc50-4d0d-b855-7ffbc67ac5c6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_DocumentType_dd9ae1f5-cc50-4d0d-b855-7ffbc67ac5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_38bbe5da-0f62-4050-ae58-8eaa19078185" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_DocumentFiscalPeriodFocus_38bbe5da-0f62-4050-ae58-8eaa19078185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c8acba88-0fbc-4534-ba83-31cc6328c513" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_DocumentQuarterlyReport_c8acba88-0fbc-4534-ba83-31cc6328c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_02648598-aa63-420c-84e3-f24b08151bad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_DocumentPeriodEndDate_02648598-aa63-420c-84e3-f24b08151bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ed1ae847-9061-43c4-bff9-d2f6250d7f23" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_DocumentTransitionReport_ed1ae847-9061-43c4-bff9-d2f6250d7f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fe589222-394e-443b-9881-a4f573b4aae2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_AmendmentFlag_fe589222-394e-443b-9881-a4f573b4aae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_91910453-566c-40c4-8b38-93caaee29af5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_DocumentFiscalYearFocus_91910453-566c-40c4-8b38-93caaee29af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c3f8aeb1-c97b-4387-a837-3cc083d4416a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_CurrentFiscalYearEndDate_c3f8aeb1-c97b-4387-a837-3cc083d4416a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3a7d339b-88b4-45d7-aa89-88bb17e2e807" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityFileNumber_3a7d339b-88b4-45d7-aa89-88bb17e2e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9a40544b-ef69-4a23-bc31-234136031da2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityRegistrantName_9a40544b-ef69-4a23-bc31-234136031da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9f53a4be-008d-4896-8f67-be21cfe8bc64" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityCentralIndexKey_9f53a4be-008d-4896-8f67-be21cfe8bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3f738e7c-83de-455a-afb0-26da5caad4b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3f738e7c-83de-455a-afb0-26da5caad4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_80807a32-e933-48dc-94b4-a0ce6c7fcffd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityTaxIdentificationNumber_80807a32-e933-48dc-94b4-a0ce6c7fcffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_88cef6d3-7f44-4273-87bd-4b75b50f1b46" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityAddressAddressLine1_88cef6d3-7f44-4273-87bd-4b75b50f1b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_835c8443-81f4-40e7-a78a-a798d4a20710" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityAddressCityOrTown_835c8443-81f4-40e7-a78a-a798d4a20710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c6a013fc-6047-4407-8d2b-b6e69ec3c90f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityAddressStateOrProvince_c6a013fc-6047-4407-8d2b-b6e69ec3c90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bcf9b181-fdb7-4c4f-9422-10ecbf3d0f77" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityAddressPostalZipCode_bcf9b181-fdb7-4c4f-9422-10ecbf3d0f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_97c660ef-25bc-43b2-a309-abe6de536b3b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_CityAreaCode_97c660ef-25bc-43b2-a309-abe6de536b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d403070d-0784-4dcb-b9d2-0ad5f1f71872" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_LocalPhoneNumber_d403070d-0784-4dcb-b9d2-0ad5f1f71872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_49bb1659-ab93-4132-b437-ca64fe43bd80" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_Security12bTitle_49bb1659-ab93-4132-b437-ca64fe43bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ace02c2c-0e63-4897-b112-e2b193084a04" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_TradingSymbol_ace02c2c-0e63-4897-b112-e2b193084a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dac7ecb9-37c8-4f0d-a003-c3c0af6046ec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_SecurityExchangeName_dac7ecb9-37c8-4f0d-a003-c3c0af6046ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_989d7497-7af1-42d0-a322-8a207dcbdcc9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityCurrentReportingStatus_989d7497-7af1-42d0-a322-8a207dcbdcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_846df1c6-19d8-4ba4-9bd1-be570b66fb30" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityInteractiveDataCurrent_846df1c6-19d8-4ba4-9bd1-be570b66fb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d5e60c7d-a01e-4a2f-b09b-e51b207508fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityFilerCategory_d5e60c7d-a01e-4a2f-b09b-e51b207508fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2291f167-5760-4c0a-a215-2439917f539e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntitySmallBusiness_2291f167-5760-4c0a-a215-2439917f539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_53c35bb4-950e-4d6f-90bc-1a109457b043" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityEmergingGrowthCompany_53c35bb4-950e-4d6f-90bc-1a109457b043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0241be10-8b9e-4f0a-960b-7347b51286c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityShellCompany_0241be10-8b9e-4f0a-960b-7347b51286c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9e6dd082-470a-4f9c-bfe5-c14d6eab6b31" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fef20263-f2e3-4d89-abb2-d8da63752287" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9e6dd082-470a-4f9c-bfe5-c14d6eab6b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_72d4e02c-f6ca-4c51-94c3-d58a62f1cb58" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_72d4e02c-f6ca-4c51-94c3-d58a62f1cb58" xlink:to="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:to="loc_srt_StatementScenarioAxis_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7db7385c-79da-49b0-abd5-97a05c6c47c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ff5cb8fa-b047-4a2e-b4bd-60ddaf9267ac" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7db7385c-79da-49b0-abd5-97a05c6c47c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8265f830-9316-4005-8de8-433992787db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8265f830-9316-4005-8de8-433992787db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0ab8d73d-0f14-4a8e-8aeb-1a82f7455abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8265f830-9316-4005-8de8-433992787db9" xlink:to="loc_us-gaap_ClassOfStockDomain_0ab8d73d-0f14-4a8e-8aeb-1a82f7455abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_67999e15-ea1a-4b1e-893c-d2168e5807fc" xlink:to="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b701bb35-911e-42b6-baa0-dac839060bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b701bb35-911e-42b6-baa0-dac839060bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_24a88dba-8b9d-4ecb-bf9c-27ffb667cb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_ShortTermInvestments_24a88dba-8b9d-4ecb-bf9c-27ffb667cb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fdceb773-24f4-4e2c-b88a-d3fa99edbe2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fdceb773-24f4-4e2c-b88a-d3fa99edbe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e742e3fe-a574-4fd7-9609-7b8b75b7b9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_InventoryNet_e742e3fe-a574-4fd7-9609-7b8b75b7b9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0f1db1b3-9418-42e1-9db0-aebff8cb3b66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_OtherAssetsCurrent_0f1db1b3-9418-42e1-9db0-aebff8cb3b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e0da45c8-fc5a-482c-bf18-fa5b2fbb6f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dc523ea-f551-4ae4-8567-93e0bbf20248" xlink:to="loc_us-gaap_AssetsCurrent_e0da45c8-fc5a-482c-bf18-fa5b2fbb6f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27d4ea8a-c35b-439c-be00-c65d807e2ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_27d4ea8a-c35b-439c-be00-c65d807e2ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab76e6e4-ed31-4fe7-980a-80345a0dc130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_Goodwill_ab76e6e4-ed31-4fe7-980a-80345a0dc130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c267683-3d42-4bb9-9187-0c6f838dcb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9c267683-3d42-4bb9-9187-0c6f838dcb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d43a18e7-be9e-49b1-819d-7fe996b1a96b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d43a18e7-be9e-49b1-819d-7fe996b1a96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b439a5ba-8d25-48da-8cec-3fc41f699b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_Assets_b439a5ba-8d25-48da-8cec-3fc41f699b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dbcfde7e-9a5f-4e0a-ada7-4993b6c22011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_AccountsPayableCurrent_dbcfde7e-9a5f-4e0a-ada7-4993b6c22011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_131e3608-f7b6-4f90-89b2-d496305382d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_131e3608-f7b6-4f90-89b2-d496305382d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b04e21b9-6a3e-493c-a61f-513ffad763bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_LongTermDebtCurrent_b04e21b9-6a3e-493c-a61f-513ffad763bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e1925dc4-bffc-4b1a-9606-515073d89480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_30446b1d-a761-4657-9508-05c5a5d04bdf" xlink:to="loc_us-gaap_LiabilitiesCurrent_e1925dc4-bffc-4b1a-9606-515073d89480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_824004d2-5590-4250-8f00-310e4d98a52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_824004d2-5590-4250-8f00-310e4d98a52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c4d4262a-60cb-444b-bf3f-e56a5312c408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c4d4262a-60cb-444b-bf3f-e56a5312c408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b8d3b48b-7a9e-4134-bdcb-80e501bff8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_Liabilities_b8d3b48b-7a9e-4134-bdcb-80e501bff8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5e577080-e56e-40ba-98e3-5916beb228d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5e577080-e56e-40ba-98e3-5916beb228d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_30161834-9d9f-4c90-a594-13d76ad394e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_PreferredStockValue_30161834-9d9f-4c90-a594-13d76ad394e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8c96af4e-3316-4bea-9cb0-629885554a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_CommonStockValue_8c96af4e-3316-4bea-9cb0-629885554a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ea3a839e-6ae8-423f-b097-b118d1906065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ea3a839e-6ae8-423f-b097-b118d1906065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cdb85691-0734-4b68-8534-f348a7c26041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cdb85691-0734-4b68-8534-f348a7c26041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9ae9e46a-fa54-4105-a7d1-b0b3ce93136e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9ae9e46a-fa54-4105-a7d1-b0b3ce93136e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d0b63475-f858-46dd-9887-733758470fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_TreasuryStockValue_d0b63475-f858-46dd-9887-733758470fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c7804a36-5302-467e-971b-423e52ba214f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2f55dde-f54c-4c1b-be8d-4781ac4f1655" xlink:to="loc_us-gaap_StockholdersEquity_c7804a36-5302-467e-971b-423e52ba214f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_89e88590-94bb-4c2c-a50d-d19b3d7f6f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d315495b-ac8e-42ea-8511-bf0fc84d534c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_89e88590-94bb-4c2c-a50d-d19b3d7f6f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52f9bb4c-05b6-4728-ab23-a48d7c4f5923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52f9bb4c-05b6-4728-ab23-a48d7c4f5923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_35ae7276-3a3c-4ec4-90c5-6c9c94c3ead4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_35ae7276-3a3c-4ec4-90c5-6c9c94c3ead4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_dcbac6a1-70b4-4113-af43-43024d1bc85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_dcbac6a1-70b4-4113-af43-43024d1bc85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6ad2ac6f-91bb-4d57-a351-e3f47ed36d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6ad2ac6f-91bb-4d57-a351-e3f47ed36d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e4a810b9-947c-455c-b126-2330979ca010" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e4a810b9-947c-455c-b126-2330979ca010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_58bfaf44-af66-4f09-bfc0-3b2fef480495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_58bfaf44-af66-4f09-bfc0-3b2fef480495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_05dc92d1-0b2a-463b-9145-1d7b3619eca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_05dc92d1-0b2a-463b-9145-1d7b3619eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1fefcbe9-64ea-4896-8877-e281b482f24f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_CommonStockSharesIssued_1fefcbe9-64ea-4896-8877-e281b482f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5c39e24a-6399-4572-b630-0b8b842f1bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_9d78d210-d333-48b0-b08b-b238098cf34b" xlink:to="loc_us-gaap_TreasuryStockShares_5c39e24a-6399-4572-b630-0b8b842f1bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_0fe4b2ee-c46d-4c27-8acb-8e74888a90d3" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5fef88ce-43aa-4f2c-baf7-abe05d59288f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_0fe4b2ee-c46d-4c27-8acb-8e74888a90d3" xlink:to="loc_us-gaap_StatementTable_5fef88ce-43aa-4f2c-baf7-abe05d59288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_944f6ff8-5498-4691-b43b-8fa2f871d97d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5fef88ce-43aa-4f2c-baf7-abe05d59288f" xlink:to="loc_srt_StatementScenarioAxis_944f6ff8-5498-4691-b43b-8fa2f871d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_490e1e76-11e0-476d-a2c9-75de4636be10" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_944f6ff8-5498-4691-b43b-8fa2f871d97d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_490e1e76-11e0-476d-a2c9-75de4636be10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5fef88ce-43aa-4f2c-baf7-abe05d59288f" xlink:to="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_434373e2-efaa-4851-a19e-c9d5da677172" xlink:href="lxrx-20200930.xsd#lxrx_Netproductrevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_lxrx_Netproductrevenue_434373e2-efaa-4851-a19e-c9d5da677172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8719f322-1b3f-4f64-af9c-a0fb55c5461f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8719f322-1b3f-4f64-af9c-a0fb55c5461f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_ee85d971-0084-428d-a1eb-ff7a452a2b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_ee85d971-0084-428d-a1eb-ff7a452a2b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_68a3b695-6a4f-49aa-9383-ddcf95b22e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_20c6c7fa-141e-4936-9437-6357e5009cdb" xlink:to="loc_us-gaap_Revenues_68a3b695-6a4f-49aa-9383-ddcf95b22e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_efad347a-495d-40d7-a5d8-da5d4d32d74a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_efad347a-495d-40d7-a5d8-da5d4d32d74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_07e54b80-9aef-469d-afd9-df22fdd4bf2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_07e54b80-9aef-469d-afd9-df22fdd4bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_ef2b445f-0779-4093-b6b6-6372ddfa16a8" xlink:href="lxrx-20200930.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_ef2b445f-0779-4093-b6b6-6372ddfa16a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e6cf4b13-63fe-4040-92ec-2aa1a51b0944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_AssetImpairmentCharges_e6cf4b13-63fe-4040-92ec-2aa1a51b0944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e792c86e-3d82-4abc-9eed-e2a6bba00829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d069601-5186-4847-b936-c9c4b2e944d6" xlink:to="loc_us-gaap_OperatingExpenses_e792c86e-3d82-4abc-9eed-e2a6bba00829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_5cdd807b-b352-4f49-bd2e-af777ede95da" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_5cdd807b-b352-4f49-bd2e-af777ede95da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79bbc0a6-4f3f-408f-b63f-4a4b450d1883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OperatingIncomeLoss_79bbc0a6-4f3f-408f-b63f-4a4b450d1883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_487efee0-86cd-40d0-bc91-f68b168f5784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_487efee0-86cd-40d0-bc91-f68b168f5784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5f9cc374-0a2d-4b69-9dcc-527733ef8b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_InterestExpense_5f9cc374-0a2d-4b69-9dcc-527733ef8b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_79e46a42-7e2b-481f-94ab-b1b71eeb9272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_79e46a42-7e2b-481f-94ab-b1b71eeb9272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba7a3544-6093-434c-9a64-0e3a4f8390fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba7a3544-6093-434c-9a64-0e3a4f8390fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_77579bd4-434e-4768-85ef-68c368b473db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_77579bd4-434e-4768-85ef-68c368b473db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf0e9979-0055-4996-a8a3-0f607a26af2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_NetIncomeLoss_bf0e9979-0055-4996-a8a3-0f607a26af2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_061759f8-2f52-4df0-87ae-584faf460cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_EarningsPerShareBasic_061759f8-2f52-4df0-87ae-584faf460cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4a20ed2c-2902-4ea0-b085-0447ac46af5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4a20ed2c-2902-4ea0-b085-0447ac46af5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa684fe5-1f15-4bb5-8628-29a6ede9dc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa684fe5-1f15-4bb5-8628-29a6ede9dc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bb598f04-5788-4b0c-bead-d3a299e7c8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bb598f04-5788-4b0c-bead-d3a299e7c8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bcb5264-9f95-4146-b85c-4c6943360cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2bcb5264-9f95-4146-b85c-4c6943360cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_33936aee-2dab-40b3-b672-12378f8c9a48" xlink:href="lxrx-20200930.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_33936aee-2dab-40b3-b672-12378f8c9a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0a58c4e9-54db-4142-ab1a-ff7576cf3db6" xlink:href="lxrx-20200930.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_0a58c4e9-54db-4142-ab1a-ff7576cf3db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_c08eb61a-05a1-41c7-bbe3-c46d50391610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_c08eb61a-05a1-41c7-bbe3-c46d50391610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6ce923cd-7923-4d6a-b555-672cfdf82a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f37fc273-7462-4f78-9098-552a6414af62" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_6ce923cd-7923-4d6a-b555-672cfdf82a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_c156dee2-cff5-420f-bfdd-1c2ae7d0e26c" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_e2697559-913a-432a-8caf-ac0a82ba9c19" xlink:href="lxrx-20200930.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_c156dee2-cff5-420f-bfdd-1c2ae7d0e26c" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_e2697559-913a-432a-8caf-ac0a82ba9c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_c2df3893-905d-44ae-80de-b71a81709248" xlink:href="lxrx-20200930.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_c156dee2-cff5-420f-bfdd-1c2ae7d0e26c" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_c2df3893-905d-44ae-80de-b71a81709248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_3c1fa9bc-0f1e-400a-b969-4bb20d882426" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_3c1fa9bc-0f1e-400a-b969-4bb20d882426" xlink:to="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3e7c95a7-7f49-410e-88e1-e956a188fba0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:to="loc_srt_StatementScenarioAxis_3e7c95a7-7f49-410e-88e1-e956a188fba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4a97b20d-84ed-4757-a48c-1a500251e749" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3e7c95a7-7f49-410e-88e1-e956a188fba0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4a97b20d-84ed-4757-a48c-1a500251e749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ade0ea57-7ad3-4ce0-bdd6-889629c646ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ade0ea57-7ad3-4ce0-bdd6-889629c646ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ade0ea57-7ad3-4ce0-bdd6-889629c646ca" xlink:to="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a0fb6e3d-59d8-4d15-90cc-3949f1cba7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_CommonStockMember_a0fb6e3d-59d8-4d15-90cc-3949f1cba7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_56aa85a7-a2c7-4894-b115-60b3d5bfd36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_56aa85a7-a2c7-4894-b115-60b3d5bfd36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cb5a48ec-029a-45f1-b65d-2cca4af1754f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_RetainedEarningsMember_cb5a48ec-029a-45f1-b65d-2cca4af1754f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4a4ca96-cad0-46db-bb10-6554fecb6e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4a4ca96-cad0-46db-bb10-6554fecb6e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_7f1816b1-505d-4836-95d9-c0c4e6ed249d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_03a3f9fd-6c2d-49d9-8b02-5f89e9422d43" xlink:to="loc_us-gaap_TreasuryStockMember_7f1816b1-505d-4836-95d9-c0c4e6ed249d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0964870c-d46c-41de-9efd-75726e76a303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0964870c-d46c-41de-9efd-75726e76a303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a041e1cd-22d1-40f2-8dbb-77dedc81cba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0964870c-d46c-41de-9efd-75726e76a303" xlink:to="loc_us-gaap_ClassOfStockDomain_a041e1cd-22d1-40f2-8dbb-77dedc81cba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e16894-74a3-49fa-9e98-7078bda4571f" xlink:to="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f01176c6-4784-4657-9cd1-37986df6f21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_CommonStockSharesIssued_f01176c6-4784-4657-9cd1-37986df6f21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f25c4248-33ae-4a53-a0b5-7918031853d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f25c4248-33ae-4a53-a0b5-7918031853d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9e41037f-8b7a-4b0d-b5e6-0481f3ef6533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9e41037f-8b7a-4b0d-b5e6-0481f3ef6533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e36dd79d-7d34-459a-b234-8f385ea4bf96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e36dd79d-7d34-459a-b234-8f385ea4bf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_87615dfc-7d22-4f36-93bb-67455a3609d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_87615dfc-7d22-4f36-93bb-67455a3609d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2b2358c-74ef-45a5-80a1-00e62dad9407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2b2358c-74ef-45a5-80a1-00e62dad9407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ecd05302-ec3a-4231-ae2d-60c58af717fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_NetIncomeLoss_ecd05302-ec3a-4231-ae2d-60c58af717fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_af4a84e7-85be-4392-91fc-da1509ba1f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_af4a84e7-85be-4392-91fc-da1509ba1f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bc98067f-91bb-44f0-8734-480c316bd14e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_CommonStockSharesIssued_bc98067f-91bb-44f0-8734-480c316bd14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7fa4d447-b348-4f00-a1e4-9f0c78ae9891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78dd5df0-dd7f-43fd-ae54-2c982a6f0951" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7fa4d447-b348-4f00-a1e4-9f0c78ae9891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_b399bcf6-3b8f-48dd-805b-fa9a82edabea" xlink:href="lxrx-20200930.xsd#lxrx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfCashFlowsAbstract_b399bcf6-3b8f-48dd-805b-fa9a82edabea" xlink:to="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_70800449-8737-4451-891d-190466b02778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_70800449-8737-4451-891d-190466b02778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_29880ae2-04e7-43ca-a4a4-fb1fd8b8a955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_70800449-8737-4451-891d-190466b02778" xlink:to="loc_us-gaap_EquityComponentDomain_29880ae2-04e7-43ca-a4a4-fb1fd8b8a955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9a927be3-ca18-4ffc-a18e-043e74e44034" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:to="loc_srt_StatementScenarioAxis_9a927be3-ca18-4ffc-a18e-043e74e44034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_79300054-f7e6-4b0b-869d-b779d19472e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9a927be3-ca18-4ffc-a18e-043e74e44034" xlink:to="loc_srt_ScenarioUnspecifiedDomain_79300054-f7e6-4b0b-869d-b779d19472e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ccea6c5-1764-47c2-9501-1940c5cfac45" xlink:to="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2b81200-3727-4933-8439-44b65c0e48e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:to="loc_us-gaap_NetIncomeLoss_c2b81200-3727-4933-8439-44b65c0e48e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e03324c8-37aa-45a5-98fd-f156abd108cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e03324c8-37aa-45a5-98fd-f156abd108cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2640155c-d63c-4f7d-a854-5d58fb267378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_ShareBasedCompensation_2640155c-d63c-4f7d-a854-5d58fb267378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c39805ce-2946-4c03-a244-40922ac83490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c39805ce-2946-4c03-a244-40922ac83490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f2d36530-8f54-46ac-a4be-fb445bf35665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f2d36530-8f54-46ac-a4be-fb445bf35665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_9d0b2306-2f5f-4963-a424-e4beed89e96c" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_9d0b2306-2f5f-4963-a424-e4beed89e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_45319304-cf5e-42d1-8f5b-98448807b54b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_AssetImpairmentCharges_45319304-cf5e-42d1-8f5b-98448807b54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2c7adf97-7a95-4607-9a39-45e7527e1840" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e19935cd-fd5b-433e-ba64-139d396c3067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e19935cd-fd5b-433e-ba64-139d396c3067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_817d6ee0-09c7-4173-902b-283767381776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_817d6ee0-09c7-4173-902b-283767381776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3653100b-902d-4cbb-8bf0-966d2740a639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3653100b-902d-4cbb-8bf0-966d2740a639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de4d787a-ff23-4f7b-a897-41eeb16271c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de4d787a-ff23-4f7b-a897-41eeb16271c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_61055746-9fc3-4d19-84d8-28e9a313e47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_61055746-9fc3-4d19-84d8-28e9a313e47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_421e0d85-453a-4e6e-a75b-52a9af5a2b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_704a4a73-5313-45ce-96e2-fef2b6797b05" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_421e0d85-453a-4e6e-a75b-52a9af5a2b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4620ed31-e085-402b-9009-8bd0b4cb639f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878491c-35dd-41fa-a7c7-ea66a375eb45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4620ed31-e085-402b-9009-8bd0b4cb639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c31652fd-f10e-4fd4-8ee7-5b292cd283f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c31652fd-f10e-4fd4-8ee7-5b292cd283f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_61ddfb9a-4032-406a-83f4-04eb53531471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_61ddfb9a-4032-406a-83f4-04eb53531471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8aaffff4-8c0d-4565-bb91-cf442d7baa54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8aaffff4-8c0d-4565-bb91-cf442d7baa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4b1b3d64-82b5-41db-b73b-1ac7fc9843bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4b1b3d64-82b5-41db-b73b-1ac7fc9843bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac8f84f1-3f4d-4538-b8d1-d243669e5a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_406dc73c-dfd7-4d4d-a572-965f0bce04cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac8f84f1-3f4d-4538-b8d1-d243669e5a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8dd8176d-917a-471a-a2b6-079b66282188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8dd8176d-917a-471a-a2b6-079b66282188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_79e6c776-a49f-428a-a014-783cdde883ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_79e6c776-a49f-428a-a014-783cdde883ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c726c521-ac81-4360-8009-02a923a288ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ddaa1bb4-204e-4981-861b-f3e395a15e65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c726c521-ac81-4360-8009-02a923a288ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb4bc4c9-857e-4fbb-a529-32990086cf58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fb4bc4c9-857e-4fbb-a529-32990086cf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_079590e6-7134-48eb-8c56-f5e55f80a28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_079590e6-7134-48eb-8c56-f5e55f80a28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7b43eeb-20a3-4c12-9575-d05258fe17a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7b43eeb-20a3-4c12-9575-d05258fe17a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_df5e8b9c-0ae9-41fc-a134-451ddc9b6455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:to="loc_us-gaap_InterestPaidNet_df5e8b9c-0ae9-41fc-a134-451ddc9b6455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera_c7316b26-7c64-4b08-b8e4-0b8998ee9f39" xlink:href="lxrx-20200930.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:to="loc_lxrx_LiabilitiesAssumedByTerSera_c7316b26-7c64-4b08-b8e4-0b8998ee9f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a61707f8-d7d1-4906-9910-80ccbc6cb2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1e0fd1c-03e2-4221-ad03-341a075362c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a61707f8-d7d1-4906-9910-80ccbc6cb2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfRealEstate_9833518e-f5d0-49d9-b7b9-76900ac55cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_ImpairmentOfRealEstate_9833518e-f5d0-49d9-b7b9-76900ac55cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5886f434-6e8f-4fd3-806d-618854bb69dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a93b8c00-2995-4dd7-95b6-656ae62eab5f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5886f434-6e8f-4fd3-806d-618854bb69dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6ac44f46-0713-45fb-b092-9b2b4851fc24" xlink:href="lxrx-20200930.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d90252b1-e4e9-4ab1-b8cc-817fe09d4b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_6ac44f46-0713-45fb-b092-9b2b4851fc24" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d90252b1-e4e9-4ab1-b8cc-817fe09d4b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:href="lxrx-20200930.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_956eb8fb-ad04-4561-bebf-a2a0a7ed9cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_956eb8fb-ad04-4561-bebf-a2a0a7ed9cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_efe0c1ac-bdd7-4477-bc34-22989408585d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_UseOfEstimates_efe0c1ac-bdd7-4477-bc34-22989408585d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_744488a3-d097-49a1-a9c3-13329eea410f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_744488a3-d097-49a1-a9c3-13329eea410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_08e5fb4a-ce1b-4fdd-b455-0dc0e2bddcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_08e5fb4a-ce1b-4fdd-b455-0dc0e2bddcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_3485f8a1-506f-427f-8cea-09d41d1a0989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_3485f8a1-506f-427f-8cea-09d41d1a0989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_651b174c-508f-4f78-afae-682af0353eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_651b174c-508f-4f78-afae-682af0353eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_66696472-951f-4705-962b-cde442f9e899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_66696472-951f-4705-962b-cde442f9e899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4bfb979e-a922-4c8e-ab21-d53544ddb797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4bfb979e-a922-4c8e-ab21-d53544ddb797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_dd3a8ac6-ea6b-4c00-b2aa-35774366e0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_dd3a8ac6-ea6b-4c00-b2aa-35774366e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7594ad87-4a2d-4c7c-9415-b35826607292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1ee648d8-04ab-486d-97bb-d8d025bde50c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7594ad87-4a2d-4c7c-9415-b35826607292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_d5c7ad57-8779-4eaf-a6b2-a6a8165c887f" xlink:href="lxrx-20200930.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7673f3fb-c8d4-4909-a5e8-cc5280afa974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_d5c7ad57-8779-4eaf-a6b2-a6a8165c887f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7673f3fb-c8d4-4909-a5e8-cc5280afa974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_45229047-9686-4f58-9c86-f508f6712d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_d5c7ad57-8779-4eaf-a6b2-a6a8165c887f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_45229047-9686-4f58-9c86-f508f6712d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c90a07fb-d977-44f7-b625-ae13360081cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_d5c7ad57-8779-4eaf-a6b2-a6a8165c887f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c90a07fb-d977-44f7-b625-ae13360081cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d6a580ee-591d-4bdc-819e-3c63063c24b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_d5c7ad57-8779-4eaf-a6b2-a6a8165c887f" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d6a580ee-591d-4bdc-819e-3c63063c24b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InventoryAbstract_bfecc360-3438-48f1-8f07-dd47ac11ef02" xlink:href="lxrx-20200930.xsd#lxrx_InventoryAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_3c109fe1-a5a0-4f36-a1bc-374c52add47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_InventoryAbstract_bfecc360-3438-48f1-8f07-dd47ac11ef02" xlink:to="loc_us-gaap_InventoryCurrentTable_3c109fe1-a5a0-4f36-a1bc-374c52add47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_21bf6ed9-5238-4f0d-92aa-06ed628a1836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_3c109fe1-a5a0-4f36-a1bc-374c52add47d" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_21bf6ed9-5238-4f0d-92aa-06ed628a1836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_77be632c-85fc-4719-a286-52c8e7d84c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_21bf6ed9-5238-4f0d-92aa-06ed628a1836" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_77be632c-85fc-4719-a286-52c8e7d84c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_3c109fe1-a5a0-4f36-a1bc-374c52add47d" xlink:to="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_2e809705-107d-4db6-b0ae-3f019e0fdf3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_InventoryRawMaterials_2e809705-107d-4db6-b0ae-3f019e0fdf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_9ce93afe-288a-40fd-9a9e-0f95aaa30e36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_InventoryFinishedGoods_9ce93afe-288a-40fd-9a9e-0f95aaa30e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_ee0c39f3-00da-4df6-afdd-eb246d714c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_InventoryWorkInProcess_ee0c39f3-00da-4df6-afdd-eb246d714c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4ab01633-587a-4411-a60b-b3879d6dd6ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_c7234b3f-e123-45c3-9945-e9d51afd0b75" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4ab01633-587a-4411-a60b-b3879d6dd6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_558c5778-42c7-4a99-adb1-ef3afcf7534c" xlink:href="lxrx-20200930.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_558c5778-42c7-4a99-adb1-ef3afcf7534c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a097acef-18fe-475f-a989-7cbaeaec30c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_PlanNameAxis_a097acef-18fe-475f-a989-7cbaeaec30c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_82338ea1-8390-43df-b453-8d84a9db5cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a097acef-18fe-475f-a989-7cbaeaec30c4" xlink:to="loc_us-gaap_PlanNameDomain_82338ea1-8390-43df-b453-8d84a9db5cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_4fff338c-a337-4998-863b-ceb6ded15669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_AwardDateAxis_4fff338c-a337-4998-863b-ceb6ded15669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_26ece069-988b-4004-92e2-541dbd32175b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_4fff338c-a337-4998-863b-ceb6ded15669" xlink:to="loc_us-gaap_AwardDateDomain_26ece069-988b-4004-92e2-541dbd32175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_97153b40-9232-4beb-bd5a-9e064b1bcefc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_AwardTypeAxis_97153b40-9232-4beb-bd5a-9e064b1bcefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_940e2b81-c8f4-4f16-9a19-c1bb9983b225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_97153b40-9232-4beb-bd5a-9e064b1bcefc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_940e2b81-c8f4-4f16-9a19-c1bb9983b225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_5f9e1579-3b98-4b93-b39b-f5f92b0de419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_940e2b81-c8f4-4f16-9a19-c1bb9983b225" xlink:to="loc_us-gaap_StockOptionMember_5f9e1579-3b98-4b93-b39b-f5f92b0de419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69c655f9-ce86-4575-b0f8-aa457d38a267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5f346c6-c2b8-4553-ba98-4ac0acf4f6df" xlink:to="loc_us-gaap_ClassOfStockDomain_69c655f9-ce86-4575-b0f8-aa457d38a267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77195c0f-ae05-470a-ad21-d98ca4a96ce1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_srt_RangeAxis_77195c0f-ae05-470a-ad21-d98ca4a96ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ded3802-2181-4472-83fb-57d38ba62f42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77195c0f-ae05-470a-ad21-d98ca4a96ce1" xlink:to="loc_srt_RangeMember_1ded3802-2181-4472-83fb-57d38ba62f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0522bb23-62e9-40e3-aa7a-777d4532c1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_VestingAxis_0522bb23-62e9-40e3-aa7a-777d4532c1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_809f2477-1d32-4767-8bbb-69710b76dba0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_0522bb23-62e9-40e3-aa7a-777d4532c1ef" xlink:to="loc_us-gaap_VestingDomain_809f2477-1d32-4767-8bbb-69710b76dba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df5f82b5-ce33-491d-a5a4-de1c8f646279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_675a1dc2-6297-406f-ada1-76d1689ac66f" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_675a1dc2-6297-406f-ada1-76d1689ac66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_e0299a03-8e36-4987-a2be-be882033f41b" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_e0299a03-8e36-4987-a2be-be882033f41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_5f1dd2a2-df9e-4783-bf61-5155f8c6aaf5" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_5f1dd2a2-df9e-4783-bf61-5155f8c6aaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_129bf153-f4dc-4da5-aeba-7aa754f494f9" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_129bf153-f4dc-4da5-aeba-7aa754f494f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_48979847-22ec-4dc0-8519-f7a465e1e8f3" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_48979847-22ec-4dc0-8519-f7a465e1e8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_ec1e6766-4efb-48ed-9323-8de3cc9b4f36" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_ec1e6766-4efb-48ed-9323-8de3cc9b4f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_48e91d59-42d9-483e-bd71-c7eb5228dbb9" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_48e91d59-42d9-483e-bd71-c7eb5228dbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_1c7f9b94-f2c8-4035-8153-cb3dc8b06376" xlink:href="lxrx-20200930.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46f75763-9cd1-42ca-b384-b40dc2d5e390" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_1c7f9b94-f2c8-4035-8153-cb3dc8b06376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1b548e9b-fd97-427e-98c6-30025d870e83" xlink:href="lxrx-20200930.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_1b548e9b-fd97-427e-98c6-30025d870e83" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_PlanNameAxis_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_af554f1d-5fe8-4d8d-9b6c-ec00f8b06da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d2b96be0-3ef7-4fb7-acd7-7eacbc56f8e0" xlink:to="loc_us-gaap_PlanNameDomain_af554f1d-5fe8-4d8d-9b6c-ec00f8b06da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_3466d636-aadc-4328-a105-bee2c325d4c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_AwardDateAxis_3466d636-aadc-4328-a105-bee2c325d4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_75b09875-aff0-4218-9610-f49109a4e1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_3466d636-aadc-4328-a105-bee2c325d4c7" xlink:to="loc_us-gaap_AwardDateDomain_75b09875-aff0-4218-9610-f49109a4e1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c0d38e2-0d3a-418e-9681-5c9160c9d262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_AwardTypeAxis_7c0d38e2-0d3a-418e-9681-5c9160c9d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c0d38e2-0d3a-418e-9681-5c9160c9d262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15e559b3-63da-4ee9-a10a-f5e955900315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15e559b3-63da-4ee9-a10a-f5e955900315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9a9bd377-ae6e-48f7-b0dc-9cddaed45393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e696d15-c628-494d-8142-b2fe5383684d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9a9bd377-ae6e-48f7-b0dc-9cddaed45393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_db29367f-38fb-4f9f-a483-ea7c4dfa15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_db29367f-38fb-4f9f-a483-ea7c4dfa15e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac03a5d4-5650-4468-9cb5-42ad84553b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_db29367f-38fb-4f9f-a483-ea7c4dfa15e6" xlink:to="loc_us-gaap_ClassOfStockDomain_ac03a5d4-5650-4468-9cb5-42ad84553b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_21b697aa-1e9a-4805-92f5-07fc509ccc3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_srt_RangeAxis_21b697aa-1e9a-4805-92f5-07fc509ccc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b27e667f-7fa9-42d3-a156-477807bd3b91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_21b697aa-1e9a-4805-92f5-07fc509ccc3f" xlink:to="loc_srt_RangeMember_b27e667f-7fa9-42d3-a156-477807bd3b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_VestingAxis_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_43bdea9e-2214-41e9-939a-b86f33162d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_e05e33ed-aa5d-4b18-ab3b-76f4131d8eac" xlink:to="loc_us-gaap_VestingDomain_43bdea9e-2214-41e9-939a-b86f33162d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ff04fb-25c8-4872-9873-70b0619f4de2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d24d2f68-8f6c-4fb3-a5a3-979095d0c824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d24d2f68-8f6c-4fb3-a5a3-979095d0c824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20a2773d-79ee-4c78-ad05-2778230ce315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20a2773d-79ee-4c78-ad05-2778230ce315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_75853f12-fb49-4967-9458-cd8443203367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_75853f12-fb49-4967-9458-cd8443203367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_351c7143-40cb-40ee-8156-e2387cd2e6ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_351c7143-40cb-40ee-8156-e2387cd2e6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_778c8ab4-9f43-44c5-b360-17f0ceee9c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_778c8ab4-9f43-44c5-b360-17f0ceee9c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_11793b29-c5ac-4ff8-8eee-ad1187434bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_11793b29-c5ac-4ff8-8eee-ad1187434bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_94b1ed03-8def-4ae7-8273-ff2876a6ae17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_94b1ed03-8def-4ae7-8273-ff2876a6ae17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6fa54418-48aa-4091-80aa-cfa14f3b279c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6fa54418-48aa-4091-80aa-cfa14f3b279c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e90a7534-bab8-4374-9403-7d808a4607e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e90a7534-bab8-4374-9403-7d808a4607e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61f0141b-f265-48a6-a965-ef483723d79d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_61f0141b-f265-48a6-a965-ef483723d79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc664d32-6abd-4930-9df8-7f5a209fc972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc664d32-6abd-4930-9df8-7f5a209fc972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c94c59e-74b2-475f-8b79-d0d905500ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c94c59e-74b2-475f-8b79-d0d905500ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_03e11768-b21e-4f4f-a502-9a0bfcdcf095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_03e11768-b21e-4f4f-a502-9a0bfcdcf095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd0ad112-aa3e-4e91-8ded-0b8db8ac01bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd0ad112-aa3e-4e91-8ded-0b8db8ac01bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_993e095a-9de5-4e05-935a-e4d68f9bdcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_993e095a-9de5-4e05-935a-e4d68f9bdcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff2a6189-41a2-4d78-9c09-d88b4a84cb5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ff2a6189-41a2-4d78-9c09-d88b4a84cb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6f775536-cd97-4968-85f6-fc35d06bc07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6f775536-cd97-4968-85f6-fc35d06bc07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6dcd987f-54f6-4b96-8b73-27c8b2dde4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6565fdb9-c8de-4e06-a1a3-aafb4b808811" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6dcd987f-54f6-4b96-8b73-27c8b2dde4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_97b7df85-2eea-4afa-954b-fdaa1cefa874" xlink:href="lxrx-20200930.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_97b7df85-2eea-4afa-954b-fdaa1cefa874" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_af8502d2-df08-4a28-98c0-e77c4c7bf8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_us-gaap_PlanNameAxis_af8502d2-df08-4a28-98c0-e77c4c7bf8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_94b4e2c2-b85f-4fbc-a6c5-e5207dcb6020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_af8502d2-df08-4a28-98c0-e77c4c7bf8f5" xlink:to="loc_us-gaap_PlanNameDomain_94b4e2c2-b85f-4fbc-a6c5-e5207dcb6020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ecdb796-d717-4866-920d-516347486535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_us-gaap_AwardTypeAxis_9ecdb796-d717-4866-920d-516347486535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c58581f-0609-40d9-9a34-e09b91fd4b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9ecdb796-d717-4866-920d-516347486535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c58581f-0609-40d9-9a34-e09b91fd4b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e932603d-befd-423e-a05a-829585866de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e932603d-befd-423e-a05a-829585866de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79f17016-49fa-47df-9a0c-09ad699eee30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e932603d-befd-423e-a05a-829585866de4" xlink:to="loc_us-gaap_ClassOfStockDomain_79f17016-49fa-47df-9a0c-09ad699eee30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_408aa1bd-0f96-4e54-b104-02554400905f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_srt_RangeAxis_408aa1bd-0f96-4e54-b104-02554400905f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aae9c4f8-626b-42bc-a14c-f3903a892a21" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_408aa1bd-0f96-4e54-b104-02554400905f" xlink:to="loc_srt_RangeMember_aae9c4f8-626b-42bc-a14c-f3903a892a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839bc157-14d9-40b9-8f7e-58d79b80ef44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e8f7f19-2d2c-4d1a-8036-071eafb66a65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839bc157-14d9-40b9-8f7e-58d79b80ef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ad63229-bf71-4885-b5a0-013787277728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_d1123c49-c11d-463f-b0a2-76736e5f2625" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ad63229-bf71-4885-b5a0-013787277728" xlink:to="loc_lxrx_AccruedLiabilitiesTable_d1123c49-c11d-463f-b0a2-76736e5f2625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_6b84df51-14fe-40bf-ac3d-7a9c63989083" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_d1123c49-c11d-463f-b0a2-76736e5f2625" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_6b84df51-14fe-40bf-ac3d-7a9c63989083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_9befc763-7239-46dd-8ddf-7976ea34d8af" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_6b84df51-14fe-40bf-ac3d-7a9c63989083" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_9befc763-7239-46dd-8ddf-7976ea34d8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:href="lxrx-20200930.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_d1123c49-c11d-463f-b0a2-76736e5f2625" xlink:to="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_9b260e9c-ca4a-47b2-963f-522b383eedb9" xlink:href="lxrx-20200930.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_9b260e9c-ca4a-47b2-963f-522b383eedb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_f2135aa3-a765-42ef-a78f-330d6c9e75e9" xlink:href="lxrx-20200930.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_f2135aa3-a765-42ef-a78f-330d6c9e75e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cb989945-1f73-4d0b-b178-a6dc31ac2e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cb989945-1f73-4d0b-b178-a6dc31ac2e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4d6d987a-75c2-496e-b3b6-bf8e2bbddd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4d6d987a-75c2-496e-b3b6-bf8e2bbddd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5e332f19-18b3-48fb-a41f-0922cf29b30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_df811a30-c70e-410c-a434-73617b22f64a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_5e332f19-18b3-48fb-a41f-0922cf29b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1bf86509-9124-415a-bda8-04e835a89ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9a5328d-caf0-4bd4-ad45-e7b92aeb7ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf86509-9124-415a-bda8-04e835a89ed2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9a5328d-caf0-4bd4-ad45-e7b92aeb7ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_823698db-aadf-424e-b1b4-91c2f1475d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf86509-9124-415a-bda8-04e835a89ed2" xlink:to="loc_us-gaap_AssetImpairmentCharges_823698db-aadf-424e-b1b4-91c2f1475d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e80979f8-d28d-4638-a85b-3b7aacb7cff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf86509-9124-415a-bda8-04e835a89ed2" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e80979f8-d28d-4638-a85b-3b7aacb7cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_af65beb9-2db8-40f4-9004-ad021eab54bb" xlink:href="lxrx-20200930.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7d3bfc0c-40ac-4bb4-81a6-303f5e18172d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_af65beb9-2db8-40f4-9004-ad021eab54bb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7d3bfc0c-40ac-4bb4-81a6-303f5e18172d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#RecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_52fbf01b-ef5f-422d-a2f8-3e7515a0bdf0" xlink:href="lxrx-20200930.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleNotes" xlink:type="simple" xlink:href="lxrx-20200930.xsd#AssetSaleNotes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSaleNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_b56c8029-8a6c-4791-bccd-8dac7cea4710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SaleOfNonFinancialAssetsTextBlock_2a808866-8f7d-4005-9d39-3d8f92fa83ab" xlink:href="lxrx-20200930.xsd#lxrx_SaleOfNonFinancialAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_b56c8029-8a6c-4791-bccd-8dac7cea4710" xlink:to="loc_lxrx_SaleOfNonFinancialAssetsTextBlock_2a808866-8f7d-4005-9d39-3d8f92fa83ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#AssetSaleDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/AssetSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_166fc5cf-756e-4829-adb5-b96fd9661a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetRetirementObligationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_24e9bc38-ea0c-4369-b95d-6f31def81282" xlink:href="lxrx-20200930.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_166fc5cf-756e-4829-adb5-b96fd9661a83" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_24e9bc38-ea0c-4369-b95d-6f31def81282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4e447d40-5d3e-457e-ae74-d526b2c77101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_166fc5cf-756e-4829-adb5-b96fd9661a83" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4e447d40-5d3e-457e-ae74-d526b2c77101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_9b2f4205-16b1-4c32-8f83-3296e40f1acc" xlink:href="lxrx-20200930.xsd#lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_166fc5cf-756e-4829-adb5-b96fd9661a83" xlink:to="loc_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones_9b2f4205-16b1-4c32-8f83-3296e40f1acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_XermeloPretaxNetLoss_a38192a5-3049-452d-8208-237d8d706514" xlink:href="lxrx-20200930.xsd#lxrx_XermeloPretaxNetLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_166fc5cf-756e-4829-adb5-b96fd9661a83" xlink:to="loc_lxrx_XermeloPretaxNetLoss_a38192a5-3049-452d-8208-237d8d706514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_93ae4dd0-ea9b-42bb-9d9c-752a99710f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_166fc5cf-756e-4829-adb5-b96fd9661a83" xlink:to="loc_us-gaap_SeveranceCosts1_93ae4dd0-ea9b-42bb-9d9c-752a99710f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureAbstract_166fc5cf-756e-4829-adb5-b96fd9661a83" xlink:to="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_5f640dc9-fc48-4b0f-afee-d75210b4e850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_5f640dc9-fc48-4b0f-afee-d75210b4e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b8d1650d-579c-4c78-8168-9ab0fd5d76d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_5f640dc9-fc48-4b0f-afee-d75210b4e850" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b8d1650d-579c-4c78-8168-9ab0fd5d76d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_BioPharmaMember_3e177a76-c6c7-477e-b0d0-15055069f42e" xlink:href="lxrx-20200930.xsd#lxrx_BioPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_b8d1650d-579c-4c78-8168-9ab0fd5d76d5" xlink:to="loc_lxrx_BioPharmaMember_3e177a76-c6c7-477e-b0d0-15055069f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b6458ce4-a32f-40b4-9465-69786d77e3a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:to="loc_srt_StatementScenarioAxis_b6458ce4-a32f-40b4-9465-69786d77e3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_25a03991-9eaa-46a3-823a-5edc9f23f1d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b6458ce4-a32f-40b4-9465-69786d77e3a2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_25a03991-9eaa-46a3-823a-5edc9f23f1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_27064a18-80b3-4d7b-be21-3a6ac6b78874" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_25a03991-9eaa-46a3-823a-5edc9f23f1d4" xlink:to="loc_srt_ScenarioForecastMember_27064a18-80b3-4d7b-be21-3a6ac6b78874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1fd2e5b9-c781-4ede-9c12-fa81957e6fcb" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RDSeveranceCostsMember_44faf3b6-9c5a-458d-85d3-7da918e6e955" xlink:href="lxrx-20200930.xsd#lxrx_RDSeveranceCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:to="loc_lxrx_RDSeveranceCostsMember_44faf3b6-9c5a-458d-85d3-7da918e6e955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SGASeveranceCostsMember_1d785382-cd76-4607-9ae8-a69a67f7efa5" xlink:href="lxrx-20200930.xsd#lxrx_SGASeveranceCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e6fe5c0b-9dce-4e15-bfdc-6cd7993c1be8" xlink:to="loc_lxrx_SGASeveranceCostsMember_1d785382-cd76-4607-9ae8-a69a67f7efa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3328fb72-fc0d-4e39-b968-6215842d9768" xlink:to="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5504e054-dad0-401a-9c4c-1051a9f4f8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5504e054-dad0-401a-9c4c-1051a9f4f8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7179a24f-c76e-49ce-82aa-2df813b21db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dd655d49-3158-47b4-8c9b-6bd92c407ce6" xlink:to="loc_us-gaap_SeveranceCosts1_7179a24f-c76e-49ce-82aa-2df813b21db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_936f229d-90c0-4522-ac88-537f3d054e36" xlink:href="lxrx-20200930.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0fc3d96c-c9b1-4ace-9b64-5039c00a9839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_936f229d-90c0-4522-ac88-537f3d054e36" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_0fc3d96c-c9b1-4ace-9b64-5039c00a9839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_c2e0b68e-7de4-4ab7-a9d9-5491f98564c4" xlink:href="lxrx-20200930.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_c19ba9b3-b4a2-4318-b32b-71aeeb9850e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_c2e0b68e-7de4-4ab7-a9d9-5491f98564c4" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_c19ba9b3-b4a2-4318-b32b-71aeeb9850e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_606532f9-e396-4b5a-88be-e00632f89a10" xlink:href="lxrx-20200930.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_4bf5e4ca-a30d-4298-9ee9-bd7071117f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_606532f9-e396-4b5a-88be-e00632f89a10" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_4bf5e4ca-a30d-4298-9ee9-bd7071117f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d3c005fc-6617-4339-9a28-010d1fa6f820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_4bf5e4ca-a30d-4298-9ee9-bd7071117f20" xlink:to="loc_us-gaap_InvestmentTypeAxis_d3c005fc-6617-4339-9a28-010d1fa6f820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_d3c005fc-6617-4339-9a28-010d1fa6f820" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_8766feae-c927-4d62-b852-9196c9dfc63a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_CashMember_8766feae-c927-4d62-b852-9196c9dfc63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_93d22b58-2e2b-45ff-b021-0f1172690c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_93d22b58-2e2b-45ff-b021-0f1172690c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_e498e002-c64e-417d-96a3-2db4708a548a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_e498e002-c64e-417d-96a3-2db4708a548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_1ea531ea-5229-455a-a851-a22b740c8868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_InvestmentsMember_1ea531ea-5229-455a-a851-a22b740c8868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_2d5eca5a-0ac1-4682-99a2-222a5dc69d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e16d15ce-99af-4ee6-b375-1d0b8b5ed4b9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_2d5eca5a-0ac1-4682-99a2-222a5dc69d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_4bf5e4ca-a30d-4298-9ee9-bd7071117f20" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_a9e1f538-d1af-4645-b2ce-5f4be182ac47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_a9e1f538-d1af-4645-b2ce-5f4be182ac47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5fa8e221-ee22-42e2-99a9-ac99e48ea761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5fa8e221-ee22-42e2-99a9-ac99e48ea761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29f83663-841a-4c1d-bff0-1720dda0b5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29f83663-841a-4c1d-bff0-1720dda0b5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_01d3034a-2d41-4c59-b35d-8323f0f88937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c185a1d-f93d-4a71-a300-c256f18a0753" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_01d3034a-2d41-4c59-b35d-8323f0f88937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_35902d08-3e68-41dd-ae75-a8137e8f27f5" xlink:href="lxrx-20200930.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_d4c0385b-9c80-435d-a6b5-e7610f25cba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_35902d08-3e68-41dd-ae75-a8137e8f27f5" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_d4c0385b-9c80-435d-a6b5-e7610f25cba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_2ffbc766-d580-440a-93c7-c8eba58e8b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_d4c0385b-9c80-435d-a6b5-e7610f25cba6" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_2ffbc766-d580-440a-93c7-c8eba58e8b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_2e641a09-64b5-4b41-bb71-55bc5516a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_2ffbc766-d580-440a-93c7-c8eba58e8b06" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_2e641a09-64b5-4b41-bb71-55bc5516a9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_56aa812c-ee01-401f-b2b7-65081e65e15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_d4c0385b-9c80-435d-a6b5-e7610f25cba6" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_56aa812c-ee01-401f-b2b7-65081e65e15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_74395092-9f46-47b2-a573-c4f4616d9dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_56aa812c-ee01-401f-b2b7-65081e65e15f" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_74395092-9f46-47b2-a573-c4f4616d9dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_2c0ef0c4-4a53-4fbc-8003-4cd98abb4322" xlink:href="lxrx-20200930.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_ed3521f0-29f2-4cc2-8ed2-92b99957832e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_2c0ef0c4-4a53-4fbc-8003-4cd98abb4322" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_ed3521f0-29f2-4cc2-8ed2-92b99957832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_771c824f-a7f0-4575-bcbb-3b42d2edc608" xlink:href="lxrx-20200930.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1389051e-d1d4-4d90-a8e9-ad4501de0db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_771c824f-a7f0-4575-bcbb-3b42d2edc608" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_1389051e-d1d4-4d90-a8e9-ad4501de0db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20200930.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_73157b8f-1dfb-45f5-a6ec-c03355ef94a9" xlink:href="lxrx-20200930.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_49b01283-37d2-4bff-9934-cec365679de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_73157b8f-1dfb-45f5-a6ec-c03355ef94a9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_49b01283-37d2-4bff-9934-cec365679de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_49b01283-37d2-4bff-9934-cec365679de7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9dc08ff3-b9a3-4d9e-93d9-f9cbdaa75a12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bcacf46a-c126-4a12-a968-923c46028eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bcacf46a-c126-4a12-a968-923c46028eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c6144f5a-2bf7-4f2d-8a5c-46d4026db629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c6144f5a-2bf7-4f2d-8a5c-46d4026db629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e2449e1e-49cb-4f48-8904-d54b0d8442f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_589ae3ac-a4f9-44e3-bf6a-61a6ce2fb8b7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e2449e1e-49cb-4f48-8904-d54b0d8442f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_49b01283-37d2-4bff-9934-cec365679de7" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_04fe263d-c85b-4e79-ade6-7d2231b726c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_04fe263d-c85b-4e79-ade6-7d2231b726c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_039e3daa-4562-4da0-bd3a-1b45b4db68f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_039e3daa-4562-4da0-bd3a-1b45b4db68f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_57d9cc54-bda1-4714-89ad-5b566765e82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5175dd38-92b2-4d9e-8046-a60996491e2b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_57d9cc54-bda1-4714-89ad-5b566765e82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_5cfea2ee-a12f-4645-8093-c29f251b2ddd" xlink:href="lxrx-20200930.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fe5bda19-962c-4c38-890d-fcf11cf23a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_5cfea2ee-a12f-4645-8093-c29f251b2ddd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fe5bda19-962c-4c38-890d-fcf11cf23a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#DebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_e812200b-ac60-4614-bb21-3a68e722646f" xlink:href="lxrx-20200930.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_e812200b-ac60-4614-bb21-3a68e722646f" xlink:to="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_24d303f5-77a0-4f23-995e-c305cffc20c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_24d303f5-77a0-4f23-995e-c305cffc20c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c1fbc8e5-44b5-4a7a-960d-1f4fabe5255c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_24d303f5-77a0-4f23-995e-c305cffc20c6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c1fbc8e5-44b5-4a7a-960d-1f4fabe5255c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a05b251e-f43f-4109-acf1-33b62cfbbc9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c1fbc8e5-44b5-4a7a-960d-1f4fabe5255c" xlink:to="loc_us-gaap_SubsequentEventMember_a05b251e-f43f-4109-acf1-33b62cfbbc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ec4b0f3d-5264-42a9-9a12-75f672f479f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ec4b0f3d-5264-42a9-9a12-75f672f479f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ad927d3-789d-485c-ab35-3cb02e7714cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ec4b0f3d-5264-42a9-9a12-75f672f479f3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ad927d3-789d-485c-ab35-3cb02e7714cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_782616ba-4be3-4165-a6ec-bb78cc66d75a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_782616ba-4be3-4165-a6ec-bb78cc66d75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe32d339-8504-4adb-a0f7-7fcd822403f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_782616ba-4be3-4165-a6ec-bb78cc66d75a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe32d339-8504-4adb-a0f7-7fcd822403f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd5bdf64-1f6b-43b0-977f-a7ec795f17f7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d3bd5905-9719-4303-8415-5a7572aa44e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d3bd5905-9719-4303-8415-5a7572aa44e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_69581f9c-0577-4b7c-a887-5a952055d7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_69581f9c-0577-4b7c-a887-5a952055d7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_ae4f87d9-d4f7-4504-923c-0c3fd9781f40" xlink:href="lxrx-20200930.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_ae4f87d9-d4f7-4504-923c-0c3fd9781f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c0d885d-8f06-438c-9b12-14133944eb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_6c0d885d-8f06-438c-9b12-14133944eb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b8fc5a5f-0cef-4c38-bf16-89bb6185a221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_b8fc5a5f-0cef-4c38-bf16-89bb6185a221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_c2d7de8a-6b7d-4a8e-bde1-cd91afd6cb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_c2d7de8a-6b7d-4a8e-bde1-cd91afd6cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_360122ee-5f70-4051-9c77-c1ccdee83079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_360122ee-5f70-4051-9c77-c1ccdee83079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_25e27949-297e-446c-a2f0-a78129956b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_25e27949-297e-446c-a2f0-a78129956b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_3965ddca-0b80-48be-877f-6ae9169b11b2" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInstrument_Revere_LXRX"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtInstrument_Revere_LXRX_3965ddca-0b80-48be-877f-6ae9169b11b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_89b2a004-be50-4aaf-afd6-6e7e3ae75ab7" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInterestRate_Base_Revere_LXRX"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX_89b2a004-be50-4aaf-afd6-6e7e3ae75ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_774114de-0249-400c-a568-4a2c6fc89ee2" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX_774114de-0249-400c-a568-4a2c6fc89ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_MortgageDebtBalloonPayment_LXRX_73f3bb59-bda3-464d-9161-90eb0aa7397a" xlink:href="lxrx-20200930.xsd#lxrx_MortgageDebtBalloonPayment_LXRX"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_MortgageDebtBalloonPayment_LXRX_73f3bb59-bda3-464d-9161-90eb0aa7397a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_650be34a-438e-4a78-8982-ddadf4914a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_650be34a-438e-4a78-8982-ddadf4914a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c336af03-e344-4754-ad35-1808f2799bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c336af03-e344-4754-ad35-1808f2799bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b6613d12-7fc6-4be1-b595-73aec4465e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_b6613d12-7fc6-4be1-b595-73aec4465e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_534d25bf-ab7b-4001-8363-3478322d846e" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchange_534d25bf-ab7b-4001-8363-3478322d846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_841af6b3-55f1-4534-a304-f4c6f1250735" xlink:href="lxrx-20200930.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_AccruedInterestOnConvertible_841af6b3-55f1-4534-a304-f4c6f1250735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a68c17f-53fe-487b-8d7d-cb64a216c78d" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_4a68c17f-53fe-487b-8d7d-cb64a216c78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_83e7dc5c-4dc7-4f20-b701-8a5b818b1e78" xlink:href="lxrx-20200930.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_83e7dc5c-4dc7-4f20-b701-8a5b818b1e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_209f33cc-a7f9-4162-84a8-769a38997491" xlink:href="lxrx-20200930.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_209f33cc-a7f9-4162-84a8-769a38997491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_33e07875-b6cf-44ef-bc74-76617ebcc9ff" xlink:href="lxrx-20200930.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_33e07875-b6cf-44ef-bc74-76617ebcc9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_d8da276d-0285-4f7c-965a-d900cff44462" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_d8da276d-0285-4f7c-965a-d900cff44462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount_7a70d4af-76b7-4f50-8538-f08cb97a4faf" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount_7a70d4af-76b7-4f50-8538-f08cb97a4faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_0163f877-6192-4f6a-ba28-8385953f44ae" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_0163f877-6192-4f6a-ba28-8385953f44ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_b1d59009-a7a0-4db0-9ce5-6d43402c2794" xlink:href="lxrx-20200930.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_43c53bdf-dccf-40e7-b442-170c2047a3d8" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_b1d59009-a7a0-4db0-9ce5-6d43402c2794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5175fe68-264c-41ac-af19-c4126b7ed2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_425f6897-9d43-477f-b462-59a6976c8536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5175fe68-264c-41ac-af19-c4126b7ed2e2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_425f6897-9d43-477f-b462-59a6976c8536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e37fe24-8162-41f9-882b-b2842bdcd48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_f2171154-2e92-4cc8-b790-f0836be0e82e" xlink:href="lxrx-20200930.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e37fe24-8162-41f9-882b-b2842bdcd48c" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_f2171154-2e92-4cc8-b790-f0836be0e82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_0f382649-46e4-463a-89e5-d35ab17adc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e37fe24-8162-41f9-882b-b2842bdcd48c" xlink:to="loc_us-gaap_OtherCommitmentsTable_0f382649-46e4-463a-89e5-d35ab17adc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86977555-1675-431c-8f95-74eed3f5cf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0f382649-46e4-463a-89e5-d35ab17adc7a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86977555-1675-431c-8f95-74eed3f5cf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4512042b-e53e-4154-ad59-9aa594cb7844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86977555-1675-431c-8f95-74eed3f5cf6f" xlink:to="loc_us-gaap_ReceivableTypeDomain_4512042b-e53e-4154-ad59-9aa594cb7844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_17fb03a6-bdeb-439f-af67-5fd24d8c5cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_4512042b-e53e-4154-ad59-9aa594cb7844" xlink:to="loc_us-gaap_AccountsReceivableMember_17fb03a6-bdeb-439f-af67-5fd24d8c5cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f13b1ffd-347b-4d8e-bf87-bae56892f5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0f382649-46e4-463a-89e5-d35ab17adc7a" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_f13b1ffd-347b-4d8e-bf87-bae56892f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d344b168-3b55-43ae-b7e2-704d6d909bec" xlink:href="lxrx-20200930.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f13b1ffd-347b-4d8e-bf87-bae56892f5e4" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_d344b168-3b55-43ae-b7e2-704d6d909bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_84262b05-c6a5-4d15-90ca-636098ea469e" xlink:href="lxrx-20200930.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e99d5d9b-e1bb-40a9-89cc-60f78cd92616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_84262b05-c6a5-4d15-90ca-636098ea469e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e99d5d9b-e1bb-40a9-89cc-60f78cd92616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:href="lxrx-20200930.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_9ff41c27-0b15-4fb4-8956-0ff1352e2cad" xlink:href="lxrx-20200930.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_9ff41c27-0b15-4fb4-8956-0ff1352e2cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_d6db0c32-4d41-4e3a-9f8e-dbc739180db5" xlink:href="lxrx-20200930.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_SanofiRevenueRecognized_d6db0c32-4d41-4e3a-9f8e-dbc739180db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments_62b21d57-ec57-4267-b678-2b8e424b1ab7" xlink:href="lxrx-20200930.xsd#lxrx_IpsenTotalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenTotalPayments_62b21d57-ec57-4267-b678-2b8e424b1ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_593cb5c3-ad26-4c21-9550-79778672599c" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMaximumRegulatoryAndCommercialMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones_593cb5c3-ad26-4c21-9550-79778672599c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_920db3b1-a3f3-4a35-9ff3-fbb6f06c3c02" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_920db3b1-a3f3-4a35-9ff3-fbb6f06c3c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalUpfrontPayments_4dc16126-98f4-4f00-8294-c8ddde49db83" xlink:href="lxrx-20200930.xsd#lxrx_IpsenTotalUpfrontPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenTotalUpfrontPayments_4dc16126-98f4-4f00-8294-c8ddde49db83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment_41de8c68-99aa-4c48-ba1c-afec65addb9a" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenMilestonePayment_41de8c68-99aa-4c48-ba1c-afec65addb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_862581e3-12d5-4408-a6ec-7966372691b2" xlink:href="lxrx-20200930.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_862581e3-12d5-4408-a6ec-7966372691b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_6614a204-4b62-415d-8be1-d7118b23ceea" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueAllocatedtoLicenseDeliverable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable_6614a204-4b62-415d-8be1-d7118b23ceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_75ac2d26-eeea-4ed4-b512-27e11609d3b7" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_75ac2d26-eeea-4ed4-b512-27e11609d3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_51304871-e00f-4c8c-ac58-9a40becb30fb" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable_51304871-e00f-4c8c-ac58-9a40becb30fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_1d56b154-61eb-44ed-abe8-ae094905c868" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenRevenueRecognized_1d56b154-61eb-44ed-abe8-ae094905c868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment_4488faf3-815f-439e-85fc-916e88091b2a" xlink:href="lxrx-20200930.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_Lxrx_sanofiInitialCashPayment_4488faf3-815f-439e-85fc-916e88091b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRoyaltyIncome_LXRX_9840bcb9-2781-486b-b907-80787ec65aee" xlink:href="lxrx-20200930.xsd#lxrx_IpsenRoyaltyIncome_LXRX"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_9d345b81-8b46-40e0-ae3c-467ce8500504" xlink:to="loc_lxrx_IpsenRoyaltyIncome_LXRX_9840bcb9-2781-486b-b907-80787ec65aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildings" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildings"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_8fd52c44-8b10-4c3a-850c-eb61c904a93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock_8235f4d6-3fa1-4dd7-929a-674d12ad984e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_8fd52c44-8b10-4c3a-850c-eb61c904a93c" xlink:to="loc_us-gaap_AssetImpairmentChargesTextBlock_8235f4d6-3fa1-4dd7-929a-674d12ad984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildingsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_0745b7e8-53b0-4ac7-b446-d6e7770cbe88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ImpairmentLossonBuildingsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_04806646-9757-428d-bd24-effd69af47c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AssetSalePrice_a79b4e65-301c-4978-9285-c97c754ba563" xlink:href="lxrx-20200930.xsd#lxrx_AssetSalePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_04806646-9757-428d-bd24-effd69af47c3" xlink:to="loc_lxrx_AssetSalePrice_a79b4e65-301c-4978-9285-c97c754ba563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies" xlink:type="simple" xlink:href="lxrx-20200930.xsd#ComprehensiveTextBlockListPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_dd6fdc65-7b47-4405-ba2a-cf358e3fd318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_c72af9e6-af8b-4fed-8ff3-3d22323f3cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_dd6fdc65-7b47-4405-ba2a-cf358e3fd318" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_c72af9e6-af8b-4fed-8ff3-3d22323f3cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89b8f7b0-e846-4885-9ea7-96d59df9819a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1597fc4e-a6c7-4c81-9a0c-e2bb9ebfde1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89b8f7b0-e846-4885-9ea7-96d59df9819a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1597fc4e-a6c7-4c81-9a0c-e2bb9ebfde1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3620b9bd-b104-4bda-ab2a-bcd52ebca51b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3b65f334-6d4c-47a8-82ea-69d01ed4268d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3620b9bd-b104-4bda-ab2a-bcd52ebca51b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3b65f334-6d4c-47a8-82ea-69d01ed4268d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="lxrx-20200930.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_87425b88-0b69-4b53-afa5-bf61faf84a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_87425b88-0b69-4b53-afa5-bf61faf84a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_69c15953-466c-42d5-bff2-36b458f9153c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_69c15953-466c-42d5-bff2-36b458f9153c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e975f1b-07a5-4c23-8981-67c9ba36961d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2e975f1b-07a5-4c23-8981-67c9ba36961d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_eaa88e44-f47b-477b-a2f7-8debd16de91f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_EarningsPerShareBasic_eaa88e44-f47b-477b-a2f7-8debd16de91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fcf54e40-8899-4adb-8950-193a742ddf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fcf54e40-8899-4adb-8950-193a742ddf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b5c2e74-56eb-49c3-baa1-e76769cfb255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b5c2e74-56eb-49c3-baa1-e76769cfb255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd511b56-459f-425b-8580-0d1df29672a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_NetIncomeLoss_bd511b56-459f-425b-8580-0d1df29672a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_55bcbd68-b599-4f53-91a5-5bb881056c37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_55bcbd68-b599-4f53-91a5-5bb881056c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_66ae42f7-9366-449d-80f2-a12a18d40b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_66ae42f7-9366-449d-80f2-a12a18d40b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8084d1d8-6bc3-4de9-89c5-75ea5f6fe69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3f81ee8-804c-447e-b010-ec9d0dfee001" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8084d1d8-6bc3-4de9-89c5-75ea5f6fe69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>lxrx-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20200930.xsd" xlink:type="simple"/>
    <context id="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea929173f03e4cdaac61287b22eed9ce_I20201026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-10-26</instant>
        </period>
    </context>
    <context id="ic3dc746618934941bc63c22f6053b48a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i47dc383a1189487da19aa61e7d8cdb1e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic39cf4efb3ba498c83f75720de63977b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb255e5708f44e258e296c77abef2148_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if3ef5ec99dcc48139089e172def809d5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7e0186178fef405988c9dab2a47db5fa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3a5003c76dd14af1bb7e8ed41020e64a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if69a42b36ef4432baa90bafa0b87bb11_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ide9306242f52400fb1ec1c48fdb617e8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia29409cf569f4995a1b8cd001ef00215_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9a2f0553a5a443f5aea2354fbbc8b9d7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if9180a0741154feab5264fc1b9481852_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6241124cc1d84b06aee3d4a995daa961_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i65ef45941bee44658e4e342d2743291a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i32edc2966d164232b4ab121550c17328_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iea93e62cb33048baa2d377777e96a31a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id5cd53676cec4b749440e76527ef3861_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i354181d4c7a546109de1070307761bf2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iab400eacbd9f495eac7d85037d5b894c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9ea33b9cf6f84275ab78882aff5c053e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i53842116e47c4c769795760d6b233005_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7eb48dd69257444d8e09beb702199378_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i98bf3f0537624ef3b1647b80d52ad9f0_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1764073b5f5c4207b578324f9d515f7c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4c45f9e1311a4a0bacccdec8642a2255_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i332232b87eed4ee0aff6a523ea254baf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i83b8ebfcf0c04a91bf51a889ee42089b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iea1b38341d5b40bfb0ded9fbd0ed8901_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5133b99acae94f1cbb47b475caaef535_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i72c686e1acee419aaf3b5b0c644d31e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f874d70a3f146138ef4f3c91a8a1390_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i227451f24d98477b8bbc0d386d19ce16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33ff9ea196e54e5eb3b7e68af2e1a1dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief1f3693c2c8436da37a4d613523cf19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2b9122c88b08450aa943128ce8672322_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i93b273419a904b9b943ab1c586c82cf2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i05d9a031b3a643939dc4946a532cd59f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iab8293cbb3b949feb1319baf6e0ac30c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i61ccbc50ca4646b7a6ca13720db0cd51_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id927be22b9564e918ad8233bbc7d2bca_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i232b139d9b954a9f988af16e8e822240_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie771e05af7234472aef6bd918b9dbe61_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i89afbb9e0fbb43e182f2150249faef37_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia46fdf6eabe5409c982b14a8191c786a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1e76433e64224cd28783a0ed1b5ea7b3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9867c02a657c412fa47e3e6fe91bccea_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib4615026499f4eaa986552fc1dfbd77a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91fb5ae41331461dac39acd650838e01_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c622449e7a742b49bfa687466d2cb4d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id0b359f3f2e54a4ca7516f16d229ef6d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i580af670a9ce4ccb936a88ec2d87b2c8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaed950d6bbe64a719b452fb582108b70_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if0699896381d48e7ad6adc8daae2f1d7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i170f779ba4fd4cdb814e7d6c94490a0b_I20200908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="i806bb79355704a3d9f9e975c7764b751_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7902597037c2463d85d00a4b46bdb6db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6dd55aa47b494c508a8707104b290757_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i16d499c22b144586ab5b1747d70c9923_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52b7cb3d54a24978a2f81d13fb5f8bf0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i45dc5d23ea3b4654bc9d1ccd692ebca9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab6089ded0c145f3a665941d75632fdf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lxrx:RDSeveranceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90f2f211830347d7b962a9ddc24c8919_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">lxrx:SGASeveranceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1258c23791be46e7aa4cc649d072022f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i73a1a6fc719140c08724cb429ea2062e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4a47a08149c54860b477528661d2c215_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i22ab63a51cfe4a52baceee717c7ac021_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifee8595c4e7d498db92de4c18088f054_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i987c8a7c27f2446f9cf494575a39b8e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i598b1a29343d4deda20d232162634172_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i338bf2c2e7b6442b8ab5f089399b8061_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16df9c6c19c64790a5837cf1d79351ff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5d3c3a225f534e188a9ebe0475319a1b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i99f83f9e3d794affb390e88fc81fa72e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d7b6895d6da4c09ac7535756e184174_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1772c994ba65403ca45d1f126c089301_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="i17b3093f9ba14f25864a4923a0f67585_I20141120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2014-11-20</instant>
        </period>
    </context>
    <context id="i9b46f889feff422fb423fe1a658c6727_I20200928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-09-28</instant>
        </period>
    </context>
    <context id="id46df437a0a442c4bead16cb71e6341a_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i2a5c874e6c9e48619cce1b61357c131e_I20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2018-08-30</instant>
        </period>
    </context>
    <context id="if73dd8addd4542a29c4ec9debd3582d1_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="ifb39716de56e4e5a895227f8630d9df3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">lxrx:BioPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb5076221df34ff6b100b90bb7f27cf6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ia91cc58958d74a18bc3bdc7678de13fc_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i0c565ac789974012b970ac1ab822623b_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i813cb4fdefa8444c86cc8630f57e27da_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i795f1b1257384f238c4605db9c94d3e7_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i2fd1f447a93c4793b6c6a92f2e209e1e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i381201bb0bd34c48a7207b7c78990cd8_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-10-01</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="ia4193bd56cb84f0d9f797512013ed041_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i2e87a1738c194bf0b536c8857a3ca790_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N181LTQtMS0xLTA_1470fcab-bda3-4994-822c-407990644a08">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N185LTQtMS0xLTA_9a21778f-f48b-4dd2-a981-7289a7bdeeb8">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N18xMC00LTEtMS0w_b45bc851-570d-4961-95af-5972694590aa">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N18xMS00LTEtMS0w_61e85acc-ee61-4ca5-a0b4-46d11af65c4c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80L2ZyYWc6MmE0NGJlNTFkYTY5NGEzNGFjMDZiOTk5MWI2NmZhMTgvdGFibGU6ZjAwMzZiMmE3NWIzNGEzMGFjYzFlZGRhMjIzODBjNzcvdGFibGVyYW5nZTpmMDAzNmIyYTc1YjM0YTMwYWNjMWVkZGEyMjM4MGM3N18xNC00LTEtMS0w_a7b86ea5-6d88-432f-8fb0-1de9b3e5b55c">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF84Mg_97ec6ed1-317c-4a0a-8a2e-c5b4a708298a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6MWM1YmY4NGE1MThjNDMzNzliMjVlMGM3Yjc2NjE4NGQvdGFibGVyYW5nZToxYzViZjg0YTUxOGM0MzM3OWIyNWUwYzdiNzY2MTg0ZF8wLTAtMS0xLTA_3067cc6a-89e9-4e8f-9374-466c5a6c4dda">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8xNjk_4e572abd-475f-4a60-b452-7bb7f7538a00">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6MmE3YjU1NTAyZjhlNDQ3MTg5YzM4YTNhNGYxNzVkMWQvdGFibGVyYW5nZToyYTdiNTU1MDJmOGU0NDcxODljMzhhM2E0ZjE3NWQxZF8wLTAtMS0xLTA_da8593e6-98c2-4525-befb-f8e999632835">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yNjU_9a72cde9-741d-42b3-8e35-619880f6e8d2">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yNjg_a31f142a-0ab9-4fec-b641-93e2375e3c3d">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTAyNjgxMWE5MWU0NGJkOGFlMmQ2N2ViMGJjMzc0ZTEvdGFibGVyYW5nZTo1MDI2ODExYTkxZTQ0YmQ4YWUyZDY3ZWIwYmMzNzRlMV8wLTAtMS0xLTA_521e8cc9-adba-4345-a823-9e4459dafbb7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTAyNjgxMWE5MWU0NGJkOGFlMmQ2N2ViMGJjMzc0ZTEvdGFibGVyYW5nZTo1MDI2ODExYTkxZTQ0YmQ4YWUyZDY3ZWIwYmMzNzRlMV8wLTEtMS0xLTA_517eb29e-a281-4e0a-9c27-3a8aa50f4d3f">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMjg_96f47500-7da8-4a5a-b030-06542f8bfa3f">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMzE_94ce2566-7dc9-4b03-a98b-d8aef7cde444">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMzU_5677a01f-5637-46ae-8301-36874b7fee50">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zMzg_5b40b80f-2758-470f-b77d-99f26a46dc47">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8zOTY_49088fbb-feb4-435a-951f-31bc79d2f882">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF80MDA_e6a041a4-db19-4ca9-b363-4dfba25a0e6b">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTdjZjc0MmI3YzE5NGVjNGExNGRjMTI3OWFhNTJkMWMvdGFibGVyYW5nZTo1N2NmNzQyYjdjMTk0ZWM0YTE0ZGMxMjc5YWE1MmQxY18xLTAtMS0xLTA_b95fe50c-962a-42a5-aad9-01c1076d1c6e">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTdjZjc0MmI3YzE5NGVjNGExNGRjMTI3OWFhNTJkMWMvdGFibGVyYW5nZTo1N2NmNzQyYjdjMTk0ZWM0YTE0ZGMxMjc5YWE1MmQxY18xLTEtMS0xLTA_e200a056-a0b2-42e4-bcab-03d399476e49">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NTdjZjc0MmI3YzE5NGVjNGExNGRjMTI3OWFhNTJkMWMvdGFibGVyYW5nZTo1N2NmNzQyYjdjMTk0ZWM0YTE0ZGMxMjc5YWE1MmQxY18xLTItMS0xLTA_09b90623-8d08-464d-8ba8-4d384ecd92fa">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6YWUwNDY2ZWQ3OTlhNDllYjhmZTI4NWE1YjE4NDdhMDAvdGFibGVyYW5nZTphZTA0NjZlZDc5OWE0OWViOGZlMjg1YTViMTg0N2EwMF8wLTAtMS0xLTA_663006bb-eecc-4734-b259-b66c23292847">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6NWZiYzczYjQ5MWFjNDhkNWI1ZmRjMDQ0NmE0OWFlY2UvdGFibGVyYW5nZTo1ZmJjNzNiNDkxYWM0OGQ1YjVmZGMwNDQ2YTQ5YWVjZV8wLTAtMS0xLTA_3dbcabcf-b276-42f0-8463-89ac05e997f4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8xNTY1_587dc535-2f19-4f8c-a14c-ef3889002cea">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yMTY4_1cac8d3b-1847-498d-98c1-8dd5710f9e8d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8xNjg0_0cbea6ee-fc4c-404c-a986-ec4f6a934491">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGFibGU6YWNhYjdkMDk4NGY2NDcxMjk0NWFiMTBmYjc0MjU2YjIvdGFibGVyYW5nZTphY2FiN2QwOTg0ZjY0NzEyOTQ1YWIxMGZiNzQyNTZiMl8wLTEtMS0xLTA_59819a9c-1906-4d54-858e-55fd748f04cc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iea929173f03e4cdaac61287b22eed9ce_I20201026"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xL2ZyYWc6N2E5OTllYjM5M2YzNDM5Y2IzNWQwZWQzOGNjNjNmMDQvdGV4dHJlZ2lvbjo3YTk5OWViMzkzZjM0MzljYjM1ZDBlZDM4Y2M2M2YwNF8yMDc3_472c29c4-76c8-4e50-9d8a-d7de3a4afe64"
      unitRef="shares">117474808</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNC0yLTEtMS0w_e21e73e3-3ab6-4ad9-b016-7b50a8429073"
      unitRef="usd">52251000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNC00LTEtMS0w_a8ea43cc-cba1-493d-8902-43158cd5b8d1"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNS0yLTEtMS0w_ba0b3d42-1e7b-42c4-9faf-a0186ee51ede"
      unitRef="usd">59195000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNS00LTEtMS0w_3b67d912-c8d4-4d2b-b6e3-8b384c4a8950"
      unitRef="usd">235547000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNi0yLTEtMS0w_7cd0f796-5963-472c-a42f-2d4569c0988d"
      unitRef="usd">1383000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfNi00LTEtMS0w_25acfcd7-f378-4ed8-9578-50a52baac51d"
      unitRef="usd">56532000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOC0yLTEtMS0w_3f45fe17-b085-4e76-b4aa-af55fb0a85da"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOC00LTEtMS0w_600f4f5a-045c-49a4-9d35-9c06b475048c"
      unitRef="usd">4243000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOS0yLTEtMS0w_9cddf5ef-5f29-44a9-94bc-554346be305e"
      unitRef="usd">9109000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfOS00LTEtMS0w_7ebc4af8-aa1d-4efb-bdb3-e3be8cce6628"
      unitRef="usd">5320000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTAtMi0xLTEtMA_d72752ed-3d9c-43b8-9782-ea80d0876953"
      unitRef="usd">121938000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTAtNC0xLTEtMA_6fb5b4d8-08be-44dd-9649-b2d10123ab57"
      unitRef="usd">337754000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjI0ODI1ZmJlNmY1NDQ4OGQ4YjliZWI2YmMyOGVkYmUzXzgw_8914c1ee-aae8-483d-a0b5-139f50a776ae"
      unitRef="usd">63795000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjI0ODI1ZmJlNmY1NDQ4OGQ4YjliZWI2YmMyOGVkYmUzXzg3_190fe0cd-1ad3-431d-9561-55ecb3481457"
      unitRef="usd">61741000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtMi0xLTEtMA_293a2c60-8187-42fa-9d6b-9f5008925196"
      unitRef="usd">11106000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTEtNC0xLTEtMA_531c2ce8-34da-42c8-9be2-ef218faf85a9"
      unitRef="usd">14047000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTItMi0xLTEtMA_c0ad677b-492c-43ec-931a-07d72a7e051c"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTItNC0xLTEtMA_44329c34-7bf9-4d03-bbfa-ee23a7b07d4f"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTMtMi0xLTEtMA_dbaef61f-0542-4298-9d31-146f58120ea3"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTMtNC0xLTEtMA_a82c6c96-a84d-40f3-9d36-2cc2916035e0"
      unitRef="usd">19716000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTQtMi0xLTEtMA_2d27b3e7-7091-4275-8e4c-750eacf069ac"
      unitRef="usd">1341000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTQtNC0xLTEtMA_9f101710-09f8-4ec4-99f4-ba67016871b9"
      unitRef="usd">1655000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTUtMi0xLTEtMA_5c4bd385-dfd8-452d-9b2b-c84dda0fc965"
      unitRef="usd">178928000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTUtNC0xLTEtMA_251b333c-eb10-4b7b-9d1e-e6ea655baba4"
      unitRef="usd">417715000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTgtMi0xLTEtMA_5a16bd69-c625-4530-90af-8a7093c51bc1"
      unitRef="usd">11734000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTgtNC0xLTEtMA_aa7e0a0f-089c-439d-b4d3-39e04323e679"
      unitRef="usd">12178000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTktMi0xLTEtMA_ad05b56d-8f07-48ee-9a48-1ab85db39576"
      unitRef="usd">58497000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMTktNC0xLTEtMA_13e8f63b-eaef-4790-9eae-f2c59b52edf6"
      unitRef="usd">42151000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjEtMi0xLTEtMA_79945f67-4892-4988-a0b1-135a142e88bd"
      unitRef="usd">8691000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjEtNC0xLTEtMA_abd0224a-1e58-4237-92c7-f202c1364f9a"
      unitRef="usd">11012000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjItMi0xLTEtMA_f84724bb-a4e1-444d-93ff-c8171cfb8c94"
      unitRef="usd">78922000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjItNC0xLTEtMA_e0180c46-eecd-41aa-bf85-76bf011a78da"
      unitRef="usd">65341000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjQtMi0xLTEtMA_d012ebd1-aa5b-42dd-b923-20b663a56c94"
      unitRef="usd">11629000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjQtNC0xLTEtMA_ada453ba-c2f3-48e7-b50d-161efa673379"
      unitRef="usd">234171000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjYtMi0xLTEtMA_51f472b3-19b6-482f-8331-cab1701370d1"
      unitRef="usd">738000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjYtNC0xLTEtMA_d14cc743-68b3-42f0-aa0b-3082e2634af4"
      unitRef="usd">1102000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjctMi0xLTEtMA_a074f1b3-7c51-4b71-97ac-aeba95f27717"
      unitRef="usd">91289000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjctNC0xLTEtMA_b0209815-7da9-4cb8-81d8-adfb280c1da7"
      unitRef="usd">300614000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjgtMi0xLTEtMA_21a972fd-4cf7-4467-b7d5-e6aba1295d14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMjgtNC0xLTEtMA_0bd288eb-fe3c-4bc2-aae6-36757130581c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzIy_3bb12007-94d5-4c69-aba6-37fa2f9272af"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzIy_59eb2b69-1a22-425b-b664-30286394efec"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzM2_535c7e29-4aa5-49ec-ab44-1b972702297c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzM2_733f6893-78c1-4210-8ae4-60ece29fd0a4"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_759d8874-6ad1-43cc-853d-bcea9fe6fee2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_7a25e55e-1f8f-46cc-a0ae-37cabddd1a6e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_a941d534-ca29-4595-a18f-771d47476263"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmI1Yzc2YjI0ZjA3NTQ3MTJhYmIyMjY1M2RiYzM5ZWVjXzU4_aa3c743e-080c-4369-b4c3-c2482afe4478"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtMi0xLTEtMA_8a08fc1c-ad28-4ed7-812c-785e857171b2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzAtNC0xLTEtMA_094838ea-b2d5-4161-b5fd-fb9dc13568ba"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzE4_388bf8fe-8fa5-459c-a168-81f2557d53c1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzE4_558a4074-eb91-4823-b162-3e56abf39098"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzMy_32748e33-276c-473b-92a9-1a963e2fced1"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzMy_d570c488-38d6-43ca-a422-7cd743088b7c"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzU0_9cf64de2-99cf-4d03-99f8-75dba7c8e6b6"
      unitRef="shares">117231000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmNiNTY2YzI1ZTRhNDRmMzA4MjVhMzAzOTE4MDMxMGU2XzYx_72ea5fd8-4182-4523-914c-da2709b68dad"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtMi0xLTEtMA_3e444cee-b2e6-427c-b8b4-8f4d6dab7f1b"
      unitRef="usd">117000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzEtNC0xLTEtMA_b766a576-f308-487a-9fbc-7992552c7a7b"
      unitRef="usd">106000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzItMi0xLTEtMA_6fb0b451-b204-4f4d-b071-ca0132b69820"
      unitRef="usd">1486853000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzItNC0xLTEtMA_6b3ccc7e-55dd-4e89-9c85-77f98bbbdd71"
      unitRef="usd">1462172000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzMtMi0xLTEtMA_1c55bdfd-9502-4e0c-973d-ec9ef809fd01"
      unitRef="usd">-1394523000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzMtNC0xLTEtMA_4a99d8fb-f624-499f-bfe6-bb4f1f5f3159"
      unitRef="usd">-1341444000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzQtMi0xLTEtMA_2c6ee8a0-2820-4dd4-b683-ed85375fcf16"
      unitRef="usd">35000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzQtNC0xLTEtMA_c24d9c58-e039-460c-b1c9-442d1e66bb62"
      unitRef="usd">84000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQwOTZlZTkwMWI3NDRmMjk4NzNjYzRkOTdjNjFkNmRlXzI5_4b06dc70-9983-42db-9380-705e890b0361"
      unitRef="shares">793000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQwOTZlZTkwMWI3NDRmMjk4NzNjYzRkOTdjNjFkNmRlXzM2_b7f3ad6c-7dcb-4aa1-a4c0-92b3ead9ebf7"
      unitRef="shares">407000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtMi0xLTEtMA_903c799d-00a0-4f34-89a9-e315ff102d9e"
      unitRef="usd">4843000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzUtNC0xLTEtMA_61aa7a97-3865-4721-a171-ecbb3b7543d6"
      unitRef="usd">3817000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzYtMi0xLTEtMA_8000c43f-a455-4fb4-9949-04ab2d321324"
      unitRef="usd">87639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzYtNC0xLTEtMA_54c5a903-e4d2-4165-9729-b039e1aded68"
      unitRef="usd">117101000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzctMi0xLTEtMA_348708d3-262a-4f2a-8e40-db0d4f962ca8"
      unitRef="usd">178928000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8xOS9mcmFnOmQ4MTA2YmNjNTJjZTQ5NTk4Y2Q5OTU1Y2YyYzc1ZGUwL3RhYmxlOjE4NTQ3NGY4NTQ1NzQyYjViOTU2NGJmNTFmYWFlNDYyL3RhYmxlcmFuZ2U6MTg1NDc0Zjg1NDU3NDJiNWI5NTY0YmY1MWZhYWU0NjJfMzctNC0xLTEtMA_0f706065-084a-4a5d-a495-30d9b92bd3ae"
      unitRef="usd">417715000</us-gaap:LiabilitiesAndStockholdersEquity>
    <lxrx:Netproductrevenue
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy0yLTEtMS0w_4b8e5385-a404-4c6f-9d87-5c702428a049"
      unitRef="usd">6542000</lxrx:Netproductrevenue>
    <lxrx:Netproductrevenue
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy00LTEtMS0w_9cf6bc9c-d894-4ca6-b484-eaba3e9dfc72"
      unitRef="usd">8351000</lxrx:Netproductrevenue>
    <lxrx:Netproductrevenue
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy02LTEtMS0w_f98aeca9-492b-447e-8eb2-6723df08cc4e"
      unitRef="usd">23404000</lxrx:Netproductrevenue>
    <lxrx:Netproductrevenue
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMy04LTEtMS0w_ae93a9ab-2dda-4bc1-81cf-ae434d7f83b6"
      unitRef="usd">23763000</lxrx:Netproductrevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC0yLTEtMS0w_324945af-294e-445e-ac8c-763c888f5b75"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC00LTEtMS0w_9393efda-8a4a-435a-bddf-52a93173295b"
      unitRef="usd">285910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC02LTEtMS0w_53abb406-d800-480a-bed2-9137055d6042"
      unitRef="usd">33000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNC04LTEtMS0w_45103d2d-9862-4646-ac85-6289e26cb9c8"
      unitRef="usd">289209000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS0yLTEtMS0w_cdac9e7e-a13a-40bb-a1f4-aace188a2558"
      unitRef="usd">92000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS00LTEtMS0w_89357ab4-1f4c-4977-8cec-b4be34296c7a"
      unitRef="usd">187000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS02LTEtMS0w_4fec0ebe-a6d9-49a0-9d33-5f8aba62f786"
      unitRef="usd">359000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNS04LTEtMS0w_79dccf7b-495b-4c76-a7ec-1fab0117dfda"
      unitRef="usd">374000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:Revenues
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi0yLTEtMS0w_0165a9fd-5f5b-4ac1-8708-678c096cad60"
      unitRef="usd">6634000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi00LTEtMS0w_094fbbcb-b28b-4f72-b9de-e9c2fdfd2700"
      unitRef="usd">294448000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi02LTEtMS0w_77cb9f17-9073-42b6-8d8a-02a3b5b482e3"
      unitRef="usd">23796000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfNi04LTEtMS0w_becdea60-b889-45c4-af5a-9f87bb22c4b1"
      unitRef="usd">313346000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC0yLTEtMS0w_0fe33069-8b23-49f4-bc84-d9492ce92ffb"
      unitRef="usd">633000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC00LTEtMS0w_0a1bc2d2-7399-4d17-8d61-0d8c968561ac"
      unitRef="usd">577000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC02LTEtMS0w_faba7f25-31ad-4a52-aa7b-1bae8a91049e"
      unitRef="usd">1929000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOC04LTEtMS0w_dc37c513-a0d3-48af-b914-2f85c5d8babe"
      unitRef="usd">2457000</us-gaap:CostOfGoodsAndServicesSold>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfNjg_1d48607e-95c1-426d-be3e-a2164b73243d"
      unitRef="usd">1029000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfNzI_76dfd68f-2e47-4796-b29b-e823ae221f59"
      unitRef="usd">1698000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfNzY_a1e9e7b9-ae04-4ba2-9764-609f4f378aad"
      unitRef="usd">5154000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0wLTEtMS0wL3RleHRyZWdpb246MmEyNGVkMjYwNzQxNGM2NjgzYWE2YTI5N2U3NTZhZmZfODM_2700ab6b-cc89-489a-8225-32a7f4a2a3ea"
      unitRef="usd">5369000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS0yLTEtMS0w_a47f1f94-9ebc-4c6a-8496-5f9ff7512da4"
      unitRef="usd">40147000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS00LTEtMS0w_adfd7646-232a-4b90-aa6b-baab437f448f"
      unitRef="usd">26659000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS02LTEtMS0w_3f05acde-6dfb-4bdf-b971-7738603442bf"
      unitRef="usd">152629000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfOS04LTEtMS0w_02db9d2d-9e1c-4844-8b16-e21f9dc9ee07"
      unitRef="usd">51318000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzc5_a90f6f6d-70df-4e59-a2a4-1d2c5ab9f49f"
      unitRef="usd">875000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzgz_74db910d-ff6f-4f77-aa39-fae06dbfadaf"
      unitRef="usd">1864000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzg3_d9b42675-1d3b-4d54-98f1-3aeaf2a30b13"
      unitRef="usd">5440000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjBhY2FhNGUzYzVlZDQ4ZDQ4YzMzZmJlNmUyZGFjMGRiXzk0_9e90776b-8113-4c5a-90ea-f116b4e9e93e"
      unitRef="usd">5370000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtMi0xLTEtMA_28eedee8-2080-46c9-9d68-ace4776587a9"
      unitRef="usd">11997000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtNC0xLTEtMA_e32324e1-e075-499d-a5c4-b93ea3886791"
      unitRef="usd">13898000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtNi0xLTEtMA_98a4131b-4db9-46c5-beeb-9740eb7db5a4"
      unitRef="usd">40798000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTEtOC0xLTEtMA_1bfc3a9f-651b-4517-a810-00fd3a9857cd"
      unitRef="usd">42271000</lxrx:Sellinggeneralandadministrativeexpenses>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItMi0xLTEtMA_d6476afe-1d1d-48c5-a520-855527ccfbbc"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItNC0xLTEtMA_1934de79-cbb4-4415-a5c4-3df91be899d0"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItNi0xLTEtMA_e0480255-1bbf-4c30-a623-8d7520dacfdf"
      unitRef="usd">1600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTItOC0xLTEtMA_ddddc0c5-c944-4b70-8f58-99d83da45757"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtMi0xLTEtMTcwNw_e17497f0-3c65-4db9-8dd3-68ea554919d7"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNC0xLTEtMTcwNw_eaf570f1-cea6-49bc-beb3-51ec48513fde"
      unitRef="usd">28638000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNi0xLTEtMTcwNw_598390ce-b0c6-4e6e-9ab6-9b81997a8411"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtOC0xLTEtMTcwNw_bc2c8f47-40e0-4ed0-8315-116ed1cb2e6d"
      unitRef="usd">28638000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingExpenses
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtMi0xLTEtMA_dd08b3ed-1eb0-4712-ae95-c458aeb3050c"
      unitRef="usd">52777000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtNC0xLTEtMA_f2a23d7c-f90f-4bac-ba27-22cb3ffac0a2"
      unitRef="usd">69772000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtNi0xLTEtMA_70201ed1-f8a1-491d-96a9-0f7c81cb43ac"
      unitRef="usd">196956000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTMtOC0xLTEtMA_f8b9f443-1494-4cc4-be4d-6314c592c1d7"
      unitRef="usd">124684000</us-gaap:OperatingExpenses>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctMi0xLTEtMjk3OA_f20283d6-f2c7-4ffc-a9f7-04bd26ed9e13"
      unitRef="usd">132818000</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNC0xLTEtMjk3OA_1bdd9e76-c08b-4606-8d15-aa2e32937fc8"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNi0xLTEtMjk3OA_f7c0b756-21c1-4edd-8ecc-4ef4b06f4fd0"
      unitRef="usd">132818000</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctOC0xLTEtMjk3OA_1739192e-c719-4d51-b451-8574e8b4f2d6"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtMi0xLTEtMA_deef3690-03ee-486a-990e-51377a0bbfb6"
      unitRef="usd">86675000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNC0xLTEtMA_4e66a982-a0c4-4117-8833-36f5e30c78d2"
      unitRef="usd">224676000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtNi0xLTEtMA_fd3e605f-8918-4953-82bc-33701c0f7840"
      unitRef="usd">-40342000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTQtOC0xLTEtMA_2d3092b1-53fd-4655-ad40-08d77b127bbe"
      unitRef="usd">188662000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtMi0xLTEtMTY5Mw_e001e4fa-40f8-40e5-8131-8e2c13849123"
      unitRef="usd">-255000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNC0xLTEtMTY5Mw_00e71993-74a5-472b-ab43-abcd382c04d0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNi0xLTEtMTY5Mw_e3445f6b-fdb8-46d6-8e2c-dfd24aae3332"
      unitRef="usd">-255000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtOC0xLTEtMTcxNQ_03bf7fee-7c11-4eef-8492-47007d0d36a9"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtMi0xLTEtMA_f210d62f-f91a-43e8-bb9b-7e1823264ab8"
      unitRef="usd">4118000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtNC0xLTEtMA_803d5306-159d-43e3-a2b4-e06e8287685e"
      unitRef="usd">5204000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtNi0xLTEtMA_8da4ecf0-12a6-4125-8903-b7f8ab434069"
      unitRef="usd">14374000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTYtOC0xLTEtMA_4c59ac7d-ecbb-41b1-8ca5-02076bd199cd"
      unitRef="usd">15485000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctMi0xLTEtMA_d34c5b7a-3049-41fc-866d-654d83cc21c7"
      unitRef="usd">301000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNC0xLTEtMA_c67e5b72-f1be-4630-af87-fd631785bf70"
      unitRef="usd">600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctNi0xLTEtMA_2cd3e5ed-32c7-4bdf-a914-befc950c7022"
      unitRef="usd">1892000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTctOC0xLTEtMA_69a12185-1034-43e7-97eb-b88bd659b24f"
      unitRef="usd">2080000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtMi0xLTEtMA_9de479ae-4e40-4e28-b1fa-0f00e993d548"
      unitRef="usd">82603000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNC0xLTEtMA_63a179d5-7b6a-477c-ae17-c4e1526ebc10"
      unitRef="usd">220072000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtNi0xLTEtMA_1e119b9e-d3fc-4355-b65f-46bb31c946d2"
      unitRef="usd">-53079000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTgtOC0xLTEtMA_d96f8999-8a83-4ca7-bf95-0bef6a90e9d7"
      unitRef="usd">175257000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktMi0xLTEtMA_7f6dbffc-b29e-4453-ad62-17b47e2372a1"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktNC0xLTEtMA_002104d4-4d11-49ab-b017-9d247912ce44"
      unitRef="usd">-6014000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktNi0xLTEtMA_299c18db-1b9d-430f-9877-01116c3e97bf"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMTktOC0xLTEtMA_1a411a41-2ac1-4b9e-8272-5838345bea95"
      unitRef="usd">-6014000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtMi0xLTEtMA_a1c75e31-3f36-417c-8a6c-23140eaffbc6"
      unitRef="usd">82603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtNC0xLTEtMA_3851af57-ad4c-4c3f-8e05-0e8c7aa29ae4"
      unitRef="usd">226086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtNi0xLTEtMA_3ff03380-0278-4351-9a84-7afed8d449ba"
      unitRef="usd">-53079000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjAtOC0xLTEtMA_b620c131-a373-497b-a262-1d3039e533e7"
      unitRef="usd">181271000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtMi0xLTEtMA_5bca442a-0ccf-4545-a51d-c587f1acc676"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtNC0xLTEtMA_be182d47-7038-4a7f-bbb1-eef7ae598237"
      unitRef="usdPerShare">2.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtNi0xLTEtMA_8ca3446d-b13c-40e8-97dd-d922d6e4c867"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjEtOC0xLTEtMA_c73e8007-37ad-4369-88c4-909f8450ea07"
      unitRef="usdPerShare">1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItMi0xLTEtMA_7ee69594-8118-40ee-b76a-d7648fee5789"
      unitRef="usdPerShare">0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItNC0xLTEtMA_93ab164b-ee97-4ad6-9772-73906f859199"
      unitRef="usdPerShare">1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItNi0xLTEtMA_ca36ba35-5105-49cd-a77b-a85269209543"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjItOC0xLTEtMA_0ce21719-dc7f-4545-bf9a-c29ce9cae880"
      unitRef="usdPerShare">1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtMi0xLTEtMA_0addcdfb-b806-40ca-ae9e-13e5ade795ff"
      unitRef="shares">107309000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtNC0xLTEtMA_29e1cf1a-323e-4d22-b313-56fa0a9cd000"
      unitRef="shares">106272000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtNi0xLTEtMA_3007e813-ebc2-4508-862b-7fa2c14cdd93"
      unitRef="shares">106974000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjQtOC0xLTEtMA_d658df1c-b00c-43a2-b0b1-86fdfbc5d5e4"
      unitRef="shares">106200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtMi0xLTEtMA_c225fdd3-d455-4d39-ab84-b77aa61e7df4"
      unitRef="shares">117552000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtNC0xLTEtMA_a449d26a-6dd0-450e-a59f-70303bbc5d35"
      unitRef="shares">116640000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtNi0xLTEtMA_97ec8eab-80cf-4faf-bffb-2768e5c07825"
      unitRef="shares">106974000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjUtOC0xLTEtMA_6d27ce67-3cfb-4001-9796-762b8f7e6e45"
      unitRef="shares">116742000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtMi0xLTEtMA_8d411e1c-01dd-441e-9386-19cef0ec1f0a"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtNC0xLTEtMA_286f9c57-ae92-40b7-9c0a-ad1890abb65c"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtNi0xLTEtMA_4e5af950-e766-47ef-af86-0a0f13c888e0"
      unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjgtOC0xLTEtMA_3bfa3c9f-2c59-4eeb-9ee3-6eb9cef4e87e"
      unitRef="usd">48000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktMi0xLTEtMA_1cf2a1f8-8ea0-4094-8455-83eab6b312b3"
      unitRef="usd">82326000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktNC0xLTEtMA_cd429bb8-48bc-448f-857e-d3afae0e4054"
      unitRef="usd">226036000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktNi0xLTEtMA_77044910-639c-4543-8d84-818f76c37048"
      unitRef="usd">-53128000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yMi9mcmFnOjlkZmI5MzFhYjc5NjQ0ZGQ4Njc5M2ZiMTQyMzE0MWZhL3RhYmxlOjg1ZjIwYjdlM2MwMjRjMTM4NzQxYzE4YmRhMDA3NDAwL3RhYmxlcmFuZ2U6ODVmMjBiN2UzYzAyNGMxMzg3NDFjMThiZGEwMDc0MDBfMjktOC0xLTEtMA_1f6a319c-4122-4277-96a1-ac657309cfe8"
      unitRef="usd">181319000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="if3ef5ec99dcc48139089e172def809d5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0yLTEtMS0w_cdb5e087-0af3-4baf-9db4-b1664b98b1b9"
      unitRef="shares">106162000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3ef5ec99dcc48139089e172def809d5_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi00LTEtMS0w_79dcd2a4-6438-433d-9e30-6ba5def54d99"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e0186178fef405988c9dab2a47db5fa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi02LTEtMS0w_88e5a37f-6a07-4029-ad18-8e825ef87c65"
      unitRef="usd">1447954000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a5003c76dd14af1bb7e8ed41020e64a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi04LTEtMS0w_16f3c264-5ffa-448b-be60-d3a6b7d4df40"
      unitRef="usd">-1471577000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if69a42b36ef4432baa90bafa0b87bb11_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0xMC0xLTEtMA_a3f8fc41-8f6e-4c47-9249-78653720cca5"
      unitRef="usd">-12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide9306242f52400fb1ec1c48fdb617e8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0xMi0xLTEtMA_fe86a0cf-1a00-48f5-8f3c-9f14fa7a56f1"
      unitRef="usd">-2876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia29409cf569f4995a1b8cd001ef00215_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMi0xNC0xLTEtMA_f2f07442-4be2-4d74-b15a-cdba3accbcc7"
      unitRef="usd">-26405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS00LTEtMS0w_6794f6ce-4250-4b67-a1db-767541a7d384"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS02LTEtMS0w_6d02f011-b2f5-4b90-97b5-38bcc7fa4fb6"
      unitRef="usd">3411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS04LTEtMS0w_6fc32725-269c-496e-a0c4-abac074a65c8"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS0xMC0xLTEtMA_eb593f57-65d6-4996-a01a-546a7672597b"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS0xMi0xLTEtMA_c72a47a3-fb85-4ded-a617-d0c3dead1a47"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNS0xNC0xLTEtMA_6be7f0b9-0d57-45e5-abf9-cf869f7f03e8"
      unitRef="usd">3411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0yLTEtMS0w_93ce7528-06df-4e37-93f8-324187ad2f73"
      unitRef="shares">517000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi00LTEtMS0w_5bd597c0-2a14-47d9-9ddc-fdb6f6c3d156"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi02LTEtMS0w_b4f937fb-1fee-47d8-9d45-255926476146"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi04LTEtMS0w_26a2ff50-8da0-42cb-99bd-0c55e3fb6e70"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0xMC0xLTEtMA_4e205830-6d92-4d71-a08d-96295bc55eac"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0xMi0xLTEtMA_b3179fcc-f356-4892-aeea-a1dce4faf175"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfNi0xNC0xLTEtMA_929e742c-e12a-4012-ab6b-581462e65050"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC00LTEtMS0w_53d4a0f0-1819-4054-a772-80b6cac497ae"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC02LTEtMS0w_7d2c392d-c0e3-4cfe-9462-5a50875acb39"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC04LTEtMS0w_bd5f28b3-5e6e-4902-8c48-ce5320bb28de"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC0xMC0xLTEtMA_d8110daf-3532-44da-9d5e-922957cbaf82"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC0xMi0xLTEtMA_500cc99a-088f-4745-a0e1-0b0a3b7ad422"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOC0xNC0xLTEtMA_2f843bf4-ee0c-4404-b847-10e52770324a"
      unitRef="usd">941000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS00LTEtMS0w_f1be4066-122a-45ee-a9cb-21643a6346c3"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS02LTEtMS0w_77ca6b42-5123-4e12-9217-46830b077bfa"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS04LTEtMS0w_3a001c4f-0a0c-4598-8c1d-731d00f56349"
      unitRef="usd">-21797000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS0xMC0xLTEtMA_5b189190-1d8b-46ba-9bae-fd9fef06b9cd"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS0xMi0xLTEtMA_6ecf0d14-0f19-44a4-bc11-5aa7e57e4ae3"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfOS0xNC0xLTEtMA_bb705df5-35ad-4d5d-bee3-466a692d6f89"
      unitRef="usd">-21797000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifc763aa2e02a4601acbfd8ec7001c109_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtNC0xLTEtMA_0664d2b7-b39c-4c71-a1ea-d86b221844e0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1878dd3d45214223b8e115840adbcc13_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtNi0xLTEtMA_16179dfa-02d0-4869-8586-ac2d66136d6b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9efe31e1af874be18df1d4b0934bc90f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtOC0xLTEtMA_8c28ebec-4d57-4386-87a0-0754887c7e3e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iecdb42132e8745ae883a6d35b19190c0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtMTAtMS0xLTA_4eafc592-bb64-4a75-a016-c287b8899e26"
      unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9644650c591d470ebecb1fa1d88de88d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtMTItMS0xLTA_e3012e0a-7da5-4900-99aa-55fbda9621bf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTAtMTQtMS0xLTA_baa1ffee-d060-4dc3-b922-0b8e51195a9e"
      unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9a2f0553a5a443f5aea2354fbbc8b9d7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMi0xLTEtMA_18338bb5-1368-4ba2-8703-728d62a0c13f"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a2f0553a5a443f5aea2354fbbc8b9d7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItNC0xLTEtMA_9d7b8d22-1566-40a9-bd03-26207c4f0ff0"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9180a0741154feab5264fc1b9481852_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItNi0xLTEtMA_76bfc607-890e-4a93-9627-84b0e1b98bea"
      unitRef="usd">1451365000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6241124cc1d84b06aee3d4a995daa961_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItOC0xLTEtMA_2f3dc9f7-5489-4cf6-8c0f-6e5a588cb6aa"
      unitRef="usd">-1493374000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65ef45941bee44658e4e342d2743291a_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMTAtMS0xLTA_151ba1de-68a5-452a-afb2-d9b144953358"
      unitRef="usd">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32edc2966d164232b4ab121550c17328_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMTItMS0xLTA_ca269be4-9def-4ef0-80db-78fd062d2576"
      unitRef="usd">-3817000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea93e62cb33048baa2d377777e96a31a_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTItMTQtMS0xLTA_aa867f7b-fe91-4c8c-85fb-5702c7042eba"
      unitRef="usd">-45687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtNC0xLTEtMA_053a33d2-7782-44d0-abd2-2d568d7d5ab0"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtNi0xLTEtMA_0c6b4215-4eaa-4924-83a9-9e394c1807c8"
      unitRef="usd">3766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtOC0xLTEtMA_56a75697-b53b-4fdc-869a-0bbcb1c596ee"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtMTAtMS0xLTA_29c36266-b7f0-49fb-ac10-cb2a4f28433d"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id5cd53676cec4b749440e76527ef3861_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtMTItMS0xLTA_b6cbde86-717d-4972-9ed1-e8fb526b7bc1"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i354181d4c7a546109de1070307761bf2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTMtMTQtMS0xLTA_947274fd-1647-400f-bb3f-b170d5955a6a"
      unitRef="usd">3766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtNC0xLTEtMA_e1e144f5-4a9c-4fff-ac3f-cf3a5b02af8c"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtNi0xLTEtMA_9fd0b92f-c7eb-4ddd-95c7-f679e27298c5"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtOC0xLTEtMA_e6d988d7-d327-4d73-9122-34d3dcd31f71"
      unitRef="usd">-23018000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtMTAtMS0xLTA_62fa9612-9586-4a29-8985-26dbf0a12d63"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id5cd53676cec4b749440e76527ef3861_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtMTItMS0xLTA_8537caac-b42e-4dc1-95cb-ec76d19f9ffe"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTUtMTQtMS0xLTA_5a635340-3d63-4581-9004-186989a89fd0"
      unitRef="usd">-23018000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4321875866af4f55b2db3b4982a23a9f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtNC0xLTEtMA_a566bf61-1282-4a57-a455-e19cbfef3a69"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i21605215a8404acea1d3bcdd24f260f6_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtNi0xLTEtMA_3b3c4e6b-67af-48bb-892c-a8817b7e2396"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7c76d0263a204008b97f82a06ce93170_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtOC0xLTEtMA_362d4a49-13eb-4529-9766-a4986b2911e8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8c6289d321e34dbcb5db029dae22749b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtMTAtMS0xLTA_a21383f2-f975-4118-a657-e7befceda3ad"
      unitRef="usd">53000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id5cd53676cec4b749440e76527ef3861_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtMTItMS0xLTA_136fae3d-7983-4ef5-aad8-5aec1add7ada"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i354181d4c7a546109de1070307761bf2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTYtMTQtMS0xLTA_f5143c39-af4d-44ca-87ad-b8ffb44051f5"
      unitRef="usd">53000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="iab400eacbd9f495eac7d85037d5b894c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMi0xLTEtMA_8987ec98-5649-45d8-bea3-0446cef5fd21"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab400eacbd9f495eac7d85037d5b894c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctNC0xLTEtMA_f8b1fbef-8db4-464b-b3b0-933b2f61a86e"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ea33b9cf6f84275ab78882aff5c053e_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctNi0xLTEtMA_9b64daa9-a100-4aab-aed6-100fd407c19d"
      unitRef="usd">1455131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53842116e47c4c769795760d6b233005_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctOC0xLTEtMA_009ebc9c-abeb-4a61-b3e6-f97183e8c920"
      unitRef="usd">-1516392000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7eb48dd69257444d8e09beb702199378_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMTAtMS0xLTA_eb56e19e-8968-4795-a553-80959243ff8d"
      unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98bf3f0537624ef3b1647b80d52ad9f0_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMTItMS0xLTA_f9cb026f-8d85-4d81-a6b5-82002ac3954d"
      unitRef="usd">-3817000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1764073b5f5c4207b578324f9d515f7c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTctMTQtMS0xLTA_57e75da2-09f7-4b0e-ac9e-01472553e432"
      unitRef="usd">-64886000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtNC0xLTEtMA_04d1ab6b-d8bd-4ec8-b954-c81495be4820"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtNi0xLTEtMA_62882e57-58b0-432b-9e5a-e319f817b1e9"
      unitRef="usd">3562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtOC0xLTEtMA_bbbd96b4-a2f0-444a-a895-2eb589aa48eb"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtMTAtMS0xLTA_b2f613a2-1f34-45f4-b07b-d1226228a423"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtMTItMS0xLTA_19d89f95-53ae-408c-89af-2fb043bf4615"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMTgtMTQtMS0xLTA_00c95db7-7656-4bde-88a0-3c79e607408e"
      unitRef="usd">3562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtNC0xLTEtMA_30e6bfa3-6743-44d1-b081-0d936e271f45"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtNi0xLTEtMA_78522f53-c465-46ee-bd2d-b2a3ae71f167"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtOC0xLTEtMA_6d605ba9-a820-48ff-a711-64201ee8feac"
      unitRef="usd">226086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtMTAtMS0xLTA_b9923bc8-0777-484a-bab5-028a73eef6b6"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtMTItMS0xLTA_3e7b8e48-02c9-4d52-9da1-ae79526aa033"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjAtMTQtMS0xLTA_0850bab5-7c11-43ea-8058-27b7e7d93d43"
      unitRef="usd">226086000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7c897872e8f34d04a29187079c44e95f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtNC0xLTEtMA_f5bdd64a-3ebe-4e94-a41f-dffa1c5cdc87"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibe1ea861034c4d8aa8abf86a8ee501fc_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtNi0xLTEtMA_62206914-e7af-49de-948c-7b977b1a7245"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iab75875383af4cc19dcd7ad5beca224a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtOC0xLTEtMA_eaf578df-4312-40c6-9adc-9bb6ca659771"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9cb85b25dc114f69b0488ed3025d3b5a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtMTAtMS0xLTA_3d5a7550-1188-44ac-8c75-764a6957e416"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7ebdb3a880fb4a159a2912aeb3b8262f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtMTItMS0xLTA_7405b69f-5fc1-41bd-826f-6390a00edc46"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjEtMTQtMS0xLTA_136084d6-1ec2-4a1f-a139-5539a5950570"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4c45f9e1311a4a0bacccdec8642a2255_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMi0xLTEtMA_30855ff8-74b5-4009-82f1-9d349ed829f2"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c45f9e1311a4a0bacccdec8642a2255_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItNC0xLTEtMA_f20fa67b-7304-463b-8a03-db3690a9d7cf"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i332232b87eed4ee0aff6a523ea254baf_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItNi0xLTEtMA_eb0ae887-f436-4498-af53-4e8b8beba142"
      unitRef="usd">1458693000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83b8ebfcf0c04a91bf51a889ee42089b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItOC0xLTEtMA_89d34765-3938-4b5c-8386-d79a35e9ccdf"
      unitRef="usd">-1290306000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea1b38341d5b40bfb0ded9fbd0ed8901_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMTAtMS0xLTA_97162770-e53f-48f6-b33d-5752cc3f4c75"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5133b99acae94f1cbb47b475caaef535_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMTItMS0xLTA_a422a237-595e-4656-a555-f5744353d201"
      unitRef="usd">-3817000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOmE5OWExNjFmODZiNDQ2MDE4NWMzNmE4YjE0OGNhZDk4L3RhYmxlcmFuZ2U6YTk5YTE2MWY4NmI0NDYwMTg1YzM2YThiMTQ4Y2FkOThfMjItMTQtMS0xLTA_62fa78d4-cd52-4c6d-b532-97439dd1b60f"
      unitRef="usd">164712000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i72c686e1acee419aaf3b5b0c644d31e4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0yLTEtMS0w_d5e68ddd-6263-4243-baad-4480a90f80d7"
      unitRef="shares">106679000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72c686e1acee419aaf3b5b0c644d31e4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi00LTEtMS0w_ccff8471-d780-4371-8cb0-ac381d8ec0ac"
      unitRef="usd">106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f874d70a3f146138ef4f3c91a8a1390_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi02LTEtMS0w_153d3930-bcea-4195-806b-1f5b7b4c8d25"
      unitRef="usd">1462172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i227451f24d98477b8bbc0d386d19ce16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi04LTEtMS0w_ab1d7665-d278-44f6-932f-9a6ff53cee15"
      unitRef="usd">-1341444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33ff9ea196e54e5eb3b7e68af2e1a1dd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0xMC0xLTEtMA_98815244-cfe7-48bd-a24d-662f7719e320"
      unitRef="usd">84000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief1f3693c2c8436da37a4d613523cf19_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0xMi0xLTEtMA_3ad26917-1032-4e26-b631-b03c666dc314"
      unitRef="usd">-3817000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMi0xNC0xLTEtMA_f4f0f92c-0743-4689-8d9d-b4483969e2de"
      unitRef="usd">117101000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC00LTEtMS0w_c8aea926-8cdb-451e-9dab-b9b6c452c8fe"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC02LTEtMS0w_4ca5c9d5-f82a-4586-ad63-5d91cdac8de4"
      unitRef="usd">4432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC04LTEtMS0w_2999b551-980a-45bd-80d5-63fa9a79abf0"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC0xMC0xLTEtMA_73e635a2-5a6e-4bf8-9d40-c77db737c46d"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC0xMi0xLTEtMA_eff782bb-a9fe-46a0-b3bd-1c0aab054bfb"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNC0xNC0xLTEtMA_e9218361-3822-4175-b083-a334206e989a"
      unitRef="usd">4432000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0yLTEtMS0w_8abdd2ae-b80e-49b2-9917-d6a33add6720"
      unitRef="shares">1032000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS00LTEtMS0w_c251b247-6ecb-4404-bcf2-02cb1a0b8450"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS02LTEtMS0w_93ca2dc2-7c0d-48af-ab63-30c1471cd29d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS04LTEtMS0w_6dc499fa-d154-4bdb-9c3e-1270765c392a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0xMC0xLTEtMA_60b13dd1-e95c-4407-bda8-abbb8cac8b16"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0xMi0xLTEtMA_40f70ec4-52b2-4c59-b459-5b320dd2e6bd"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNS0xNC0xLTEtMA_2a757f40-faaf-4797-b14c-bdd2825b5a3f"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy00LTEtMS0w_e1f9493f-76de-4743-a16c-e3506634f5e3"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy02LTEtMS0w_68f063a2-3e8d-49d0-8fb5-93f1c022d97f"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy04LTEtMS0w_48528953-0898-49a9-93fa-3943a88ad008"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy0xMC0xLTEtMA_a9e82da5-b527-4c71-bfbd-957b11de6992"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy0xMi0xLTEtMA_abc82305-42c1-4197-8656-24030e4e8d0e"
      unitRef="usd">923000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfNy0xNC0xLTEtMA_88b493f6-24cb-458f-a46a-d674004dcafc"
      unitRef="usd">923000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC00LTEtMS0w_c4eb839b-0b76-4852-9d56-b483a375e059"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC02LTEtMS0w_f1e2d2ca-94fb-417f-a8ec-c486a42526f5"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC04LTEtMS0w_a29b21dd-bc0f-42f1-bfd8-5f2cb08ff3e6"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC0xMC0xLTEtMA_9f08fcaf-193a-48b7-9381-d2b7ff203edd"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC0xMi0xLTEtMA_590d5b89-cea4-4332-84cc-877a0bd93de8"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfOC0xNC0xLTEtMA_7ee6a0bd-fa7d-49f9-8c01-588c99051830"
      unitRef="usd">-66611000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i85c9eb6250ee43f8b89b49a206696dba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtNC0xLTEtMA_4552ed3c-d8b9-43b0-8d01-de4754f5eb41"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2b9122c88b08450aa943128ce8672322_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtNi0xLTEtMA_eded77ed-95fb-4d8c-94ac-ed6e88861467"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if2131527db39408487eb2e8c34eeb5fb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtOC0xLTEtMA_a9f348d2-56d0-4cf2-aed3-1d733b7c6f93"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ica716cc9a55a41278a6162a4ba80a3fc_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtMTAtMS0xLTA_5eed29a3-f0dd-484c-bc9c-2df805fc105a"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id254f5e6dfe34564ad456518853a9e71_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtMTItMS0xLTA_d0389d5d-344f-4818-ae2e-0e6a208902a4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3e6f951bba4d4a3ea1979594cceee127_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTAtMTQtMS0xLTA_54a61375-4ca0-40b7-a2d2-4f7ed15b48be"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i93b273419a904b9b943ab1c586c82cf2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMi0xLTEtMA_cf6fddad-66e6-4258-a0da-7dcc6ca818b1"
      unitRef="shares">107711000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93b273419a904b9b943ab1c586c82cf2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtNC0xLTEtMA_5f1351a8-9ec0-4e71-853b-1c40ef6083b4"
      unitRef="usd">108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05d9a031b3a643939dc4946a532cd59f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtNi0xLTEtMA_abc28933-dcc8-4b96-8d18-c0c92685fc2c"
      unitRef="usd">1466604000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab8293cbb3b949feb1319baf6e0ac30c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtOC0xLTEtMA_1817d34c-0f13-4acf-b28b-e38d4397846d"
      unitRef="usd">-1408055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61ccbc50ca4646b7a6ca13720db0cd51_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMTAtMS0xLTA_33cd09f2-1668-4b3f-9d0a-2528cd1bb452"
      unitRef="usd">860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id927be22b9564e918ad8233bbc7d2bca_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMTItMS0xLTA_ba4a9939-2b44-4502-af66-698d44480791"
      unitRef="usd">-4740000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i232b139d9b954a9f988af16e8e822240_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTEtMTQtMS0xLTA_52a43dc4-b682-4dca-b728-3e22d9d32e06"
      unitRef="usd">54777000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItNC0xLTEtMA_0fbb2a99-520c-4faa-b635-dd8c5c334338"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItNi0xLTEtMA_8772e416-d6cc-4194-badc-adf1e9739f11"
      unitRef="usd">4258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItOC0xLTEtMA_fb011d29-e50f-42fb-95d0-627046e73b28"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItMTAtMS0xLTA_48056bb7-4565-4828-80d5-45c9e64eb492"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItMTItMS0xLTA_1b6703bb-b344-4363-87ea-4e54ebe8d388"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTItMTQtMS0xLTA_562b4230-df99-4763-93bc-9c68ac01eea8"
      unitRef="usd">4258000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMi0xLTEtMA_a3dbfac8-49d9-496a-aa78-28b71e75ae39"
      unitRef="shares">187000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtNC0xLTEtMA_f8a4c866-f110-4689-bfd6-eea88233c64a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtNi0xLTEtMA_3a67abe4-6672-4f17-a504-8b30d3127cb1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtOC0xLTEtMA_2b1f903c-9d68-47d0-851a-9eb6cbb09625"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMTAtMS0xLTA_be51a4fa-1202-4fd2-a036-626d107cb327"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMTItMS0xLTA_a906328c-3f46-4c53-951e-17ee562f36f7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTMtMTQtMS0xLTA_8820b4f7-ee29-4368-8c6d-6fee5ed501a0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtNC0xLTEtMA_56a26d4e-8425-4f58-a690-0612185f1703"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtNi0xLTEtMA_7db7b200-ad42-457f-a277-d5a2fcc8c799"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtOC0xLTEtMA_a4d10c19-651e-4d54-b0c6-00d3791fe3e2"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtMTAtMS0xLTA_c1424c04-db88-4b91-aa0b-c01c6ac69fcd"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtMTItMS0xLTA_14ba84f6-4aa5-46a3-bcd8-adcc12959e6a"
      unitRef="usd">103000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTQtMTQtMS0xLTA_f7803dab-7c0f-4c89-8f76-65cba1e9064e"
      unitRef="usd">103000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtNC0xLTEtMA_3a0b2ca8-4ae2-4875-928b-237f3db4b4ea"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtNi0xLTEtMA_e55688d3-89ae-4214-a674-25085929544b"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtOC0xLTEtMA_b41483c1-a2cc-47f5-880b-601063fca3d7"
      unitRef="usd">-69071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtMTAtMS0xLTA_7fbc3056-f63d-4a0c-bf5f-5705d16d1089"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtMTItMS0xLTA_f462248b-47e6-4720-b842-c38db7094866"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTUtMTQtMS0xLTA_029b43bc-cff4-480f-8e95-6a560e82de71"
      unitRef="usd">-69071000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2edef56e0c5742ada6bd078c82cb2b74_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtNC0xLTEtMA_3c0a7051-85e7-46a6-afcc-a0f8cef70185"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ice12f63065b54e95ba85c8d4038bca2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtNi0xLTEtMA_5e4d62e4-0e43-4b7b-b812-b720fb783e8b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icd83da259b784c0a9ba1f37a2317de9c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtOC0xLTEtMA_f98da19f-4d22-430b-a234-8933f441bfa1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iac767ed49dce485caab53b971c01ed2f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtMTAtMS0xLTA_d8882b5a-1db2-48b2-818d-c2a7ab14936e"
      unitRef="usd">-548000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iecb6ceada95546e5a1b0b3686c6667c5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtMTItMS0xLTA_1befca34-5b9d-4bf9-960d-9461e2c92e78"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTYtMTQtMS0xLTA_2aa3c8cc-a3c0-42c2-b68f-f9791e4e6dbd"
      unitRef="usd">-548000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie771e05af7234472aef6bd918b9dbe61_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMi0xLTEtMA_1fb04178-2baa-40fc-a425-056802241e87"
      unitRef="shares">107898000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie771e05af7234472aef6bd918b9dbe61_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtNC0xLTEtMA_3b485590-0ac8-42eb-8597-ffe8484e6de1"
      unitRef="usd">108000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89afbb9e0fbb43e182f2150249faef37_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtNi0xLTEtMA_d27b09c8-ed55-4c3e-b934-6eef861dde87"
      unitRef="usd">1470862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia46fdf6eabe5409c982b14a8191c786a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtOC0xLTEtMA_6042d88f-0b72-4ffc-a973-8c5efa73557b"
      unitRef="usd">-1477126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e76433e64224cd28783a0ed1b5ea7b3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMTAtMS0xLTA_a762748e-bc18-424d-be94-374ea9e36696"
      unitRef="usd">312000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9867c02a657c412fa47e3e6fe91bccea_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMTItMS0xLTA_18af184b-15a3-428e-afd9-911ec61df409"
      unitRef="usd">-4843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4615026499f4eaa986552fc1dfbd77a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTgtMTQtMS0xLTA_12e35ef3-1132-4aa1-9c66-e3eb6d8141f2"
      unitRef="usd">-10687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktNC0xLTEtMA_31488d59-16fc-410b-b05b-28dde59e297a"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktNi0xLTEtMA_4665d229-2a95-4f07-a326-e152bf4a4abf"
      unitRef="usd">1904000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktOC0xLTEtMA_f7e2fdaa-7efe-472d-b9bc-d064ccdc09c0"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktMTAtMS0xLTA_3ffd0132-5e64-4428-8121-69dd3c8c5aad"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktMTItMS0xLTA_a302e6c3-8560-411f-942f-21f5965b59b3"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMTktMTQtMS0xLTA_a421c2ff-cef2-4e3f-b7f8-46a7525546f6"
      unitRef="usd">1904000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMi0xLTEtMjA2Ng_0009651a-3e2c-4324-b415-95680538761e"
      unitRef="shares">9333000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNC0xLTEtMjA2Ng_5ffa12ee-37cf-4586-8df2-b652f35105ae"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNi0xLTEtMjA2Ng_4d9e7cb9-bc1f-4ab5-a338-1c71d9da42e8"
      unitRef="usd">14087000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtOC0xLTEtMjA2Ng_07bc2120-ec40-4196-9b4e-dd63fb8283ee"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTAtMS0xLTIwNjY_e71c1c6d-0a6c-4ea4-b64f-fd5241ad6eaf"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTItMS0xLTIwNjY_68a19d7b-e738-430d-a90f-5df593e3058a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTQtMS0xLTIwNjY_034288d0-21d5-4522-8733-1ae659b122e4"
      unitRef="usd">14096000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNC0xLTEtMA_96a71d52-ce26-4f32-ac6b-7d2089b3c148"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtNi0xLTEtMA_a945ea8f-05db-40b0-9c77-1e8d9b596926"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtOC0xLTEtMA_a96c5788-1237-4da4-8534-855162ebd135"
      unitRef="usd">82603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTAtMS0xLTA_cd845e87-304c-45e8-8ccd-7a9cc70cb161"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTItMS0xLTA_d80f7009-7f0d-4ebf-a4ef-17d65edd115b"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjAtMTQtMS0xLTA_dc2b93c4-cfb4-450e-ad07-a1049210c6a7"
      unitRef="usd">82603000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iecfe46b55b164b3f8d06c40419e8aed6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtNC0xLTEtMA_d117f46c-dad9-420e-9083-a8c52a14bc32"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i095246f537f44ccf9da7ec8214f6b846_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtNi0xLTEtMA_d5a2b672-e432-450c-80e7-b205e4510029"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i91fb5ae41331461dac39acd650838e01_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtOC0xLTEtMA_c7cd0fb5-e1ae-4b6d-b3e4-135497b6bddc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ief2592a6e795434581967ed7f4d08e9c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtMTAtMS0xLTA_c9a6b992-9b31-44a1-80f0-3fabc8a839e9"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i05b7a067aa894bf2b683fdb621671812_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtMTItMS0xLTA_26f00afa-a065-44d1-8e67-1bd788c2866e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjEtMTQtMS0xLTA_d896dee1-022f-4509-935b-312ad445f80a"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2c622449e7a742b49bfa687466d2cb4d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMi0xLTEtMA_2c79c3bf-8c1f-4d9a-aa3e-40620a12d239"
      unitRef="shares">117231000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c622449e7a742b49bfa687466d2cb4d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItNC0xLTEtMA_9d63d6e9-e414-42a9-b2e3-1ac1e64e4764"
      unitRef="usd">117000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0b359f3f2e54a4ca7516f16d229ef6d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItNi0xLTEtMA_bad99830-5109-4cda-a76a-38ea77cfb8d7"
      unitRef="usd">1486853000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i580af670a9ce4ccb936a88ec2d87b2c8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItOC0xLTEtMA_fffc8a2e-502c-4d07-98f8-158668dab518"
      unitRef="usd">-1394523000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaed950d6bbe64a719b452fb582108b70_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMTAtMS0xLTA_58fcaae0-56bb-47f5-a509-7c2e82bb056e"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0699896381d48e7ad6adc8daae2f1d7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMTItMS0xLTA_db1954f6-b0a0-426e-877b-5b9a0c57d596"
      unitRef="usd">-4843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yNS9mcmFnOmZhMmY2MGU0NWU0MTQwOTM4ZmZmNDAyNDUzY2E3YzY0L3RhYmxlOjE1OGUzZDQ2ZGRhNzQ2MzU4NzlkMzQ2N2NiMmNmYmNiL3RhYmxlcmFuZ2U6MTU4ZTNkNDZkZGE3NDYzNTg3OWQzNDY3Y2IyY2ZiY2JfMjItMTQtMS0xLTA_2de3d6cc-7589-43d8-858f-6093b2953c5d"
      unitRef="usd">87639000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMy0yLTEtMS0w_8115fcb3-d29f-4ba7-ac5a-c6ee5189646a"
      unitRef="usd">-53079000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMy00LTEtMS0w_2d53d23e-320b-420b-b7fc-d284c75fc81d"
      unitRef="usd">181271000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNS0yLTEtMS0w_62ea5057-96d9-4757-91b0-eea732860002"
      unitRef="usd">2590000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNS00LTEtMS0w_ed0e4354-90fd-4595-a482-1a3f88d54395"
      unitRef="usd">2719000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNy0yLTEtMS0w_1a8e6d60-2618-444f-9b6c-2a81046ec4b6"
      unitRef="usd">10594000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNy00LTEtMS0w_a35ba686-f6d0-4f4a-a556-ddcebfcbf1eb"
      unitRef="usd">10739000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOC0yLTEtMS0w_305f30ed-01c7-4f24-97f3-1b2be58bee71"
      unitRef="usd">995000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOC00LTEtMS0w_26248526-d7db-4530-87d3-33bc34702555"
      unitRef="usd">1087000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOS0yLTEtMS0w_cf2cc1ff-86bb-484e-8805-c36a46a54cd3"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfOS00LTEtMS0w_0cd0cbab-8504-47c2-9446-32a587537d77"
      unitRef="usd">-6014000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtMi0xLTEtMjAwMg_b86797bf-2f82-404b-a8d4-4f2effb41d69"
      unitRef="usd">132818000</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtNC0xLTEtMjAwMg_4e3a77f9-acae-44a4-887c-7e3a03316558"
      unitRef="usd">0</lxrx:GainOnSaleOfNonFinancialAssets>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtMi0xLTEtMA_1c6cf545-9e61-47c0-85cc-1871457fc429"
      unitRef="usd">1600000</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:ImpairmentOfRealEstate
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTAtNC0xLTEtMA_456e0022-4c3d-4883-8ed3-96106e55ba68"
      unitRef="usd">0</us-gaap:ImpairmentOfRealEstate>
    <us-gaap:AssetImpairmentCharges
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItMi0xLTEtMjAwNg_8532951f-66d6-4618-8192-0dd07e01d4a0"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItNC0xLTEtMjAwNg_80359697-0704-4377-a2e4-df72ccc868e4"
      unitRef="usd">28638000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtMi0xLTEtMjAxMA_0c34e94f-d76c-4134-8797-c9087f69716a"
      unitRef="usd">-255000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtNC0xLTEtMjAxMA_479bc0d0-971e-4757-acd5-ca97454675f6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItMi0xLTEtMA_993c65e4-0432-4dac-b536-37c215313ebe"
      unitRef="usd">-52201000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTItNC0xLTEtMA_ef825b0d-62d3-47e8-b2d1-6808b6db3269"
      unitRef="usd">50917000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtMi0xLTEtMA_dee2989d-bebd-4c17-85e5-e5cc89346861"
      unitRef="usd">-345000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTMtNC0xLTEtMA_df950a49-82fc-4ab3-9a4e-88058805470b"
      unitRef="usd">-204000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTQtMi0xLTEtMA_3f1d7555-f161-402c-9091-d902d64e5768"
      unitRef="usd">6008000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTQtNC0xLTEtMA_c29c2cd6-ca24-4305-87ae-dfe0ce0f5c03"
      unitRef="usd">3305000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTUtMi0xLTEtMA_dcfe3f0c-3e2f-47e9-9cd9-f64d91cbdcdc"
      unitRef="usd">-314000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTUtNC0xLTEtMA_ec1c256d-23db-41d6-abe5-96a411300064"
      unitRef="usd">-330000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTYtMi0xLTEtMA_b3e175c8-6323-49b0-9b03-6d085d8b4fae"
      unitRef="usd">14281000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTYtNC0xLTEtMA_2ecea822-82e1-444b-b77c-a3ae5f11221d"
      unitRef="usd">-645000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTctMi0xLTEtMA_46fd3386-a325-4e0a-b647-d8d9b0b57b0b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTctNC0xLTEtMA_de618d96-48ad-41fc-8cfd-8d57a1adfc61"
      unitRef="usd">-25929000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTgtMi0xLTEtMA_4cbf90cc-6652-4726-9757-fb21d9d31e2e"
      unitRef="usd">-108730000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMTgtNC0xLTEtMA_13c20d51-98d2-4261-bd13-abe72a0adb42"
      unitRef="usd">138178000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjAtMi0xLTEtMA_3c2896bc-2797-40c4-9837-fba748d4d3bf"
      unitRef="usd">33000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjAtNC0xLTEtMA_3435c997-c5b5-4a91-91cf-38ab6da841ad"
      unitRef="usd">70000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjUtMi0xLTEtMjEzOA_7762fb8c-8a74-4eb1-9b50-6c073332881e"
      unitRef="usd">160385000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjUtNC0xLTEtMjEzOA_9aa91441-041d-45aa-ac87-5a1b4eb20c24"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjItMi0xLTEtMA_316e9800-40fa-4d78-8e5e-94e3d21edfe7"
      unitRef="usd">53197000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjItNC0xLTEtMA_0ac7914c-e0a9-4afa-b9ed-248e2768c6d2"
      unitRef="usd">176987000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjMtMi0xLTEtMA_271ccf37-7ca6-40bf-ba63-f1db3bb748b3"
      unitRef="usd">229500000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjMtNC0xLTEtMA_c944656d-50b0-4011-b752-5531a53c1fef"
      unitRef="usd">130600000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjQtMi0xLTEtMA_6488be25-97f2-4a9c-9bb5-044d718bd920"
      unitRef="usd">336655000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjQtNC0xLTEtMA_1c383885-8cfe-49e6-a513-e81b325ab289"
      unitRef="usd">-46457000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjctMi0xLTEtMA_74bf752d-a191-457a-af53-18c7fbc144d6"
      unitRef="usd">1026000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjctNC0xLTEtMA_a61948b4-d064-4071-bc19-31b9c900e145"
      unitRef="usd">941000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjktMi0xLTEtMA_c6c3814e-07cb-4470-913a-53432a98b5fb"
      unitRef="usd">210760000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMjktNC0xLTEtMA_153f0abd-c185-4913-88ee-8dc177624273"
      unitRef="usd">963000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzEtMi0xLTEtMA_81b88304-4a74-4c08-99f3-ddc286571e6d"
      unitRef="usd">-211786000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzEtNC0xLTEtMA_0fae2db6-78f9-4c82-a667-099b80bdb64d"
      unitRef="usd">-1904000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzItMi0xLTEtMA_1e9355b1-87ef-41d3-9395-d89523f9df4b"
      unitRef="usd">16139000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzItNC0xLTEtMA_26657c83-3ea0-4219-aff2-bbeb013d1c4a"
      unitRef="usd">89817000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzMtMi0xLTEtMA_2a335efb-e297-4b62-becd-4e68418c8d4b"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia29409cf569f4995a1b8cd001ef00215_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzMtNC0xLTEtMA_4d96f037-5650-48c9-9d43-db36165eb4a8"
      unitRef="usd">80386000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzQtMi0xLTEtMA_2bc2182a-01ac-4a7e-9ef7-ca40c8843de8"
      unitRef="usd">52251000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic39cf4efb3ba498c83f75720de63977b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzQtNC0xLTEtMA_932d0038-76ba-4aa8-90c7-702778340a7f"
      unitRef="usd">170203000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzctMi0xLTEtMA_3b8f9a6b-9385-4563-bf0d-1468098a00fc"
      unitRef="usd">16892000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfMzctNC0xLTEtMA_17664838-383d-44fe-9589-fab01780432d"
      unitRef="usd">13243000</us-gaap:InterestPaidNet>
    <lxrx:LiabilitiesAssumedByTerSera
      contextRef="i170f779ba4fd4cdb814e7d6c94490a0b_I20200908"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNDYtMi0xLTEtMzU2MA_705668bf-5b5c-4993-862b-686d41ed9cb1"
      unitRef="usd">3180000</lxrx:LiabilitiesAssumedByTerSera>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8yOC9mcmFnOmQyMDhmZWE3NGQ0YjQ5YTI4NDY0YWRjY2UyNmExZDFiL3RhYmxlOjJmODU2YjBmYTUwODQxMWNhYjAyNWI2YjA3MmY5ZDRiL3RhYmxlcmFuZ2U6MmY4NTZiMGZhNTA4NDExY2FiMDI1YjZiMDcyZjlkNGJfNDctMi0xLTEtMzU2MA_d66819d7-5191-4562-9135-f5e6df74d2ed"
      unitRef="usd">14096000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODg_b004a4bc-94f7-42cc-aa69-0497822082e7">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information, refer to the financial statements and footnotes thereto included in Lexicon&#x2019;s annual report on Form 10-K for the year ended December&#160;31, 2019, as filed with the SEC.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of September&#160;30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inventory was comprised of supplies of XERMELO supporting the Company&#x2019;s commercialization of the product in the United States.  Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method.  As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively.  See Note 3, Asset Sale, for additional information relating to inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Intangible assets, net consisted of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  During 2017, intangible assets relating to XERMELO of $24.7 million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;).  Intangible assets with finite lives are amortized using the straight-line method over their estimated lives.  As of December 31, 2019, the net carrying value of the finite-lived intangible assets was $19.7&#160;million.   During the three and nine months ended September&#160;30, 2020, the remaining net carrying value of $18.5 million for the intangible assets relating to XERMELO was reduced to zero as a result of the Xermelo sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#x201c;Ipsen&#x201d;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#x2019;s net product revenues reflected the Company&#x2019;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Sales: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.  For the three and nine months ended September&#160;30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September&#160;30, 2019, includes $0.4 million and $1.3 million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the nine months ended September&#160;30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s stock-based compensation plans for the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) In connection with the reduction in force in September 2020, unvested stock options were forfeited or cancelled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments.  The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(1) In connection with the reduction in force in September 2020, unvested restricted stock units were forfeited or cancelled.&lt;/span&gt;&lt;/div&gt;Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyOTk_da4bd51c-237b-4c6e-b5de-563b76201369">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNDc_5a4e0f4a-e538-426c-b7b8-cc76974c13e4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMzMTM_639ab400-b142-4ecd-bed2-c67fe42ae154">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of September&#160;30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMzMTQ_43080a65-dc53-40ca-ae14-fffd7a85ee44">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.&lt;/span&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNjg_07383640-454d-4343-8826-3ceaa6f68075">Inventory:  Inventory was comprised of supplies of XERMELO supporting the Company&#x2019;s commercialization of the product in the United States.  Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method.  As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxMDc5Mg_82cfad69-7e4d-4757-a74e-bffe846dcfd9"
      unitRef="usd">3200000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxMDc5OA_57a009a3-0b92-4791-ba41-c96c453b8a4a"
      unitRef="usd">200000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxMDgwNg_b42825cd-2679-4fe0-b284-d16474a7e59d"
      unitRef="usd">900000</us-gaap:InventoryFinishedGoods>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i806bb79355704a3d9f9e975c7764b751_I20170331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxOTc5NQ_c18ffd39-7486-4c99-b493-542a615577ef"
      unitRef="usd">24700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzI5ODUzNDkxNDEzMw_131b2c98-09c5-4189-b55e-b7419857ecbe"
      unitRef="usd">19700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxOTYxNg_12d4f016-0884-49f7-b8fe-f4912b4a07ad"
      unitRef="usd">18500000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzI5ODUzNDkxNDE0NA_c2e86c63-2dd9-4027-843f-477f1b3d9afb"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODA_80f12ca9-2e2c-4659-ae39-f20f127fe7c2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfMy0yLTEtMS0w_b93b8f08-416e-444f-b342-37dbf77b7d41"
      unitRef="usd">50217000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfMy00LTEtMS0w_275a068d-367a-4f2d-bee0-d8266c66155d"
      unitRef="usd">29033000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNC0yLTEtMS0w_e8cb5ea8-3201-4dcf-aeed-429bdf732afe"
      unitRef="usd">6023000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNC00LTEtMS0w_ff5f2ebd-58bf-49fd-90e7-fd0b008fd30e"
      unitRef="usd">9644000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNS0yLTEtMS0w_c74d0975-aa5d-4fa5-8906-fc66bb302d19"
      unitRef="usd">553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNS00LTEtMS0w_f264b505-af34-4ead-92d0-7685f7eb6266"
      unitRef="usd">553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNi0yLTEtMS0w_703ef531-cdca-43af-905f-71f4f93243c1"
      unitRef="usd">1704000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNi00LTEtMS0w_6f8596ee-6a01-4d4f-9099-b59efb8200bd"
      unitRef="usd">2921000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNy0yLTEtMS0w_41820e3e-8310-41f7-ae3c-c77a159fd543"
      unitRef="usd">58497000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjA2MTBkNzU4MjI3ODRmYjU5ZmVjMzk4YzBkZGJjYzY3L3RhYmxlcmFuZ2U6MDYxMGQ3NTgyMjc4NGZiNTlmZWMzOThjMGRkYmNjNjdfNy00LTEtMS0w_ac9366dd-8b12-472d-826f-b2b6d029dd83"
      unitRef="usd">42151000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMzMDE_e4e74d2d-41f1-48b9-a812-72687371aad4">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#x201c;Ipsen&#x201d;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#x2019;s net product revenues reflected the Company&#x2019;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#x2019;s customers and such costs were included in cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related &lt;/span&gt;&lt;/div&gt;sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODE_50286b21-db1f-4f08-b467-240b82ad265f">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.  For the three and nine months ended September&#160;30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September&#160;30, 2019, includes $0.4 million and $1.3 million, respectively.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxNjI0MQ_a0de9e40-e0ac-4278-8820-7140876eef65"
      unitRef="usd">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxNjI0OQ_b7787608-a675-4622-9335-7dcb1e202136"
      unitRef="usd">1200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcxNjYwNA_1413e506-6630-47fb-80dc-a4f4ed469659"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMzg0ODI5MDcyMTk4OQ_42c44b5e-0eb7-40f2-987d-3a7eaf5b14e9"
      unitRef="usd">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNzc_b906b2a8-abf1-4b33-a175-15809536e5a1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#x2019;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODI_e90f4fd1-b449-4cbc-96b8-dfb177f587d3">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODM_ee45a959-a9b6-470e-82a8-76ac65536f11">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi0yLTEtMS0w_7fe0d0db-2441-4a3a-8975-3d03d1e53a39"
      unitRef="number">0.91</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi00LTEtMS0w_52e71e63-b25b-4067-b852-aaa4233be24e"
      unitRef="number">0.013</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi02LTEtMS0w_16dd0465-67f1-4023-b848-0c21dad3e6a4">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMi04LTEtMS0w_9fc9aad6-b516-4123-81e2-4aca48862db4"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy0yLTEtMS0w_30a82bca-1d24-49de-8000-226a662df797"
      unitRef="number">0.78</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy00LTEtMS0w_500c7895-3bab-433b-95be-a72a63f653b7"
      unitRef="number">0.014</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy02LTEtMS0w_f570ed05-aa12-4f4f-9fd0-948a57498d50">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfMy04LTEtMS0w_ae2b79b9-3ea6-47e9-aeb7-5d0f2571d92e"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS0yLTEtMS0w_1e3048b8-49ac-4d31-9298-6ae20b01e7ca"
      unitRef="number">0.88</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS00LTEtMS0w_795644d3-5e9d-426e-bd43-29df667644e7"
      unitRef="number">0.022</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS02LTEtMS0w_551e6cd4-d475-47f0-ad84-be8d1624a297">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNS04LTEtMS0w_b6f4a45c-633d-460f-a2bd-d10f31a5713e"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi0yLTEtMS0w_f144e077-f0f7-4ffd-bf7d-fc4e237149ea"
      unitRef="number">0.78</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi00LTEtMS0w_674d1394-22cb-4be1-bfc6-1e67d44d0009"
      unitRef="number">0.026</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi02LTEtMS0w_e9aea5a1-872b-4db4-815b-c6687161899b">P8Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="id631f1c208414cc9a3802c6a2ad1a51d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOmJlZmNmZTVmNDE4ZTRiZGQ5MzlkNzI3M2M0Mzk1NmVhL3RhYmxlcmFuZ2U6YmVmY2ZlNWY0MThlNGJkZDkzOWQ3MjczYzQzOTU2ZWFfNi04LTEtMS0w_434ffbcb-b4bd-4886-851d-00b0d01746bf"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyODQ_ce6ba4c3-6982-4f1e-8be7-e38c341932aa">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7902597037c2463d85d00a4b46bdb6db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMi0yLTEtMS0w_74a3e785-8ed3-4f1c-8ae4-31dea786079e"
      unitRef="shares">7695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7902597037c2463d85d00a4b46bdb6db_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMi00LTEtMS0w_1b8da3e9-ddec-4947-92c7-2efd2c4142c6"
      unitRef="usdPerShare">8.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMy0yLTEtMS0w_d74a3d16-e0ef-481a-b540-d9cb837af224"
      unitRef="shares">3445000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfMy00LTEtMS0w_1bfb2ef9-ebc2-487b-bae2-53e4eee1fb00"
      unitRef="usdPerShare">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNS0yLTEtMS0w_59528046-5b23-48b6-9cfb-507b51aa01e2"
      unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNS00LTEtMS0w_894df406-a48e-4e3d-9111-e50ce7744ae7"
      unitRef="usdPerShare">12.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNi0yLTEtMS0w_97ce75f2-e27f-48dd-a2d1-5419a3916553"
      unitRef="shares">1909000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1790a67af1764e35b1a6ebc3e70c9ccc_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNi00LTEtMS0w_2e7b94c2-6dfe-4317-bf08-4640d5f55f4a"
      unitRef="usdPerShare">5.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6dd55aa47b494c508a8707104b290757_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNy0yLTEtMS0w_a0634570-74ec-4d22-823e-ac7a9d8a4ee4"
      unitRef="shares">8995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6dd55aa47b494c508a8707104b290757_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfNy00LTEtMS0w_90a615b3-367c-4295-a3a3-4b6c98c5ba33"
      unitRef="usdPerShare">7.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6dd55aa47b494c508a8707104b290757_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfOC0yLTEtMS0w_ae06f3fc-3d81-4ade-8c36-80bb01f43b77"
      unitRef="shares">5108000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6dd55aa47b494c508a8707104b290757_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzYjY3ZDAyMDg5NDRlNjdiZDIwZjllYzJjMTEyNzMxL3RhYmxlcmFuZ2U6OTNiNjdkMDIwODk0NGU2N2JkMjBmOWVjMmMxMTI3MzFfOC00LTEtMS0w_ac8d2050-2fed-4d34-91fc-657fc29b623e"
      unitRef="usdPerShare">9.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNTc_1bf9a1a7-f578-4f4d-9b60-3852e79aeeb9">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i16d499c22b144586ab5b1747d70c9923_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMi0yLTEtMS0w_bdb674d9-b458-4815-b7ae-a0aded021836"
      unitRef="shares">2830000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i16d499c22b144586ab5b1747d70c9923_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMi00LTEtMS0w_08c4db79-35fd-42f4-87c9-043c06d64170"
      unitRef="usdPerShare">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMy0yLTEtMS0w_9ac29088-8b9a-4e30-9e7e-ce1b5aa22810"
      unitRef="shares">3144000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfMy00LTEtMS0w_b27ffd18-e41e-463d-b0de-bd13583b8717"
      unitRef="usdPerShare">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNC0yLTEtMS0w_40de4841-fe99-430f-b109-10df88482be2"
      unitRef="shares">1219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNC00LTEtMS0w_2cfeb57f-6f28-46bc-9947-9fea35b6a24c"
      unitRef="usdPerShare">6.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNS0yLTEtMS0w_584c0874-d4fb-427a-b95d-9549d95a4e3a"
      unitRef="shares">1892000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i22becc5bfc8445ceb498900e91d71891_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNS00LTEtMS0w_6a175689-605a-4a77-b925-d7233ac7f47c"
      unitRef="usdPerShare">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i52b7cb3d54a24978a2f81d13fb5f8bf0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNi0yLTEtMS0w_8d05b364-5853-43df-b9a4-dda7feea426f"
      unitRef="shares">2863000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i52b7cb3d54a24978a2f81d13fb5f8bf0_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RhYmxlOjkzODBmM2NmYTFmNDQ4NGNiYmNhOWJiZTYwMmUxZWUwL3RhYmxlcmFuZ2U6OTM4MGYzY2ZhMWY0NDg0Y2JiY2E5YmJlNjAyZTFlZTBfNi00LTEtMS0w_249d6723-679d-4a75-a6ee-61a1ead78b6a"
      unitRef="usdPerShare">4.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNC9mcmFnOjAxM2UzNTgwMmI1NTQ0NmViYmQ1MmNiYmMwNWYwOTViL3RleHRyZWdpb246MDEzZTM1ODAyYjU1NDQ2ZWJiZDUyY2JiYzA1ZjA5NWJfMTMyNTg_f5ed4868-9295-4ab8-bee9-1cddfadf8fc9">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl8zNy9mcmFnOjNlNzM3MTMxNjE4MzRmMzJhNDFlZTQxZDVjMDQ0OTRlL3RleHRyZWdpb246M2U3MzcxMzE2MTgzNGYzMmE0MWVlNDFkNWMwNDQ5NGVfMTcyMw_2d4070fb-108d-4558-a0a6-db3232befb7f">Recent Accounting PronouncementsIn November 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <lxrx:SaleOfNonFinancialAssetsTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzkzNDU4NDg4NDExNTg_ef3e9520-d3dd-4549-a04b-825d8f72cc1e">Asset Sale&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company completed the sale of its XERMELO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (telotristat ethyl) product and related assets (the &#x201c;XERMELO sale&#x201d;) to TerSera Therapeutics LLC (&#x201c;TerSera&#x201d;) pursuant to an Asset Purchase and Sale Agreement entered into in July 2020.  The upfront consideration paid by TerSera, subject to a working capital adjustment as set forth in the Asset Purchase and Sale Agreement, was $160.4 million and the net gain recognized in connection with the XERMELO sale was $132.8 million.  The gain is reflected on the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65&#160;million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer.  The Company has determined that these amounts are constrained until the achievement, if any, of specific events.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company&#x2019;s operations.  For the three and nine months ended September&#160;30, 2020, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company&#x2019;s XERMELO operations is $2.1 million and $12.1 million, respectively, and for the three and nine months ended September&#160;30, 2019, the pretax net loss for the Company&#x2019;s XERMELO operations is $4.1 million and $10.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company currently expects severance charges to approximate $5.7 million, of which $5.5 million was incurred through September&#160;30, 2020. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.</lxrx:SaleOfNonFinancialAssetsTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzMyOTg1MzQ4ODc4NDk_6fa44998-70a4-4974-847e-c36f7450a361"
      unitRef="usd">160400000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <lxrx:GainOnSaleOfNonFinancialAssets
      contextRef="i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTc2ODY_7269756e-04a4-44e9-b7ef-707bfbe33482"
      unitRef="usd">132800000</lxrx:GainOnSaleOfNonFinancialAssets>
    <lxrx:TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzMyOTg1MzQ4ODgzNzI_11462b29-5703-4b72-90d9-cd4982c749cf"
      unitRef="usd">65000000</lxrx:TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones>
    <lxrx:XermeloPretaxNetLoss
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA3MDE2OTc_94fc64c3-9747-45d9-80ca-8419ff14893e"
      unitRef="usd">-2100000</lxrx:XermeloPretaxNetLoss>
    <lxrx:XermeloPretaxNetLoss
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA3MDE3MDA_23e884e0-b139-452c-b676-753e6ca7f154"
      unitRef="usd">-12100000</lxrx:XermeloPretaxNetLoss>
    <lxrx:XermeloPretaxNetLoss
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTg4NjA_7143180e-1cd5-4e13-bc95-bc8d439c919f"
      unitRef="usd">-4100000</lxrx:XermeloPretaxNetLoss>
    <lxrx:XermeloPretaxNetLoss
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTg4Njg_0cf88b79-220b-49b4-aa67-ce566590ee49"
      unitRef="usd">-10800000</lxrx:XermeloPretaxNetLoss>
    <us-gaap:SeveranceCosts1
      contextRef="i45dc5d23ea3b4654bc9d1ccd692ebca9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA3MDE2OTI_fedd46cd-e288-4742-9d18-029048b11988"
      unitRef="usd">5700000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTkxMDY_1cf178c5-c0b6-4f01-a248-4e6438a5020d"
      unitRef="usd">5500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="iab6089ded0c145f3a665941d75632fdf_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTkxNTI_9d2d5aaf-7edb-44a3-9fd7-729bca21f714"
      unitRef="usd">2500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i90f2f211830347d7b962a9ddc24c8919_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84NDkvZnJhZzphYjY4Y2Y0MTljM2M0NWFmYmNhYzQ4NzdmYTJlNzkxYy90ZXh0cmVnaW9uOmFiNjhjZjQxOWMzYzQ1YWZiY2FjNDg3N2ZhMmU3OTFjXzM4NDgyOTA2OTkyMDk_d95c4b11-ec0b-47a2-aadb-d473c65cbda5"
      unitRef="usd">3000000.0</us-gaap:SeveranceCosts1>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMzQz_2ccf2990-e278-4f9e-830e-b695170e5c56">Cash and Cash Equivalents and Investments&#160;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of cash and cash equivalents and investments held at September&#160;30, 2020 and December&#160;31, 2019 are as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized losses during either of the nine months ended September&#160;30, 2020 and 2019, respectively.  The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMzM5_6bdf185a-9b66-4595-b2b7-1def2f13ca9f">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy0yLTEtMS0w_e36db5ad-df06-486d-acd7-fe044f996d6a"
      unitRef="usd">52251000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy00LTEtMS0w_fb00cf66-3e6d-4021-a691-81bf082b5054"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy02LTEtMS0w_69dbe730-0cde-47ef-9b44-97e0202f3024"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i1258c23791be46e7aa4cc649d072022f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMy04LTEtMS0w_aa03b0f1-4256-406e-8cff-bc2d5a38ae75"
      unitRef="usd">52251000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS0yLTEtMS0w_91e3196c-baa6-4fae-9225-664d60bed06c"
      unitRef="usd">38796000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS00LTEtMS0w_1c370c19-0a29-41e3-a43a-5a7e62e2d508"
      unitRef="usd">40000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS02LTEtMS0w_90164a82-dfcd-47f4-9e26-e6c8fdaf0ec7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i73a1a6fc719140c08724cb429ea2062e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNS04LTEtMS0w_b01f1f75-0718-415f-ae33-a8a0a998bf57"
      unitRef="usd">38836000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi0yLTEtMS0w_0edd56cc-1d1b-42fe-bf35-5e966a481a59"
      unitRef="usd">20364000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a47a08149c54860b477528661d2c215_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi00LTEtMS0w_bbe6e701-8f14-4409-a2ae-4f3d1504aafc"
      unitRef="usd">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi02LTEtMS0w_82da2cd3-ab6f-4080-b729-330cd6a67e8b"
      unitRef="usd">-6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ie1b7f19fd2fa44cea1749021d8ac4863_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNi04LTEtMS0zNzMz_bfe928f8-85b5-466e-b661-48b0e5c1c8ce"
      unitRef="usd">20359000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy0yLTEtMS0w_c7c2c9a1-6054-46d1-b352-c3855dda578d"
      unitRef="usd">59160000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy00LTEtMS0w_3b09137b-6653-498b-a96e-fe8d2cd60bfd"
      unitRef="usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy02LTEtMS0w_609defc9-fac6-4283-b4b5-13837fb1a276"
      unitRef="usd">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i22ab63a51cfe4a52baceee717c7ac021_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfNy04LTEtMS0w_ea58aa2c-ca0c-4a87-8355-e32693cdd303"
      unitRef="usd">59195000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC0yLTEtMS0w_3f869a0e-7bc9-412a-b7a3-988bfbed6f31"
      unitRef="usd">111411000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC00LTEtMS0w_bee708d5-9b8a-4649-bccb-4fdfefab0de0"
      unitRef="usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC02LTEtMS0w_1fb587e0-50a2-4d1e-ba19-633e8cb2a5eb"
      unitRef="usd">6000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ifee8595c4e7d498db92de4c18088f054_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfOC04LTEtMS0w_91a05d4d-22df-4773-b908-915e4e3e9f1f"
      unitRef="usd">111446000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtMi0xLTEtMA_b7800558-8f89-499d-a47e-384298e14266"
      unitRef="usd">36112000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtNC0xLTEtMA_cd8b9d76-9fb8-4fa6-b12f-d46db566dd32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtNi0xLTEtMA_00d4d960-a5d1-47f2-9233-03649b147643"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i987c8a7c27f2446f9cf494575a39b8e3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTMtOC0xLTEtMA_49eb3320-595f-4752-a354-34f5184c41da"
      unitRef="usd">36112000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtMi0xLTEtMA_364ed4d9-d532-47e8-a602-ab9164ea90f7"
      unitRef="usd">235463000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtNC0xLTEtMA_8cff7d04-d503-42bc-8a4b-a740583ea4d1"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtNi0xLTEtMA_f632945c-26f5-4ef1-85b6-b8286f90c362"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i9c9e06af61094d4b89f3cbd8d3597ddb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTUtOC0xLTEtMA_5e1e49b5-e9a9-4474-9e9d-ac7a475463f1"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i598b1a29343d4deda20d232162634172_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctMi0xLTEtMA_b12fbd75-9a94-4b0c-8976-0d237c1567a3"
      unitRef="usd">235463000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i598b1a29343d4deda20d232162634172_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctNC0xLTEtMA_8c5e5de1-b8a3-45c0-bfb3-a4d56454715f"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i598b1a29343d4deda20d232162634172_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctNi0xLTEtMA_56a0bb7c-3590-4c8c-a29a-fb9dac94518b"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i598b1a29343d4deda20d232162634172_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTctOC0xLTEtMA_4bfaaa3d-59e4-494c-96a1-88359f551226"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtMi0xLTEtMA_9e154ce1-2ca0-4e6f-ae55-e310fe713937"
      unitRef="usd">271575000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtNC0xLTEtMA_00351c43-07ad-48b6-8233-ad57b92b1606"
      unitRef="usd">94000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtNi0xLTEtMA_3468b5a6-3a48-4764-9c33-8efd80c33511"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i338bf2c2e7b6442b8ab5f089399b8061_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RhYmxlOmU2NDYyYWJkN2U5MjRkYmNhNjU4ODA4Y2YyMzFiODIxL3RhYmxlcmFuZ2U6ZTY0NjJhYmQ3ZTkyNGRiY2E2NTg4MDhjZjIzMWI4MjFfMTgtOC0xLTEtMA_11e0dfc4-cdc0-45b6-ade4-2b0efe454e9c"
      unitRef="usd">271659000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMTcx_350a0f8f-899d-49e3-9447-e69ccdda06da"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80MC9mcmFnOjliZThiODFiZDdkNTRjODBhMTI1OWM0ZmU2MTU0NWFkL3RleHRyZWdpb246OWJlOGI4MWJkN2Q1NGM4MGExMjU5YzRmZTYxNTQ1YWRfMTcx_d5618df9-9b64-43f6-a2b2-cf85de167405"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RleHRyZWdpb246YWJiMjM0NGEzZjAyNDJhM2IzMzc3ODRjNzhjNjQ1MjNfMjE1Mw_2c27baf3-3b6c-4877-8c22-049882c889b5">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of September&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets or liabilities as of September&#160;30, 2020 or December&#160;31, 2019. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.  These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon, Inc. in 2010, and intangible assets associated with the acquisition of Symphony Icon, Inc. in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 6, Debt Obligations, for fair value measurements of debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RleHRyZWdpb246YWJiMjM0NGEzZjAyNDJhM2IzMzc3ODRjNzhjNjQ1MjNfMjEzNw_f8747973-bd36-4e93-bf91-dd30ffe129f4">&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i16df9c6c19c64790a5837cf1d79351ff_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC0yLTEtMS0w_20404609-1f81-4c5c-95f0-802976ca9e90"
      unitRef="usd">52251000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5d3c3a225f534e188a9ebe0475319a1b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC00LTEtMS0w_7b8f6835-dc39-4c0d-90aa-e4d4595d559d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC02LTEtMS0w_a8d2c754-b62c-4d2f-a034-394542ad6152"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNC04LTEtMS0w_bc3132dc-b8d3-4b3b-b710-f68270c11997"
      unitRef="usd">52251000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i16df9c6c19c64790a5837cf1d79351ff_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS0yLTEtMS0w_3a964375-c29e-44e1-a736-8c845e72ea20"
      unitRef="usd">38836000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i5d3c3a225f534e188a9ebe0475319a1b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS00LTEtMS0w_84c17c8d-f3a1-4574-ae21-69049cea989d"
      unitRef="usd">20359000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS02LTEtMS0w_ef2f85e7-9780-4dce-84a7-17d92328fa76"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNS04LTEtMS0w_73c09ac8-88f9-4fb4-9abb-7a1498b20778"
      unitRef="usd">59195000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i16df9c6c19c64790a5837cf1d79351ff_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi0yLTEtMS0w_dc1f1de4-06aa-44a7-aabf-abf94da9d07a"
      unitRef="usd">91087000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5d3c3a225f534e188a9ebe0475319a1b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi00LTEtMS0w_01594086-6570-4fc0-b4fb-59601de6ae2a"
      unitRef="usd">20359000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4a05310c12704ba98f66d0bdbe7a3d2b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi02LTEtMS0w_c612c1a4-5c24-4937-bafb-7e770114f55f"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOmEwMzJmNDFjOWY1OTQzNjhhNjQ0NWUzYzQwNmY3NzliL3RhYmxlcmFuZ2U6YTAzMmY0MWM5ZjU5NDM2OGE2NDQ1ZTNjNDA2Zjc3OWJfNi04LTEtMS0w_bc4b647b-2269-4160-a126-7a7c36f81310"
      unitRef="usd">111446000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i99f83f9e3d794affb390e88fc81fa72e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC0yLTEtMS0w_61ad6364-6bbd-4ccb-8de3-ba0c54f10011"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5d7b6895d6da4c09ac7535756e184174_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC00LTEtMS0w_042ba9a8-c25c-4b86-85d4-3832d94407bc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC02LTEtMS0w_540fc905-32c2-4562-b5f7-07600b57cbd5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNC04LTEtMS0w_130c9cbb-ed4b-41d3-843e-7380aac82fd4"
      unitRef="usd">36112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i99f83f9e3d794affb390e88fc81fa72e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS0yLTEtMS0w_3c35e70c-6bdf-4be6-a67b-0f17be061ecf"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i5d7b6895d6da4c09ac7535756e184174_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS00LTEtMS0w_7a2e5d1d-1e64-4d7d-9e8d-14eb5924aec9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS02LTEtMS0w_a6a4a0c8-e022-48f4-8fb5-3dd7c35155f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNS04LTEtMS0w_331ac7be-21b6-4e09-9058-e74a54018aec"
      unitRef="usd">235547000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i99f83f9e3d794affb390e88fc81fa72e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi0yLTEtMS0w_2c40c3b4-a4f4-4c1c-af39-c2d1f0154de3"
      unitRef="usd">271659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5d7b6895d6da4c09ac7535756e184174_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi00LTEtMS0w_eed58b6a-e1f3-4782-b14b-e18127702bfc"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia069aa1cd1ed48a1a923244e1fa3ed51_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi02LTEtMS0w_4f9db557-6861-4540-88fb-f47e46694be9"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i47dc383a1189487da19aa61e7d8cdb1e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80My9mcmFnOmFiYjIzNDRhM2YwMjQyYTNiMzM3Nzg0Yzc4YzY0NTIzL3RhYmxlOjYyNDA2OTIzNzI0NjRjZGQ5MzhmNTgwNmRhMDRmNmZhL3RhYmxlcmFuZ2U6NjI0MDY5MjM3MjQ2NGNkZDkzOGY1ODA2ZGEwNGY2ZmFfNi04LTEtMS0w_4159570f-4ec4-4b82-9f64-700547c5acfc"
      unitRef="usd">271659000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzI5ODUzNDg5NjA3Ng_c60f85c1-9d4c-4dc5-af05-0b96ca85b308">Debt Obligations&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Debt.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s condensed consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes.  In September 2020, the Company issued 9,332,471 shares of the Company&#x2019;s common stock and paid $44.0 million in cash, which included $1.1 million of accrued interest, to exchange $67.1 million aggregate principal amount of such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $8.4 million was recorded and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.  As of September&#160;30, 2020, the carrying value of the remaining Convertible Notes was $20.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company issued 1,036,484 shares of the Company&#x2019;s common stock and paid $6.0 million in cash, which included $0.2 million of accrued interest, to exchange an additional $8.8 million aggregate principal amount of such Convertible Notes.  As of September 30, 2020, these notes are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The remaining Convertible Notes are governed by an indenture (the &#x201c;Indenture&#x201d;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of September&#160;30, 2020, the balance of unamortized debt issuance costs was $0.13&#160;million, which was adjusted in September 2020 upon execution of the exchange agreements and offsets long-term debt on the condensed consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the remaining Convertible Notes was $15.4&#160;million as of September&#160;30, 2020 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mortgage Loan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#x201c;Property&#x201d;).  The loan agreement provided for a $12.9 million mortgage on the Property and had a two-year term with a 10-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3 million, which was paid in full in August 2020.  At December&#160;31, 2019, the condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $11.0 million and is included in current portion of long-term debt.  The fair value of the loan agreement approximated its carrying value.&#160;&#160;The fair value of the loan agreement was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BioPharma Term Loan.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma under which $150.0 million was funded in December 2017 (the &#x201c;BioPharma Term Loan&#x201d;). The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO sale in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6 million was recognized and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the BioPharma Term Loan were secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contained certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investments, transactions with affiliates and subordinated debt.  If an event of default occurred and was continuing, all amounts outstanding under the BioPharma Term Loan may have been declared immediately due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. The remaining balance of the debt issuance costs were written off and included as part of the debt extinguishment loss.&lt;/span&gt;&lt;/div&gt;At December&#160;31, 2019, the fair value of the BioPharma Term Loan approximated its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i1772c994ba65403ca45d1f126c089301_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTAz_b2c70142-13cc-4657-8ba8-7bc6338d5723"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="i17b3093f9ba14f25864a4923a0f67585_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTQz_564a6717-10f9-4da3-85a5-f7aa6b17374d"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvertibleDebtExchangeTotalPrincipalAmount
      contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTI0Mw_05a6154d-a938-451f-9921-fa957d3425c1"
      unitRef="usd">75800000</lxrx:ConvertibleDebtExchangeTotalPrincipalAmount>
    <lxrx:ConvertibleDebtExchangeSeptemberSharePayment
      contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNjg3OA_4dbb2ee0-076f-405b-b561-9b7581a329e2"
      unitRef="shares">9332471</lxrx:ConvertibleDebtExchangeSeptemberSharePayment>
    <lxrx:ConvertibleDebtExchangeSeptemberCashPortion
      contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNjg4Nw_33cb50e4-d689-4396-b57f-05ae9c64b7c1"
      unitRef="usd">44000000.0</lxrx:ConvertibleDebtExchangeSeptemberCashPortion>
    <lxrx:AccruedInterestOnConvertible
      contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTA2Mw_133e6651-5e9e-4fe4-bd30-a0c674ff2df8"
      unitRef="usd">1100000</lxrx:AccruedInterestOnConvertible>
    <lxrx:ConvertibleDebtExchangeSeptemberPrincipalAmount
      contextRef="i9b46f889feff422fb423fe1a658c6727_I20200928"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTA1Ng_d3a3726c-898d-4b81-b8bd-62554e3914ad"
      unitRef="usd">-67100000</lxrx:ConvertibleDebtExchangeSeptemberPrincipalAmount>
    <lxrx:ConvertibleDebtExchange
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNzI2NA_c305451d-a138-42f2-8b41-cdedb2f75921"
      unitRef="usd">8400000</lxrx:ConvertibleDebtExchange>
    <lxrx:ConvertibleDebtExchangeRemainingNotes
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNTY0MA_cf5e22c9-5fbe-4192-9e8b-8a44bd448d14"
      unitRef="usd">20000000.0</lxrx:ConvertibleDebtExchangeRemainingNotes>
    <lxrx:FutureConvertibleDebtExchangeShares
      contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNjk0MA_5f7b9b6d-fd4e-4d7d-8523-f4aa7232fcdc"
      unitRef="shares">1036484</lxrx:FutureConvertibleDebtExchangeShares>
    <lxrx:FutureConvertibleDebtExchange
      contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwNzAzNA_d77c9930-cbf3-4bf0-b0c0-1f9a8cf5be2a"
      unitRef="usd">6000000.0</lxrx:FutureConvertibleDebtExchange>
    <lxrx:AccruedInterestOnConvertible
      contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTE1MA_4026e60e-36fa-4c39-85fb-a4b66a203007"
      unitRef="usd">200000</lxrx:AccruedInterestOnConvertible>
    <lxrx:PrincipalAmountOfConvertibleNotes
      contextRef="id46df437a0a442c4bead16cb71e6341a_I20201001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwOTExMQ_f78fcfd4-646c-4eba-b2da-150c99dedbeb"
      unitRef="usd">-8800000</lxrx:PrincipalAmountOfConvertibleNotes>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="i17b3093f9ba14f25864a4923a0f67585_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNjYx_564a6717-10f9-4da3-85a5-f7aa6b17374d"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i1772c994ba65403ca45d1f126c089301_D20141101-20141130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTM4OA_e05f531c-32f1-4e9c-b054-8595caa07770"
      unitRef="number">118.4553</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i17b3093f9ba14f25864a4923a0f67585_I20141120"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMTUwOQ_2be99744-5a55-4ef9-9873-87f96987e72d"
      unitRef="usdPerShare">8.442</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i1772c994ba65403ca45d1f126c089301_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMjM2Mg_1b71a52a-80bc-4a94-907d-552ee127d073"
      unitRef="usd">3400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMjcwOA_34ae451e-1cee-47fb-b304-7f3e8a568c04"
      unitRef="usd">130000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMjg5NA_d4c7ec07-43dd-40a1-a7a2-4e675a550232"
      unitRef="usd">15400000</us-gaap:DebtInstrumentFairValue>
    <lxrx:MortgageDebtInstrument_Revere_LXRX
      contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzQyMw_e37c3224-9541-4cbc-a6f5-ceb58ed4b0b7"
      unitRef="usd">12900000</lxrx:MortgageDebtInstrument_Revere_LXRX>
    <lxrx:MortgageDebtInterestRate_Base_Revere_LXRX
      contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzYxMw_19d78de7-cb19-45ac-ba6e-380f39b13115"
      unitRef="number">0.055</lxrx:MortgageDebtInterestRate_Base_Revere_LXRX>
    <lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX
      contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzYyNA_0a49335b-0cd2-4e2a-869d-0fa96cbfda05"
      unitRef="number">0.075</lxrx:MortgageDebtInterestRateBasePlus_Revere_LXRX>
    <lxrx:MortgageDebtBalloonPayment_LXRX
      contextRef="i2a5c874e6c9e48619cce1b61357c131e_I20180830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzY2NQ_115ee0d8-76bf-4ab4-a39c-7e4468d332c5"
      unitRef="usd">10300000</lxrx:MortgageDebtBalloonPayment_LXRX>
    <lxrx:MortgageDebtInstrument_Revere_LXRX
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNDExOA_b4c547ff-4fef-4782-a6f7-cd2b561e554e"
      unitRef="usd">11000000.0</lxrx:MortgageDebtInstrument_Revere_LXRX>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if73dd8addd4542a29c4ec9debd3582d1_I20171218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNDc3Ng_fa3bb6a5-a51d-4a1f-ba88-7e9c2e6a0744"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNDkwNA_2372ffc1-143f-42fe-a0ba-fc4d127356ce"
      unitRef="number">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifb39716de56e4e5a895227f8630d9df3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfMzg0ODI5MDcwODA0Mw_dbea2c19-4f54-4618-8e0e-e5a388c868f5"
      unitRef="usd">8600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="if73dd8addd4542a29c4ec9debd3582d1_I20171218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80Ni9mcmFnOjY0MzUwMjE1ZjhhMzQ4ZTA4ODIxZDgzZTZhZWJkYjk2L3RleHRyZWdpb246NjQzNTAyMTVmOGEzNDhlMDg4MjFkODNlNmFlYmRiOTZfNjMwMA_93fae6f1-ef73-48dc-9a44-cc870a26d6e8"
      unitRef="usd">4100000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMTgyMw_98a63505-2eae-439a-8c1d-a62bc9ff6c5c">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  The Company&#x2019;s motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#x2019;s securities during the period from March&#160;11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sanofi Arbitration.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (&#x201c;Sanofi&#x201d;) seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the &#x201c;Termination Agreement&#x201d;).  In September 2020, Sanofi withheld approximately $23.2&#160;million from the final $26&#160;million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement.  The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement.  The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys&#x2019; fees and costs.&lt;/span&gt;&lt;/div&gt;In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="icb5076221df34ff6b100b90bb7f27cf6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMzI5ODUzNDg4NzE2NQ_1157e003-4d92-47a6-8bc7-37a67e7c0e10"
      unitRef="usd">23200000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMzI5ODUzNDg4NzE5NA_4a6601d5-c460-4bc5-87e7-7c5cbdcf1d1f"
      unitRef="usd">26000000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl80OS9mcmFnOjE2NDI3ZDRkODY1YjQwNWViNmEyMmIwYjNkN2Q0OThmL3RleHRyZWdpb246MTY0MjdkNGQ4NjViNDA1ZWI2YTIyYjBiM2Q3ZDQ5OGZfMzI5ODUzNDg4NzE5NA_df1fcd92-f589-4d70-968a-b9ac024d08e6"
      unitRef="usd">26000000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfOTcyNQ_595741d7-5955-4a15-831a-b7be4ef1d77c">Collaboration and License Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ipsen.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#x201c;Ipsen Agreement&#x201d;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#x201c;Licensed Territory&#x201d;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $47.2 million through September&#160;30, 2020, consisting of $24.5 million in upfront payments and a $6.4 million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen&#x2019;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen&#x2019;s first commercial sale in Germany, a $3.8 million milestone upon Ipsen&#x2019;s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen&#x2019;s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen&#x2019;s first commercial sale in Canada.  In addition, Lexicon was eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#x20ac;72&#160;million upon the achievement of specified sales milestones. Milestone payments that were contingent upon the achievement of a substantive milestone were deemed constrained.  Lexicon was also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen had entered into a commercial supply agreement pursuant to which Lexicon supplied Ipsen&#x2019;s commercial requirements of XERMELO, and Ipsen paid an agreed upon transfer price for such commercial supply.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5&#160;million upfront payments: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;The development services Lexicon was performing for XERMELO;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;The obligation to participate in committees which governed the development of XERMELO until commercialization; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;The obligation to supply commercial supply of XERMELO under a commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the license had stand-alone value because it was an exclusive license that gave Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considered the license and the development services under the Ipsen Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the commercial supply agreement was a contingent deliverable at its onset.  There was inherent uncertainty in obtaining regulatory approval at the time of entry into the commercial supply agreement, thus making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen.  As a result, the Company determined the commercial supply agreement did not meet the definition of a performance obligation that needed to be accounted for at the inception of the arrangement.  The Company also determined that there was no significant and incremental discount related to the commercial supply agreement that should have been accounted for at the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the initial transaction price was the $24.5&#160;million in upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the allocation, the Company recognized $21.2&#160;million of the $24.5&#160;million in upfront payments for the license in 2014, and an additional $1.4&#160;million in 2015 upon entering into the amendment.  The Company recognized the $1.7&#160;million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $0.1&#160;million allocated to the committee participation performance obligation ratably over the period of performance.  Milestone payments that were contingent upon the achievement of a substantive milestone were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deemed constrained.  If or when the constraint was determined to be resolved, the Company would re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  Revenue recognized under the Ipsen Agreement was $0.3 million and $3.5 million for the nine months ended September&#160;30, 2020 and 2019, respectively.   Royalty revenue of $0.3 million was recognized for each of the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sanofi.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#x201c;Sanofi Agreement&#x201d;), with Sanofi for the worldwide development of Lexicon&#x2019;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of September 9, 2019 (the &#x201c;Settlement Date&#x201d;), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.&lt;/span&gt;&lt;/div&gt;Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $208 million in September 2019 and $26 million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  See Note 7, Commitments and Contingencies, for additional information.  In March 2020, Lexicon announced its plan to close out the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Revenue relating to the Termination Agreement was recognized in the third quarter of 2019.  Revenue recognized under the Sanofi Agreement was $286.0 million for the nine months ended September&#160;30, 2019.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:IpsenTotalPayments
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTcxMQ_0c26df95-b570-4428-a515-45f9091fa098"
      unitRef="usd">47200000</lxrx:IpsenTotalPayments>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTc0MA_0d08fddf-e42f-4211-8038-c5e334c941ef"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenMilestonePayment
      contextRef="ia91cc58958d74a18bc3bdc7678de13fc_D20170101-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTc2OQ_0c9bc2a6-80db-4df8-a712-f55d852a7138"
      unitRef="usd">6400000</lxrx:IpsenMilestonePayment>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i0c565ac789974012b970ac1ab822623b_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMTk4Ng_e80bf66d-2288-4aef-9285-d404018c3054"
      unitRef="usd">5100000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i813cb4fdefa8444c86cc8630f57e27da_D20171001-20171031"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjE1Ng_3b2b83b9-c959-474a-8184-97aac52d9c95"
      unitRef="usd">3800000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i795f1b1257384f238c4605db9c94d3e7_D20171101-20171130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjIxOA_cf81e919-2a72-4a8f-9784-e13537df386b"
      unitRef="usd">3800000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i2fd1f447a93c4793b6c6a92f2e209e1e_D20191001-20191231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjI5MQ_a168d3cd-abc6-4e2f-92db-08df4a58da75"
      unitRef="usd">1300000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMilestonePaymentReceived
      contextRef="i381201bb0bd34c48a7207b7c78990cd8_D20190201-20190228"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjM2Mg_d3ae68bf-10b0-4c9f-a43a-c75847439f86"
      unitRef="usd">2300000</lxrx:IpsenMilestonePaymentReceived>
    <lxrx:IpsenMaximumRegulatoryAndCommercialMilestones
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjUxNw_9f253b42-8794-484a-b75b-327592e1ffde"
      unitRef="usd">9600000</lxrx:IpsenMaximumRegulatoryAndCommercialMilestones>
    <lxrx:IpsenMaximumSalesMilestones
      contextRef="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMjYyOA_0d64f031-31aa-4f65-a75a-a74bf4d4f7e6"
      unitRef="eur">72000000</lxrx:IpsenMaximumSalesMilestones>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzQxOQ_0d08fddf-e42f-4211-8038-c5e334c941ef"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNTUwNA_0d08fddf-e42f-4211-8038-c5e334c941ef"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenRevenueAllocatedtoLicenseDeliverable
      contextRef="ia4193bd56cb84f0d9f797512013ed041_D20150101-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNjg3Nw_c60aaec7-39aa-424e-904e-8bd50e1c74ec"
      unitRef="usd">21200000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
    <lxrx:IpsenTotalUpfrontPayments
      contextRef="ib75618e00a2543b69ae790323c7eab56_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNjg4Nw_0d08fddf-e42f-4211-8038-c5e334c941ef"
      unitRef="usd">24500000</lxrx:IpsenTotalUpfrontPayments>
    <lxrx:IpsenRevenueAllocatedtoLicenseDeliverable
      contextRef="i2e87a1738c194bf0b536c8857a3ca790_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNjk1MA_62b0922a-3cc1-4d18-acdf-83c1f89fd3b8"
      unitRef="usd">1400000</lxrx:IpsenRevenueAllocatedtoLicenseDeliverable>
    <lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable
      contextRef="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNzAyMw_d607dc30-73ad-4d59-9646-9c33a69fa3cb"
      unitRef="usd">1700000</lxrx:IpsenRevenueAllocatedtoDevelopmentDeliverable>
    <lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable
      contextRef="id8829851cba145d4badf4ae97d7a1ed6_D20141001-20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNzE2Mg_4f26616f-e0be-4eef-8091-7c0537a89941"
      unitRef="usd">100000</lxrx:IpsenRevenueAllocatedtoCommitteeDeliverable>
    <lxrx:IpsenRevenueRecognized
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfOTM0NTg0ODg1NTY1NQ_47325532-c5d0-468e-9024-319bafa5b141"
      unitRef="usd">300000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRevenueRecognized
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzg0ODI5MDcwNzkxNg_6d570a73-0196-4e18-9791-c65038887772"
      unitRef="usd">3500000</lxrx:IpsenRevenueRecognized>
    <lxrx:IpsenRoyaltyIncome_LXRX
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfNzcyOQ_17c8d65a-2a4b-4707-b509-2829bec1ce45"
      unitRef="usd">300000</lxrx:IpsenRoyaltyIncome_LXRX>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzI5ODUzNDkwMjg1MQ_073b209e-3b46-4ad6-8d04-fbe65a9592eb"
      unitRef="usd">208000000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <lxrx:Lxrx_Sanofiterminationcashpayment
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfODcwNw_7bb0700e-0cd8-42f3-9a96-5e2b6dca01d6"
      unitRef="usd">208000000</lxrx:Lxrx_Sanofiterminationcashpayment>
    <lxrx:Lxrx_sanofiInitialCashPayment
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzI5ODUzNDkwMjg1Mg_91c657e3-5ad1-41c2-bf70-4c4e25db4339"
      unitRef="usd">26000000</lxrx:Lxrx_sanofiInitialCashPayment>
    <lxrx:Lxrx_sanofiInitialCashPayment
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfODcyOQ_86f3ff65-3c2a-48fb-a797-aa121ef67b2e"
      unitRef="usd">26000000</lxrx:Lxrx_sanofiInitialCashPayment>
    <lxrx:SanofiRevenueRecognized
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzI5ODUzNDkwMjg1MA_4f86f877-5bef-4430-9f53-428d83959324"
      unitRef="usd">286000000.0</lxrx:SanofiRevenueRecognized>
    <lxrx:SanofiRevenueRecognized
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81Mi9mcmFnOjIzMTRkYjZjZjdlMzQ3YTg5M2M2N2U5NzE3YmE5ZGEzL3RleHRyZWdpb246MjMxNGRiNmNmN2UzNDdhODkzYzY3ZTk3MTdiYTlkYTNfMzg0ODI5MDcwNzkzNw_165aa31d-8610-48ab-a0e9-5381cc8f6fed"
      unitRef="usd">286000000.0</lxrx:SanofiRevenueRecognized>
    <us-gaap:AssetImpairmentChargesTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81NS9mcmFnOmQ2YWExMjc1MDhiODRmYzNhMTM4MjJiNmFjNTlhMDIzL3RleHRyZWdpb246ZDZhYTEyNzUwOGI4NGZjM2ExMzgyMmI2YWM1OWEwMjNfOTM0NTg0ODg0MDUxOQ_db70a6bc-b7e3-4283-a5b3-ab7b85b0db94">Impairment Loss on Buildings&#160;In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which the Company agreed to sell its facilities in The Woodlands, Texas for a purchase price of $11.9 million.  The sale agreement is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement at its discretion.  The property did not meet the criteria for classification as held for sale at September&#160;30, 2020.  Due to the negotiations to sell the property in 2020, the Company evaluated for impairment and recognized an impairment charge of $1.6 million in the second quarter of 2020 in order to reduce the carrying value of the property to its estimated fair value, less estimated selling costs.</us-gaap:AssetImpairmentChargesTextBlock>
    <lxrx:AssetSalePrice
      contextRef="ic3dc746618934941bc63c22f6053b48a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81NS9mcmFnOmQ2YWExMjc1MDhiODRmYzNhMTM4MjJiNmFjNTlhMDIzL3RleHRyZWdpb246ZDZhYTEyNzUwOGI4NGZjM2ExMzgyMmI2YWM1OWEwMjNfMzg0ODI5MDcwMTI3MA_5d615499-0d7c-4400-ac44-26275d70faa9"
      unitRef="usd">11900000</lxrx:AssetSalePrice>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4cbcaa4394a54302a137c10455b53959_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl81NS9mcmFnOmQ2YWExMjc1MDhiODRmYzNhMTM4MjJiNmFjNTlhMDIzL3RleHRyZWdpb246ZDZhYTEyNzUwOGI4NGZjM2ExMzgyMmI2YWM1OWEwMjNfMzg0ODI5MDcwMTI1Mg_e0480255-1bbf-4c30-a623-8d7520dacfdf"
      unitRef="usd">1600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzMyOTg1MzQ4ODQ2MDE_a4de345e-f26a-4f8d-8af2-97b1e77bccba">Earnings (Loss) Per ShareThe following is a summary of Lexicon&#x2019;s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Add interest on Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add effect of potential dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Share based compensation awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 11,773 and 10,576, respectively, for the three months ended September 30, 2020 and 2019, and 11,859 and 8,452, respectively, for the nine months ended September 30, 2020 and 2019. For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzMyOTg1MzQ4ODQ2MDI_0b221511-3dfa-4f66-a063-94b3af08a0da">The following is a summary of Lexicon&#x2019;s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Add interest on Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add effect of potential dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Share based compensation awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in computing net income (loss) per common share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtMi0xLTEtMzI5MQ_425b85f9-0116-47d4-ab48-48042bd8e952"
      unitRef="usd">82603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtNC0xLTEtMjI1Mw_c9d9818a-e741-4ebf-8cd6-ac8cbe031a6d"
      unitRef="usd">226086000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtNi0xLTEtMzI5MQ_396ef072-5a89-43ff-aed9-4b245e7dd33b"
      unitRef="usd">-53079000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzMtOC0xLTEtMjI1Mw_25a713f0-c676-44c8-8f9b-9e8ba47a90ae"
      unitRef="usd">181271000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtMi0xLTEtMzI5MQ_5a646368-ec09-48e3-ae7a-76ee9be5c273"
      unitRef="usd">1258000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtNC0xLTEtMjI1Nw_f9b11fe0-e17b-40bf-b72a-a4d7c0a6e9cd"
      unitRef="usd">1277000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtNi0xLTEtMzI5MQ_6fcdbef0-491e-4820-bb39-caa8a09173f9"
      unitRef="usd">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzQtOC0xLTEtMjI1Nw_feea6e8f-2e65-4989-a2e0-2be75a95cf0f"
      unitRef="usd">3790000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtMi0xLTEtMjI1Nw_8a30e523-699a-43fe-9564-c599c4611b57"
      unitRef="usd">83861000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtNC0xLTEtMjI1Nw_6a1e560c-4a6b-4042-b7d7-68b3e6212fcf"
      unitRef="usd">227363000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtNi0xLTEtMjI1Nw_987b3ded-6ba1-4bb5-a77f-267c45b1bacf"
      unitRef="usd">-53079000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzUtOC0xLTEtMjI1Nw_3d43fcee-f52e-42d3-a594-04ac4a1c8251"
      unitRef="usd">185061000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtMi0xLTEtMzI5Nw_d33b6b37-9956-4d0b-b1fb-f2faf3021788"
      unitRef="shares">107309000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtNC0xLTEtMjI2MQ_c3992a27-06a8-4a48-8412-4884a09d14ad"
      unitRef="shares">106272000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtNi0xLTEtMzI5Nw_882fee00-4e9f-498b-b663-dbc4406b9ea2"
      unitRef="shares">106974000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzgtOC0xLTEtMjI2MQ_14c5f326-ca42-48b1-ba26-1eb9616e6ce1"
      unitRef="shares">106200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTItMS0xLTMzMDM_42b51dd8-d580-455b-b00d-b0f120c6fa4e"
      unitRef="shares">51000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTQtMS0xLTIyNjE_a2f7a9e1-fb36-4e07-b174-7c949bbe15f1"
      unitRef="shares">3000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTYtMS0xLTMzMDM_1a73fc2a-6bca-41f1-b5fb-5bec2d9b028f"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEwLTgtMS0xLTIyNjE_5f75f1d0-0327-4aed-916d-fc6e5eaa38f2"
      unitRef="shares">177000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTItMS0xLTMzMDM_be07ca49-2447-42f2-9611-90f44d450ffc"
      unitRef="shares">10192000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTQtMS0xLTIyNjE_02549bcd-72ca-4c58-b1ab-b111c1f49b49"
      unitRef="shares">10365000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTYtMS0xLTMzMDM_497a41cf-2e9b-4324-a21d-00b86d633e3c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzExLTgtMS0xLTIyNjE_b1fc2375-15f8-42b8-a985-e17559d251a8"
      unitRef="shares">10365000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTItMS0xLTIyNjE_09136aea-bfe9-4f08-a9f4-79eaf685515b"
      unitRef="shares">117552000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTQtMS0xLTIyNjE_1db5074f-16ea-4cf7-8c9f-37e06d3c48cf"
      unitRef="shares">116640000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTYtMS0xLTIyNjE_0ee67a10-8fd8-42a4-9e96-bf0868b49a48"
      unitRef="shares">106974000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzEyLTgtMS0xLTIyNjE_ffd94489-6403-4b27-a721-29652f0254e6"
      unitRef="shares">116742000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTItMS0xLTMzMDk_51dfbb44-dd46-448b-b44b-e02ad996c322"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTQtMS0xLTIyNjE_eb5d5cc3-79eb-46da-aa13-e19cea6cfa1b"
      unitRef="usdPerShare">2.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTYtMS0xLTMzMDk_ab184d89-81c8-4030-9fed-7b7eabef7363"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE0LTgtMS0xLTIyNjE_3bbbc317-0e21-4591-9e24-e88eb1ceabff"
      unitRef="usdPerShare">1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTItMS0xLTMzMDk_94f4fd1c-d3f2-47ab-ab77-54e885719df8"
      unitRef="usdPerShare">0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTQtMS0xLTIyNjE_f11a0708-7344-4ad4-9c09-35ba659d73fc"
      unitRef="usdPerShare">1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTYtMS0xLTMzMDk_1112a1a1-43f4-410d-acdd-39ce9584eda1"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90YWJsZTowZjU0YzMxYjIwMWU0ZjYxODYyYWQ2NzIxOGZjNDMwMS90YWJsZXJhbmdlOjBmNTRjMzFiMjAxZTRmNjE4NjJhZDY3MjE4ZmM0MzAxXzE1LTgtMS0xLTIyNjE_2486a32e-5c28-40eb-8857-85614f854c20"
      unitRef="usdPerShare">1.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0NTA_6533cabf-1c73-49a4-83b3-c87b6d13906c"
      unitRef="shares">11773000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb255e5708f44e258e296c77abef2148_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0MTQ_e56d22fb-e1d9-4051-a18a-6f225c6aa75e"
      unitRef="shares">10576000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0Njk_6a29fa30-1cf2-4e95-9caa-8d513e2f77a3"
      unitRef="shares">11859000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifcd5deaaa8d5451684810bae3fb9488b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE3NjhjNWMxZDFiMDRmNWU5YTBkYzlhNzI2YWE2NWZmL3NlYzoxNzY4YzVjMWQxYjA0ZjVlOWEwZGM5YTcyNmFhNjVmZl84MzUvZnJhZzo2NWRiMDBiMWQ3NzI0NGJkODBmODBjZTQ3YTUyYTYzZC90ZXh0cmVnaW9uOjY1ZGIwMGIxZDc3MjQ0YmQ4MGY4MGNlNDdhNTJhNjNkXzM4NDgyOTA2OTg0Mjg_0b5e4004-7f00-4d61-a9bf-c7ab08d99c31"
      unitRef="shares">8452000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798400358280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,474,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798400328968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets-Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 52,251<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">59,195<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="nump">56,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,109<span></span>
</td>
<td class="nump">5,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">121,938<span></span>
</td>
<td class="nump">337,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $63,795 and $61,741, respectively</a></td>
<td class="nump">11,106<span></span>
</td>
<td class="nump">14,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">178,928<span></span>
</td>
<td class="nump">417,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,734<span></span>
</td>
<td class="nump">12,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">58,497<span></span>
</td>
<td class="nump">42,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of deferred issuance costs</a></td>
<td class="nump">8,691<span></span>
</td>
<td class="nump">11,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">78,922<span></span>
</td>
<td class="nump">65,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="nump">11,629<span></span>
</td>
<td class="nump">234,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">91,289<span></span>
</td>
<td class="nump">300,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 225,000 shares authorized; 117,231 and 106,679 shares issued, respectively</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,486,853<span></span>
</td>
<td class="nump">1,462,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,394,523)<span></span>
</td>
<td class="num">(1,341,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 793 and 407 shares, respectively</a></td>
<td class="num">(4,843)<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder's equity (deficit)</a></td>
<td class="nump">87,639<span></span>
</td>
<td class="nump">117,101<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 178,928<span></span>
</td>
<td class="nump">$ 417,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798396981400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 63,795<span></span>
</td>
<td class="nump">$ 61,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">117,231<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798393767528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Netproductrevenue', window );">Net product revenue</a></td>
<td class="nump">$ 6,542<span></span>
</td>
<td class="nump">$ 8,351<span></span>
</td>
<td class="nump">$ 23,404<span></span>
</td>
<td class="nump">$ 23,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaborative agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">285,910<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">289,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">6,634<span></span>
</td>
<td class="nump">294,448<span></span>
</td>
<td class="nump">23,796<span></span>
</td>
<td class="nump">313,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (including finite-lived intangible asset amortization)</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $1,029 $1,698, $5,154 and $5,369, respectively</a></td>
<td class="nump">40,147<span></span>
</td>
<td class="nump">26,659<span></span>
</td>
<td class="nump">152,629<span></span>
</td>
<td class="nump">51,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Sellinggeneralandadministrativeexpenses', window );">Selling, general and administrative expenses, included stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively</a></td>
<td class="nump">11,997<span></span>
</td>
<td class="nump">13,898<span></span>
</td>
<td class="nump">40,798<span></span>
</td>
<td class="nump">42,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,638<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,638<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">52,777<span></span>
</td>
<td class="nump">69,772<span></span>
</td>
<td class="nump">196,956<span></span>
</td>
<td class="nump">124,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">132,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">132,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">86,675<span></span>
</td>
<td class="nump">224,676<span></span>
</td>
<td class="num">(40,342)<span></span>
</td>
<td class="nump">188,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="num">(255)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,118)<span></span>
</td>
<td class="num">(5,204)<span></span>
</td>
<td class="num">(14,374)<span></span>
</td>
<td class="num">(15,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">2,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Income (Loss) before Taxes</a></td>
<td class="nump">82,603<span></span>
</td>
<td class="nump">220,072<span></span>
</td>
<td class="num">(53,079)<span></span>
</td>
<td class="nump">175,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 82,603<span></span>
</td>
<td class="nump">$ 226,086<span></span>
</td>
<td class="num">$ (53,079)<span></span>
</td>
<td class="nump">$ 181,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, Basic</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share, diluted</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per common share, Basic</a></td>
<td class="nump">107,309<span></span>
</td>
<td class="nump">106,272<span></span>
</td>
<td class="nump">106,974<span></span>
</td>
<td class="nump">106,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (277)<span></span>
</td>
<td class="num">$ (50)<span></span>
</td>
<td class="num">$ (49)<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">82,326<span></span>
</td>
<td class="nump">226,036<span></span>
</td>
<td class="num">(53,128)<span></span>
</td>
<td class="nump">181,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">5,154<span></span>
</td>
<td class="nump">5,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
<td class="nump">5,440<span></span>
</td>
<td class="nump">5,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfRealEstate', window );">Impairment of Real Estate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Netproductrevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Netproductrevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Sellinggeneralandadministrativeexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Sellinggeneralandadministrativeexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings in the period to reduce the carrying amount of real property to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798315905288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss Parentheticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedStatementsOfOperationsAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="nump">$ 1,698<span></span>
</td>
<td class="nump">$ 5,154<span></span>
</td>
<td class="nump">$ 5,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 875<span></span>
</td>
<td class="nump">$ 1,864<span></span>
</td>
<td class="nump">$ 5,440<span></span>
</td>
<td class="nump">$ 5,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedStatementsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedStatementsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798393404984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2018</a></td>
<td class="num">$ (26,405)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 1,447,954<span></span>
</td>
<td class="num">$ (1,471,577)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (2,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(941)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,797)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2019</a></td>
<td class="num">(45,687)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,451,365<span></span>
</td>
<td class="num">(1,493,374)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2018</a></td>
<td class="num">(26,405)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,447,954<span></span>
</td>
<td class="num">(1,471,577)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(2,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">181,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Sep. 30, 2019</a></td>
<td class="nump">106,679<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 164,712<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,458,693<span></span>
</td>
<td class="num">(1,290,306)<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2019</a></td>
<td class="num">(45,687)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,451,365<span></span>
</td>
<td class="num">(1,493,374)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,018)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Jun. 30, 2019</a></td>
<td class="num">(64,886)<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,455,131<span></span>
</td>
<td class="num">(1,516,392)<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">226,086<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">226,086<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (50)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Sep. 30, 2019</a></td>
<td class="nump">106,679<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 164,712<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,458,693<span></span>
</td>
<td class="num">(1,290,306)<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">117,101<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,462,172<span></span>
</td>
<td class="num">(1,341,444)<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(923)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,611)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,611)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2020</a></td>
<td class="nump">54,777<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">1,466,604<span></span>
</td>
<td class="num">(1,408,055)<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="num">(4,740)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2019</a></td>
<td class="nump">117,101<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">1,462,172<span></span>
</td>
<td class="num">(1,341,444)<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(3,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Sep. 30, 2020</a></td>
<td class="nump">117,231<span></span>
</td>
<td class="nump">117,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 87,639<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">1,486,853<span></span>
</td>
<td class="num">(1,394,523)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="num">(4,843)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2020</a></td>
<td class="nump">54,777<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">1,466,604<span></span>
</td>
<td class="num">(1,408,055)<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="num">(4,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,258<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,258<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(69,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">(548)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(548)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Jun. 30, 2020</a></td>
<td class="num">(10,687)<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">1,470,862<span></span>
</td>
<td class="num">(1,477,126)<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="num">(4,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,904<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="nump">9,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="nump">$ 14,096<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">14,087<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">82,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">82,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (277)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Sep. 30, 2020</a></td>
<td class="nump">117,231<span></span>
</td>
<td class="nump">117,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 87,639<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 1,486,853<span></span>
</td>
<td class="num">$ (1,394,523)<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="num">$ (4,843)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798400646056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (53,079)<span></span>
</td>
<td class="nump">$ 181,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,594<span></span>
</td>
<td class="nump">10,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">995<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="num">(132,818)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="nump">52,201<span></span>
</td>
<td class="num">(50,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventory</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(6,008)<span></span>
</td>
<td class="num">(3,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other assets</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and other liabilities</a></td>
<td class="nump">14,281<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,929)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(108,730)<span></span>
</td>
<td class="nump">138,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(53,197)<span></span>
</td>
<td class="num">(176,987)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">229,500<span></span>
</td>
<td class="nump">130,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">336,655<span></span>
</td>
<td class="num">(46,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(1,026)<span></span>
</td>
<td class="num">(941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt borrowings, net of fees</a></td>
<td class="num">(210,760)<span></span>
</td>
<td class="num">(963)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(211,786)<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">16,139<span></span>
</td>
<td class="nump">89,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">36,112<span></span>
</td>
<td class="nump">80,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">52,251<span></span>
</td>
<td class="nump">170,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">16,892<span></span>
</td>
<td class="nump">13,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfRealEstate', window );">Impairment of Real Estate</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings in the period to reduce the carrying amount of real property to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798390791240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2019, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of September&#160;30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventory was comprised of supplies of XERMELO supporting the Company&#8217;s commercialization of the product in the United States.  Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method.  As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively.  See Note 3, Asset Sale, for additional information relating to inventory.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Intangible assets, net consisted of in-process research and development acquired in business combinations, which are reported at fair value, less accumulated amortization.  During 2017, intangible assets relating to XERMELO of $24.7 million were reclassified from indefinite-lived to finite-lived assets following the approval of XERMELO by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;).  Intangible assets with finite lives are amortized using the straight-line method over their estimated lives.  As of December 31, 2019, the net carrying value of the finite-lived intangible assets was $19.7&#160;million.   During the three and nine months ended September&#160;30, 2020, the remaining net carrying value of $18.5 million for the intangible assets relating to XERMELO was reduced to zero as a result of the Xermelo sale. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflected the Company&#8217;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.  For the three and nine months ended September&#160;30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September&#160;30, 2019, includes $0.4 million and $1.3 million, respectively.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the nine months ended September&#160;30, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) In connection with the reduction in force in September 2020, unvested stock options were forfeited or cancelled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, Lexicon also granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three to four annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(1) In connection with the reduction in force in September 2020, unvested restricted stock units were forfeited or cancelled.</span></div>Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392408424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements Level 1 (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text">Recent Accounting PronouncementsIn November 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.  This targeted amendment to Topic 808 clarifies that certain transactions resulting from a collaborative agreement should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer for a good or service that is a distinct unit-of-account.  This amendment is effective for fiscal years, and interim periods within years presented, beginning after December 15, 2019, and should be applied retrospectively to the date of initial application of Topic 606.  The Company has applied the provisions of Topic 606 to account for its transactions for collaboration arrangements, including recognition, measurement, presentation and disclosure requirement, and adoption of this ASU did not have a material impact on the condensed consolidated financial statements.In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other, which is intended to simplify the subsequent measurement of goodwill.  The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount.  An impairment charge is immediately recognized by which the carrying amount exceeds the fair value.  This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019.  The adoption of this ASU did not have a material impact on the condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392268968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Sale (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SaleOfNonFinancialAssetsTextBlock', window );">Sale of Non-Financial Assets</a></td>
<td class="text">Asset Sale<div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company completed the sale of its XERMELO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (telotristat ethyl) product and related assets (the &#8220;XERMELO sale&#8221;) to TerSera Therapeutics LLC (&#8220;TerSera&#8221;) pursuant to an Asset Purchase and Sale Agreement entered into in July 2020.  The upfront consideration paid by TerSera, subject to a working capital adjustment as set forth in the Asset Purchase and Sale Agreement, was $160.4 million and the net gain recognized in connection with the XERMELO sale was $132.8 million.  The gain is reflected on the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65&#160;million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer.  The Company has determined that these amounts are constrained until the achievement, if any, of specific events.  If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company&#8217;s operations.  For the three and nine months ended September&#160;30, 2020, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company&#8217;s XERMELO operations is $2.1 million and $12.1 million, respectively, and for the three and nine months ended September&#160;30, 2019, the pretax net loss for the Company&#8217;s XERMELO operations is $4.1 million and $10.8 million, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div>As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company currently expects severance charges to approximate $5.7 million, of which $5.5 million was incurred through September&#160;30, 2020. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SaleOfNonFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Non-Financial Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SaleOfNonFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392244568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure</a></td>
<td class="text">Cash and Cash Equivalents and Investments&#160;<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at September&#160;30, 2020 and December&#160;31, 2019 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,411&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized losses during either of the nine months ended September&#160;30, 2020 and 2019, respectively.  The cost of securities sold is based on the specific identification method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392160664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value, Measurement Inputs, Disclosure</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of September&#160;30, 2020 or December&#160;31, 2019. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis.  These assets include goodwill associated with the acquisitions of Coelacanth Corporation in 2001 and Symphony Icon, Inc. in 2010, and intangible assets associated with the acquisition of Symphony Icon, Inc. in 2010. For these assets, measurement at fair value in periods subsequent to their initial recognition is applicable if one or more is determined to be impaired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, Debt Obligations, for fair value measurements of debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392890648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure</a></td>
<td class="text">Debt Obligations<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principle amount of the Convertible Notes.  In September 2020, the Company issued 9,332,471 shares of the Company&#8217;s common stock and paid $44.0 million in cash, which included $1.1 million of accrued interest, to exchange $67.1 million aggregate principal amount of such Convertible Notes.  The Company recorded the exchanges under the accounting requirements for debt extinguishment of convertible instruments.  As a result, a debt extinguishment gain of $8.4 million was recorded and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.  As of September&#160;30, 2020, the carrying value of the remaining Convertible Notes was $20.0 million. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company issued 1,036,484 shares of the Company&#8217;s common stock and paid $6.0 million in cash, which included $0.2 million of accrued interest, to exchange an additional $8.8 million aggregate principal amount of such Convertible Notes.  As of September 30, 2020, these notes are included in the current portion of long-term debt, net of deferred issuance costs in the accompanying condensed consolidated balance sheet. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The remaining Convertible Notes are governed by an indenture (the &#8220;Indenture&#8221;), dated as of November&#160;26, 2014, between the Company and Wells Fargo Bank, N.A., as trustee.  The Convertible Notes bear interest at a rate of 5.25%&#160;per year, payable semiannually in arrears on June&#160;1 and December&#160;1 of each year, beginning on June&#160;1, 2015. The Convertible Notes mature on December&#160;1, 2021. The Company may not redeem the Convertible Notes prior to the maturity date, and no sinking fund is provided for the Convertible Notes.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the Company will deliver for each $1,000 principal amount of converted Convertible Notes a number of shares of its common stock equal to the conversion rate, as described in the Indenture. The conversion rate is initially 118.4553 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of $8.442 per share of common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Convertible Notes, the Company incurred $3.4 million of debt issuance costs.  The debt issuance costs are amortized as interest expense over the expected life of the Convertible Notes using the effective interest method.  The Company determined the expected life of the debt was equal to the seven-year term of the Convertible Notes.  As of September&#160;30, 2020, the balance of unamortized debt issuance costs was $0.13&#160;million, which was adjusted in September 2020 upon execution of the exchange agreements and offsets long-term debt on the condensed consolidated balance sheets.  </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining Convertible Notes was $15.4&#160;million as of September&#160;30, 2020 and was determined using Level&#160;2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Convertible Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Loan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In August 2018, a wholly owned subsidiary of Lexicon entered into a term loan and security agreement, refinancing the previously existing mortgage on its facilities in The Woodlands, Texas (the &#8220;Property&#8221;).  The loan agreement provided for a $12.9 million mortgage on the Property and had a two-year term with a 10-year amortization.  The mortgage loan bore interest at a rate per annum equal to the greater of (a) the 30-day LIBOR rate plus 5.5% and (b) 7.5% and provided for a balloon payment of $10.3 million, which was paid in full in August 2020.  At December&#160;31, 2019, the condensed consolidated balance sheet includes mortgage debt, the carrying value of the debt, of $11.0 million and is included in current portion of long-term debt.  The fair value of the loan agreement approximated its carrying value.&#160;&#160;The fair value of the loan agreement was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioPharma Term Loan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;In December 2017, Lexicon entered into a loan agreement with BioPharma under which $150.0 million was funded in December 2017 (the &#8220;BioPharma Term Loan&#8221;). The BioPharma Term Loan was scheduled to mature in December 2022, bore interest at 9% per year, subject to additional interest if an event of default occurred and was continuing, and was payable quarterly. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BioPharma Term Loan was subject to mandatory prepayment provisions that required prepayment upon a change of control or receipt of proceeds from certain non-ordinary course transfers of assets.  The Company repaid the BioPharma Term Loan in whole, together with required prepayment and make-whole premiums, upon closing of the XERMELO sale in September 2020.  The Company recorded the repayment under the accounting requirements for debt extinguishment and as a result, a loss of $8.6 million was recognized and is included in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September&#160;30, 2020.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the BioPharma Term Loan were secured by a first lien security interest in substantially all of the assets of the Company and certain of its subsidiaries, other than its facilities in The Woodlands, Texas.  The loan agreement contained certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, including among other things, covenants restricting dispositions, fundamental changes in the business, mergers or acquisitions, indebtedness, encumbrances, distributions, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments, transactions with affiliates and subordinated debt.  If an event of default occurred and was continuing, all amounts outstanding under the BioPharma Term Loan may have been declared immediately due and payable.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the BioPharma Term Loan, the Company incurred $4.1 million of debt issuance costs.  The debt issuance costs were being amortized as interest expense over the expected life of the BioPharma Term Loan using the effective interest method.  The Company determined the expected life of the debt was equal to the five-year term of the BioPharma Term Loan. The remaining balance of the debt issuance costs were written off and included as part of the debt extinguishment loss.</span></div>At December&#160;31, 2019, the fair value of the BioPharma Term Loan approximated its carrying value.  The fair value of the BioPharma Term Loan was determined using Level&#160;2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392779608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;On January 28, 2019, a purported securities class action complaint captioned Daniel Manopla v. Lexicon Pharmaceuticals, Inc., Lonnel Coats, Jeffrey L. Wade and Pablo Lapuerta, M.D. was filed against the Company and certain of its officers in the U.S. District Court for the Southern District of Texas, Houston Division.  The Company&#8217;s motion to dismiss was granted and the action was dismissed with prejudice by the District Court on August 14, 2020.  The lead plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Fifth Circuit on September 11, 2020.  The lawsuit purports to be a class action brought on behalf of purchasers of the Company&#8217;s securities during the period from March&#160;11, 2016 through July 29, 2019.  The complaint alleges that the defendants violated federal securities laws by making materially false and misleading statements and/or omissions concerning data from its Phase 3 clinical trials of sotagliflozin in type 1 diabetes patients and the prospects of FDA approval of sotagliflozin for the treatment of type 1 diabetes.  The complaint purports to assert claims for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.  The complaint seeks, on behalf of the purported class, an unspecified amount of monetary damages, interest, fees and expenses of attorneys and experts, and other relief.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Arbitration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On October 16, 2020, the Company initiated arbitration proceedings against Sanofi-Aventis Deutschland GmbH (&#8220;Sanofi&#8221;) seeking to recover damages for breach of contract relating to the Termination and Settlement Agreement and Mutual Releases with Sanofi, dated September 9, 2019 (the &#8220;Termination Agreement&#8221;).  In September 2020, Sanofi withheld approximately $23.2&#160;million from the final $26&#160;million payment due to the Company under the Termination Agreement, offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by the Company under the terms of the Termination Agreement.  The Company disputes that at least a significant portion of such costs are properly reimbursable by the Company under the terms of the Termination Agreement and asserts that, in any event, Sanofi was not permitted to withhold any of such costs under the terms of the Termination Agreement.  The Company is seeking payment of up to $23.2 million in such disputed costs, together with late interest and attorneys&#8217; fees and costs.</span></div>In addition, Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392299624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure</a></td>
<td class="text">Collaboration and License Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In October 2014, Lexicon entered into a License and Collaboration Agreement, which was subsequently amended in March 2015 (collectively, the &#8220;Ipsen Agreement&#8221;), with Ipsen for the development and commercialization of XERMELO outside of the United States and Japan (the &#8220;Licensed Territory&#8221;).  The Ipsen Agreement was assigned to TerSera in September 2020 in connection with the XERMELO sale.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ipsen Agreement, Lexicon granted Ipsen an exclusive, royalty-bearing right and license under its patent rights and know-how to commercialize XERMELO in the Licensed Territory.  Ipsen was responsible for using diligent efforts to commercialize XERMELO in the Licensed Territory pursuant to a mutually approved commercialization plan.  Subject to certain exceptions, Lexicon was responsible for conducting clinical trials required to obtain regulatory approval for XERMELO for carcinoid syndrome in the European Union, including those contemplated by a mutually approved initial development plan, and had the first right to conduct most other clinical trials of XERMELO.  Lexicon was responsible for the costs of all clinical </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials contemplated by the initial development plan. The costs of additional clinical trials were to be allocated between the parties based on the nature of such clinical trials.  Under the Ipsen Agreement, Ipsen paid Lexicon an aggregate of $47.2 million through September&#160;30, 2020, consisting of $24.5 million in upfront payments and a $6.4 million milestone payment upon the acceptance of the filing submitted by Ipsen to the European Medicines Agency for XERMELO as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome, a $5.1 million milestone upon Ipsen&#8217;s receipt of approval from the European Commission for the marketing of XERMELO in all member states of the European Union, Norway and Iceland, a $3.8 million milestone upon Ipsen&#8217;s first commercial sale in Germany, a $3.8 million milestone upon Ipsen&#8217;s first commercial sale in the United Kingdom, a $1.3 million milestone upon Ipsen&#8217;s receipt of approval from Health Canada and a $2.3 million milestone upon Ipsen&#8217;s first commercial sale in Canada.  In addition, Lexicon was eligible to receive from Ipsen (a) up to an aggregate of approximately $9.6&#160;million upon the achievement of specified regulatory and commercial launch milestones and (b) up to an aggregate of &#8364;72&#160;million upon the achievement of specified sales milestones. Milestone payments that were contingent upon the achievement of a substantive milestone were deemed constrained.  Lexicon was also entitled to tiered, escalating royalties ranging from low twenties to mid-thirties percentages of net sales of XERMELO in the Licensed Territory, subject to a credit for amounts previously paid to Lexicon by Ipsen for the manufacture and supply of such units of XERMELO.  Lexicon and Ipsen had entered into a commercial supply agreement pursuant to which Lexicon supplied Ipsen&#8217;s commercial requirements of XERMELO, and Ipsen paid an agreed upon transfer price for such commercial supply.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the following as its performance obligations with respect to the revenue recognition of the $24.5&#160;million upfront payments: </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The exclusive license granted to Ipsen to develop and commercialize XERMELO in the Licensed Territory;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The development services Lexicon was performing for XERMELO;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The obligation to participate in committees which governed the development of XERMELO until commercialization; and</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The obligation to supply commercial supply of XERMELO under a commercial supply agreement.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the license had stand-alone value because it was an exclusive license that gave Ipsen the right to develop and commercialize XERMELO or to sublicense its rights.  In addition, at the time of the agreement, it would have been possible for Ipsen or another third party to conduct clinical trials without assistance from Lexicon.  As a result, the Company considered the license and the development services under the Ipsen Agreement to be separate performance obligations.  The Company recognized the portion of the transaction price allocated to the license immediately because Lexicon delivered the license and earned the revenue at the inception of the arrangement.  The Company recognized as revenue the amount allocated to the development services and the obligation to participate in committees over the period of time Lexicon performed the services, which was completed in 2018.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the commercial supply agreement was a contingent deliverable at its onset.  There was inherent uncertainty in obtaining regulatory approval at the time of entry into the commercial supply agreement, thus making the applicability of the commercial supply agreement outside the control of Lexicon and Ipsen.  As a result, the Company determined the commercial supply agreement did not meet the definition of a performance obligation that needed to be accounted for at the inception of the arrangement.  The Company also determined that there was no significant and incremental discount related to the commercial supply agreement that should have been accounted for at the inception of the arrangement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the initial transaction price was the $24.5&#160;million in upfront payments because they were the only payments that were fixed and determinable at the inception of the arrangement.  There was considerable uncertainty at the date of the agreement as to whether Lexicon would earn milestone payments, royalty payments or payments for finished drug product.  As such, the Company did not include those payments in the transaction price.  The Company allocated the transaction price based on the relative best estimate of selling price of each performance obligation.  The Company estimated the selling price of the license deliverable by applying a probability-based income approach utilizing an appropriate discount rate.  The significant inputs the Company used to determine the projected income of the license included: estimated future product sales, estimated cost of goods sold, estimated operating expenses, income taxes, and an appropriate discount rate.  The Company estimated the selling price of the development services by using internal estimates of the cost to hire third parties to perform the services over the expected period to perform the development.  The Company estimated the selling price of the obligation to participate in committees by using internal estimates of the number of internal hours and salary and benefits costs to perform these services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the allocation, the Company recognized $21.2&#160;million of the $24.5&#160;million in upfront payments for the license in 2014, and an additional $1.4&#160;million in 2015 upon entering into the amendment.  The Company recognized the $1.7&#160;million allocated to the development services performance obligation over the period of performance as development occurred, and recognized the $0.1&#160;million allocated to the committee participation performance obligation ratably over the period of performance.  Milestone payments that were contingent upon the achievement of a substantive milestone were </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed constrained.  If or when the constraint was determined to be resolved, the Company would re-evaluate the overall transaction price and recognize an adjustment on a cumulative catch-up basis in the period that the adjustment was evaluated.  Revenue recognized under the Ipsen Agreement was $0.3 million and $3.5 million for the nine months ended September&#160;30, 2020 and 2019, respectively.   Royalty revenue of $0.3 million was recognized for each of the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, Lexicon entered into a Collaboration and License Agreement, which was subsequently amended in July 2017 (collectively, the &#8220;Sanofi Agreement&#8221;), with Sanofi for the worldwide development of Lexicon&#8217;s diabetes drug candidate sotagliflozin.  In December 2016, Sanofi terminated its rights under the Sanofi Agreement with respect to Japan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of September 9, 2019 (the &#8220;Settlement Date&#8221;), Lexicon entered into the Termination Agreement with Sanofi, pursuant to which the Sanofi Agreement was terminated and certain associated disputes between Lexicon and Sanofi were settled.</span></div>Under the terms of the Termination Agreement, Lexicon regained all rights to sotagliflozin and assumed full responsibility for the worldwide development and commercialization of sotagliflozin in all indications. Sanofi paid Lexicon $208 million in September 2019 and $26 million in each of March and September 2020 (less amounts withheld by Sanofi offsetting certain third party costs and internal costs incurred by Sanofi and asserted by Sanofi to be payable by Lexicon under the terms of the Termination Agreement), and neither party will owe any additional payments pursuant to the Sanofi Agreement. The parties have cooperated in the transition of responsibility for ongoing clinical studies and other activities, and each party is responsible for its own expenses associated with such transition, subject to certain exceptions.  See Note 7, Commitments and Contingencies, for additional information.  In March 2020, Lexicon announced its plan to close out the clinical studies related to the Phase 3 development program for sotagliflozin in type 2 diabetes, heart failure and chronic kidney disease. Revenue relating to the Termination Agreement was recognized in the third quarter of 2019.  Revenue recognized under the Sanofi Agreement was $286.0 million for the nine months ended September&#160;30, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392189192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment Loss on Buildings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesTextBlock', window );">Asset Impairment Charges</a></td>
<td class="text">Impairment Loss on Buildings&#160;In October 2020, Lex-Gen Woodlands, L.P. entered into a real estate purchase and sale agreement under which the Company agreed to sell its facilities in The Woodlands, Texas for a purchase price of $11.9 million.  The sale agreement is subject to normal and customary closing conditions, including a study period, which extends until November 20, 2020, during which the purchaser may conduct inspections, analyses and other studies of the property and may terminate the agreement at its discretion.  The property did not meet the criteria for classification as held for sale at September&#160;30, 2020.  Due to the negotiations to sell the property in 2020, the Company evaluated for impairment and recognized an impairment charge of $1.6 million in the second quarter of 2020 in order to reduce the carrying value of the property to its estimated fair value, less estimated selling costs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392391688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings (Loss) Per ShareThe following is a summary of Lexicon&#8217;s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:40.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Add interest on Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,861&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Share based compensation awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share.  The average number of shares associated with stock options and restricted stock units that were excluded from diluted earnings per share that would potentially dilute earnings per share in the future was 11,773 and 10,576, respectively, for the three months ended September 30, 2020 and 2019, and 11,859 and 8,452, respectively, for the nine months ended September 30, 2020 and 2019. For periods presented with a net loss, the shares associated with the Convertible Notes are not included in the computation of diluted earnings per share because they are antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798393506808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of September&#160;30, 2020, short-term investments consisted of U.S. treasury bills and corporate debt securities.  As of December&#160;31, 2019, short-term investments consisted of U.S. treasury bills.  The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations regardless of the stated maturity date of the security.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Lexicon records trade accounts receivable in the normal course of business related to the sale of products or services, net of an allowance for expected credit losses.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text">Inventory:  Inventory was comprised of supplies of XERMELO supporting the Company&#8217;s commercialization of the product in the United States.  Inventories were determined at the lower of cost or market value, with cost determined under the specific identification method.  As of December 31, 2019, inventory in the accompanying condensed consolidated balance sheet consisted of raw materials, work in process and finished goods in the amounts of $3.2 million, $0.2 million and $0.9 million, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consisted of commercial sales of XERMELO in the United States and sales of bulk tablets of XERMELO to Ipsen Pharma SAS (&#8220;Ipsen&#8221;).  Product revenues were recognized when the customer obtained control of XERMELO, which occurred upon delivery to the customer.  The Company recognized product revenue net of applicable reserves for variable consideration, including allowances for customer credits, estimated rebates, chargebacks, discounts, returns, distribution service fees, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S.  These estimates were based on the most likely amount method for relevant factors such as current contractual and statutory requirements, industry data and forecasted customer buying and payment patterns.  The Company&#8217;s net product revenues reflected the Company&#8217;s best estimates of the amounts of consideration to which it was entitled based on the terms of the respective underlying contracts.  Product shipping and handling costs were considered a fulfillment activity when control transferred to the Company&#8217;s customers and such costs were included in cost of sales.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Agreements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under collaborative agreements include both license revenue and contract research revenue.  The Company performs the following five steps in determining the amount of revenue to recognize as it fulfills its performance obligations under each of its agreements:  (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.  The Company applies this five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.  The Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestones based on a level of sales, the license is deemed to be the predominant item to which the royalties relate and the Company recognizes revenue at the later of (i) when the related </span></div>sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text">Cost of Sales:  Cost of sales consisted of third-party manufacturing costs, freight and indirect overhead costs associated with sales of XERMELO. Product shipping and handling costs are included in cost of sales. Cost of sales also includes the amortization of the in-process research and development intangible asset for XERMELO using the straight-line method over the estimated useful life of 14 years.  For the three and nine months ended September&#160;30, 2020, cost of sales in the accompanying condensed consolidated statement of income (loss) includes amortization expense of $0.3 million and $1.2 million, respectively, and for the three and nine months ended September&#160;30, 2019, includes $0.4 million and $1.3 million, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company&#8217;s estimates of the clinical study costs and costs to transition activities from Sanofi for development of sotagliflozin for type 2 diabetes, heart failure and chronic kidney disease, including the costs to close out those studies, are based on actual costs incurred for activities completed subsequent to the transition date and estimates of the services to be received and efforts to be expended pursuant to contracts with multiple vendors and the contract research organization that has conducted and managed and is now closing out the clinical studies on its behalf.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798394927944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract', window );"><strong>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.163%"><tr><td style="width:1.0%"/><td style="width:52.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2019:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798390886744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,411&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798390783944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,359&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,446&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392378472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">The following is a summary of Lexicon&#8217;s earnings (loss) per share calculations and reconciliations of basic to diluted earnings (loss) per share.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.807%"><tr><td style="width:1.0%"/><td style="width:40.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Add interest on Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,861&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add effect of potential dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Share based compensation awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798400741064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory, Finished Goods, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798397197048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392930488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">8,995<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.35<span></span>
</td>
<td class="nump">$ 8.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="nump">3,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="nump">1,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">5,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">2,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 6.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798394903768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services current</a></td>
<td class="nump">$ 50,217<span></span>
</td>
<td class="nump">$ 29,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedCompensationAndBenefitsCurrent', window );">Accrued compensation and benefits current</a></td>
<td class="nump">6,023<span></span>
</td>
<td class="nump">9,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 58,497<span></span>
</td>
<td class="nump">$ 42,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current - due within 1 year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798393783896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,716<span></span>
</td>
<td class="nump">$ 24,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 28,638<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 28,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible Assets, Net (Including Goodwill)</a></td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798393355336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_GainOnSaleOfNonFinancialAssets', window );">Gain on sale of non-financial assets</a></td>
<td class="nump">$ 132,800<span></span>
</td>
<td class="nump">$ 132,818<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 132,818<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from Sale of Productive Assets</a></td>
<td class="nump">$ 160,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones', window );">TerSera Maximum Development, Regulatory and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_XermeloPretaxNetLoss', window );">Xermelo Pretax Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
<td class="num">(12,100)<span></span>
</td>
<td class="num">(10,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (255)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=lxrx_RDSeveranceCostsMember', window );">R&amp;D severance costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=lxrx_SGASeveranceCostsMember', window );">SG&amp;A severance costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureAbstract', window );"><strong>Asset Retirement Obligation Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=lxrx_BioPharmaMember', window );">BioPharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_GainOnSaleOfNonFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of non-financial assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_GainOnSaleOfNonFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>TerSera Maximum Development, Regulatory and Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_XermeloPretaxNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Xermelo Pretax Net Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_XermeloPretaxNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=lxrx_RDSeveranceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=lxrx_RDSeveranceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=lxrx_SGASeveranceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=lxrx_SGASeveranceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=lxrx_BioPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=lxrx_BioPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798393891336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 52,251<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">52,251<span></span>
</td>
<td class="nump">36,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">38,796<span></span>
</td>
<td class="nump">235,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">38,836<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Total Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">59,160<span></span>
</td>
<td class="nump">235,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">59,195<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">111,411<span></span>
</td>
<td class="nump">271,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">111,446<span></span>
</td>
<td class="nump">$ 271,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">20,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 20,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392389144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798400579240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 52,251<span></span>
</td>
<td class="nump">$ 36,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">59,195<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">111,446<span></span>
</td>
<td class="nump">271,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">52,251<span></span>
</td>
<td class="nump">36,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">38,836<span></span>
</td>
<td class="nump">235,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">91,087<span></span>
</td>
<td class="nump">271,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">20,359<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">20,359<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798397234744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 28, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 20, 2014 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage', window );">Conv Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="nump">118.4553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Debt Issuance Cost</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInstrument_Revere_LXRX', window );">Mortgage Debt Instrument_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX', window );">Mortgage Debt Interest Rate_Base_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX', window );">Mortgage Debt Interest Rate BasePlus_Revere_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_MortgageDebtBalloonPayment_LXRX', window );">Mortgage Debt Balloon Payment_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchange', window );">Convertible debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedInterestOnConvertible', window );">accrued interest on convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeRemainingNotes', window );">Convertible debt exchange Remaining Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount', window );">Convertible debt exchange - Total Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount', window );">Convertible debt exchange - September principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeSeptemberCashPortion', window );">Convertible debt exchange- September cash portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeSeptemberSharePayment', window );">Convertible debt exchange - September share payment | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,332,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedInterestOnConvertible', window );">accrued interest on convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FutureConvertibleDebtExchangeShares', window );">Future Convertible debt exchange shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FutureConvertibleDebtExchange', window );">future convertible debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_PrincipalAmountOfConvertibleNotes', window );">principal amount of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedInterestOnConvertible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>accrued interest on convertible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedInterestOnConvertible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeRemainingNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange Remaining Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeRemainingNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeSeptemberCashPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange- September cash portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeSeptemberCashPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange - September principal amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeSeptemberSharePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange - September share payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeSeptemberSharePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange - Total Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeTotalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FutureConvertibleDebtExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>future convertible debt exchange</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FutureConvertibleDebtExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FutureConvertibleDebtExchangeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Convertible debt exchange shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FutureConvertibleDebtExchangeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtBalloonPayment_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtBalloonPayment_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInstrument_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInstrument_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_MortgageDebtInterestRate_Base_Revere_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_MortgageDebtInterestRate_Base_Revere_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_PrincipalAmountOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>principal amount of convertible notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_PrincipalAmountOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798401629560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_Sanofiterminationcashpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_Sanofiterminationcashpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798397026184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_Sanofiterminationcashpayment', window );">Sanofi termination cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SanofiRevenueRecognized', window );">Sanofi Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalPayments', window );">Ipsen Total Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones', window );">Ipsen Maximum Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMaximumSalesMilestones', window );">Ipsen Maximum Sales Milestones | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenTotalUpfrontPayments', window );">Ipsen Total Upfront Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMilestonePayment', window );">Ipsen Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenMilestonePaymentReceived', window );">Ipsen Milestone Payment Received</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable', window );">Ipsen Revenue Allocated to License Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 21,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable', window );">Ipsen Revenue Allocated to Development Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable', window );">Ipsen Revenue Allocated to Committee Deliverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRevenueRecognized', window );">Ipsen Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Lxrx_sanofiInitialCashPayment', window );">lxrx_sanofi initial cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_IpsenRoyaltyIncome_LXRX', window );">Ipsen Royalty Income_LXRX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMaximumSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMaximumSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueAllocatedtoLicenseDeliverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueAllocatedtoLicenseDeliverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenRoyaltyIncome_LXRX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenRoyaltyIncome_LXRX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_IpsenTotalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_IpsenTotalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_Sanofiterminationcashpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_Sanofiterminationcashpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Lxrx_sanofiInitialCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>lxrx_sanofi initial cash payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Lxrx_sanofiInitialCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SanofiRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SanofiRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798390852856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Impairment Loss on Buildings (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AssetSalePrice', window );">asset sale price</a></td>
<td class="nump">$ 11,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AssetSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>asset sale price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AssetSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798393825960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</a></td>
<td class="nump">10,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">117,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,640<span></span>
</td>
<td class="nump">106,974<span></span>
</td>
<td class="nump">116,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, Basic</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">11,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,576<span></span>
</td>
<td class="nump">11,859<span></span>
</td>
<td class="nump">8,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 82,603<span></span>
</td>
<td class="num">$ (69,071)<span></span>
</td>
<td class="num">$ (66,611)<span></span>
</td>
<td class="nump">$ 226,086<span></span>
</td>
<td class="num">$ (53,079)<span></span>
</td>
<td class="nump">$ 181,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</a></td>
<td class="nump">$ 83,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,363<span></span>
</td>
<td class="num">$ (53,079)<span></span>
</td>
<td class="nump">$ 185,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per common share, Basic</a></td>
<td class="nump">107,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,272<span></span>
</td>
<td class="nump">106,974<span></span>
</td>
<td class="nump">106,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139798392358936">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LiabilitiesAssumedByTerSera', window );">Liabilities assumed by TerSera</a></td>
<td class="th" style="border-bottom: 0px;">lxrx_LiabilitiesAssumedByTerSera</td>
<td class="nump">$ 3,180,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LiabilitiesAssumedByTerSera">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities assumed by TerSera</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LiabilitiesAssumedByTerSera</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>50
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[B_S];Y\1XMUMF2V$%J+.-L,./.Y-!? ^:40^K!C;E"NNH[^!5!+ P04
M" !IA%Y1I0/!^Q$&  "M%P  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;*U8;6_<-@S^*\(AP%K@DK,DOZ;) 6VZ=04V+&C:[;-B*SFAMG65Y*3IKQ]E
M.^<[2_:EV+XD9YND'](D'U(7CU)]U1O.#?I>E;6^7&R,V9ZO5CK?\(KI,[GE
M-3RYDZIB!B[5_4IO%6=%JU25*Q($\:IBHEZL+]I[UVI](1M3BII?*Z2;JF+J
MZ1TOY>/E B^>;WP2]QMC;ZS6%UMVSV^X^;*]5G"UVEDI1,5K+62-%+^[7+S%
MYU>T56@E_A;\4>_]1M:56RF_VHN/Q>4BL(AXR7-C33#X]\"O>%E:2X#C6V]T
ML7NG5=S__6S]M]9Y<.:6:7XERW]$83:7BW2!"G['FM)\DH^_\]ZAR-K+9:G;
MO^BQEPT6*&^TD56O# @J47?_V?<^$'L*.)Q0(+T">:D"[15HZVB'K'7K/3-L
M?:'D(U)6&JS9'VUL6FWP1M3V,]X8!4\%Z)GUE:RU+$7!#"_0.U:R.N?HQIK3
MIU]JUA3"/CA%7V[>HU<GK]$)$C7ZO)&-9G6A+U8&,%A+J[Q_W[ON?63B?3=\
M>X9HL$0D((%'_6I>_3W/01U;=9P=JJ_ \YW[9.<^:>W1*?<;I7AM$-,:/#Z?
ML4AW%FEK,9RRR/0&06Q0;G_P;XUX8"6\PANKSE3<FK(%]["."(GPQ>IA/R2N
M%(TQ)CNI YSA#F<XB_-F(Y4Y-5Q5\$4?N#;5%,C.3K0/,L-9- +I2A$:16'B
M1QGM4$:S*-_FN6P %W2,G$,D;TN^1#4W/IR1@P#3E(Y@ND)1'-&)6,8[E/$L
MRH\0P-I(]>2#%3MO#$:87(F0A-0/*=E!2F8A72N^9:) _#LT?,UUFY+2;+B"
MKK*?\S[(B0,HPT$V0NT*01P#/^ITASJ=1?U9&E:^ &#J?FJ",YJ.(+IBE"9)
M%/I!9CN0V9'0 HDJ\]2&U!;XUI9.FY9(W@$QY4W5E&U#+3AP:RY8QU@@SBJH
M.O&CNP'")S%=)EG4/CN)\3()H;<IKK>\I;?2FU&9ZSW&03QRWB,5!E/UB(.!
M+X)9[S](63R*LO2V_L#-Y# *QS5X5.P0VAZ5X2-E:%A]+Z!']*DSV2IZ0W-%
MZ1'!68+C"9 #X6 R"_*OM@:G4[M7/VQCX9@2?%)Q%$V &[@+SY-75W\SX*C[
MVB3-R+CP/'(A3A(\!7 @+1R^B*]+P6Y%*8S@LZ2-!Y[!+R2:+7NR+./UWL,P
M.*'AV'F/&($P3?@^D R>9QF J!IH*GN^>U&Z=!*E89:,4?I8!^_-'H<H!][!
M\\3S_(6VMM%U3:Z4]7TW:13\=FB4,&QSD"V0T+IIY\Y<ZHF\<\DFC3.G*%PI
MZ(M3@Q(>2 G_#"L="[]+.K9"R!BK*P9S2#@5_H&;\#PY_?'?8^VCEYB,Z=\C
M1@!_,N$!&0B&S!-,UR"'G#D2;^*22>(, AXAR(R)Q" #X9!YPND2XQA ET@R
M3-)Q/#UB%%9Q/#&LD+T-9YYPKF15B6ZZ[_8261M1W_,ZGP(\:\^>*YSK+<OY
MY0*&&\W5 U^LD6^5^Q\,'?H\\!BALS3Q*TQEYFF.&<A .61^48))NJ\=6,;S
MKTMT<A9@H F%8+%K^!L4+8,@0'K#E!VS&P.+E?C!BS>HEL]W;=6!@78&;XR&
M,:6 3^ -OKM'C2>369%#)P?Z(_/T9Y,$FO7@X:&+L)1..0D,N"04M[[!$+J,
MD^S0Z^/S+/'RZMAKCU P,8V1@5/)$4XM"F%I"LK8KDNGHH:]?2N@K+U 7<[$
M81JGT7C"]0K&, 1,M9R!7LD\O;X]V"[N1"Z\ RYQJ? 4TRR,B /5*QGB,)SJ
M/ -ODGG>W,?:KYZR@E+?V%/ !PX]7OL;D&=O&Q\W>&32*< #>9)Y\ORL.-.-
M>GJN V9:FERB)*-M@H=!TB?W"[+:)<C3,'66(9\83?'$GD8'&J7S--IQ4^O(
M1I8%5[_H=EF%O?55GSBOO4=2+E6F24S'=.41@YJ%:6L"]\"I]"<Y=;=F&V^8
M>W/[IV/>E<0CYUU)5GMGJ?8@^T^F[D6M4<GO0#$X2\!EU9T-=Q=&;MOCU5MI
MC*S:GQO.(.!6 )[?26F>+^R)[>Z$?OTO4$L#!!0    ( &F$7E'!4G/<#@,
M ",*   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG9;?;]HP$,?_%2OJ
MPR9UQ$F 0 5(+=6T/4Q"I=T>ICV8Q!"KB9W:#JS]ZW=VTBR! &U?B'_<]^YS
MQUGV9"?DHTHHU>AOEG(U=1*M\RO755%",Z)Z(J<<=M9"9D3#5&Y<E4M*8BO*
M4M?'>.AFA'%G-K%K"SF;B$*GC-.%1*K(,B*?;V@J=E/'<UX7[M@FT6;!G4UR
MLJ%+JA_RA8296WN)64:Y8H(C2==3Y]J[FGM68"U^,KI3C3$RJ:R$>#23[_'4
MP8:(IC32Q@6!SY;.:9H:3\#Q5#EUZIA&V!R_>O]JDX=D5D31N4A_L5@G4V?D
MH)BN29'J.['[1JN$!L9?)%)E?]&NLL4.B@JE15:)@2!CO/R2OU4A&@*O?T3@
M5P+_K8*@$@0VT9+,IG5+-)E-I-@A::S!FQG8VE@U9,.X^1N76L(N YV>S057
M(F4QT31&-R0E/*)H:=PIM""2<IU0S2*2*O0%/2QOT:>+ST@EL*,0X^@^$84B
M/%:7Z*(UG[@:Z$P,-ZI(;DH2_PC)DN8]%.!+Y&,?=\CG;Y9[X[;<A9K4A?'K
MPOC67_"!POR^7BDMH0/_G @4U($"&ZA_)-!U%!59D=HX,86S&#%2=CB/$<F$
MU.S%+ERB7,+QE?K9;M&G@N5PH'17J<N00QO2G.3M;!B$X\'$W38KVF'EA7VO
MMFKETZ_SZ9_,9P'GD$H)V4#S1H] 323:DK2@".#+WNE"+KV&#1C<P]X>\1FC
M%O"@!AZ\#[AJ;U+H1$CV0N,NW-+GH$$RP!COX9XQ:N$.:]SAAW"94D4WZO"
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M\V;>/(UF/*BX>)(I@"+/>5;(H94J5=[8MHQ3R*F\Y"44>+/D(J<*MV)ERU(
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M]])J_8FW.E9UN6L':P]VQ?[U=_9G&XB+ 4ST#.#M #YT@&@'"&L #WL&R':
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M) H()5;2:A<3J>LZ;1"&N1D&7@"TSR%<V(%>BMSV&='!"P"2ADYN41 +^P)
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MI$Y#W= 94%6C0?5BMQNG%(4 J!]&<<\S=>KB Q5C 93R9:XP%O3A(TP*(5"
M*8@Q)D,_ AO'Z%$U'#%N;^\@2@&>S\3,]2.H,@BJW @Z!E,4_. &BVT^6RBZ
M58=(H*$E;2BA):E3T@V:067E1N6K8XJ"$!H+T3>YAD&5FT&OSBF04S5YQW;#
M44$RC.T5@'3?-,.']A*@2966I$Y)-[2&5)6;5)V%%^F7\0#B"?EABWM:LAQV
ML(2VE#HEW8^6&5(.W*0\ONP&D(6G'-Q2(BKP&3(:AVE)@DB@.ZG34#=TAHB#
M@;W&$?VA &TVPOX0K>LZ;7@T&/A9CN']H0#N&6/](40&^T.8".T/(<*>_A"B
M!/TAS!I2G&<7'\YOOMWAM^SP6.PK;YL_Z''^VU#/Q^'U"Q->W]3ET^GS^I_+
MNBYWIY>;/-.INQ'H_S^49?WM3?,5 .>OK;C['U!+ P04    " !IA%Y1BW4&
M4LT&  !M&@  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;)U9;6_;-A#^
M*X2Q#PE0UR)IR5:0!$B<=BNP%D'<;I]IB8ZY2J)+4GG9K]^1LBU'HIAD7V))
M.9Z>>\B[YTB=/TKU4V\X-^BI+"I],=H8LSV;3'2VX273'^665_"?M50E,W"K
M[B=ZJSC+W:"RF) H2B8E$]7H\MP]NU67Y[(VA:CXK4*Z+DNFGJ]Y(1\O1GBT
M?W G[C?&/IA<GF_9/5]R\V-[J^!N<O"2BY)76L@**;Z^&%WALP5-[ !G\9?@
MC_KH&ME05E+^M#=?\HM19!'Q@F?&NF#P\\ 7O"BL)\#Q:^=T='BG'7A\O??^
MV04/P:R8Y@M9_"URL[D8S4<HYVM6%^9./O[!=P'%UE\F"^W^HL?&=I:,4%9K
M(\O=8$!0BJKY94\[(HX&@!__ +(;0+H#I@,#Z&X =8$VR%Q8-\RPRW,E'Y&R
MUN#-7CANW&B(1E1V&I=&P7\%C#.7"UEI68B<&9ZCI8$?F".CD5RC!=,;]!GF
M6:.3'Q6K<P$VIVB,?BQOT,EOI^@W)"KT?2-KS:I<GT\,X+%>)]GNW=?-N\G
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M6;K+#6<Y5]8 _K^6TNQO[ L.7Y@N_P-02P,$%     @ :81>4851Y<-\%@
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M@W/K9/N>8H0%C'>]P/C\B(J$/A4MWC(.98>ZTK#H8AP0J5.?H*RP&/"_-U1
M!8 A1_&I2")=$X<2>1SA!5K@?2.N?-8Y!'U'8TL6C@]$+'>\KQM;='G+INMT
MLR9=&B'J\YFRBAR#?6 D2<H08WL.>&):S\ Q>Y>JM<WFMO]5/62.)=08)_;D
MNKHNO=OXU[M//[_[^P=^!M$&-[AM69B_0G@V)+H8@-A?"MWAW+]4#,CO6_&)
M@0C:[ $R@V,@ZS256!7-P+'@$-CKDP";8$[>V-CE\:MD:H=PVCQ-FH?\CHGL
M\90_!?MX%**D0C'P44WV0/:&Z,&9!&7_M#+80[A-H 4P*F9"\:TM7-RW#T[/
M+L93I-5ER7CEV7G_B>?CP4W_&@9 .@ 06,*P[N'[*2-6%R.<&7%6W4.Q1H)7
M"Z@(YFQE$*R(+&_;<X-Q&/("0[I\)P'[-GTF05PT<\  4YV&PQ(PSAIX#S9C
M1-S2UHPCLMQG 3A[- BP?49HCGP9&+<T-''@:X;NEQT=I-6M.K$D<!"*^X?'
M?V\EED/*+]BA# D?G#KH/K%^>CE^$;G-J@JC[F,&AWS@;DU";#6"\UIL>/#9
M[S&W9*S!E+(:? 'MJ;4A"V)KH<#V$[2!.?6VZ1;JKEB1FK0>YATG.>=/;^_Z
MM&Q')&(I0HXB<L1O>N:0T;A $:U.]:%32M*]J2B[%I,"HP.H*62=1ZR(71UI
M B(E&P[+*$%G/6]V14%^Z=GDIN=[%!Y-%CQ#?*F82@$VA_*DD4=\5/FC%?83
M]6QR/;Z*4@X(_6E*0M1"=;M<Y/Z';JQ$08&(X<S_@H^"OK-?YV#2='J =V_W
M/1R:$O,NZ-#M7K"V5R)(%TDLZIA=B^T<N(=$-NQWT"Q#O%'/U-7Y" X?OTQO
M1N<7%W$N^48XQ#ZUGR&?F!.,>3XZGUZHF]'SRTO!N8KQ5PFTIN,1-^KJZH+_
M?>#$;#)Z<7ZIIJ.;Z60O.T#(]>CRA@BYG(XF5Q-$8P;N%)7MHC)2$OKH@\^G
M@.K#@PCS!WSM@QB+9Q#_]L4O/F@<.>O*+ZJE(-\.9D(9WM=.AW*2NK^[CY44
M?M$;[0YYP='0D<A&'Y9:Z)!B*P7&69MQS*.DJ+&I%PG.TN8,"F'A &$0+-D;
MXIH'&&&E(0Q-]JR'1$7,01@A9TQ#BM.L?4%FC7R=GX:DQ:?7 M"XBA*@BJ_@
MA*,(5H&/[_U+HV?$Z)'*P;L%/N1?\(&R00Z*%.4 82MYUC9FUK$">H55<TUS
M24H+<E\5:W-<DP$L3/1G3>42,/IC!NU\"\(Q%JDM &B-T68U(Y 6T^?HF,&O
M-,,380VPY(IP26F^:$JK.8X';TH'AQ?1:RK/S;,<L=5%@@*&9Y%FDFBRJD'K
M.L8D/@EGFHBU!7C8,([/?)4" LQ8KR-[9QT[.RX,9AMF19VU,,;J0+94<=*R
MI9&-GI<"+??!P!FA[IXCWE<E$&:@%*2"HJ* J.0_":*U)0.IA(OD+^):/:P1
ME%<&/,:<<KT-N:6IZW#@)?XK9:!KO:22^EVFYETYA]OW* 3+<W6$K"W8%9><
MD-TW/3;? <&>U=XQD#23_=(,)28CY#S&6*A$(D>I,9WK;H'()NH6'9<@VGPP
M+NO'A?K:S"+&PRP)FT:#E=1;&-0[>?]V:/9(&@D NF&(0:!>$RK0-1M  -H1
MP(AF]]43XD]T(*30$*]GL*2V?AO&RG96FH7/5.64.B.G-9<D.)[Q%F'K),!X
M@4?A4,<(8HQNLBB"'S!Z>_C^78-)A\5X)J;&=$)TL"\X2B)/P]8G[,MR2G'W
M#@J*\K2=Q5,=8]6>>8&CK(K'!-9QUD3W%(5<-S=2CSRPT5#&F4_NVJ5Q+-E3
MDBQ\%2(#$1QM23:%[# .?F#&7IT+>2D!#Y J*V8H[0U-7*9'P^9< NFIOUP(
M$$LRGB2UI7G!XMQNJ+KKG2/IOJXEQJ1T$53C4L7^]7&@%>>[I#A$4L;6&B01
MI>]\(4\*F,TA%L>*I^P)SC&.X57C5D1%0@0QIN#;AKP=BJ@EQD<EX&)/-*V!
MP1W0.J+5N*B<T6$ESO. 2N[HV2'5=5'SBB'M'CBZW?*O#UKJMZY8A++QT,H0
MX*KB-"MM176HLO2EYU#48&8>H,>G]^)>4ZMZDK)H2@$DB'O)I?@7"0%BFJU\
MRI0$CF@6A/^T7.6 2BT)6Q\($ZE)R34-!ON%V*=C!U$$LKSY7OO,E$ON4(/J
MT,\&$4=,EBZ-&!D*)R M"^1+RK+WZ#Y),N[;I"--V\^\:$.TM[>[*"H;;PF#
M4+QO\.%,IQ!2;%(42KC.]YD$C4(Z/8H[/2HO2,OH-=>,6E/ZA;<$'L:(HN^*
M:MO4'E-42H]\_KA^3.%G=,DM]1F!2"EG$M=P,$ \R7#OQ&4C:R:.,-U25F%"
M^*ICM+7S:6\KOKXW"SD<907"JI7N_=,A2R)_R2M*E8:D1'6'RL=!,^^O54?^
MYE70PPZ^9+Q>EOLT\8Y"),/JY)HW\TE54PC()-C Q2(2":28+T^[.DA N/_
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M&.!]Z7'YZ3>28+@SG_\'4$L#!!0    ( &F$7E$I\'V?,@4  !(,   9
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M$\P3+![!HM(Q:)E7"G$G6=4</%>[3, WE*NYR@4V@3 0;^8".BV1_'6Y)+3
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MY+D^GZR7/SX_%?DD\+OF;3BX)HFD<.Z]W/Q2G4\6 H@-EU$L*/S<\B4;(X8
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M%P&<U\[%_8TX&+\V+_X#4$L#!!0    ( &F$7E&K..FK[PP  "(G   9
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M17'E(S+]ZZJ?.-V&%PTR'N^C,%SA0<K&'\#^4L,-P\0KV#YQ3_\%4$L#!!0
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M,-Y_9RKB#(H6C\P>&/G7!M!3'\*;'PO>_'@0"*YR$OX"=T?,T0D^$F&>O/"
M(=X@_& LI.]Z1 3\H(,5 [1$D1N"7B_I<-X'" HTMF&_ 6JPI<@E\7OG7=U7
MD5$E&']';GZL6L/FUBUAEML00V _)?2O:)7*F]K&=+:'[/JZV/7UP>T3=+;1
M^>U3<?N1RUXJ53ZKC0[LUMX& :'0=UV3L/;_/G_Y[?.O?^5GB(><Y.[#$>:O
MP:LL^7NA%YP-Q:+Y1+ZVE@QV$SGC#5J0M T\'7!*F&9;P2*: HL#1CFID]O[
M#$()HCA1\$^CJ3TXI7],#*C]<&V+@9+NCZ&MB4 J*5XGT.[UAF *[$ W<"JJ
M"VEE&*@BCR0< !FQF F\<*X.1>Y /O[\8G:!@JMIF)?_^6SXQO/QX,WP,W"#
M_!/U9;,]Y)1OBE.^.>@]7X3Y/-85#RY&=?UEZ'1EWA^!E%*LF:,B 4'O4.[0
M05VJZ^1!7S+QR@\*$YN8>?!$CNJ)$^]R0C9<&3GOFUL5"4/B9"9PXI<NF%9=
MKS0P1=U<W:AGY/T79V_Y!_Y\_O;Y[*%Z[-=>MD3)8+,RHH=4TN3<\ZC9;XFW
M>I3;@V0XRLHB.[F*TR%<&^D'KM[@6.&:";_R2M,$/)+9394JD$:!7C%DID,(
MC&QWJ);X::9KJ1*4U$3^7Y!0)I2M"!3"OS.OK;'R7.J;"K9;XDMUBR]$V-FO
MR5&1O%MY%KV=]QRA"7_5PM!<.J6EPYY;KB?*FIRZ 6"_06Q%V?-:^ZA^@N(8
MB^H#J;?#:+N>4PXH%0Z[ 7$MV&M,PN6P)EET3=C2V%M#E0^'8@(/WC@2B;FC
MHGR!.M*!UF:%,GOA(]52"["KP>MZAI54)ZV%G]NVA@T],Q@M:.!P@)K]NIAW
MWC/ZT,^=WK(I.AT!*NT>GM@R7;OGD=XL&LE<N[!\3GQCL$@"\A$*39R"7%!<
M%!F04@G!;&P8"T=6)&@N:PW()$C=9$AE2X4AAL+*=EW>\ K_-#(PQ'12615*
M%VK1-PN 'UN%&VM<P%*TY;CB@A\%F!]2_X-,EDR=@(%.<R1OS,T*#2/PF&&A
M!A26B@+:U]42-8JX6P$NR4K59)P>QN7NQMPAHR$L*;V4@)6B0PS$L:H]-$N_
M3L,>=)FJ]R#UK:- ):LM2!R\J>, R,DR)_3DV4.!2_8I $(.C>--!A92G\1P
MNG/SQBX31Y==&DV@M1#Z7_9XJ9[9YSD5;P6ZTJ:>A>>2RW4Y@K<8?7_X;JDY
MI/-B/!-3"R40'QS:/5+"T+"[YXQE%9'[G8.RHSQ.LB#5,ZPZ&"];E%WQ&4!#
M8Z\CWX,'11L6Q('V"YJ>L4X,+:Y ^NED3^AD@57(#*1PB241BK/#..# G%&=
M>RUC!38X57;,W'V9AKA,+X&-];%K\PUXWBZ%"M,<(2TCYDSS<L2%AZGJ:@!'
M\GW328X9ZT4-'R[2=J^/#:V9M)+CD$J:HS6?1#G]D'HMTF/R^TQ<FE(B$Y:#
MV.3*111I,5*"#$-I"QN(TR.*9/CB!%SFEM":!-P>KR-=;2C.60!K!)Y[7/*!
MG^USW5 \KY[J7D/1QG7A88<N)2WUS[Y>YL[>-,J0X-KZ1#>HDF&DIDG=P5PS
ML3'WZ),HNL#K.*H>Y2R&*@))XNGDTC983]!BY#37IO)^E#A*6!#_,Z2N)RTI
MI5"+KR3"T:E)LVF<#'8?(I6;R\,L8J9^6>R,3ZW"J.>?78?^]\@X$K*MB\(,
MQ1(X+0?F2\ZR<^M2,Y&H[ZH^0TFTTW@EADAVBKMR5$)=QX>2L"&E,S.FD!*3
MXE!B]66/JIRH$>#-.RA[7"0=/"^<EH6V5/=%VZ2%[QUX'B.._O"H[H?:(4>E
M<DM:"))3]SD\&) %M2._%XHTMLP(&O8FB$<%[I5 MFFY_F&]I7G%BG W^OB>
MY),A5E*1/I<N.=\U)5.MS8!/^R*)\))7E'8*G1),:]N4!^T"!)3*6TVM#%W_
MLR<F19S@ ;]DOMXTNSSQBE(DTVI>8.AT2B-(2";1AG6?C@2G6*U.^BZ?@%A_
MPRWX=,<PHF'<4DH<+7FSF(V-4632Y=&4KZ5U=6%K>S@E=?$XMU(1 &-C=5B:
M,L?0LLA)1.X&'./7OC3U$"B+6O=/>K>/C4*2U-A!BW/ EKN0\H "A4'*<:.6
MK\U,:Q8VYFN-,GBF?B9G'DPF22WQ7.;-)U(E>+?5#74RQP Q<K122\#6Y(J%
M=Q_?WTM-LNJ$T.+<IG9TD0?71=V_'@H6SJ99</+ALM\#)LR-*6KFD"+$:8M9
M<R@<:+B<GPWWX&??N8B5$N._F/KP_4JB'8]LPCQR_1LRY:52G\8ES;2O J#W
M]4FGR7/AD3W5NW+IQ>414,[SRP82]VT-D@!GIJA>&5VG&FJ4H)CKW^_0/*[R
MN]\D?U"(C3>AF^#RZ)+#@8W3-J5M3W(CKA17W)D?X1ZB&'S7DN_S123C>FX0
M#9F> 1"&."%CYU8!V4%0NK1%$#RHI^"Z"\YDYR_5%G*I*?IS2IIRST5JM+R4
M7'@9>EEAN-#ZRY_.7YV]'6ZU)L9X2NNRW']RV<;7#>H9M;2?#^:;F"Y=?G)?
M\FSV8MJ)/!\W*L>=R./<V_CWMBB=V:0.Q+Z\+_;%TQN@YZ/W4LZ_TP(=^<:8
M('T66SRU7?\?BD/(?MGGK>5J.D5Q[J S]Y-6(C?NQ"].0D>^X.6^:X-LQ3VL
M2:MB;V"D7DN^  QF$,1 G[" IN4U3C),%H H^N8KR?2 %<HJ8WU3K5K7N.6V
M@#XU",6A\F]VS%-[4$+N@=KVP!889>Z(:P(QJ)\F>U[TD5XIX$0WUDFJZJ+5
M33\G%ABIZ\S,B[+TE D7,H!\5.&@0>NE(5B^1+X9&->GU$3;3I W'0=?F!P#
M7&J>"3M 9>JP/N@0.;_4;8I8L:U0"V2RVA':$-B,50H1R3?GU5*'5Y4G=E0.
M2?(Q]Z('1(/6I EU7;%WON @]VI,3+74N*0;9W=OZ%4]8).H\U"7P3F8R9,R
M]5@'ONSK^0*';O&P6Z8;IO74TQB$U[V?P#X)V.YNG#X@J!.MMCD5M3FU$6\B
M&F6']_KD:I9)T8UNW<*REX[=CG#:P6!( HW[%QR4W7C;&76!J-%SPSUNQ(?G
M>_F&?)%%KKR#,NK6UJW9$G<T.MPKKLR@&+T9@S/I8RJ-BEWUN-F=FM0[0&*T
MF^% Z;TJU&ZI!U"*2-E_G:G4 S.6YHTP-+FTS;7V M)B_HD/G1)!U_O0:Y$S
M:FP1@0#CC_364?;GAVZV,Q($'58,<2WQC:2 O+$DG\$E6^0'LAT95*QG'CBG
MXOX8=<U7NEE,VRA(9Y8O!9)')H<<>#HX!\BQO,WP8&'!2X')T0DD8R.Q</<?
M"=I*S\"[?KF2-P9:?O%(7L# TGRE4%YHF!8I@C!3 PZJ@#"K.XO_]EPO#,=;
MFXXKT-1/L&O3R%4[XSGU*'2U+>4D*40EOJTSQ@T:R$L> YW2L0^ELF6+Z;6<
M,T*G*4\"R6<,N=<,1R%'FVG&':(Q%0O3'I9=/*@S2PU+[0SN3: R)0\OL6-;
M>1<Y=4N35Q]\%^#\8F =%P=IP,T*2J1"Z3K=^EQY3\U7_OQ8LG%0RNX;V1MZ
MP^7D(XLFDP*%M5S+[KQH%'S(@PI#M!(BWR.>Z7)I#?$K>L7ZSO K%0Q!862#
M=/,UJ17Y51SENB'/T6LSWE8B@7[L6U("OM+F%@^@S&WY>G%\5V7]Z!VHD#UZ
M_&(1KY%>/1"PV;'IT>UK8?^IK3!T#MJB!.%-:JZR<BDZAC[SCHZ[[$MO$"[@
M('Q4LI&="C&2TUC!3@*T<8.!3L>F_D*8:$]5][2JX;;*TT4^4MX]:Y6N0IWO
M:'8N<Z^?(CEDW"N4*W3!%<'*C%12(PUWX9,U4<'-#E;SP]O<YR\.QO%G[8GD
M!'6-#7)0/[E>."R WCG[E2(&!J+@1/X1.9?\.EJ3?ZKD)XXIVB*=72\U:8;=
M#1?SE'G2/?I KWA:CE5>1V*OC]P)90B^D3'WZWT8%LM%3ECTXN3QX^,V-X)+
MX3\WE>[Y4@<,B'DA^'<-CD3$?2?PGH[^(F%M_)+_[H+?S&VC_'%">5K^MN-*
M_J)A&"Y_&/*;]DMZI:\Q"TP]F_WXPY'R\K<6\B6ZCO^^8>YB=&O^2&6.\30
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MQMJ'*/" !2S8A>>GQ5_!B5IR(J<O>D\?U6R^+M"QL^(*CVS&YC#CCU1(IB'
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M+Z:V$M72#;/V8T:#5S/ M;OMO#QU8V+_^7@S;'_B:BFH"@I<D&C@#ZEWJF:
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MCM)LH/6-$'KOF +#_X3YWU!+ P04    " !IA%Y1#1W9:=T"   -!P  &0
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MJ>%Q+_5 ULNW5K0HW<*;"6W6IQ-S\UZAM '&OQ!";Q1;H'T!QW\ 4$L#!!0
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MB@C,\%H-&Z>[\$*LM*/W)BP;>N#1> &Z7VM*UV[C#1S^,BR_ E!+ P04
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MG+N6JC4O+A3%0++,'$\K)M5A9QX3=0=#7!NH]VO&Y':@'52WNOX_4$L#!!0
M   ( &F$7E$75@\9FP0  ),4   9    >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;+U876_B.!3]*Q8:K3K2M(D-"="E2)0 6VFZ6Y69W96J?3!P 6N2F+&=
MTOGW:R=I0DEP45'[ HESS[D?OCY.W-MR\4.N 11ZBL)87C762FTN'4?.UQ!1
M><$W$.LG2RXBJO2M6#ER(X N4E 4.L1U?2>B+&[T>^G8G>CW>*)"%L.=0#*)
M(BI^74/(MU<-W'@>N&>KM3(#3K^WH2N8@OJ^N1/ZSBE8%BR"6#(>(P'+J\8
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M9(7S5,[9XS6I)A1HO)BEHO@+'LMW!UX/Q+F0+*N"%8,LH>5__%0EHA6 H"$
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M3D6%M:"):5#[G9VQM7#>M7M.C451QJ1:\31)[G@MI&9Y%M?6-L],ZY34N+9
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M-K0AP._OC'$G)UR \?GF?P!02P,$%     @ :81>44/K5%KC!   $1(  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULM5A;C^(V%/XK%IJ'76F&W$@"
M(P:)VTRGZF[1TND^5'TPP8"UB4UM9YC]]SU.0@8<DZ6M^@*Q\YWC<SZ?BYWA
M@8MO<D>(0F]9RN1#9Z?4_MYQ9+(C&99=OB<,WFRXR+""H=@Z<B\(7A="6>KX
MKALY&::L,QH6<PLQ&O)<I921A4 RSS(LOD](R@\/':]SG/A"MSNE)YS1<(^W
M9$G4RWXA8.346M8T(TQ2SI @FX?.V+M_\@(M4"!^I^0@3YZ1=F7%^3<]>%X_
M=%QM$4E)HK0*#'^O9$K25&L"._ZJE';J-;7@Z?-1^V/A/#BSPI),>?J5KM7N
MH=/OH#79X#Q57_CA)U(Y%&I]"4]E\8L.%=;MH"27BF>5,%B045;^X[>*B!,!
MT&,7\"L!WQ3H71 (*H'@6H%>)="[5B"L!,)K?8@J@>C:%>)*("XVJV2WV)H9
M5G@T%/R A$:#-OU0[&\A#3M"F0[%I1+PEH*<&LVQ8)1M)5H0@98[+ CZ,",*
MTU1^1'?H93E#'VX^HAOD(*G?2D09>F%4R=N3B=]V/)>8K6'RYFP\=!08J9=R
MDLJ@26F0?\&@ 'WB3.TDFK,U65OD']OE!RWR#I!3,^0?&9KXK0J79-]%@7N+
M?-=W+?9,V\5_SEFK^*Q=_!,6(.Y=%)]?;;PWL)'YWWQ_^M>KGVU%4 =K4.@+
MK@_6/\8KJ004M#];]/=J_;U"?^^"_F>6" )U5N$437F60:E<EC$^5DK05:[P
M*B5(<32C::YK*)IO-E!4$=^4R#M=%M=H@;]K-6@L!&;;0J4U%4ISPL(<W31>
M1Z$W=%Y/][<)"<X1CTV$>XYX:B*\.*XQ9U2%-57A_T?5E+-7(HIN!J,962FT
M)$DNJ*+$RE/8=  BRC>HLJ&"*#3H:J),NGZDYXRPJ"8L:B7L:]$4(3;&X#HT
M>?0YSU80QL?(D>C77$D%11,B_+9DS5K_)E'3/"\.0Y,-&RR*>H:SCQ:8&PWB
MGL&)55O<\^VDQ#4I<2LIG^&L15G",^@Z*9?0<O9 25+&4]%>;M$$2YK8>"A5
MQZ<;V3T)ZY*%)LCO>F8&-4%W;M>(FZ<FR.O&GMW_?NU_O]7_9D%KW?F^S6.S
M8#1!7G=@)D$39/'8IBD<V#T>U!X/6CT>,T77QXKPGO1H_I:D.31LM!$\TQ5E
M#Q5$517"1M,XXSE3-I8&MOR(C3V?6U!N&$<&3S9=_1,.2J*:J'XOO) :GOM^
M,G-_F!S/57+\4B2'65H7P(2=@TIU=&J2'[D&"5,+["X:N&9,S:RX*/+,V+/@
M?%BV;])JTQ<&;FP2:\%Y?<^_E';>R:G7:^5VU@S!V[I!L;+F6,.N%BQ[F*)Z
M*]J;5V7*61#Y8=^DSH8RR]FC!65V+PLDB ?N!<;\=\;\5L9>H#'),OP@2VMJ
MCI&9ICS!^DT9EHHF= _YR[9G#+?4MFKYLX@-^E$CPIHPWX^#R"SI%IP]PIHX
M2' WNA1A[T=5+VCEJVKJN3X.PHTH*2J:YH-!6NM>]T]:7;76>;6* W=@LF/#
M17[LF^Q8<<VN?T&?:T:3<W(!S8C8%M\6)'@');H\WM>S]?>+<7%K-^8GWOW<
ML\P_ZN\=Q87W77WYL00N2%O*)$K)!I:"?@C&BO+[0SE0?%]<?U=<P66Z>-P1
MO"9" ^#]AG-U'.@%ZJ] H[\!4$L#!!0    ( &F$7E'B:QL6RP$  /\#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;'V3[6Z;,!2&;\7R!=0$UJZJ
M *EAFS9IDZ)F[7Y.!@[!JHV9[83D[G=L"&)3*3^PCWV>U^?U1SIH\VI; $?.
M2G8VHZUS_0-CMFI!<7NC>^APIM%&<8>A.3#;&^!U@)1D<13=,<5%1_,TC.U,
MGNJCDZ*#G2'VJ!0WERU(/61T0Z\#3^+0.C_ \K3G!]B#>^YW!B,VJ]1"06>%
M[HB!)J./FX<B]ODAX47 8!=]XIV46K_ZX%N=T<@7!!(JYQ4X-B<H0$HOA&7\
MF33IO*0'E_VK^I?@';V4W$*AY2]1NS:C]Y34T/"C=$]Z^ J3GUNO5VEIPY\,
M8VZ"*U9'Z[2:8(R5Z,:6GZ=]6 +)"A!/0/P?L%D#D@E(@M&QLF#K$W<\3XT>
MB/'9J.8[86\"C6Y$YT]Q[PS."N1<_IV7(%/F4,H/L&K"MN]CGR7@4;HWP&($
MXQ7PA<LC_(LQ+'FN.Y[KCH/.A[6Z!2^%%$Z )=SB'82:E!?R$\P>#'_+T/MZ
M\FS.OQ>BCZ/F]K*N6(R*=T'1OY93GFSN(_Q2=EI:8XOC\4_C!S<'T5DBH4$R
MNOEX2XD9K]L8.-V'K2^UP_,/W19?*!B?@/.-UNX:^$LPO_G\+U!+ P04
M" !IA%Y1RZ7J,%@"  "^"P  #0   'AL+W-T>6QE<RYX;6S55MUNTS 4?A7+
M16B3T-)TM!LLB023)B$!FK1><#>YR4EBR3_!<4J[2YZ'I^))L.,T2;L&5;N
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
M+AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*
M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC
M)8QQ8K3^-8+)#^Q^ %!+ P04    " !IA%Y1T'?*>HH#  !;&0  #P   'AL
M+W=O<FMB;V]K+GAM;,696T_;,!2 _XJ5)_; VCA0+J)(7+=*#"HZ>)W<Y+2U
M\*6S'6Z_?B>)RMS!CO;B]2FQG3A?3ISSV<G1DW4/4VL?V+-6Q@^S10C+PU[/
MEPO0PG^V2S#8,K-.BX!%-^_YI0-1^05 T*K'^_U!3PMILN.C55]CUXL+-D 9
MI#58V53<2WCRO]N;(GN47DZEDN%EF+7["C*FI9%:OD(US/H9\PO[]-4Z^6I-
M$&I2.JO4,,N[AGMP09;OJB<-Y'<Q]6U-$--;@2##;-#'#F?2^= >T?8OD/$1
M\."N5 =[*54 =RX"?'&V7DHS;[K!N^A%M]'&8;7M@GCH_B6,=C:3)9S;LM9@
M0A='!ZH!-'XAESYC1F@89JM#F# 5NS !@\1&INL*CVWN%"\]JKJ[#H@;Q= =
M2FQPHZH%3P=YAF6K9(57K]BI4,*4P-K@^NT[(R)(3D#RC4&RL7 19$% %O\1
M<M) -"=X9F?LS.IE!+E#0.YL$/('CR!W"<C=C4%.@BTCR $!.=A<)(5?1)![
M!.1>6LA)K;5P+VWDY-Q(/$U@0CHI2UMC0HH@]PG(_;20MU!"!&7F#-5C<+]L
M0QI!'A"0!VDA3[S'GB=" =NZ1C'Z3W'^[E,)O)]X(.)H:Q73[ES\K.4C4C9#
ML:D<Q9BD9Q*+YE)(Q^Z%JH%] ^%KU[TO,1YEF#RQ8LYA&MC-5,EYUQ9S45+)
MDUM%:QGTV_/$M-.\(F!*"6N0E%3RY%912DRM:UM:S"L\T7A@)W,'$&-26LD3
M>V6DES@(VRG9E?68J@T[K:6J,)YKH:2LDB?6RH5PIN%A8W XQ1%N+7J42O)-
MNF1MZI!3,LD3VX3&+&),2B=Y8I^067LMFIR2"T\LE[]D;;:%ZRVUEH X)1>>
M6"[OWYH58:QI3BYA$@N&'I<[,2;E&Y[8-S3F;HQ)&8<G-@Z-.8@Q*>/PQ,:A
M,?=B3$HZ/+%T:,S]&),R$$]LH'@.?@Y!2+7^>E/:X8FU0^?S6#N<T@[?J';B
M+%10VBDVI9WNL<>8E':*Q-KY<]'PX; L*.L4R;^<$<L'MA5CDI_.DJ]RB 7$
MVFRHH*Q3)+8.M8# 9Q]C4M8I$EOGH]G01P.34DZ16#EWIL0KSYO_ E"Q40#M
MV393S^YYF_?;*>\;)J6<HE5.;_4QOX*9-%!=XR4\UI="E6/'FDWW@6%GMYGT
MSVJESK#NQEQ94:W^#:S^:QS_ E!+ P04    " !IA%Y1F3ZBA'P!  "6%@
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M79-:E<W!GW7_P&=?4$L! A0#%     @ :81>40=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !IA%Y1
M&YE0H.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !IA%Y1F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &F$7E&(@H8%/@4
M ($5   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !IA%Y1I0/!^Q$&  "M%P  &               @(&!
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ :81>4<%2
M<]P. P  (PH  !@              ("!R!,  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( &F$7E$A)CW^G@<  #(@   8
M  " @0P7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !I
MA%Y1;SQI%MX"   K"   &               @('@'@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ :81>43I>0',1"@  PD(  !@
M         ("!]"$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( &F$7E&+=092S08  &T:   8              " @3LL  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !IA%Y1A5'EPWP6  !T0@
M&               @($^,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ :81>479'(H[6!   /PL  !@              ("!\$D  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &F$7E$I\'V?,@4
M !(,   9              " @?Q.  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ :81>4:J&FH"/ P  2@D  !D              ("!
M950  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !IA%Y1
M-W78ZMT%   :#P  &0              @($K6   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( &F$7E%IP,H?$0P  -4C   9
M      " @3]>  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ :81>45R1T8A8!@  >0X  !D              ("!AVH  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !IA%Y1JSCIJ^\,   B)P
M&0              @($6<0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( &F$7E%X'$_0J@,  .4'   9              " @3Q^  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ :81>48,)1#YY
M!   [@H  !D              ("!'8(  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !IA%Y17B,QW^H0  #],@  &0
M@('-A@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &F$
M7E%'K*+DF@0  %$,   9              " @>Z7  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ :81>412N,64] P  ,P@  !D
M         ("!OYP  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !IA%Y1#1W9:=T"   -!P  &0              @($SH   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &F$7E'HK+#'I0,  #X(
M   9              " @4>C  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ :81>48,.8IS: @  NP@  !D              ("!(Z<
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !IA%Y1+4.%
M5EH#  "H#@  &0              @($TJ@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( &F$7E&$M(P@EP0  "<7   9
M  " @<6M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M:81>42GT:5*W @  9@<  !D              ("!D[(  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !IA%Y1N#N)(0$#  #A"0  &0
M            @(&!M0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( &F$7E$75@\9FP0  ),4   9              " @;FX  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ :81>449YV3LC!
MAA,  !D              ("!B[T  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !IA%Y1.=UFL#@"   @!0  &0              @('E
MP0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &F$7E'@
MT5Q!+0,  ,T-   9              " @53$  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ :81>47@$Y >D!0  C1<  !D
M     ("!N,<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &F$7E'B:QL6RP$  /\#   9              "
M@=K<  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ :81>
M4<NEZC!8 @  O@L   T              ( !W-X  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !IA%Y1EXJ[',     3 @  "P              @ %?X0
M7W)E;',O+G)E;'-02P$"% ,4    " !IA%Y1T'?*>HH#  !;&0  #P
M        @ %(X@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ :81>49D^
MHH1\ 0  EA8  !H              ( !_^4  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ :81>4:IG%&&8 0  "Q<  !,
M     ( !L^<  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "T +0 R#
&?.D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>302</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>22</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</Role>
      <ShortName>Summary of Significant Accounting Policies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes</Role>
      <ShortName>Recent Accounting Pronouncements Level 1 (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Asset Sale (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/AssetSaleNotes</Role>
      <ShortName>Asset Sale (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Impairment Loss on Buildings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ImpairmentLossonBuildings</Role>
      <ShortName>Impairment Loss on Buildings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables</Role>
      <ShortName>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EarningsPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Asset Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/AssetSaleDetails</Role>
      <ShortName>Asset Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/AssetSaleNotes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails</Role>
      <ShortName>Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Collaboration and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Impairment Loss on Buildings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails</Role>
      <ShortName>Impairment Loss on Buildings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/ImpairmentLossonBuildings</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/EarningsPerShareTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lxrx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - lxrx-20200930.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - lxrx-20200930.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lxrx-20200930.htm">lxrx-20200930.htm</File>
    <File>exh11openmarketsaleagr.htm</File>
    <File>exh311certificationofp.htm</File>
    <File>exh312certificationofp.htm</File>
    <File>exh321certificationofp.htm</File>
    <File>exh51veopinion10-30x20.htm</File>
    <File>lxrx-20200930.xsd</File>
    <File>lxrx-20200930_cal.xml</File>
    <File>lxrx-20200930_def.xml</File>
    <File>lxrx-20200930_lab.xml</File>
    <File>lxrx-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 135,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 342,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 49,
   "keyStandard": 253,
   "memberCustom": 3,
   "memberStandard": 19,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.lexpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SaleOfNonFinancialAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Asset Sale (Notes)",
     "role": "http://www.lexpharma.com/role/AssetSaleNotes",
     "shortName": "Asset Sale (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SaleOfNonFinancialAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Cash and Cash Equivalents and Investments",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Fair Value Measurements",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Debt Obligations",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Impairment Loss on Buildings",
     "role": "http://www.lexpharma.com/role/ImpairmentLossonBuildings",
     "shortName": "Impairment Loss on Buildings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - Earnings Per Share",
     "role": "http://www.lexpharma.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables",
     "shortName": "Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.lexpharma.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i47dc383a1189487da19aa61e7d8cdb1e_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies Inventory (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails",
     "shortName": "Summary of Significant Accounting Policies Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i47dc383a1189487da19aa61e7d8cdb1e_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i7efb7b2a47df4973aaf590e990ab13cd_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i6dd55aa47b494c508a8707104b290757_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i6dd55aa47b494c508a8707104b290757_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i806bb79355704a3d9f9e975c7764b751_I20170331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:GainOnSaleOfNonFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Asset Sale (Details)",
     "role": "http://www.lexpharma.com/role/AssetSaleDetails",
     "shortName": "Asset Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i158fdeeeaa6742cdb8b246d35978db61_D20200901-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:GainOnSaleOfNonFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i1258c23791be46e7aa4cc649d072022f_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
     "shortName": "Cash and Cash Equivalents and Investments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i1258c23791be46e7aa4cc649d072022f_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2",
     "shortName": "Cash and Cash Equivalents and Investments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "if73dd8addd4542a29c4ec9debd3582d1_I20171218",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Debt Obligations (Details)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails",
     "shortName": "Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "if73dd8addd4542a29c4ec9debd3582d1_I20171218",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "lxrx:Lxrx_Sanofiterminationcashpayment",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Lxrx_Sanofiterminationcashpayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "lxrx:Lxrx_Sanofiterminationcashpayment",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Lxrx_Sanofiterminationcashpayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Collaboration and License Agreements (Details)",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
     "shortName": "Collaboration and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "lxrx:SanofiRevenueRecognized",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "lxrx:SanofiRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AssetSalePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Impairment Loss on Buildings (Details)",
     "role": "http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails",
     "shortName": "Impairment Loss on Buildings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ic3dc746618934941bc63c22f6053b48a_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AssetSalePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.lexpharma.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Netproductrevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:Netproductrevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ie267d826ab394ebb9012f8d4a5e3cc36_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
     "shortName": "Consolidated Statements of Comprehensive Loss Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "if3ef5ec99dcc48139089e172def809d5_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "ifb4df3ac85e8498494d97264b85c936a_D20190101-20190331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes",
     "shortName": "Summary of Significant Accounting Policies (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes",
     "shortName": "Recent Accounting Pronouncements Level 1 (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i214e8ad8f42f4deb860de5a4079b0622_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i170f779ba4fd4cdb814e7d6c94490a0b_I20200908",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:LiabilitiesAssumedByTerSera",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - lxrx-20200930.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - lxrx-20200930.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20200930.htm",
      "contextRef": "i170f779ba4fd4cdb814e7d6c94490a0b_I20200908",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:LiabilitiesAssumedByTerSera",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 22,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_AccruedCompensationAndBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued compensation and benefits current - due within 1 year",
        "label": "Accrued compensation and benefits current",
        "terseLabel": "Accrued compensation and benefits current"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedInterestOnConvertible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "accrued interest on convertible",
        "label": "accrued interest on convertible",
        "terseLabel": "accrued interest on convertible"
       }
      }
     },
     "localname": "AccruedInterestOnConvertible",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedLiabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "accrued liabilities",
        "label": "accrued liabilities [Axis]",
        "terseLabel": "Accrued Liabilities [Axis]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAxis",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Domain]",
        "terseLabel": "Accrued Liabilities [Domain]"
       }
      }
     },
     "localname": "AccruedLiabilitiesDomain",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_AccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Line Items]",
        "terseLabel": "Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "AccruedLiabilitiesLineItems",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "accrued liabilities [Table]",
        "label": "accrued liabilities [Table]",
        "terseLabel": "Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTable",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued research and development services current",
        "label": "Accrued research and development services current",
        "terseLabel": "Accrued research and development services current"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AssetSalePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "asset sale price",
        "label": "asset sale price",
        "terseLabel": "asset sale price"
       }
      }
     },
     "localname": "AssetSalePrice",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/ImpairmentLossonBuildingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_BioPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BioPharma",
        "label": "BioPharma [Member]",
        "terseLabel": "BioPharma [Member]"
       }
      }
     },
     "localname": "BioPharmaMember",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows [Abstract]",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement",
        "label": "Conv Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Conv Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible debt exchange",
        "label": "Convertible debt exchange",
        "terseLabel": "Convertible debt exchange"
       }
      }
     },
     "localname": "ConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeRemainingNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible debt exchange Remaining Notes",
        "label": "Convertible debt exchange Remaining Notes",
        "terseLabel": "Convertible debt exchange Remaining Notes"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeRemainingNotes",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberCashPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible debt exchange- September cash portion",
        "label": "Convertible debt exchange- September cash portion",
        "terseLabel": "Convertible debt exchange- September cash portion"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberCashPortion",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible debt exchange - September principal amount",
        "label": "Convertible debt exchange - September principal amount",
        "terseLabel": "Convertible debt exchange - September principal amount"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberPrincipalAmount",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberSharePayment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible debt exchange - September share payment",
        "label": "Convertible debt exchange - September share payment",
        "terseLabel": "Convertible debt exchange - September share payment"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberSharePayment",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_ConvertibleDebtExchangeTotalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible debt exchange - Total Principal Amount",
        "label": "Convertible debt exchange - Total Principal Amount",
        "terseLabel": "Convertible debt exchange - Total Principal Amount"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeTotalPrincipalAmount",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_FutureConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "future convertible debt exchange",
        "label": "future convertible debt exchange",
        "terseLabel": "future convertible debt exchange"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_FutureConvertibleDebtExchangeShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Convertible debt exchange shares",
        "label": "Future Convertible debt exchange shares",
        "terseLabel": "Future Convertible debt exchange shares"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchangeShares",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_GainOnSaleOfNonFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain on sale of non-financial assets",
        "label": "Gain on sale of non-financial assets",
        "negatedTerseLabel": "Gain on sale of non-financial assets",
        "terseLabel": "Gain on sale of non-financial assets"
       }
      }
     },
     "localname": "GainOnSaleOfNonFinancialAssets",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_InventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory [Abstract]",
        "label": "Inventory [Abstract]",
        "terseLabel": "Inventory [Abstract]"
       }
      }
     },
     "localname": "InventoryAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_IpsenMaximumRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum regulatory and commercial launch milestone payments.",
        "label": "Ipsen Maximum Regulatory And Commercial Milestones",
        "terseLabel": "Ipsen Maximum Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "IpsenMaximumRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.",
        "label": "Ipsen Milestone Payment",
        "terseLabel": "Ipsen Milestone Payment"
       }
      }
     },
     "localname": "IpsenMilestonePayment",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoCommitteeDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This is the amount of the upfront payment allocated to the committee participation deliverable.",
        "label": "Ipsen Revenue Allocated to Committee Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Committee Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoCommitteeDeliverable",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoLicenseDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the license deliverable.",
        "label": "Ipsen Revenue Allocated to License Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to License Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoLicenseDeliverable",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRoyaltyIncome_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ipsen Royalty Income_LXRX - represents the royalty income earned during the period from Ipsen's sales of XERMELO in countries outside of the U.S.",
        "label": "Ipsen Royalty Income_LXRX",
        "terseLabel": "Ipsen Royalty Income_LXRX"
       }
      }
     },
     "localname": "IpsenRoyaltyIncome_LXRX",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.",
        "label": "Ipsen Total Payments",
        "terseLabel": "Ipsen Total Payments"
       }
      }
     },
     "localname": "IpsenTotalPayments",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the total of the upfront payments under the agreement.",
        "label": "Ipsen Total Upfront Payments",
        "terseLabel": "Ipsen Total Upfront Payments"
       }
      }
     },
     "localname": "IpsenTotalUpfrontPayments",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LiabilitiesAssumedByTerSera": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liabilities assumed by TerSera",
        "label": "Liabilities assumed by TerSera",
        "terseLabel": "Liabilities assumed by TerSera"
       }
      }
     },
     "localname": "LiabilitiesAssumedByTerSera",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_sanofiInitialCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "lxrx_sanofi initial cash payment",
        "label": "lxrx_sanofi initial cash payment",
        "terseLabel": "lxrx_sanofi initial cash payment"
       }
      }
     },
     "localname": "Lxrx_sanofiInitialCashPayment",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtBalloonPayment_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Balloon Payment_LXRX - Balloon payment due at the end of the 2-year maturity date of mortgage loan with Revere.",
        "label": "Mortgage Debt Balloon Payment_LXRX",
        "terseLabel": "Mortgage Debt Balloon Payment_LXRX"
       }
      }
     },
     "localname": "MortgageDebtBalloonPayment_LXRX",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInstrument_Revere_LXRX": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Instrument_Revere_LXRX - Principal loan amount borrowed, using Woodlands Campus as collateral",
        "label": "Mortgage Debt Instrument_Revere_LXRX",
        "terseLabel": "Mortgage Debt Instrument_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInstrument_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_MortgageDebtInterestRateBasePlus_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX - represents a base for the range of the interest rate that will be charged on the Revere loan. Interest charged will be greater of 30-day LIBOR plus 5.5% or 7.5%",
        "label": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate BasePlus_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRateBasePlus_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_MortgageDebtInterestRate_Base_Revere_LXRX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage Debt Interest Rate_Base_Revere_LXRX - interest rate in Revere loan agreement is 30-day LIBOR plus 5.5% as base rate. Interest charged is the greater of base or 7.5%",
        "label": "Mortgage Debt Interest Rate_Base_Revere_LXRX",
        "terseLabel": "Mortgage Debt Interest Rate_Base_Revere_LXRX"
       }
      }
     },
     "localname": "MortgageDebtInterestRate_Base_Revere_LXRX",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_Netproductrevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.",
        "label": "Net product revenue",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "Netproductrevenue",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PrincipalAmountOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "principal amount of convertible notes",
        "label": "principal amount of convertible notes",
        "terseLabel": "principal amount of convertible notes"
       }
      }
     },
     "localname": "PrincipalAmountOfConvertibleNotes",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RDSeveranceCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "R&amp;D severance costs",
        "label": "R&amp;D severance costs [Member]",
        "terseLabel": "R&amp;D severance costs [Member]"
       }
      }
     },
     "localname": "RDSeveranceCostsMember",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_SGASeveranceCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SG&amp;A severance costs",
        "label": "SG&amp;A severance costs [Member]",
        "terseLabel": "SG&amp;A severance costs [Member]"
       }
      }
     },
     "localname": "SGASeveranceCostsMember",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_SaleOfNonFinancialAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Non-Financial Assets",
        "label": "Sale of Non-Financial Assets [Text Block]",
        "terseLabel": "Sale of Non-Financial Assets"
       }
      }
     },
     "localname": "SaleOfNonFinancialAssetsTextBlock",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_Sellinggeneralandadministrativeexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.",
        "label": "Selling, general and administrative expenses",
        "terseLabel": "Selling, general and administrative expenses, included stock-based compensation of $875, $1,864, $5,440 and $5,370, respectively"
       }
      }
     },
     "localname": "Sellinggeneralandadministrativeexpenses",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock-based compensation expense associated with selling, general and administrative expense",
        "label": "Stock-based compensation expense associated with selling, general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with selling, general and administrative expense"
       }
      }
     },
     "localname": "Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Abstract]",
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.lexpharma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TerSera Maximum Development, Regulatory and Commercial Milestones",
        "label": "TerSera Maximum Development, Regulatory and Commercial Milestones",
        "terseLabel": "TerSera Maximum Development, Regulatory and Commercial Milestones"
       }
      }
     },
     "localname": "TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_XermeloPretaxNetLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xermelo Pretax Net Loss",
        "label": "Xermelo Pretax Net Loss",
        "terseLabel": "Xermelo Pretax Net Loss"
       }
      }
     },
     "localname": "XermeloPretaxNetLoss",
     "nsuri": "http://www.lexpharma.com/20200930",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r216",
      "r225",
      "r227",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r216",
      "r225",
      "r227",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r342",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r196",
      "r226",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r20",
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r318",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r53",
      "r54",
      "r55",
      "r331",
      "r348",
      "r349"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r97",
      "r98",
      "r99",
      "r272",
      "r344",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r254"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r228",
      "r230",
      "r255",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r84",
      "r294"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r84",
      "r182",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r84",
      "r185"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentChargesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.",
        "label": "Asset Impairment Charges [Text Block]",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentChargesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ImpairmentLossonBuildings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetRetirementObligationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Asset Retirement Obligation Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetRetirementObligationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r150",
      "r153",
      "r159",
      "r174",
      "r269",
      "r273",
      "r283",
      "r312",
      "r330"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r50",
      "r93",
      "r174",
      "r269",
      "r273",
      "r283"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r231",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r231",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r28",
      "r86"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r87",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r92",
      "r93",
      "r112",
      "r116",
      "r119",
      "r123",
      "r127",
      "r136",
      "r137",
      "r138",
      "r174",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangement Disclosure"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r195",
      "r319",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $.001 par value; 225,000 shares authorized; 117,231 and 106,679 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r66",
      "r322",
      "r338"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r217",
      "r224",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68",
      "r309"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r313",
      "r314",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r37",
      "r205",
      "r206",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r293",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r95",
      "r205",
      "r207",
      "r208",
      "r209",
      "r292",
      "r293",
      "r295",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r258",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r94",
      "r258",
      "r261",
      "r262",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r149"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r110",
      "r112",
      "r123",
      "r126",
      "r127",
      "r131",
      "r132",
      "r323",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per common share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r112",
      "r123",
      "r126",
      "r127",
      "r131",
      "r132",
      "r323",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income (loss) per common share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r135",
      "r175",
      "r204",
      "r210",
      "r251",
      "r252",
      "r253",
      "r259",
      "r260",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.",
        "label": "Extinguishment of Debt [Axis]",
        "terseLabel": "Extinguishment of Debt [Axis]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of debt extinguished.",
        "label": "Extinguishment of Debt, Type [Domain]",
        "terseLabel": "Extinguishment of Debt, Type [Domain]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r277",
      "r281",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r277",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table Text Block]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r278",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r217",
      "r218",
      "r223",
      "r224",
      "r278",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r217",
      "r218",
      "r223",
      "r224",
      "r278",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r278",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value, Measurement Inputs, Disclosure"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r84",
      "r200",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r179",
      "r180",
      "r311"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfRealEstate": {
     "auth_ref": [
      "r84",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.",
        "label": "Impairment of Real Estate",
        "terseLabel": "Impairment of Real Estate"
       }
      }
     },
     "localname": "ImpairmentOfRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ComprehensiveTextBlockListPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160",
      "r310",
      "r320",
      "r325",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Net Income (Loss) before Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Decrease in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Decrease in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "(Increase) decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r117",
      "r118",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r181",
      "r183"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible Assets, Net (Including Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r62",
      "r148",
      "r291",
      "r294",
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r79",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory, Finished Goods, Gross"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r47"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r48",
      "r89",
      "r134",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Inventory, Raw Materials, Gross"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r93",
      "r154",
      "r174",
      "r270",
      "r273",
      "r274",
      "r283"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r93",
      "r174",
      "r283",
      "r315",
      "r333"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r93",
      "r174",
      "r270",
      "r273",
      "r274",
      "r283"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r57",
      "r59",
      "r65",
      "r85",
      "r93",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r121",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160",
      "r174",
      "r283",
      "r321",
      "r337"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r150",
      "r152",
      "r155",
      "r158",
      "r160"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Debt Issuance Cost"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r231",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from Sale of Productive Assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r187",
      "r334"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $63,795 and $61,741, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of debt borrowings, net of fees"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r257",
      "r367"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $1,029 $1,698, $5,154 and $5,369, respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r89",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r210",
      "r254",
      "r332",
      "r347",
      "r349"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r175",
      "r251",
      "r252",
      "r253",
      "r259",
      "r260",
      "r344",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r146",
      "r147",
      "r151",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163",
      "r213",
      "r214",
      "r309"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r63",
      "r93",
      "r146",
      "r147",
      "r151",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163",
      "r174",
      "r283",
      "r325"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of cash and cash equivalents and investments",
        "verboseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r231",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r234",
      "r246",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r84",
      "r189",
      "r190",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance Costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r236",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r229",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r89",
      "r231",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r316",
      "r317",
      "r329"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Total Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r92",
      "r93",
      "r112",
      "r116",
      "r119",
      "r123",
      "r127",
      "r136",
      "r137",
      "r138",
      "r174",
      "r204",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r135",
      "r175",
      "r204",
      "r210",
      "r251",
      "r252",
      "r253",
      "r259",
      "r260",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r135",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r204",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r204",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r93",
      "r171",
      "r174",
      "r283"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholder's equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r93",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r174",
      "r175",
      "r210",
      "r251",
      "r252",
      "r253",
      "r259",
      "r260",
      "r267",
      "r268",
      "r275",
      "r283",
      "r284",
      "r285",
      "r289",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r290",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r290",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r290",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of trading activity.",
        "label": "Trading Activity [Axis]",
        "terseLabel": "Trading Activity, by Type [Axis]"
       }
      }
     },
     "localname": "TradingActivityByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).",
        "label": "Trading Activity, by Type [Domain]",
        "terseLabel": "Trading Activity, by Type [Domain]"
       }
      }
     },
     "localname": "TradingActivityByTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r41",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r41",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r41",
      "r211",
      "r212"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 793 and 407 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r204",
      "r210",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/AssetSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r217",
      "r224",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized Debt Issuance Expense"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r120",
      "r122",
      "r124",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "terseLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net loss per common share, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1930-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2029-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2740-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r368": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r371": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r372": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r373": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001062822-20-000067-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-20-000067-xbrl.zip
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MJ>*L3BGU#$</A1UA$E(3R\1GP<E6MDW=1$7B9T$[F#TO#XK8"'"*84R,GQR
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M]\=O_W47DI%)K,:P.%\HNZ)*EYCG*!KV(&^BJHKPCZ9D!Y/,^UH*]+2=@Q@
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ME;F0^"EF/'A:'IXM,+ 8&FCA]P]DL_]VGS;[VS(X=F60GDC!,KVC]3R7]?Q
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MY+^;<MUV0/P/(0CI1Q,&VYI2_RK,2_828K8@XX;VG3H#0,_79>?F?W#&]^$
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MA\'5?;Z$J9\7CT?JQ(_4O5XU+"'&3$?5H0"GE*/JC*8+]8^)/).Q($@"#?G
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M!$?WK-$DJPUS)U[J^UI^>RIXQ#6&<7"[4OZ(>+LY'T5[&)TN_P:Z1+6+[L<
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MB(#H5JW+N[<- C_/RPG5FOB3L5),(%D$T@%Z5WH$C]M@1E07!$.+$03A.6=
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M.3D]>W]S<7KR^KH77%R>+IL@.&S3MKSDVO#@YQ]W#K=?E/_=SF0W]4GG].\
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MAEF6_@,VH&4JW*N&7V;U/U=1KTL3\2,>YW_WT^$<_G,W'<?__G]02P,$%
M  @ :81>47#?=33:!P  9R4  !H   !E>&@S,3%C97)T:69I8V%T:6]N;V9P
M+FAT;>U:;6_;.!+^?K^"ZV+[ OA-L9W$3AI@-\EB _3:;BZ'XCX=*'%D\4*)
M6I*RX_WU.T/*;['3.DBWYP9;H(XDS@R'G(?/#"F=_G#QX?SF/Q\O6>9RQ3[^
M^^=W5^>LT>IT/O7..YV+FPOVZ\T_W[%^NQNQ&\,+*YW4!5>=SN7[!FMDSI6C
M3F<ZG;:GO;8VX\[-=8=,]3M*:PMMX43C[)2>X"]P<?:/TQ]:+7:ADRJ'PK'$
M '<@6&5E,6:?!-A;UFK54N>ZG!DYSAP[Z!YTV2=M;N6$AW8GG8*SN9W33K@_
M[?A.3F,M9F>G0DZ8%&\;LGL8#^$X.CJ*0?1Y[SCFT!\.^7$R2 0<#7O_C=#)
M#HH''>MF"MXV<EFT,J#^1_V#]M&@="=3*5PVBKK='QM>].PTU87#_@SJA\M@
M9L.8@SO7XDJ.BY$?4B.HSIL3K;09O>CZ?R?4TDIY+M5L].I&YF#9>YBR:YWS
MXE738AA:%HQ,@Z"5?\ HBM ]?SL-+A^A'24+F \A.B"G+^\R&4O'>E$[6O=X
MNZ\)3BZ8QH/C7)TN;L8X8[%V3N>C0W3G(3M?;]#=G09]?GE]<_7+U?E/-U<?
MWO]KEV'_K[).IK._W-_^5G^OFNR=+@I0N *XLTV6@"%WF,NX>_EB<'SR^#$\
M)G9#]++D0N"2;"E(W:BWB*8L!$9RU(J.RZ\/X=UF)VK/A_'M>U^?EJC;'M T
M7+&,3X 9F$B8(IFY3%KV6\4-0E[-V#64VCBF"_:+-CF+NJW?F$[9.[B3"3[\
MF'&3\P0J)Q.N,-I71=+&* \?CO+W%*Z#O0O7S]QBD'#F\QF[+?14@1A#,T3-
MA%@)C2X4&O,3]L!EP7@Q8U7A3 4X LQ8/GEA$#G+\<Y(KEC*$WQDF,Z17YT.
M<AL"!21@+3<S$LGY+6"_*S8M/A/H#':I?.;#/D@@D08S'8H5J(Z>"#!LFLDD
M8[:BGZ7^% S41F@ N;0*4R)EUZET&0[0EI!X!\ENB:YI@<.<H)I@\6QU&CP(
MV;- 8>_[02&P5!889X+,,JY-A""*8[-9:9=%BI3"J2;#ZT15 FTB=E:"V$3<
M2:*A$D-/J"4T*[6$98T(>Z]K1+[PQ5Z3)"J% HA%C8#QW5GO3\)MQE*EIW8.
M5 -C:1U6BHYQ>AC\1B^;*WBS<V<VO V0>QZ8Z^\=YF[6 O3*UGBJRPOB")VF
M$F]#=*\8-^#Q@?&6L0**(P,$9:RDS4B>Q'(D2"))NA?2)DK;"O6(.HU6P51I
M= ("'UOV&G$A ($6@G]YEV2\& /["5GINE(H$?5X*QJ\AC=>-1J(<!=N)162
M10 HV6=$72NX#3@B7W;N*%WK*,6.:)SWT8P2E.8_7W]] 9^#_A[AD[_9(WP>
M]&D></^'I2O&RV>U+X.I20DWX97=784R7PQLT5/(I;HR: #9:2*MYSR4@L+;
MH:)[R9:KC&M <8^T.IDNT=*LV9@:)3(G^F*UDL+O=6T56RDD-Y(&($/*]SF@
M($N5I33L5Z;U.=LS)&ZFT2'<Y7JE$FM+F52*$['CL+P3RW2.&J$X6*UI\"H&
M$D3N17T03ZHQ]PK)\=X@>=@^/-H$\LZ<M8'GW=EN9UCC4IA(06CE5A><:)U;
M1#J5E@1A;L0<3@APR6.II)M1?M_6+2TNCSP/JK NUD172E.?/>[J 965*1'4
MUM<C2:*-\ [X(G4,!989"K&-+5#2HB$1+, #?G%QR1()_/D@.-D;!"^X&"9<
M59ZP*+Z0IE@DR@E&QFXI]K"6V(%ZP^WVRL]C%161-FVH+V-=N8?[WB4Y\(4T
M4/&<?GG+P^)Y6>Z77ST'Z$\H3+&#9P$WL3=P6Q!F".<F+&CG71=NON4>ZAY!
MD)3'=9)4AL*^DC37[.7:.GQ"YY5HQ29HXO=PDL->;PBGB%FDJWMRM9NX-P)_
M1$"G!T6U\.5-\"3C=E%5$-%YC(/P&<"/OF;G&5/R%E1]7G!/OOF$"7DRHO=J
MLS7X_C=;_A!QL0Z:2RHB9ES%Y9*5"%^/*"XVZE3TBF.5ZG3M!+7Z!V@LSZ5S
M %NY/M98)5"+D.B35W^-N$5JM43=^)>JY/D"@]\KB2[[)545B3\^>//W/NHO
MS-UTP$.%H$2 T>:5ML&)! 1$G847^YDI\%M*JZ$0\XG5EY#^)'-^V/,HF-5;
MCW!TL(7$N$!%"PL.VP+)NN1$84075H;-D-4MIG1;Y8@-G!\_C#I';#T0>UX9
M>_^V.)284X-LT<2(@^<VQ(P_<Z[!U0R93A83K29 Z:[@X_KHW-1T"'FI] RP
M=9KI0(%\#;H(M2=F_O;N /@_!?<")\SS(?N 9!J#>?DB.NR>]+K-\.;[B>]<
MG=_DU2HQKB<P+1R:XJ6%T?SB!#-/J?AL) OOH%<ZF5"VPN*F-NET6;\#'P[:
MO8.(7H,[@__%W'S]AKSMWY!WG-ALZQ^V!\/A@\W==O1@V^?,#J+V0?=AU56S
M'>]R<!N';TM>O&WT&G.%&NVC+HL\(N;V/B-Z4-Z1\.;LWY_ $*EO#S/_Q<++
M%_VC$^M_UUXP+^#U=2>G1AIB9H2RS!^ L?DHOZ^9^P:SM7<3XBV.I,/>DAVF
MZ"/NN"6E29^8SS,)*;N\@Z2BC3O[$$K=S;GK>)Y9H;9=/E>X]U5.J<-G2:-P
M(#N!C>]TEI#T1-E=JO 8<5FYAU4>\3',VF_X!,E_#'7V)U!+ P04    " !I
MA%Y1!@>+MML'  #F)   &@   &5X:#,Q,F-E<G1I9FEC871I;VYO9G N:'1M
M[5IK;QN[$?W>7\&KH'D >DNV8]DQD&L[J(LTR77=!OU44$NNEC5WN9?D2E9_
M?<^0JX<M&5>!FUO%:#XXVN5P.,,Y/#,D]_2GB\_G-__X<LDRGVOVY6\_?[PZ
M9XU6I_-U<-[I7-Q<L#_=_.4C&[:[/79C>>&45Z;@NM.Y_-1@C<S[<M3IS&:S
M]FS0-G;2N;GND*IA1QOC9%MXT3@[I3?X*[DX^\/I3ZT6NS!)E<O"L\1*[J5@
ME5/%A'T5TMVR5JN6.C?EW*I)YEF_V^^RK\;>JBF/[5YY+<\6>DX[\?FT$P8Y
M'1LQ/SL5:LJ4>-=0J11#WCWNR[?#P?"HG_"N..X.CY/>\% .^>'Q/WLPL@/Q
MV,?YN9;O&KDJ6IFD\4?#?OOHH/0G,R5\-NIUNW]L!-&ST]04'N-9](\_HYI-
M9=Q.H&]LO#<Y-$"9EW>^Q;6:%*/@92-J6_1(C#9V]*(;_IU02ROEN=+ST:L;
ME4O'/LD9NS8Y+UXU'2+3<M*J- HZ]6\9!PF/L^C%$?1H5<B%5[T^^7%YEZFQ
M\FS0:_?O.[&S^0E"(.W_R/[SR^N;JP]7Y^]OKCY_^NN.'AS?=^!?E?,JG7]W
M#X9;/;AJLC_+-+5RSCZVV5<N9),ETI)%S&?<OWQQ\/;D&QPKN1!83BTM4S\:
M'"Y<585 G$:MWMOR^V-MNZ>]]L*-WW_T^]/2Z[8/:!JN6,:GDEDY57(&(O*9
M<NR7BEL 6L_9M2R-]<P4[(.Q.>MU6[\PD[*/\DXE>/DEXS;GB:R\2KAV3795
M)&V$Z_AYA*N_=^'ZF3L$"3.?S]EM869:B@E62XB:C;$2!B84!KD%(W!5,%[,
M655X6TEX@&P3$@^"R%F.)ZNX9BE/\,HRDX,(O8ER&P*%3*1SW,Y)).>W$N.N
MZ71X1TL70^J0M3 &"23*(DM!K$!W6"*D9;-,)1ES%?U9]9])*VLEY$"NG$8Z
MH\PX4SZ#@ZZ423"0])8PS0BX.44WP<;S]6D((&3/ H6#'P>%DJ6J0)P),JNX
M-@%!B*/9KK6K(@6E<*JG\#O1E8!.8&<MB$W@3A$-E0@]H9;0K/4*EC4BW(.A
M@7P1"K4F250: L"B 6#"<"[8DW"7L52;F5L U<J)<AY5GF><7D:[865S#6]N
M8<R&M1%RSP-SP[W#W,V] +UR-9[J.H$XPJ2IPF.,[A7C5@9\(-YJK"7%D4F
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MA2I6>K#CN[\AC33&/)'Q8O#+2";"L ]BSBY4PM-?Z@8@-XS0<EQ,-/(O,3C
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M!#>PYCPU(F9CI=FCUE%GG)V*F,^Y%EBE,Z4YU37LE851[.X<M-O?*ZYO$JT
M.!)AR=8@!]::9M6.3E0"AUW\..8HD0.?UO!UG<VEG3)X529"RZQB(6(#ERF+
MQ83'+.%4=AB&%]!$BCD$L5M#,&=:92@1(R:-R7D:"F>HAB.JCK5*F 7/1-3]
M'RS<FE)ZIL8@F20@9ZP*K^LLXYK->)P+]K/O^2A6GX4F28!+$F [U EOHBJ<
MIXQ/)AHZM )(CT$6;S,M0WID>49:^7G/KX,O^O<,L+Y$%!!F.U#.<DWV[AS&
M3KE=>LW'3*3L-ZZOA667Y 9OH02*V;;.(M<EW:UFG@/R$,2L)-D&%;! V+D
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M+XFX8DRXA,W@94*-E[N5VT&?"CMMW/5X@6;2?!G]64G^=J%4CF(0A:N*<^M
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M9=1QZP@E B@;48SJI1'9]&)UDQ-.M(9%2;UC#'/MK*6!J?PO&FG9-.UI5CT
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MDL$#BS6FJY4&:&BC6(Y:U$JN]RY6QPVGJ&KIC[,>#WI[4)P]ZU^G7I1T#W6
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MQFHG&>Z@9HV*.6<D>^V>;4R"?$S0GWKP1I?EP[AI3#R5\/9$>(-V]:IU?%Y
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M?/<P7GOJ,<',DZ[\46/U&I.J;.O/WE9%'W37?PB0+W@UZA^_U'=G]LQ#WG^
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MKSG+T\WPG>)W*:63ZW^2J.YS"MBZ^UWUH8OQ4,VOUYG0...&:(;7N>ONO:3
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M=]DA]X8G]=.>G5643D]HPD<'D::C=' 7]5!_]7M+1ZSK(>;Q13SEO>#_U6_
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M'NFHO05J%SI(D:RR2@0!2VRC%JH#Z#E!0F\)E5&VF([:+47M*J';&H20U7<
M=1#? L1+.QU5B$KF##&) JA*2YAF#Z:H5%FXE!J7'QY;>V3EQ\LK5M[DT^$[
M/*.[(>6CX_46>'UO(V&IL$Q40 9-;2.A@Z"]A*RB*T4)S;GW/NP!;C?4R]1Q
M>RO<+@0.$T0VT0=(3 BHM0*/*8%WCD3,06=>7Z5!Q^UPW>4U*!W=7=XLC)=D
M#\=L&U[K8^1:]5\)X%,]*N-]"D%4 M9B6 YS;V#JK^P-3'?)_C^>3[A>Q9^<
M#U[3Z/R@\O_H_%>^FA';FYAZ$],NGM+PY+AGLQ.>M'G+$S[A\^GH5[[T>1;X
M_,_Q:;O+WU:4-D?HV?ES3A>3T6S$TX>3T;3^:+GMNSI-S\H+^KW[2ZNLQWWQ
M<+;D+Z$QBK-.D'T,->R) GRNYYP9W3R C2A[1>;N4\"&M+U. 4.A@*4=#9FS
M<]RJL)M0F'V"@)2 LV7OO95H7:> W:> #35,=0H8" 4\6^[+*!I]5F!L%H!M
MPC%5KP!D=EI'EVP)O0%Z#RA@#6)C!_L@P3[_W_,&^(>O#'-6@304D=LPY#;?
M*84$*A<O3$E2&#H\=LYVI.\LTC<D3W;\#P;_C]_A/POM0S89-&*I^)>^6GO%
M(-B2$CZ(ROC=VN\^!ZR]IZNC?3!H_WYA[;$Z<=J9ZM93]>U%=$"JNOI8:LPO
M340?>6C6?J>ZP=RU./TGG<[WK='LX E-TLF!ED<'#6;WW1X6QY/,$YB-WWS5
MCF\Z/AWE@W8[=HD,KUVW%G143J,,% 3&$-N,D2B3\39Y56/B5X]OO67MT7QZ
MXKSG]7*SVN4PVTYP*Q'<-[.EPJU4;,F9,EC+%E"9ZLV(3.!R2C91]6ZB/#R6
MPAVY:TH^;E:X]648V:*2KKT _<<>T,T1?\U<ZI/JV_!D>KDJLSH^IQ?MQGTW
MGK2K>#B;34;Q8D;QE%^,GX[/VW5,QJ?U\E\_KE=4J6#666!%%EC2,4V1VDCR
M$#A5+Z=&L%!#V0@RH>!BA=<1&POXS@"= 9880)@<2&@9-5G408>V6@@M&:U2
M-J&LP>9W<K@?<GAO>(WR06NH+H&'2O06?)8>DDA!66]*4JGM7L56%RJP4\3N
M4\0J%>$4O0HZQ:BK@Q *1ZEEB%0L"TI:I$]SQ.J%X)TL[H4LEK10Z:7+&A.(
MZE( 4BH0E8_ VN=J(9Q'F^=D(?R1,.;V1>2=)P;,$RO0A)4IQ61$(K1HHZ,:
M?4KME,A15%]"]F!BT!2PK)!JG;((18&TMCD,ND#(@D 9Y5.6,:)1A\?>BNXJ
M[#X%K#37,B@76:D8C$4.TE/V2NL8D\LJ)NJNP@[PQ$))C804:M (*B("&J&@
MNH46;*B^ J(7+LC#8SQR^#%3=#]AETABE5)KK6H$$7*H)%$?GQ*\IR(M>_9*
M*10]Y;"]U+ DNRI"G1-"M%Y!F[<)T2D/FML*BJP5"WMX;"HW.+<57L0>- K.
M80.1IMP^XMD;/I]2.X_>(MA;!'?QE%8Q6IRY&,LB&8>*,MF8A?--)HLJ.KRJ
M%<*WM4)6BYO4"S[,/U]<]>6^&#^L][-=%YU^1Z/\^/P1O1G-Z'0NG,]!^F@)
MHS]PM7/3T8R?\^374>++"J(?.(U?G\_?93YCNINTE4S:XV6)3908575WP2B1
M  M5BV:U@9Q],DEKU+KO8MD#*D@L5:GXMB::&N.:2-ZD&N\([6N$J\J*5/!9
M1[;SP=#X8*&J>><4H[20;4IM)43U=2DGH%PD!Z=#D?/@5YE;B^Z=#8;+!MGK
M3,J$Z#PF02&2+-J1TM)E#JD[!KM)!$N*68E"RJP"L+D<4AHAF"S *B?0LM-1
M=<=@#ZB DK..,X:<&*M/0!2-CL'))"3GE1V#3@5;0@7+RAEZ86R,#EH[&:!7
M'KS(];LV8L8B1^P;WO:!"SA%FY@R!6.J#3 DHXC:>INLM2Z9S@6[R@4+=4Q&
MZX2.$:)NZIBV&KQC N0:-T;V6?ON%^P!%V"*U1= '9 ,:J%:54R2 HVI_D$P
MH2<,=IH0EC0QJR(J+2"7$ !=)82@8X*0K*?F)#+YX64,=JH9\7HPMRZT>3?B
MN#3AZVS<+F"<?JFHSCPYN)20#Q[75YS/1K_RP7>G]=^Z[T;%'>+,:]L1UT";
MUU0%7#8<+G=97S8BUD\X_U&?/KT:PSU9[D4DG6.AUF,0<B6X8 F(G ?EHY/L
M#+$.A\?2KTOQW]+"GQU"[KTII9\ \]Q)Z5B^*9:7Y,[B"9.W%HJ4 M#ZT%8O
M66A.2JOI3!:I+X38?3RO6>[L>-XHGA>V69-U%!G!6M>FGT@'9 2"CUID+95+
M<7V3CCN>AXOGS0B6'<]W@><EU5%%68+0"4)N/3HN"_!&$K1)]BE&$:SJ^TWW
M ,\;4AT[GN\D=EZ2#B-7^&(AD/6<JH'."DAH"U;9+$4USUJM;PYY!_1@ ;TA
MZ; #^FX O=#_*-2S43Z!+F@!D]$0C&20CME85;0M'=![ .@UZW\=T)L%]$*_
M\UZ)B,4!LVK+@JK?[9/-8$L%-&<C)(DA GH/6M=^X#<7DW1"TX\TO TUKPV)
MP:186Y/:W=F3W;ZWPQ-,7DR8IA>3/^9F8FX4'J;_O1A-6A7(=/:$9R?C/H=U
M->OP_7L3&"W50 T9/"I3P[<VA]4& <)*);TITHF;[I#I(+QS$&Y(Y>@@O L0
M+D0.EZ.+]7B ,BI XPJ0<@ZRJ6>8DD\NA ["P8)P,])$!^$=@'!YFQIF*9(,
M8%NV [-!B")9$")K%V1AS3?M@>@@O',0;DA/Z""\ Q NRPE)HJHDBI"CGP_]
ME4 D(M1C3):2#27ECL*-HG"527IK4 $ZX#8 N*5VG[8F$HL%)*H!H"4-L7HT
MU15-2:I@ EMJ(_CU%X_"ZSB[>YRMO<J\X^Q.<+;(PA?G10T3(KC4VNV3#^"+
ML]7;3#5>X" L\N9QM@==,D]Y=G ZGO;&E[M)M7=-]]Z/:7A9^XJYRQV2;5UD
M-QLKF8T?E]/SNL8^*E&-A(@5H'<&0EMKH+0K.D>,R+V=81^ NZ%,?P?NK8"[
M2.FS,=;[K,$'8D E$<@Z!&6$-Z'&58BQ W=PP%W_;H$UJ .K+QGH,+X-C)=$
M@8@2O4X22+5IB:X8\%Y$L$+6DRJ)=':'QS8<"??QEM*5=P5T  _0\FY(6>B0
MO0UDER4$5V+2PEBH_E*NCK-($(LI8)PP6;:N!']3-;TC=YN0NZ&6A([<VR%W
MH444M$IA#6_1M:7@3@F('A4D[7-T(J"WMB-W6Y&[87VC>\V;!O)"[! J1&PS
MPE(I".A% <_!@"5C!7N5V<EAN<U[T&SPX_F$ZU7\R7FNAQQ4!([.?^6KN7M]
M6\Z&Y)$^\G*X'N.&Y)%GLQ.>M"F6$S[A\^GH5[ZT.PN$_N?XM-WF;VETWHS1
ML_/GG"XFH]F(IP\GHVG]T7*S7#5<S\H+^KW;K)5LULOWE)8DJ :($KQAU^I@
M+%!)"4@4G[@X(?WZ!E-T#A@N!VQ(:>D<,!0.6(@VAC%;Q0B"40-&%VO\*55;
M 2E*=%ZS7Y]HTSE@P!RPF9:.S@$#X8#EM3C!9Y*A &:E +6(4(\=P0>M"Z*,
MA=8W<*YSP'"%VS7H/N]24!WV@X3]LFJ4O?<J&@*98ZNTJE^\]/615^0H2@S:
M<MO\_/&,^R_/5W6X#]?D;T@LZM@?#/:75]YP*^5 ,#'DZO>7 ,&*# &M9)6"
M8M=7WFPM"=R7[M2!/U#@+W0J1:23;UD^G02@2C76M[Y "2Y(1K8YY@$9_;\0
MJ?)H^N:4_FC7R9^GB/[*_LK57[E3S6+N6EOQ3SJ=;U2BV<%_79SS@19'!XWH
M[[MY+(XGF2<P&[_YJI''='PZR@?M;@S*(-_%/B5V3K(P5)S2B$X1%QMSD+ZZ
M:I&M?/7XUMOG'LWG[LT[7R^W*EV.H^R6=27+^GIYI9(L4:!L.Y0B$: HU<2V
M 6/"6"^40LG>M6Y7=^3#K;?&K821+:KQV@O07Q.)WQCQUTR6/:E.-4^FE[OP
MJL=]>M%NW'?C2;N*A[/99!0O9A1/^<7XZ?B\7<=D?%HO__7C>D65"F:=!59D
M@65-/:(WIDT3G&]74QS!F^"@%/;HFWO-LK% 9X#. ,L,X .5& .+^A4U2Z^*
MDD8H#*62@79KL/F='.Z''!8N0E8NBE!Y@;,Q@$DSQ* 1;'WRO94Y7[H(1^C$
MD;>J4\3N4\1*\AS:DHMEBFRP/D?!JRB1O PR.6_ITQRQ>F%X)XM[(8LE5=X*
M5-G[ B+.U\"U>"(X#3X9+N2T,2Y>DH4[DLK>OJ:\\\2 >6(%FI#L+&K-%FO4
MF;+RSFL2G&4T3"[J'DP,F@*6%7IR5CGTU4U(LD43F"%R0- .F0)K:X,]/-:R
MNPI[0 &KN K!6Y>$(FM<0JD*H>/*"(6#C/76=%=A%WAB2<WW5*3'"-*0KCQ1
M&8-*#A"DY%0#BU+=Q<-C//+XY;/V.DGL.DE$M"W%8#&$4NT)5=(P1I54GY>8
MG>LDL0LDL5#^I6)=0P<-4FK59M]*",E:J(8AVNPERJ)::O+(>C=TEMB#WM4Y
M8B#2E-M'/'O#YU-J1]&[5E>]D[UI=1M.::7"U<)HHS%16HRZ^"QL0H$RL"?.
M]JIDS;TM60LW*UQ]F'^^N&H5?S%^6.]GNRXZ_8Y&^?'Y(WHSFM'I7#V?@_31
M$D9_X&KBIJ,9/^?)KZ/$E_5K/W :OSZ?O\M\W'2W9BM9LU_>T]DD>I]- &E+
M I0B0A0F@O(YLPFL@EO?E-!.!8.E A&,0EN,=@4QI1(R.4[UU+'8Z'%5*OBL
M#]OY8&A\L)#6T%J3E0J@*+2E?L(!:56=6VE4+$A(L;1L>1#8V6!GV2#($@TQ
M2EWM@Y69D@Z4LC7":\]"=L=@-XE@N9G5L2J9"!P7;@/5,L00$U07L=J'G$1(
MZUO]W*E@L%3 19F@R+(+!C4:+T/K;:UN0A9^T<_>J6#'J&!9/M.E9-&2788M
M J+RX*628$/.K0G&$-UTLUKG@BWB@AH8.A+6$?F L:AHO2XY6B6MD_6)Z%RP
MJURPD,A("\4V:?#&"D I"P14!90L)K3!1R'>=.MWYX(MX@)6UF6O+$4=D&,,
M0JKB,Y)AG9+N"8/=)H2%'$:H9%*E0*JN(B#K M$5W^;@.:/:1(1BAY<QV*F&
MQ.O!W%K1YAV)X]*$K[-QNX!Q^N7HX)QG[2\+<U]M=]<]B!NDR;G2>=F N-SN
M?]F86#_\_$=].O5*9/?SPT5OXL\/U=/7K^K#5?T<2:!9)4"M$")* Z'U)QKM
MG95\>!R.M/ZX1JC/F=].:-^)=/I%X)W[)QV[-\7N.Z7S$KNF%)**&;1+!=!X
M"SZ7-KG#J**-%(8:=CMN=Q:WF]0Y.Z3O!-+OFV/,@5V*H97V5TA3-$!:>Y#)
MR5Q/%Q7[&G[@D;BF&J_C>MCSMX8G679,WP6FG[UOIH6+24DE@*M+!=6GLA B
M,N1L=8E>><W<ESGM :@W)#YV4-])W/Q.07S\V].?7[YB)Y-,-H,@6P-GIAHX
M6RQ0<G7))&7+5#JJ]P#5&Y(1.ZKO!M6/WT.U]21#=A'85:\;M<A 010PN9B@
M60OCUU= W%$]V,!Z (GNCNQ;(OO[]Y M-"KOLP ELP$T2OT_]M[]J6VD:0/]
M5US4=ZIVJQA>S6BNV:^H8D.R)WL6R.:R^R:_4',%)<;FD^T0\M>?GI%DR^82
M+@8,:*LV(5B61C/=3S_=T].-I,ASA+7G3!E,B*>59ZW.5LUX.,5^!D?:=OVX
M5Z02T-TAMNX0VU-<I=4[Q-9U^%W*/LS6ON):@$$AR )E0#3D!&G+#1*.9%*9
MW&+:=4QX!GJ[Y)V83F_O=+-E:U\KRKR.==28,XAF)D/*"H&PETX9IK@BO-/;
MIZ^W2]YHN=31ZY1W*;LJ47FY94)*A$DN$'6:(LEB:T+&,"?>.)RSM4U)UGEV
MZZRE3G=75G?O:3^E4]OE[)ML[5LGP>I*@?*,6A1_1-):AX16UHK,@L_3M11]
M!HI[3ULFG>(N9VLD]@3-@H!U0")D#E%O M+4!X0%,"7O',:LZP?^#!3W/K=%
M.NU=SO8':*\E1N66(AL,!;.;>:1=+(6",ZH(SBS78@7I\C,XU#3K>=GK@Y3W
M0/N*P3=?GP[L3C/=SW9(MP^_N@;G?K9#NIZT*V&V7K5W5H!4@B?/+7+:*40)
M6"V5R1QI:1G1F!J;DRX5Y^E#P#WMK'00L"H0T.J,Q30Q7!#D::Q-S3*+9.8%
M,B1CGC(0):(Z"'CZ$'!/IV$Z"%@1"&AM]5AA70:KCSS6'E'#'3*YIPCGC"IA
MN''.=A#P2"'@.FTIEK#9,^U/T:G]2JK]W%:1TMPH19 R.4:4:@RF/V0H#]I8
MJ66N/)A^(I;0DZ)3]]6S^/>T0]2I_LJH_FRSB?"093IH! + 0/4=J+[G F'C
MA)262,Z[\[*/%0.N9?)OO]O4F?Q5U_O6-I54W'F/449(+&>3*:1R9E".B7:4
MLB SO4(F_TF=S!'G*NOONI]*[NEQ[[T_'OLCX\M>GJWWHKH]]&&=NI58-3\O
M<EA%-YR8ON\UTW)AK['L4?;PNUZE/F(Y(90J+[2@Q%!E@N924,X=L8:ZNHO?
M;3;H7Z8JC.GT8E64KSK#V&'@M3#PS:PB'U ?*Y3-34 RE?]Q"DB0SCVB&2>9
MQL21'+P>C,4ZR?&2MNJ7IT</G*7SP("Q:KD%__-P@G - 5@E(#W+0&^.HEV?
MTQ5 UO8Y/<=SQ[U"GF***-$*&>+C\6^+/:>>"DX3LG:HVJ%JAZIWBJHN,SE3
M(0_$,ZJIU8)A'C"/G=I\X,O@IAW@/@S@SJBLT4XIF6>(87#DJ75 9077*)=>
M"V&#D4[$0OI4\G7)EI5WVL%N![O/"G:O$T]E,M.!BTPKZZFU1N5<2^DM<5(8
M8N7%N#L-HW8 O-H W&YY&(*5FGC$LEC9/R;\*QDDPDQR+ITV#,=2PNNYHNN,
MG 7@JP=5.^SML/<Y8N\UH%=[IUCFN#'@;&J!E:&,!,,DP9DT(NL""2L-J^W,
M%":#U=H#L8751%0$AG3<JQ*6>$F,R5C<GLY9QV@[5.U0]6X9;<@X.)F*YQ([
M*KW0CFMG@=QH3P)VHF.T3P!Z6\?0#5:,!HY,IC-$"?=("F$0,TIGE@G'%%_;
MI.N2=G2V ]X.>.^,SMK<V;@+AJ7*J:+86)Y;0@+/6&ZHU%T$]_'"[2PABSB?
M.VXM$DPJ1',GD03VBS@LK"&*Y9:YM4TIUGE^ZR9C*P.Z*:WK/TFHX&]7?-O\
MW_1']1ZF_,_F])WF/[R#%@7ICB]B/^#"7J[ )"KPAT/?T]8.CV TIS /O<%P
M#,_3)?PZ%A88^X-2]WO'NDP-4\>'?N2C7CL_&/EH:P9I.O48_A&*@1[8 BX?
MC>$7J1[!Q@5O?NFT7/!A,UNMQ;$^*NW:E;Y6OS<E&X+!;!T/1ZG_\8O2]_6X
M^.9_.RG<^+ !MM87:\G*9E_1!MYZ,K[X*Q<-\1Y[4J3EY?.ST?XSCC;!&Q9<
M6F:QPR:C@7G@1<XJ+0C7FK,0]HE<:[YT6#9O<*P//#*EUU^1#O""+W3_1)^.
MUOXS-P]'Q0 MS/MUI^R\5;VR2-S=?)_)?DSS_9?_7H!.]-X>:K!9UD\2:(S6
M>V"(SJK".:./;;Z+</I XK( P*LZRR^G^/.RC3_OIZ@3H>JE'AWV7O>')Z.5
M?Y]?W@P 68<3N(<;_;KZP_TXT$"J8,JO--:5%NDC71X 1M40SY,3E SY#/P3
M>8#A]O7QR+]H?OC-%:/COCY]40S20].7%FD"4(X:[Y3:8!Q'R*O3O^O;UVBX
MD=!P@?%4GXE\ _CRA1]G&_B&G[&<WNB;EPT69QM"W>RV#S!8^%!>;69_DKC_
MT]ST:URJSEQZCH-<Z?\#M;\Z/_%_%W[3VX'+#D>]5X#/;C[_?X[5W^-TMH(@
MUW #5GRNKWJ6XBIO_-QF#JOKB.)J5XR[8F>Z1(5"I$*]4 Z/>L-C7X++ ]Y>
M=+R_I1-J+^ZT<MP5[K$T85VM02[IR%<5)<4;A*VXK,TZ,_5^B?4)S\30[R,\
MO4(!YBM.V[4CS*L0([[BNUUG=XY@ZJ5V,E 2J/-&\LQYIFDFE,DX:0[QXZN<
MWWWD96/W7C;AW[]/=[8/CS[_"\_[X^_LTY>_X=HW='?[4_;IWW=?/I&/\+U7
M:0RS\.^?1WO;'\FG+[\???KP\61O^^_O.__N'L(S3W?_A7%]V<IWCCZQS]OO
MSH9_CS[1W0^?BYT_/A_N?MB"Y[SZ_HG$]WN#/WV!WV_;T\]?^E]W__@S[)QF
MIREW['UVLB\Q9L&:'#FB J)&"Z0MT\AR[QF6BE.NUS99O@Z+>?N]MD>T6];!
MT2J]VW5R!:QCSFNMI6.482ZIQ)G1/@]&42E-1".L:C2"'YY>[>I' D+9%(2(
M8[DCN4<YR4PL 6J0$<$")DEJ!>"3Q&YM$TN\3L2RCL.N4.7J1\,3MUR,"U;1
MVO&P5WI0/%OT?6^P2"#CQ_&7-GHQDQCU+0:KZ<*L]#V6Z8@06NWEK+* ;?MC
M$*I")XS7 ]?31S$'X$?ZQ4,7HEBE4A++-YM+(/%7-IOM98:?^SZE>0S<5FNU
M.VMZ#6NZ^[Y%Z3GQFF5,(,5C06T1?\(F0]YKD1-8URPC:YMDG:ELA6QII]"/
MF =W"KU\A9[18^\R3W-&D<J"0Y0IAC25!&&=!QE7-U<L*K3 RTK/N@=RW&S%
MPF#]Y1BP>E<ND_<_!EJ6<C21T57VV-&Q'XQNSLB>:%G$Q\W(4F&OW^,"OVRM
M;P?9UX'L=E@5:^FYXQDB'$M$*0U(&6X1T6"$*?>6&KZVB3,@8;0K;?IT=?@^
M25BGP\O0X1GMTCDSFDN. G<9HH%JI!GCR#GK3; F8&^2#HO;I\6O7KW21T-.
MVCY&S"$%2SGN%:/1))4TM</1#1OL=8[F_?&4>2!KK^A>>%V=4!@<O(Q+"4[E
M=C&R,,GC;L/E.M"V][)%3_*,A3SS#F78"H V KZE"#G"AAC/I/%>X+5-I99U
MN+T+$*V@WMXG-^E4^FY4NK6'R@F5C  ]$<X@RO(,2>%RE.?&YE1DA#$6RP!E
M<EFE+U=M!_4QD)5M'WQ9>M<;Z^\]XP<^%.,NBK+B[.0J'6::A:W203[H[Z^^
M1Q?,_UZM<8=KU\&U]FZ6#<1:' *2J0R/I!Y)F3%D<ZXIUXQ:EW==8AZK(E^K
M",SM^<KUTTP[O5ZJ7L_X2F9=9HTV2+*,(BHL08I2CG*BF10L%TZ(M4V^GN&S
M =+'W ?FT5"5V!*I!QHY OF.<97_OGJW\^JOO9X>C7P74EG]E/J?0ES_>_G]
M15SEO<%[6..]L MC:\I!;*55[N#M.BFML7A@4QC[R];)SL$^K)M0P@1$@B2(
M9M0@L%XT1EP E@S%CL<^+SE9EU@^J?3Z)Z[+#Q=F671 .BU>OA9/^XE46DQ]
MKH4("FD;>U-33<$%$18)^'V6YY@S)I?F@G3!E1LKY9NC8UV4,3V]%Y/0(WDQ
MDR+U=[P97WG>OMF*T97&(YNM\EYXYW7_52I<U6'<39G*UCZVW :P34AYCJ,K
MEH%39BW"4F#*1+"41):RSK-;)PQW 9;55>([)BJ=_MX-1]G:IXS[+"/@8-C<
M(5BJ'$GO<J0XSKAG*8ME%4.DSRVB<@X_*09C/3@H8NVJ%%?IPBJ/B*9<A'#)
MZYHM]LM#71[XS@N['L*]F8NE[![L2Y83Q7! G#N.:,RKE5@1E#F7"9]A1W6V
MBEY8I\6KS5,NSUOI5'D9JMP.J$15SG*FN!(H$W'O)Q<":>(I<D$0:ZWDTM.U
M32+7>7XV*MK%4^Y+)_^J24K*J(5QPCM,BM%A.O^_'H_W=T&5%6<KT_WN>52+
MX>)17%T_VAN\FEO8O; -J]T!W+4 ;J?-5;Z#1Y;9G'I% W*"6T1Q3I$4@'=6
M95($0#X<JRH1=NO\VBZ>LKKZ>T_QE$Z9EZW,+;82E9D"WMK,90C4UE?U%#0L
M+;):"<HH%RSP+KSR\*H)Y'P Y'RATE#: 4VU9/J%-D7_%E6'KNJA/?9[+)/G
MYGS%I>:7-P-;>CWROT;L33]%"8K]5>*!A%CDRA??8J'XCNT^%K9[];W$>NVW
MZY5_,]BJU_W==-D[\WG3N-W6OE*YY0P\^XSF!%&G+3(LYR@7EF"6X]P;O[;)
MR#H0H!6RG)URKV#N=J?4*Q'!V]KW01)F,H<X<3GP82^1(0XC+C-IN#,YB4F-
M+%M7^.Q1LT>?NKWRA&:[Q6**P3=P X?E:;>O^%BXR\^P[$V]I$6W#7'S*-W6
MOO.>**D<,MXX1"T62#+/D&?6QF:G7'*\MIG3[@3\$];;99XHZ_3V'@)RH+=!
ML4Q3A20)%E%M<J1T?28T_D]%9F+'H%M7U5K1?<.5IQ^-Y$?Z<5SZ8UVXGJ_.
M3%9AN.'XT)<].RG+F AUB]-DG?>UDNG99Y#O;24%S4G:^@#MUL#M14GHCJC<
M !+_;E.9/& G&&,HX)B^G1&+P%1AY%1&'*>>B9C^R=>S[#9'S+KPR@HK^,.&
M5SH%OP,%;W$>2Y0EUG%D-8GI4AE#4FB/7/"9]5E@-LO!5UF'#U9#P9]MO*7B
M-MT)^:<5<DDPMM=L*7=X=@,\^S@7>[$!+%-F4>Y)B %DA91U"@5.G<+6..LL
MX-DYA3^ZV,N34>#[C+UT"KP$!6[O %EL">,.D3S6&L1 3;3Q#"FN*<8YR!BG
MH,#Y*O67>9Y!F%^:G)9?YY):CO6I3F?.IO&85G)4%XQ9<>*RA)WPMY4 Q!8]
MUI83[_Z:K7^'C-="QD]M:F-RCP6S$O&<Y(C"DB+X/T?<99(Y:6C0?FT3TW4B
MNX27QZ;E#U6LL%/J!U#J%MTAWGHM"4&2>!R;N<3VM,(BG6O/ L:$Q/:T_)R]
MXB[Z<I_1%]<45R[]-S^8W"QAMW/@5NLP_5FX:^+,[ZI5[I#M6LAFVW2%\N#R
M7(+[EA.&J,\T,IP*Y*2#131,F+B;WIVI?YS*O/+%E3O=7K9NMS-E/,>@QAQ1
M0&E$<;!(VN 0++#06+M@8X8;8>N*G&U?]2"E1Y<9HJ%B@ZSZ@;5=/^Y9,'F]
M7R:QLV8Q^+5W7 Z_%0[^84[;A]A@4;ZM1&S&#$OG2S0>'K^(,ST:]@O7:V;J
MB4/D@YQ0 AEY"2+RMI:+WT\_CF(Q^EDP>RH:'59>"RL/YGB0-4%EUB+.&4%4
M$(Y4/.<;#+AVRN78DQBVR>2Z.">H?6TO[\I:](CB.4\-&58T^Z;#@SO#@Q9W
MPKDEF6,8*>D #PC'R#B<QUTN072FG:$DUFV7ZUC<ND+1?8'"DN)"*TVIHF[T
M0G]X,NJ%<GB4#D"-%CC4@Q_^O])*/W1E@.L/<IGT'>/5I^]O)Z4]U#&M?1@B
M<0<('I^F+57_?Y/B.!9@>6BZ_@CM[CTS\GGK^E:?INIF'X9;%M:P]&_K97W;
MUX/QUL"]:E:VLZ[7L:Y?YNJ-@W&5BAN+2*R)13-+P<[FD6UK0:6C+C<AIH^L
MQG9*I[8K&&OLU/:>U+9%BG.:,ZMB%3MF&*): 3W&-J!<:L.=EA1KM[8IEN ?
MWP/;=<7HN*]/XSC]Y9J^>E<N<X/W41"M<@ARX6I*W_2ABWWINAW>NXQK8":#
M\QZ0F@M*K#/2$,I=SI20SG!<TRNUC%2U9HU?PQ)7?:S@-VX2G3;?)>S> +I;
M&?=?7OW8V]H7@I-@I$426!:BW@!\&Y8A;C.1YSF1$L<8)\_6<]E5/7C":GU/
M=4D[C5ZZ1L\*DR:-5AHX&*48910[1)G62%LI$-/8@'Z3S!*ZBMD;SSI05$4D
MD[O218=6/3IT=?JRZ(&^F2US!W/7@KFY I(YYE[)+$,T"QI1)R22GGFDJ,\=
MP=X%+]8V6;Z.U8K4FNOT> 7#19T>/X0>MV)'F;8"N(I%/M,*40W*;)1WB%#I
MB>#2<A<W5 5?5W)%%/FY15EV]'A2I@W29="4SAM;19:RX)+52WZZ-7 OA_V^
M3X,=[84.]&X*>G,U)HG UH9<(&$U!P9C C*:YRA@9W)C!)4F7]LD1*VSVW?6
M[2(NJZOC]\I@.AV_<QUOUV92E/)8"H%E)GHI&",C&$&,Y5BSW.+@0\P4RY;1
M/7M%8S"/H3G,-->^G6$_R[L_+T_LH<,SSSBC]CY)T049M6\:B>@R:F^(DW-%
M*GFT<YXPI$0@,7G (F4,0QFE3F!IG")9S/GAZWQI7?&Z-/O5!X65/Z/8P<.=
MP4,[X=[F,I>2Q2.*'E'E.=(,Y\A+;'+"M"%2K6U2OD[9$L)#7:K]':3:AV*@
M!W;%4NU7^AY=BMJ3V>)]YX_K3=X8/+7#HZ-A',/0?GUH+^*)<X*'V.1]/2QG
MZ[T77J;5?A\7NZ, UZ( <[5(!#5!,.*0Q@HCL/,:Z<!RA*45P5@,C@)?V\3K
M&>&KL4'4*?,*$OQ.8^]88UND77,,RV(H<AFG"" 7(]!3A7)LE%59YC%E:YN*
MGJUTN(H;NJM'HKH3 9?0K4JS(]L"JS_N@4M7#D_@7;KMZJ=#N*;+/-H+?PT'
M!Q]\>;0-J]V!]K5 ^VN;9EEN<PEKB#)A#:)49$CA7".6TYQH)0T+L8$:SM8%
MO\U1KFX_>H65>.E$J]/4)6EJ.R;*\I!I Z*))4,4M!1)Z3V2SN)XF(<2D0.]
MXK<Y)WU_.\JK1YH>)IKUJ K3U?OCY\9V'SJP]9QWPE:I%-WK1C:ZG;";H?Z/
M5VU^)K&1,L_ GT['-&TFD5(A1\Y9(CD3V',7^1E>%W()@;!NC_QI(<,J[9%W
MR'![9&B?H0C:$V<X$C(H0 9)D.9<H$PI(S,#GU 7 ^3JG.;7JX<+SV&+//*H
MHM4/.W&J6" L_1"KA'T#95B!(Q9/#3%7-)X503+F8<-?KV:+_Q;><>@6:Z%W
M2'DMI)P[-8J]RADS&$GA0^Q/ER.5*X:<5(SD0;E 32QUL8[SLZ7/;Y:3O3(\
MJD.%QW9BHT.%.T2%=ALG#NZ3E3G*O<X0)5@A'0)!QGB3X=QA2_7:IE3K$I_-
M,5Q15%A29&JE6=3+BUA33X][QA\4@T&,3,4BK$EG'CHP];21D0H7<W4UQA*0
M4#B-E=8<>^&D=0;[_3<1$#')\9(!<0M\S+(\A9G]1_>[UC#71,+Y@ZDZSYD/
M!GD2"[ :#B#HK4/4@Z'#TDH7^5$._ B3KDOET]5E313-E V,JT"5BG6C0(G!
MV?$ARPAF29=EI\LKI\LM5D.=XB'+!6*< :N15B'E:(Z<R3GFS!NJ);":6-7O
M;+CXX73Y.81_+B4N/K;>OA5E^8FG=[?>W<I-]O_<&3>_AFBO.-[;W%E!.0?J
MEE-%L;$\MX0$GK'<4*DCWM])B*O#^]O@_=Q!6F(LP9)HE&%MXR:A1\H'@:RF
MF962YLX#WC.R3MBM.XP_LMA6AW@=XIU!/*"W%%R=W&BJP+/)@V""9,[S7 EA
M*F^U0[R50[P6PU4Y 9\DETAPHP'QM$0JLP*)C @A<YII$4NLB&R=9&=SX584
M\FK^VPRDD6^2 &W9CNX]W:,U:3E,BQM.3-\OI['5PX[R.3@K[R?'QWT?4WAU
MO^>*D>T/1Y.R.L[:G/3N%8,*%D&QNJ/=MSC:_>3./R=7]U@#2(* @)B,?>E'
M=]+^[-81NY6;NZOSN/->\<E0M?M,Q'A3"^A;D-A=WYU2N!X[FSNVG1L9E.8&
MJ3R>4F \1R9D#F'*9::DSK)@4ZZ%5$]P+Z%#HR>*1O>9 -*AT>W0J'UF2G!.
M)?B*N<P=HC1XI)A4($XFPT)F%'S)6(YSG=!;NXK+WPVYG3?X&'CQJMSC.>3-
M7.+1@=2CY-6UZIX.W!)+>*U89.+.[O%\#SVNWH#OO5S&2FO_7X4V1;_JYZ!'
MH\E15?+X@R_?^U)7)?O&A[YKIWE_[31%%@0XLYH&1V,W37!XA>.Q@KC*=&::
MW==,7IM)]K^7WU^T5GRK6O#?3^OE[BCE-2@EC&'FX/[X2&)MLHQQ+DU S#"+
MJ%(YDIP8Q"5W%'NGK,%KF_DZEJM4X[W3X*MH<-T?\=&7XE]I:_2R51&S5P Z
M574%1GI<C$(-G:EPYB"-.N[(I+)._KL]U(.#AZ\V\ @%^QJFR1,NG"1<FUQ1
M;XS*, G24<U\;FW.Z]BK6$;L-97=>Y-$8'M2PIQ6)UW2-CF\>?JD.R=\/8-E
M%PV6 W.%E1.(5<4T.8E5GA@*S',7!'7$QS@(7<_4*F6%=HI]=Q9KV>&J_XPU
MP#3\[8IOF_^;_JA&8LK_;$Y'U7S8C*OU(.MCW//NYC#=\44QAJ?9RV>5Q%G]
M ,Z0MG9X!*.)>3N]P7 <?:<2?CU(6YH'I>[WCG69J@Z"[S3R$46='\0J.?!3
MRA+18S\-I,#EHS'\(A7&VKCVG/QD*NO14U)UWSD>CHJT,5_ZOHY-MG\[*=SX
ML#$&K2]6B_DBFWU%&QC[9'SQ5^YQV2Y=)#$_&^T_XVB3J<"QGR2SV&&340 \
MI3-GE19@WC1G(>SG>*WYTN$TYGJL#SPRI==?D0[P@B]T_T2?CM;^,S</1\4
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M7_BWWK!,^Q'UAR^K8=0?_MH[U-]\SW@_Z!V7'CAX%3^*PRT=C,'W3HKQ8>_
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M(6@LBLUI>E4#[Z31#XN\#:ML/,=1<D /X1+@EOT"WL#5:=H5_"3,'98%\#T
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M"-@V02K/&1+.&NQA(7 ._AZ^M'5SNYWK>I/$<C-(JSJ2U_!SK1YLAC#FF<A
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MAM$,.66-S$$6"*%KF_DZI;=&O?.1YTZI6Z?]U^0ZMX2 ZY.>T;7TO",^R\.
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M.NCM-S^*VY/M(BJCWHDO8\659N]R6/:L'EC?[WNW<7FQF/-FY7$4F=F>E#%
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M#BE&E5-,4Y_KR)JD(EV9FL<#"T^:-;7JUW24:<G(,*-,7&/!N%2(9TPCJH4
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MN@Y\;5P-_%R^= &$UK!%R8:(9.5X.$HO^:+T_22M=46?.IS5^F(-NMGL*]K
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MY:HM^7E*/^]TQ:2+1&'C'L1Y9VNJ1(3T0=VA+T;RJ\_,:4SN*H??BZ,JAR$
MGS^-#E1,F]F8\T/MI"SAEW"1_QX%)\;\HV\'+FN=$#%*,9K9_:X%,T"S+'-@
M='5N*&<48,UA:QU7Q!NKU0(#.M.)XCK!_??-P%\.1^,1[K!E2G[?[ ?O'.76
M(4^D1%10@E2L_ID1E5%I,%92KFVRC;/5/F?0 D);2=U]4N!. &YK7+Y^W]G^
MM(]MP$):AFQF.*(!YEL3"J+@.<VE9C#W+@K V<C;E&+$4 'XSQ$P8ABF'$X.
M#B^.B._564<5B*Q?2VBTX9E4L3>)Q92%7$?[1[$3C.<DN+#40E.=T)PK-+N
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M/!6L4@*J3$6YE&AV.R7@0VG8;=4P.>I7[N7M*1:]7*7@^##;.3MP.34F8(-
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M*J1;L9'/$ND>,@/I1B!8DL 05KX;MX,=32L$&@2\'0)^6W166+!AG!&:<"$
M 3E.J\\9(YJ"U>J%I#$ZC')L,/W=Z0JK@>@Q2Z,:MG^DG*2&[1^:[><=&91+
MH:WSI.!HV#BIB&4&$Q(9<RS"9T(GML]RV;#]LV;[=?)F-!Q_CQP_[\H0NC""
M.>RSIBT1&1?$<.8)I7#B/L\RT.WNS971L/Q:L_Q#YBPU?/_0?#_OXK L.IX5
MDC 9%2CX5A&CE<3.R5)JSR4S:@TE_4M(Q/BN8BQ?UL8_=H;&]S6/>.I N@:U
M6E6/A*4<T 8X;P><YU//2&4B:9;E)AAB8]!$1(K &04I=# Q5U(R:0$X6;$A
MY7U5<JQ-2YD&(9Z@4Z5!B!^-$/-.%.:MI(6(A.4!G2BQ(,KI2+(BT-QG3BAL
M-\58OI&+^\H0?U$(\?SA80U*Q!IXN#=XV)]7($+("\,H4=&CY64$T4'GH$]0
ME2LKM!'JOJO$;L9*SP$;7@0\K$%Q60,/]P8/\XZ9&+T60FD"RD&&(X,+8@H.
M!ZESR2,&:$)>:@^%>#+VQ;UT95NS0J$?V VL6>5S6>5+\%?NK'1+)L'5(C^N
M.]1W9YZNW4;>O$7MJE=\H@K.>.CKP5GWZT7EBYK,XIRN^7)XVN@K-]%7Z'RF
MV)<#R7RT5@CBO< )X]CT0@A+ N7&:YV[C/-7K^GF6B7+-A#40-!-(.@[W;0-
M!/T@")IWN 8KO02)@#$82T3N#3&&920P[8+)733,OGK--]DSK,!K(.@I0="5
MPTHNP:#O] 7SF9DE#1C]"##:G].'C&5*>*6)8DX103-*= R>%+8(*#:*+,]0
M'Y++H9^;CQII<*C!H0=6A;[3Y_S_M_<MS&DCZ:)_1365<RO9 @:!L6%RSE1Y
MG&0VLYDD&V=W]NRM6UN-U$"/A<3H88?Y]?=[=$LM(6QPL %'4[6S8T#J[J^_
M][-1A1Z(^Y2]Q_WQ>.SUW;-V5_;<]LE@Y+9'LG?2EL.A'+N@#8TG&'ONG!U2
MFY%OH73Q=B?9UV3MW>'@_.JLYH,#Y=:3G)XV8WYH-UEUVE+#FC=BS6[5438Z
MF9Q,?-=K^_U)KWUR)L9M,3X[:P] O1\.SMR1/QF2HVQ7LY8.J,RB84)/G D]
MM*.L84+W94)E5]G$=07<PK!]UC\Y:9\(_Z0]\KJC=G\P%J>#D8]];5 _'!U2
MT4?#A+Y!)G30KK*&'=V7'96=9:[K]H2+0WG[$V!';M=O"\_WV_V1)T>#X8GT
MA?O5SK*&$S6<Z(DYRQK^<U_^4W:7]4Z&IZ+?D^V!UT-GO1RWT19K#P>G[LED
M.#CQ>EU4AP9?/7CK\6I@?94L K'$S<K;^5;SR_O^LKF"O?^RN8*]_Y*NX'OJ
MU? C\4>4@2K,:%0 ?.*KZQ__F_[%3'(<?_]CSC#-EV8!XH$J]&68_M _)77I
MD85]#X7]FRA&S[R*_,19Q#*![4C?N5'IS!%4@(_.^Y:3SJ1SHRLC',&E$4Y(
MM1$X>H2K-IRHJ(MPT-&/3R4@V+'ZP@&F/N/L6 =^8D( ^1HKM?T=Q_D,SZ]=
M3"1)Y"F1;S=)(^_*B19X&0DM ;]*8^7A+_A+U&02V)5(X3"P/_G%"S(?OI[$
MT3S?D=3*AQ6QX$>B+/"+*2O!4C]1]X *Z?"3+,W@KQN1.(=;47\.QS$38XJ.
M(Z\U;-X :"ZH)0.A^8=)53<[GX/<3X^^#N;?_YIUO?D_0_';*/OP^_^Z__X9
M5+.?W\(>/5"K_M[]W_G?3W[]^7_A?^^#]Z_\V?O/O\":[Z_^]>>O)^]?39<?
M/I_W/GR>=M]_/O_/Z:#?]\1XTG:]LWX;*]S:P_ZXW_:&9^-3W^V/NJ?H=7);
M9V>K*5J$NH=;7=U@RRZQY=?/?_^/')SZO=YDW):N/P*E?."VA3L4[=-)KS?P
M3H4X&TAJ33,X.UW!EA9RN87T\#J"98LX+7*>=!9+Z0 S36>)(T-D<I=RD4IB
MHOUNRT&V0:B&&-&Z!](]9LUN@W0[95&_7_WG5/1&$]'O HO"Z)P<#=HC3X@V
M&/!N7_8FP#SZQ**&-;;@/;#E,4LX&VS9*8OZ??J?[G@@07\\:9]-<-RG?PHL
M:@3RS0,1TQWZHY'7=[_[<=@ZJ6D!LXY# <PW9U =9PM%=8V"B%^M=-$F/36,
M*%F%=4&MNGD%BJ#2>8MR.):>R!+2=I?T.F'A7Z=L *Q:#99)H!7SDU[G; #*
M^R)*%/[FAU@& M_U\D;YZ<QXZ:P'V5_R0[=X1(R3"#>\]A'+!>,A*.,]V1_N
MJ (@Z]^X72(]]^QTZ T\UW?'W9/)0(Y$U_=&X@ST8W$ZF$S^,QA^9QZ:Y56W
M"S ;VN-8BJNVF, )?Q#!C5@FWWU? L1<A>T*X*LP6V_/54R^AP/>62WPW@*Y
M.+V.W2;^5Q$*'HM /2S/7B;.*Y5X69+0.#L@I_-0!,M$)8C5;U0H0@]'1@)A
M^"HUO_DDDRQ(Z2<? -$)59/;35G&I=^S)%63Y:Z1:;@1+E5<E/N]FP_ 9ZZ5
MO#E6J!V8G^(WR:S5&:MH 6QW+CR9D<^8.+4(ET86S!7C.DY$A?^7L%XX=>;2
M5QZ\59O_:0Q[087"60!RXQ 132Y. (PVZ3AZ/5]>1]2+<!XE-&0URF*49_!_
M'KXK(EF!XDC$WHP=&Q+D7+1 $C0/T,/"OP9: Q'BQ]G4\=!-XH-PLB:S;N4_
MFHMX"JQ+L_X1R@OVM;<Q6$97]=*^N[8[W-OE(6Q[ISF./?X6RK!Q3SK4B:&X
M8[PPO.5W_QKU0.>%>W2B&%T\;5\B0L3H0@)-,X"K#$"C!.VA?(OP"*@2@%92
MI'3SJ.6$,HLCP*^9\@#-5-AQ$*T47H>:*'@E&6IPCY(P)5_<%Z 'Q6U+?[D"
M/@T:!GP)KST__QO\!Z@IB%KZ<1]X? 3[7.(\X"A.$][/ G1=E9 [;@'_+0!%
M<P,QWRHL7=TIVX/63GEO]*D ;6D&RH^-YSD<<%N"7Y=X0%>>!E2Q/P"B0CI@
M<OTI5DD:!>U?ES).G,L_,C4>LS?N!O8R<VZD,XL"GSUU"8XTMI?%[:#+4,8H
MP]2?K*U12 E(V'D;HJ;H 3(0GTC2S <[H&4.XTO0/A/@! AA5(+@QF'K\764
M)4ZR3%"X+B2HEK'(!2,@0L;F#AP4(07:WTQ<*P J_/<<A*9:!*C6 MXDZR$[
M@]L92QF6]X!J*' 4H2<Z+_#ND3_-4&UAY(&UD-TLX(H1?Z)%&U$=&1#):X)<
M>A,Y'V>$+TY^^#0&""4E-,.[).7W!DTU.A<BBGZV5WFV>!1/ZBLQEBF>"<AQ
M >A H"L?E5: "U@(XL!P,GA?2H<2.)D:UMQH+5!J4R#F>$$+XBHBF"K1:5CC
M8[+&?R]#H,XD%;#CDV'OI?,\B5(Q#=0DB/Y4X8M=,<UTN9"LDK@:RY!D 0V2
M;(%HC[B1\P84_8&DF(1&I3[RO&DLYO#(=11<Y[SOBYK#DL'2Z;< G+G8UZ8A
M+.H4Z^G0PYM7YT2IH%!DM(19CBQ:H%OIP%_ JN'OJ8@I[($\&=8+ )F)3>"1
MX-L,++@(N1]NY1KQ/'( 3:\D=A^RP)B#P-J-L4C_ =2#5G(JR&[5; 3(:*+B
M.4D34&R,!4A$*L,E41XP!%A8:@9@K-NZD\#)\XLNN!3ONK"-7R.A2[AOV)(^
M(QK >)OP8__W+/12IG=@2_Q,+!9+^FA.KW*FP=*3<Z!GM(;C*"#!X1,3J[L1
MYE;../*7 +<$8>+++P[@XK [>.G<0CY]^N<!*;AWYEQ-OY\_R!9.D1HW(.$5
M3P'V[&GWZ>EJ;@50";X -KX_IO/=CRT@X@@N'T-J*/= -5' ;  'Y!\9BH@5
M!/$!4X$ *,('7*6*7"UGG*6$LOBZ)1 6H6ZA'@#I!P(P<R;]]:)C15#L(0?K
MC,T=+>I1,8&MUW$Z6Q4R7 ]IL<Q1$$1(3#V;H=2SQD&9-0HOQL L.>JT\N0\
M+S0Q,FY2+/%*S-<O"K5";YCX#S*<($ID&WY/' @84O71M9O"P$>7/8%NJV?M
MK^I8)+ZQB.$Y5(-#?Q$I/(4$=HO.-M)M<%=(++3[%. $YB-R;N#)"4@H@6HM
M:# MT#H1VW*E,B' SL#* RDE5)"1F\]W,M"^ ?K7H&2G-;_9'M$:J^^15!M+
MY;6-A+6F_(HRJU]0J*X5PY]0+0M]K94+*X,!MX58A0]5K*/*JIJLD_6(="#^
M&;"U"O<]NNY;9?V,4T$":5PB_WK]Z=?7[SX\"'(\J-0$W?3L9(](_=V/SG/@
MBU&*EC,H?#*=+8,7B"B$C6RD!F1/@IXD4W)2?9;Q)4A)U&I!5I+C+''>O;L@
M?X+^D@W,6GEI;@L87!!$-T@ =3IMK9X*'[Z1XSA#IMSKNF?U#@A@PIX*(P46
MPS+T8RP;!FD5Q\!-]4R0L0I9HR8V?WEYGFN5A>8(/]'J TE,TAL"V,IX:3_
MG@'X.I1>\4:#H*T<6 "^#/5JK2*KL0I4NLSWK\,X<L7C9X!58]S@*Q 0*0;'
MT!#R9-QRO"R.6<J3]Z3>)N;K0<X%B#BE !9<+.H'%:](JW0W@ YXJL0!1)1)
M&H7H4: )RIHOF=/"QK,%N1]@#],I6C0L)9^=#O#AP&CZ>/:[G3 6',A38EM;
M=5"@U\R5WTY!:Z/H&BH^F/@51TL1 -S7;#NDX!^?L;QHW3);\]'CR.*[M#6^
M5H&!?#6[$T/ +@#W0N(N]#IDY=$-*IE@/-:\2'LC62VTG(CL0BSVQFY,9"SH
MW:Q=!F 9B'$4$ZN^U<5H7*!K/8P=9(1 8_D/,1G0C^&](?(*H;U_L)+7,A[6
ML8*[G"[;^F>Y/Q40+7='T @C4 BE<Q5&WA5JNZGT9B$^J8P1R\":LLMO 71*
M80BZ#AT@H%@%TKW]+%!FL2OBSJ@X+XD<%[-E0MNCQW 5XY6$/R=HC9,*BVL$
M%(M@11]W2@P:S"Q69U%B)(D6UR EB.%IEP&<-Y5@=(%J[44^<U7F@S%S2/)_
MS#) 9OUF8(!YMB3?$<.2PRMDWU@N9EP?I AYALC3$"BV!D+* 2%1]<!BE][X
M ZG]W@94!WN\5M?1?LWH><3YJ2$82ET#8&,+&>\__-<$^3\Q\#*U/%&.J&7E
M311?(0 H^1AWM9"TM8!Y7#J+HVR*N<-(CE/R-N1<QJ01FXB%\4S-5 R$"U:>
M)DM/:$M1HC1"5F7A>@YH0_^;*OPD[A,IKUC,I^A0MVQOY(?MXF^.>9AXY!C(
M;Z(X?@]"CY[=E,,#55M>WZIPQ\\J\4L== "#619O,?( [7("%1G7K.&LZH@3
M"I_XVF>:L-+$' 8-?%P9F!9Q.?@CK "GN#(=5&+A4HD2$U=44<Y3ESINK,R]
M:F<"OK$"JVV4'@-N;>948%4!1G7=U3<BN&0<*U#FE$ZP!Y99 \(H7O/T-L V
MSA,/2:< -['>FYDTB5$6A3ASL61XWRB^_VO<7Z9A*CP@&T)+^66!%E4B36:^
MB:!S,K[C1^2W YL,)9"%/[AVX4^B"9HQ>9*UZK&>?WV+Z52][OITJGUF1AV'
MT/@88R!7,U$V?BV;@CP:OD3]#XRJ;(RE+KH0!(-<>7((J(>988NW"A;F4VL]
M3C5/6-P+5!0PE#A6!1R+PFDW6JM"]8OU2V%OU,'XF>93JUL5\,HY,0JKU(:I
M](GJ"!^0@W!Z&WDT.(8.<&ZQS6HX=8NC>MK^!_0P\+4MJ!R8'#?5>H9#+#)<
M.A.P0:.8(IF89VK<XDG&'%+?2!1.(YI\&H6Y]4^BIL['F&=ZH(Y2;"X:DP *
M);X8>66-JR:/ U9E.9LR>>U6-OZ=4A$FN-&96?%E%1Z2,A;(#<^.?H=,'WC#
MUX8J6C4^=P^4-H"&<Z7\4&(1%M!/HC-/4L"/ $.$(=S02^,ER%,AK3UKR$\R
M*N3B[:V(=6EYONJ]-TS(1$R>5 N"58VKA80>.3)4SAI6(&J0 36]!,L,53+C
M.;@W=<S <("7]!?C)*,+D%8&G&?9)NUI K#";(M(1],89<U=HP#7&2=K.1$*
M;WP,;N"I\H(W7*E79HET*=II;1#!\J8BF62AT?A*:>#, )#ZD0IT<-,X"'/\
MX'O42(+?%"ARPV6%)6=7CL;;NM]J/6&.\Z%,Q0F62N0UBQH2;<WKR!B8QE+.
MM1\O",PALX4V>ZQW 6.,2?/#1'\I_9S#%0X!O4Z!V, >;;R6VFL$;POE--*)
M0\46C.8XE@%'CKGL$A<)@(^V0:^9PY=)RLHD_$=2RI0&"P)QWY?X0\ 'RD8Q
M$I2TU[MT>=H!?I,OX' ] .6$ ")>LUK-UAO)F-Q,HQ=63$-V )DLDK3PU1=V
M%8+60>\^ZG*@Q;4T%7,@G00X/1P"\C $"KE$C,&+B5D21:/V8$/D)XW!+!NT
MJLY*2BZ^HEJ923";!)F79L9[0RXCD:1Y0#A05\B:T;P"7(O*);)\U84=8"Z5
M<UJH[*.=1FW^+[;<8I5HIU;]GCA=>!I%OF7NF)]KY(.'J*H("&+7?&TU4GL@
MG.Y2H<N4T=:35"Y=:([P$08C?&H,A9(#-$>JK)%:,1($\3S4QXACRG7T>\C)
M":9?-L\X$.5+>),B#O?,[9SP0V..*72(#>DE=,X#7B Z1V/8CEJ0ADU\T(L2
MBO+H/0(&K1-9+2 _>'TX;94$H_"!TA4IY>@UX?=5ZX0L=(I"S81 (6M[(M%5
MYFT,!S(: A4Q8AF*NG]=.E!XR%F=C@1;-UI*3;4@LQ$B\"UH^Y]N%=*X ?PY
M^4O(FE<!>7!!C(F<T9@ (1PRP3!8P)!HP3NT&S^'*X/(/* 9UUKU-'?W8^X&
M97+J%P/_8-F@_P;1$:-CAVD2\W01XBG[I>0?F=*W6'"@_'B5O6SL3[O< "'N
M </\$=00Y1>0H?BFEHY(452+\OQHZ9HE\SMHD9=64O$"BD=S^R94$B_8Q646
MM$T)%7)Q)$*SL!%SL"LZ4:+U4'/^0$X1"JBXTT_(*X]O-\XHCF]R(I^'JI#%
M$VZQ6IE&:P.L^IWD15PMDZ@(V(YSCA%49@?$6DCK0'6B9(19VX)[F@&KDY9M
MBQ)3YY:1%SS56DK'V9QU/SBGKB\ANL#"522K<\_#DE0$V\<(U".XK..3.Y\I
MAH0)-+DDGN3E9YC*H/4Z1AW$9^07A#H:8]'1XJ'(0L=& 1(M)@+B#< ZL/8S
M2SC#]DHZOV?^=,[Y8L!W*:LL,<&N;*[9LE%8ROOCL"-"CME]2)-".2Q9MW5Z
MJZ?KD=B.3RLZUCFJ2$&NI+#>YBLPP&+;D9[OM*JR%HH1QBQ)7E*>8QB5R-.;
MB7#*P3TZA,$D&VP:DU"D^UPBR#(5'S@/0]SF)\DIUR&6W\YU6G:W_;<\$6 )
M3$!7[[X" ]A2"=P6%^X>/)5]HA3+$HW%8"RC84>W>I24%DM=VZ$S2,OT8A^/
M56Q")%&(;04HS&)@2QH LW)[QGJ'*OU-.O+=7=1%G[I[KHM^O&+7C:G]L"J;
M-\ZE?=S2YK69$.N@RMK6H]=>'W-)\V=*/R_Y9WQTAK%/V<J ,\*<JGW0\\$*
M\&KRC>F/D6LS&,XB$4W.D$3G;R;.<[,0M3IA7TG15(,R@L@X3UZL5B?7,W,&
M(_7&*[@OC8\F!]\BD3^8_WAI>NNID(!"#U43;M-HH?G-:-0Y<0?(<G3W0_UZ
MS8TZQ(TJ_4CYNQ.W,SQQUW[=[=SWNT%_<*\G;]NLV^^XIR<[WZS;<7O]W6_6
M[9R.=K_9!X)LK],;]HYELVYG--IL0W=T!-UR6A00W)[Z3==W%K[E1&MGVH\V
M.3RK=?LX_HKL[+*VCIW:?HVH$=+KU49(WRQ@WF/=V89P:6CAEG;]+(>QN 5;
M<)/]YIBC'!$^8(1ADXEQFQSWFP*;U6.K0:@&H7:.4%O/LZR?I7FX7+ELJ=UK
M:N57CA/>&'<V'I^R/VAN/6AX\\/?.5EB?Z<^[9S>;^+L-FQCP_D:#(4&?QO\
MW?S4O=&)R=QH,+C!X&/$X'YGV"!P@\!'B\!]M]_I'R(&/Q7ORRN.BOB2LV2_
MPFJN.?D1D]6Q$,CSWO"L,UPW*?.!&/46'H =_+1!K#TAUJ@S.'S$.GA$J)%>
M3]Y[]+&(Y&\A6;;6__)W]+:#72W[.#3Z&ZWEZIOBQU94N8\S_M>#(L6AO.-)
M(F>O0<['0JR#Y_;K)%P^-_2@4^/VVDUT;=+A/ON+;K6I^HZC[V6:]V?40:2]
M]H^D.F+WI5.S+TP7CZ8AO,TWY0ARI01Z;5N9NP8/EJL%<VW(=WJ]_\*,QF>G
MG:+7X(;9CK@;'F'H<ZT2_O!?,I[+(-([MUN3#GGMCE-[^@UFDU7.8"IJ?>>$
MC]#K=T[N>P;8U2>S$VH18+H:CK/@RB$&DB:58O2WBT2&W,'NF=OIK[1JW/ H
MM/C',C@X+Q0Q(O;UI%Y8VY2F^!;TTBS&2LE%K*A\F<KQ,B[F,25JL1QSHR(L
M=<&'LSC)L%2%ZG1"GQM43*2?U^9148$SQ;J^L-RCBKM 8'\ME!>T,$ YQ4IZ
M:VV>,HREEN.,>_$7!95M_*E(L,:/BG\+P&L"H ?R$AE=5V05$.G^&0+ 3(4/
M.&G(M-H4F&3+'<,DM@CD2[ZS$@:=<WOOZ/Q4>?!%J7MDT4;@(!AQB>B]-3NM
M<%BJ2MZ4MFD"];/><- 9%;P)7O ,_1H]\U&5_3S(3O(YB\]ZI]V"6QE9\YF:
M,7 %WKE94??\%6$T4;KXMB!2[&IITMB!\#Q3'$P9\$5]OQ.-03,LAG*4>FCD
M-;#<]*C:DP;>I!?/M]2I*7.ZM9CI4$HU+O0@LTMD5?<;/790]1.>/D]1;WU,
M113;]99XH *+86=T=GJO HM^IWMZOQSXNS+KAP]1!M!_@&H0MW/2NU\EQ!UE
M &>#]5\?&&2[G>&#E*X\&&1/=UE@L8O SU$FZ#>5"X]7N;#;Z.)N4Y&Y!+!)
MXCXZR!UV84"#5D<*N6^S/*!DB!Q4C<"WF]UW-*E]W9U7!QQ_7FJ#M@W:-FC;
MH.WNC^QV1@W:-FA[;&C;ZPP.#FVW5NXG],_Q*/?;UP3<>>:-:;8&5D^*,NO.
M=\#TU^UTMZ2_>F1_..%P!Z(=RCL:A#\.A'\.^OWFJ:U/#=F?O-^J*4SX>I%P
M/X6L2?\^Q'<\0?Q\WG.;VH2](%9]TO_]\GX.+/'JHI1RI4=EZ)18%?MMG)Q'
M,]@R'!N4Q9A59>: Q/0B,Z5,Q31>#E!I)H6_9AY+=;9[QW'*.]@ZU;E(0EP9
M;T+C<XML:[V"R;->N_36F9"<.HZ;2)QG72MOF](RW2(ILV4&Q-)X/1XALH/\
M2UKUI+IJ?]VJG&0)!%_,%U.@.813A?EH.#;<@!$O&\!E[NHXDR1+0W9>69FB
MK_7PE>-H=/U--L[O'=H$W /CWG</D#KP)-J= NUT%W3VB*W0W5[O7IFZO<Y@
M</8@^:3W>^L=K=![W<U2- ]@L[U.O_<P3>8?8+-NYZS_,#G0]VNP?E=:\6"S
MUSZ5!D1-*_0FH;AIA=ZT0G_2V:D'U+FZ0:@&H9I<Y_NT0K_=ACRH].<J3CVI
MB/)3ZF]Z BK](;8W;1"X0>#-$O1..V<- C<(?+0([ YZS9B*!H./&(,'[K?0
M(OV1"CQOS8@VG<^:+NEUQSA@$G'[=]01'$X_ZZ91^K'A5O<N_GLXR'7PR+"_
M9NE[E2]66O(6,J9)^RQI04U>\F'D%#<(6B\G1O=TE#08^E0C"QLW3J]D79FV
MN4>37J<3IC$I#HX .ZAF3N.343J3L0-[N%;81QA^&WIJ(0+XM96M'$:A!UO
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M@Y@>_48WK*$=[45LU=>$_RRP5)[KB,'2)CFO';";G^90?-)O5[T.PIG2"2=
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M[:5II-'1(D7Y^HTIQNHK::^8 -ZR+YXL^) T'A1*+W6;;7:G,Q]8F-;*G'I
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MAPG\ N341RM?Y%(G^?6[O3S'1,1C$<JD_>%+()<F7;77[?9V[HXY?A;0:UA
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M\0^3&2LAFI(@"N390#Y72%ZBN 4RM57;2QH^RZOA!O(0Y4!<3]TQ"D?X$4]
M=H"9/ KR0%G<LH*>&V'4F_(5OV/FI>I-<\Y](??#>VA;O/G42SI:Y*Q,$+;M
MNQ[_Z#UB4$DYLI>4"_Y%Z6%1UPJ+;[P?\2759QX-$ DK=.0!.NR2"?)[@3RD
M?S],F5IR0KU 02M(UM4255!UL?K.8H\QZ51DT8O719'$]-2U!O-#(SW.HV"B
ME+)/^,\;AO%M*# $7*(/FGL_'!(7,PXSTE<:7@<3G[YB?$48=@5EQ6.Z_89M
M7B%!&T%<O@FR5HRC5B+5XYND^ :ZX8FS\:ML>310$=.:GN(K%A-&O<@5##Q
M&.%"\G-*UM;;KYQ0*'/MA<6W[L>Q#^N1T0C"1B9'SD-> $L8V3QYF0DL\^0.
MAL9@J\J_@4D/#[87G2EW4Q:KF($8S HFE,LZ>(4>W\G_<132(;F5BU7DJ^BQ
MI(LE4K4UU,7K^6YJ1DGT$G%.72+C+?FC(;R2+A>;PN9KJJO1?(&EQ@B-E+*G
M9U<Y+3_X$?_1E\$>_G'WO?^]<+S,0#9M-&;3<FJ"50$&]BY>G\"N@;YBB]')
MU#4R+%J#9"^X7'<UHT/:]FQX0>B#2FOJ5S.98EM?Q7S'+, ^?6# \Q3B*+D9
M5ZB8^87KZFMRSZF7*5^)T+;UK"!>>*("^2O+2M.8(Q^CQNXFKQ-]+/4>QE*_
M J\HO7[GWSORS'60\PMFU_6P.0 U4/C\F^U-^E@@N.V^;31G<0VAGPM]_9/*
M[2>('EYKDTY9LVGU2*CT,<3@S!U#,Z_DG2ET(HM!+/8,K:^ZUU(1I+;.%OQ"
M+_-N:V_IW=92>S3"^*5,,R^=.-/W[24T%RW8LJ$M'7_MY9RL+7?UE0&VK5=J
M;TI%6M\F0T9#D3!7LG69+U';U,GR AVZI>XU6F-MGR]:5S<YO]*W3&%S"M9"
M,?OT%?GJ+FP:E/!46+ZV2CF_D C6.&ZQWUTM5E=EDTN892-).W<5U7L/L0\&
M<]*NA$Q@MIM->Y>P] FSH%9Q<J4&O9/#F E5=AGQAEO/]^6OD6)/T%2 >X5]
M(O?N5_8A<QQ)993:NI=WT83G^8J)I2*V?U@="QNQY;BQ?V5RD*2H]-8SL/*'
MV[W(QW2HJ!FL4J/2WO<Q)?/KWU,TE04;F\/?=HR2[($DY_A2'J*/1_+0K0RH
MY!O,00 Z1)!?X6#@6R!WRQ5=D6?BX=#K;\\1%31ARVXH?;9T?44T1*FM[MU$
M(F*XZ%B#.FE0. :59+=\!F*Q'#=8N9LLV;>SFLBY8U[-7]6/C\W*;WT^S3:M
M-R4&Y_SCTILY!N>10+XP%X?3ZZ8BY?R<<:77\4F/WOQTR%]$C//3S-=5CI]L
MI(*Z[@07N!33[<':;@@6'8CY(5E]TY&:'(1?, .0#BQJE0DP:MB6XR"9,[L?
M0M-N2 @Z#P%+_&L1\Q>0BX>N7/*]9A4QJ\(PW]''+AV%Y+]E+\OE%*]MZ'87
MLR@/:H(#"( +B>\B/IY4.>*IEZQMK_^ J.(^+%+!PBZ7B=6VO\D/O]R7_.90
M65+!$&7;J0/MTF*]!4EMHX&"C&I\)9N *6/]K&P^1FUUO>QT_1M/S!7CU'R9
M-XOP[L-4S\K.L!0(U;6KZ8CV H$*TS")NJI'PKER=>VP_I>(RAQZ5>EM._(X
MRJ@>A166KZW3>K<MQ2UE;5>JKNV^97)JZ VS8Q["]M5,70G"W3$.T.</_P-0
M2P,$%     @ :81>45)#>^4:$P  /+P  !4   !L>')X+3(P,C P.3,P7V-A
M;"YX;6SE75ES6S>R?L^OT/6\7D38EU22*:]W7.7$+MNY,V\L+ WI5*AS-(>4
ME_GUMT$MUD))% E0=&Y52HYH&OBZ^SN]  V<G__^Y6BZ]PG&63?TOSQA/](G
M>]#'(77]P2]/_OCXBM@G?__UAQ]^_B]"_O7L_9N]%T,\.8)^OO=\!#^'M/>Y
MFQ_N_3/![,^]/ Y'>_\<QC^[3YZ07Q?_Z/EP_'7L#@[G>YQR>OUOQY^"8YQ&
MJ@A/,1"I9"(^,$%\UI)2SJ-S^K\/?HK6,BHY)1"X(E):0[Q6AIC(I.74XZ=N
M,>BTZ__\J?P(?@9[*%P_6_SZRY/#^?SXI_W]SY\___@EC-,?A_%@GU,J]L^_
M_>3LZU]N?/^S6'R;.>?V%W][\=59M^R+."S;_]=O;S[$0SCRI.MG<]_',L&L
M^VFV^/#-$/U\H?-[<>W=^HWR&SG_&BD?$<:)8#]^F:4GO_ZPMW>JCG&8PGO(
M>^7//]Z_OC+E%+X<'_KQR/\8AZ/]\HW]<Q/[/KWLY]W\Z^L^#_B- A=%6 PY
M_WH,OSR9=4?'4SC_['"$_,N3Z9?Q"RFVID[0 N1O=XZW_PUF]--X,EU\_ 9_
M/QNU0*J'&+[,H4^0+L_[0/4\'_K9,.U28?\S/RV&_7 (,)_]T?N3U.&GZRAI
MA5&KJ.JAZ"\45B8_GWXZQ"M?FA8R#^/YOYSZ -/%IY.3&3GP_GCRIO.AFW;S
M#F;/3\81;34!P;(30A*7,B72ZT@"IY8P9;V@60>AU56MG4FV> :RGX7%@W V
MPW[1YCY,Y[/S3Q;Z)92=/0]_NQW*J6;7%^YIC,-)/Y^]\U]]F,*Y@"QF&FC0
M12ST61P8<0(RX1J$,5HEKFD+ 9?#N2KD)0(]'>/>,"88T?T_V?L,Q5F?18)3
M;'Z,-YAUU0^=?6-_=G)T^M 1)-+1^;\O8:$J&^9#=?V?FAKEJ,"%\032$@F#
M"(QQ[@A+T2$<#')6688&-* LQ&P\-*+#<D2K,()_MXRH8(5JI'@S] <?83QZ
M 6%^P4Z!&0T'1YP6F/C0D(G5.9'@-$W<>DT#;^+^;F)9A0CB^R3"IIJO1H$/
M\R'^>3A,49FSE_\^P1QE8CU8GM A)9,LD=ESX@)SQ!N5C0Q2,)5;,. FE$V%
M>X?H )6;%D/_KY^>P 2B9\Y0231/&1-[YTA(AA(=#<\Y<2^5;2'=$BR[%/HV
MY,%U?F^J^6K\?CX<'0W])11&ZNA  HE4,*S8HB;6286%G:=6""Y]:L+NZT!V
M*<I5-OY&.J^7\20L&U!V/WWGN_2Z?^Z/N[F?3J+5C NKB! :W2RRCE@+6)ZB
M,P^6 3 CF^0[R_'L4I"KS(,:%JA&A_<P]UT/Z:4?^ZX_F&$J=G)45 WI!>0N
M=IB#>1^DH8FXG(%(!$)\XH)$Y]%OA922\RV8<3^T54@BOT^25+9+S8+I',?;
M^2&,Z-2.1SB$?M9]@M=]'([@S3";_0[SM_FC_S*QA@HN@B':>]1!<J'X."!"
M,^$]MTP$W:B,>@C.59BDOD\FM;18-5I]','/3L:OE_,BE8/RS!,N2W0$DS P
M<D^2THX5RCO3)".]"645<NAOY"#?$SLV5'R]FOM;(3GQVD43,!D&%@0&0F^(
MPYR(9!8ERR$B#6/CI<:*XES4Q=2!T%01DR+F^<ZAXS;6$F,X-3'Y*-6C+*#N
MS-KB@^Q^8^5@,X4W63OZ?>CC&18>?(I1<I*"X1BKG246C"8 5F>?E;'<M%X^
M^@9GEXJL:@387/'52+"(LY<$NX2',J,M#90$;5'$'%6I]AEAD(+(,BF;FA#A
M=DB[5&G5(D,E [2(;D_[M"2$<QI-MBP3:A&:="83C\&;&.]H%-)R;UN'O*7
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M>YU;1FJBAD8^YOHT&[B6VX9JHHY['<E99VWY47H<?OWA_P!02P,$%     @
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MCFDM! -+#FE4GIQ1F[--30HK/0[K['6A1ZDWJ1.X'.Q/5]/IG=BFX*$@03'
MF2Z*%%7$Q)33R4@@,ZU5";<U: YU7-QJ#=A9LJ=R:OSF*I)U_<=\F3IW.[!%
M3$R*6"SFP PY8#0@3ON9!&"<?FBE!^';6 V/@3K6"4$/E*]>6>Q+]"VJSFS
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MI7XF*VPQ+EU*(3B)@:HE0T+PS%L5:=V*-F,6QMHF%LH]%%_W>K\[(2UN:=R
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MOXVN^_='H_&V6 /-"G'A4UP]\;W(C3/_6,&]K](N?EZV1ZK\90=R\Z4:D/X
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MH*8ZA%B3 !+&+1FJA B&B!2I"P^V"9D:O^VH":31$ZB5HFX4UXIG.W7UA=+
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M_5K.HH"DFF$%%9:)/8L,(,51:F\3<N/_8A3'3F%/5^HQ->9=60)6IH =6V[
MUII5#N6U/=L\U3Z7.*[H/8>=DW'Z9/#]V-]%=WALMHS3+2/MO@S7/7[;,=>#
MVKH_<T7SXVW87(_!W@Y.#\UU+/U2USFJHW2:Z%$ETU %"8=QBA@T<Q2"E <2
M!HFDF#"**)->A5\.!$QM"GJU*O34A(W]ZW=!$()'5H GJ^R_@2B*;X(@6$?@
ML65UGQ=V)?=O( S3FPB%]7 +@^0F2>E^H-X-,'^WET.,CS)_]BPD<]@O;I[^
M-6@/OD]? [V*SZNUN^D]/N^<_;V6D3F4,6X1F3,6'I60.?=<U[H#GQ_8?/[#
MLLP,Z92SF&E$$0NAY@F%6##9G.LQQJ6M_A@@MX*_9]J?&DLT*H):1[!6TK<
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M$R=X+,*+"4:(!_QB933WXQL]_UC6EZ>J9_"-5#H36>59@? $K&YD<!U8 _/
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M.-*2:DV94]1JJY2ID=A&R1M@U 0;/6TM4&_^.HVK&TM=C=; 7-05J ZA5RU
M]!MK=4K0R,%5+;8>1U.U/=SU(O*ME.8S*5^9OWXHON2_+68:!5JS6$.1T!AB
MC@GD,9*0",8TD9%.0^YW%?E(QM188'7E=J7G#;":&AR!U=7W0O(QH.T$T!-,
M P__3@AUN)A\%H.KKR8?MSSRY>2SIAU?3S[_Z-4'<9N__H],%;:TY?,[6]CR
M]FM6SC@+>*IY"L/8;J4P*6TV-0HE22E."(\#[C3R_<1.C0RVAT-@HVR],?#^
M]L_@5ZMQ]_.V-O2]3]MZPG2TLS9_.*\Y5G- 9Z!#M3;)+W6DYH!&RX&:R]N=
M2W9712;,NJ?>WOEED57EI\^__*P>N"IF22Q4I%D 68H5Q!II2)F2D&D<2"+M
MM5OB6:S[O+2I\=!6V:8B"JC5!=\8A<MOP:^-TOX%N5O@=F.@WD <F'BNQ*]+
MN>W+N/1<:+M%X-@EMB_;?J*XML-+'?=VC1\E5UDEMGD!FAO82OYH#+!;+,OF
M#/*#?L,*6]:C_*B*.M/ [8.]IC(3L:(L91C* %&(8TDA#VAB^D)%3$8!#Y27
M0]2+5E/CJ5VC=G)T@+59307*'</L)N7:-&!L:[*"W(#&/,\MXU[ZV7$C>>S>
M&WI[>:2.\]]T[A/H7K>B>U%LW WJ/K$\VK;NM?%N3/^QR(52LK32;!S"*J?&
MLRV0DL_G2EC9Y0?=E.:T<2?E+*)12J(T@M2L:R%.4PUY;-:].)$AB<W_$K]"
MZ!UTF!J+;U.1V%&>;17UX^,NO>'&O@-C/##7KK5O.-7J?[/._M*LAK<V6/S?
M.N#O3:M7(-@GB7918U3*O *G0X*\IJEN-Y^>5%%E?*[LU4I#Q/>V4/LG]< R
MR[SO\TJ5,ZT">^DQ@:&V!WTD,#Q(M(*1"#5384Q4[+2J=A<Y-;+;4;K.:@74
M2FVPT1O4BOM=X7' OIWKAD%T8&I[.3#][D3U"^IX]Z*N!-?[:I0[3I>N1SFT
M-.H5*7?+#J])>;S9S8MM MJLMYPOS%?U.K=MSWBB<: T-_ J;OQ4F\6"A#&,
MA:0)"M(X2+W\U)-2ID;.JSO8&RW!KXV>GEN=IQ%U\S6OQFGHTUAOB+R=Q58(
M^G0'3PL:U>%KM?70I6M_N(/3]O:Q5(LZ@/LC>VY61'&8*I2@$!(411!+%4"N
M> 15RE/&(QY+[)1I]$S[4QOQM8:@B6%?Z^CA+)P T,'-N@Z6@0=X_XAX^$K7
M(3.28_1V 3Z(*N>J %$0XAOP3GW-A*T&LC"?;%V.J\H! ^\RT10'6:VQ&<^+
M9C/S]JY0=8[AIEI( _G'>U8\,/#Y]C/0>0&J>^MV/:EY_E@_6=>ASA\>5&$O
MN63_V&R+KJ3_L02R6-X!81ZL[U6#RKQ;%5E9V6K5U?WS_#OPY3ZS>> >#1P6
MW%I(?4D$/*[P7F6),U88&^IFE@O#)O63;*WV=SVY?.>[N]6_._':>,[<>9WW
M/+>6QSH7[FC24=L#JR8G]8=E93IW8?/ZSE@:TB@F,40!,_X:32AD*:?0WDZ2
M.*&4NA7D<A,W-1I?%ZY8I7JW.M^L,[[OJ.U=X:,-\7:B[Q_'H1V[*R'L4@K$
M 9GKZX*T"1F[2(B#P2<JAKB\U=^6W6=C2GT.7@M;L=<,!2+%6"$8(V[X!24!
MI)'24$8ZBJ227&GW@G\^DJ=&->>W12#8& !*:\%Z4KU^]^ETGW3?T;L:Z1?;
MV!L=Y.MW^JX&^\4W_/Q![V7KKQ6X+CN IQM\\8W 5CM=]@/;&^BV+6C+TJZ"
M\V+"PB06D0&Z*74=0A*R" H:DRA&E KL%8NT;7IRY&[K*]?K-?L7N]_RQ.;^
M1]$[V+GM^G5#9&@2MACT'ZQX;&N?>WH[K8^ZD7=LU>'NW8DGNHW,]37-AZPY
MMGVWR9 <<YE@05.H%$T@UD$*N8@CB!-,0\H80]0KF=E925,;MYLKRFM-KT@_
M?1Y>M['<"V@##^V.>'F/]8M8]#GTSPL;E0DNVGQ(#)=?Z,839VK+KQ+E[-:6
MWZ;Z##&C:13#6$DSTS-L3_TTAPB%G,>*JHAZG?KYJS U9JDG03W/?UO%3^FU
MZH!M=/^3'\%TZ!<WYAD6[8$IR::0J,%>JV_3(WYC+0#9XENP,0)LK>@U/>OU
M(/;)91VT&)7DNJ-TR'Y7M-0Y:O?1K*&>/YK/K[I=2.OEUT<L1A-;54A'FB4P
M$(GQH&@00R9$"+5,4$(29<NJ>8;GGA4V-:I;Z[I)X%4KNBF[R'92PDA[A&0K
ME]LSJ+JV_4-NEJ7;0ZE_3=!-2N/Z=_^:A#<I#F^ 4?;1QAT^J;EG:K#6/G,C
MQ[YZ8F :7*MY VI%-VG!5GUAE.TU*O<B)#V'WYZ7-W:<[47+3P347GZGZ]G>
M%_;UK31M93H3]2!ZOZRW#U D(A8BFX]:*8CCU#AD29)"&? P$4@0@3R/]<Y(
MFAH9K8ZCC+9@7UW0Z.M[E'<.8-=3O!Y@&^< SQ^Q#B=W%]"X^M#N7/LCG]==
M,//XJ.[2"QUOE.Y,KC9@OS+=;K> FTRG,Q)3Q&G (>8D,AQ!""1!*B%/$5>I
MU %-E-=5T59Q4R.*VP//8ZNO5_9G1ZS=?(W^$!R8,[J#YW^ST@F37J],MDL<
M]RZDD_5'EQS=WNJ\/;1-[S=37")&A#;\P8RW$<<I9 E%4-$P3"5'5"KJD\9X
MKW4OSA@A9['=:\A6&2QMKE#/<F3[R"68&^P2!'$2F/^D@D-*0F;86"5)(%BJ
M!9D]J8+G'KMFW;#;E3(L>OX95@\^-T0C;J]_*102X]QB!9DR'JY@ 4=(IRER
MR_1V_><VPA1E =M+F.I;Y<T!4.<=PFXPC;#Y=Q5"7;;YCI'H>0=O1\#8FW/'
MMIW8=SOQ4/>LKJL[I.OT22KA/*()5$)*B 7#D!&;2"F.=9@2S!*_LDI'$J8V
MQIN ^;/Q _4/7:Y6.^+K-MRO0FW@(;^CVP!!!F<M[SN-Z[Z0T5.XGK3Q5/K6
MTP]V'>Z'Q;4_/"I[M6%Q]XH]9F8@; ZN HPP(\:/%-A>^(ZQ69MRC6&B5(HQ
MXL@X37X\X"IZ:@3QJH[4*FW]^'RM,F!-G1U+#CL5-#S/$SVZPY4VA@!Y<#YI
ME 7?K-7^UF*]T1RL5!_DT- ?L7YYR%GZR 3EB\HQ<WFW<$5,5;.L?F^,6Q;6
MVYPEA$12X03J ,40(ZH@3S&"R*Q/".$1I\)K9^VDE*D151,;Q#KLG9T&T8US
MKH9F8'II4&D4O %;%7N.E3J'0.]Q4D>"QH^1.F?KR?BHLP]W# (PG?O>='>=
M_I@('@E* YA&@7%2&$\@UUI!&D:I4%P@1)'7H?].XU,;W58W8)7KE$]Z#S:W
M@=T5C(''LS,._J?J)PSN]11]M_UQ3\U/6'9T2G[JF2MKQ?PE+_[V=E$GM"K+
M62H$#4B20#-B$<0T%9"I6$.9Z @)QF(=.&4H:!<SM7&[4P3%ZFE=VY6FU]6+
MV<?6?5OA.L1&V%OH!E;WFC$GL1BD:,R^I)>I&G/2VK-E8TX_W8T5ZGNP;\MR
MJ>3K96$6 A]5D>6RSA'_7OU6_Z:<(9K$*(Q3&!&N(":40!HQ!0D-$TDITQ'S
MVG=PDCHYSC!:U=7%<UVGCL@7H*S3D3<I'5:I?,P:RT8L/*DZXLR,D"=KE!^=
MN'6*&[OT#O7 9--D>&\4!HW&H%'Y9EWHW:C=/- C\7C!U"</N0D>E9:\L#AD
M*;^7NU^FM(DWS1\[AP*;VA:OLU+,\W)9J!D*6*AH*F$<: IQDF)(&$NA5@F*
M0\2H4EYK$6?)4R.O'J]BNB'OQDZ#X#DP0YV%\@;LE,C9JM[O74\OM/J^"NHF
M?/2;HEZ8G+I(ZM= Q[##)N1-!C157$B8<J4A9H)!*B,,F<T$F1+*DD#Z1 9U
M"",<K8QYEUU/O\C R44 ]AWF-UPXWTN$[;6'YUT3AN>4S^'_:^]+?R/'E3R_
MSU]!8&>GNP&S5P<ED3/  *ZCW_JANEPH5\WTHC\D>,G6OK3D)V56E>>O7U)'
M'LY,):FD9+W% (UJ5UEB1/PH!H/!.#XI>X1G3W39=@N)* JYGWHP(BF#*!4"
M4NDGD+,P56:")+&.TG-4A><%\=D9"$;E2IXZ(72*DG&/ET&3TZ\!QH9\;!MB
M;F@[K,MS >JS*LUCC+[;ZCPGX+NH0,_+,>=3H^>$M%9E>DZ-,<Q.^U#D]TKA
M/FI27]00]>4,DMQ+4YZHG<(/())A DD8"F6_>80&<2R"R"J1]1B1N>T(FD>H
MF02:RRN@^1QTS74443,#[U*<1E;C0R"RM@'[,'!I$1ZE,ZE]V"?I2VNQ]]E+
M3FAOVT +$7HD0EX("0]]B!BED/&40"].F0QIPA)_P$'M[8 HE<G.:VTPP 7G
MMK=642J#(9GD%'<%WKH.2CDJL/M3W=O7"$(Y*MOQ,][+A^R6:U6N%G?*1*QK
M9]]QF=,R*YK(DY3*T.<A]),DADA@'Y)(8BAQ*@E")!&QT5WV20ISVZ(W3%Z!
MCDVK'?HTE/T+V E 8U\D&0)BO(C/"MVSD-6[.XM8_>WE CX]^"2+^*QLW4(^
M_Z!]S896'?R659PN_X^DY?M<O%,D%H(D6'"40G7<01 1'D'JI0F,.:.(>TD@
M66!:KN$4D;DMZ99/T# *-*= L0HTK^95&DY"VK^N70$UMO=D"$96=1G.@7!!
M28:30T]6C>&<<+N%&,X^.S! O(L[?__C27?UV-9F8Z$05"0(!C(-(<)(0))(
M#Q(?81)'DGFA;Q4D?HK2W!;^-K5"MIQ:)JZ<QM3,&G>"U,@K?PM2Q^0H"2AG
MH7 :0'Z2V+1!Y.=D/@@D/_O"P YZ+YM+=Y]Q1,- "(F4/1\QB *10()H!(4O
M))=,!!&Q"E4]16ANFN&P4[O)1V^'K9F*<('8R!IB&%CV7?7.(.&TL=XI6M/V
MUCLC\4%[O7//#[C@_;TH5_?TOKX&N,G5>/5MT>*S_"9+N?CPQ^<_%@%*O" 1
M :1(=X1' 88XTITV8Q1''HZCB$7&=[KGZ<U-5W0<UPYI<)QGBVM$ \#[-<<(
M,(ZL0*9'T.+NU2V2$UVWFB *(-A<XX%E0?/VTA6PHBR+[U)<@76E[;[_+ JA
M1A<5>$L?G]85H!7@NAV@6EUTZ>B.UASFWFM9@V&FNXDUEVGO\M7BM8$9"'IS
M>$,K*70K5F5(UE_C=5GJ.UY-Z\WS]I&V&<OU=UJ*)N!^RU-59S9^>:#Y[9,>
M0J<WZDH-4K3%*3&7 G&B]M?44UM#Y N=Q<!TJI.,* J\-#8*]YF<\[EM,K54
MD&FQP*[H8$=V76]\][E6?E #<+7-EMA@ )J<X)5" ;0PU)G!#1!75H5*I_^V
MS.SG67XQ8_OA9_BQV*>'3#UQ3E-,)F-^VC25J>?D(-5E<@;L[U;N)%^7BI@?
ML"_9:BD7J<!2>DD,B52G(N1%(62<)Q#YGO "@7TIC4H%'AM\;OM4S91.U_.#
MG]DOH&/7_!KE +WSUR>78#*R)K:%P^K&Y)3<%]R4' PYV0W)*6%V;T9./C/0
M#.8/4JR7\C:]YKQ<2_%A6\'JBR[;^$7^6+U1#/YMD<8R1A(G$"-!]<(E$-,
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M3_UP71A'$]9_6;??S5,[76U5=OTKV@GYJZ/T@+/?2&]6P.FWITL&."O!7@[
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M9AK(+9XC:Y]+H;1O]VJ,CM,FL.>I3ML:UAB%@X:QYF\.+(^_U6^+%+$@P<K
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M<>>>'>B&XP]2K)?R-JWO1]XH<T<WIM#E$NL/ZKHLU5=9?T75F^?M,^VFTM1
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M(A\B[A&(=<4V#\LP2=) QL(BZ?^5I9F;C>3@%FJG^OX.-E= HP,T/*##!VB
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MYH-)OP-+\]?%(O\QG<TF(5J#AE80DFAH0T5:1HZ15)A4.K"<^+:\[.-1<TE
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M\. :_*]QDE16PH@ AM6IN;6K?RRR &H3M.0B*=8D[>]^DL:9G]'RV.9XR7>
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MGI]]K",9_GOS^;U%0!,MBH^1C#?3-0_)"@>!V(6@7+9DP;476[I3#^ID'\5
MU_TE]\'3 ][XZ33<@9M^\V26;,*KY6:_R!MG\C4N-\U[)U('M,(:D$&FVKQ!
M@6=)@TD^U1Z>&'*3,M/=R!OG"/0$J&R@G>XP=]X=^MG9^L-B.?UOS).<8D@F
M<+ LUD"7T^(IBD1'7JK*/":GFQRL/TS6.,>F)\?84=KH%%LO5JLSXL2$+(B5
M IY7OS1K"T%J#BB+LIBER>YDN#HG:9S3TY$P=8 6.L73]4[VJ(+CK!96*DNF
M5^L$D0L#0DKFK4^!;1NKW@94^PX1&/R4="1D':J/#N!U[<[SWMU=NUC(Y"JR
MNZ;6+C!/<7IB(*,H6)1C%,DWOF@^RO$:_!SU!# ;6B]]0>W.)L]T3EYD#BR*
M ,K(2.99:>#91FFXQQ2:)=7=0],X!Z^GA=91>N@14A=[/"?\IX@>C,+:,<<;
M<,Y:0.%X5$X4T>;X_AYZQJD>& -*!\B_ QC=N,0Z9V2BD_0H5  CO:=]W J(
M1I+2HXM.B4+.8Y/;Z"VTC%,\< +X'"OW)S&9Z>KV8[4H-Z[8Z^7Z8).:=GS+
M\$?ZA[ W].G^-QI>E5>?<+GAZ1M$64$5!2(D97*]#[+@0BT^0*N<<\&S+!^3
M]9[O''BVDR9[ZEQ"4#+4<66U UPH%+A&I!U;>^%<H^OH#F<[#:CM1X8\[2/V
ML>?X;!U7XY4JIA0'6OF:BN$Y1$4^G2M!%&=Y]G:7;GO?R9"GO=3YZ)"G?60[
M-CCNG3ZD/$..U@#GR$!96C%!) ]69R3OW]3QFH,!Y*D,>=I+LSL->=I'S!WX
MPUL2-HJTA4RI!*N,H+5C'7AR[T!K$8SB*A0CFNY O^TU=.548YT.,2D#2;D#
MG+S!SS@_PV][KV#))%L"<,4W[2H,>"4M^?+:HB9O*N4F"5"W">EDVSE0L7<R
MPX^0\H@HV3AN+W']:;G(9VF]/&=CHB31*E$ EKIDG.80N"=WS6>=@[&66[&3
M-W[GT>-J_3@U+0:363]VX5>242W?K=+XC^GZP_.SU7KQ$9=7?4)KHS_Z?Z[9
MY;2O^B*% !YEH15BZK&V3Q!8B5HGK0QO$N(<0.NX.] @.#N5IGH X^)KF*V_
MGA<TO%S,%^<A8[VJ0Z?)E^/ F%.@A".OC&.$4FQ09)A%9$U\FGLI&K<R;EA@
M#2+U'N!S(96)<4%&XS68H CVG@RQETY"SJEX'85 T21[XY* <2O=6EB=_63:
M00' JTL0__+E$\Y7UZ3!,C/>D/(T=X8V:&4A5I$DG^IA%$64N<V\E/LHZB1*
M&L8#'D;N'1B3YXO5^E6I[=$WI0NX_#Q-N'J[F.4)>799*EM'0.L,BF4*(G5V
MD.FKRE)DJQI5\]]'TKCN]$ ZOW-A.8@".H#2&U('$5"')?Y,YG2VV&1_7PAK
MPL@&J^@8^("E'F'1)ENRAUR$*#FK6-ITSWN0JG%M4AM #:>&L2/UMSBCS]^_
MQSG):1;F.>2/T_FTRF@]_8QX(35:)R(JI0LP:SVM$R\AFFAHX[<BYQ*X";?:
MT]P3O^_XPG&=XF%1TTS0'1BD3=?^%Q\_A>ER,\?\0UB^KUR85%3DDL@NM6.7
MHL4@,($(@0?-(R-!M;!$V\D9UXEN8X(&$'P'\+DCFPE:+Y(S"#([\AA#3. 1
M,U!,8&(,%#Z*)A,U[E R;L>'-J Y3MPCQF(;$_K7,)V_FK\-,WQ57B[FOT[G
M89ZF878Q.42G7,>918A2UUA#>8A9(.V]UEK,2 Y>V&F+>O@]W4T%.R3&&EJ>
M/9F2;TU,)M;'F%BH:=+UT)*Y4M/*Z*>@HM(L<^>:U+UNH:6[,6"#A.8'RKJ#
M4YT*_E4E'%>OYK]\J<R<35<?JHQ>E=HC>Z*<)=*0@3-I$QHRB,ES*,9%;ES1
MUC7Q81ZEK+MI8,= :5@]=&"'7LSI6;BZB@9U\2E)JX %D6O_+@\^IP1:6"LE
M%A?;U-[?HJ.[66''@.88&7?1?&C3>NOZ!<FY(;WDQVY:;BD!%D4D'X\7\.2;
M0>31<L3HQ>W;\@%;V=]+5G?CPX[:PH;30!=&YW(?OKS4G<[/B*EOF;(_85DL
M+QJ\O0M?<$6V=AE(:>3U+;]NY%D[^M?KX,7FI.)RC4UBL$%JI<#4PP@E%84(
M)%Y@*(,J3GI6&@U7;<93=X,]CC.&?>B^@V7P\\5K?Z7P9!EF5QQ?K.J?<(YE
MNIY8J\E;S:HRA#4QL[;4Q +&)4E.A;*R3<+:;N1U-S7D&' VT,BQ&_B[P>#V
M$M?7 J!8&'IO/3"F=9T5:""X(($5PVP0)A31!%4WJ.AOF,@QZ#E<P!U$F)<]
M?2\KMW\*JVF:,,.M]L6!*/54)1>*:VQ T$[5LF[#4FD2#FREIK\1(L>@Y7B!
M=["%W6;BY^GLC(S61 7!,(L$PM>NF1@V%9<:F%(V)/)5BV[BA=U#3W_C1(9$
MSB%"/Q@[GW$9%P.AYS]P^OX#4?Z,'AK>X\NSCQ&7K\J=AB7G2R,$0XL -?#"
MR:#&J,$902N%?+QZP)N3;))]LA>5_;4Q/09I[134@>VZKZ'X[_,EAEEM-?&_
M%[/*73WTJUOZJ_E;3&?+\ZZNR^F*_M//].O\/2W$Z2)?-2$GQKTK3(&VSI$<
M6(*((4.607B/-KG2!*BM&-H-TT_F-J 'M7< _RTBN&)%Q!2UH,C9%T\KF2L#
MT>G:3=MX)64=G-C$[7N IMU ^%3N$882_MB7W)NN&&3],5>.B)V-1B["Y6>K
MU:*VB,5<ZS4>SD*3TDL3$$'D$.O0O)I(9 5P(:TK+OF@=LS8&HBBW?#6^Q7$
M>$H:/56P,ATKT^D:TQ>):^&*Z3^(Z=5.R6X3%K1+"CUHE6-=EP)"'5Q=BM76
M4%R6H]D=HD.2MAM6>[_KZ$!M'6S+WY+D7I4WY)#\LJK2G23F,!HBF^G B8MD
M(4:4FP8BFDG/39L6FMO)V0UP3^9*XGB1=P"<U\M%0LR;:Y7S+*G7YP6ZM!8N
M<J1,0B]DRF#I&ZAL D2M-9 -3R47)X)K4@'T.&F[ >JI7",,K(JGWT)LV'D@
M^[SJQ,W$3CDOY)$>4XEKDQ$%I%(HC!"L0"PY T\BH,T,A4D[N2OM.XH-ZZ42
M8]YJ[<%S&4!)$<"E4" D%IR(P2?N.PPEAK9M+?'2)KS81W'?7WB11"[2>4G;
M3*WM4P'!L8P0+0^.6^;%/A'PR<.+]I-#FN)W-%4^N<W][C"SB]FO3?J$[O"V
MMEO\ONRVW.7OTG*%?IEX"3XF8*6V.F",_$EO?+V%$2P[)Y38[7!B_W</W4>4
M(3?.*W*\ WG&O@3P2(ZW9=;%')2V;9KL=-]'="#M/]9/= _QC]TR<FMG1(DV
M>1TLV%H#I#@CX^N0 WIM G>NQ#!<N\C^^XGNH\Y'^XGN(]NQP7%_H\O@;5T6
MX!36L;!UN(YR"7C0C G-T:I=:C:_KWZB>VEVMWZB>XBY@^.S*[&<F]8:RI 3
M2(9W(YZ0D6$@%FS(M(P2,H@YUXD!W@B?C#*IR97^@U1UTC_G<$,SO.P[ -(M
M'BY6 Y-!%E\RF%1K?GSVX"(3H(LC,2DALFJ32+F-FDYVJ..U?3LQ[FC1=X"?
M:_-*_H8UWVI2FQ8:E!FTSPY4YKI.KDP@/2TSGF*PS;(Q;E(R+FX&T.[]HV$.
M$'47*93/,L6@I( P>QVF^<7\>?@T78?9!3NT=P=7=_4@DJTS;A1$3CP9%F76
ML61Y^PQXH,8F#U$U[K8U/(J&4T$'UN<-KDD>F"]SC"^X2%&3\X848 H?0.G"
M(1J=0:045"C<ZC;#JK:3,VY3B^$1-(#0.X#.M>G@]^587EI9%50*WD *F8$R
M.4*,G('1Q!$FLL"J2<'PSA2.V_ZB@8EJHIH.,'=C.M<%"[9PQTWDH#>G[ZYV
M?=4DK<220H-9D.Q:H&L++>/VOA@>1\>*NP/$7$4?SV=A=7FJNHD\F#?*698@
M4XP!BF>D");D9+45!JT)DC5QL^^EJ)/>30/&]T?)O /P7*?_8CD%ICCR1+MR
M'4FJ6!'@<HQ@;<:<7(T9FNQE=TGI)*H_3L>W([3C!-X!9+:DEEF7LZZ5G3G;
M DJ2+ )J17Z==R*8PKSF30W-;WO-*6I?V#.@A3E,RAW@Y+XQM85Q;DTRH&P=
M16"T!9\(^-)Z9W(Q1? FWLPQ8X)/68*]EYIW' V\C\P/ALZG3?48<;1<#V1H
M;E\/DV-_/AGE]6*YT=!ZO9S&LW5=;>\6]_10*4(G)90#*0.""EI"8%&#]=PQ
MR9V6N4E'TV'([^1*9!AXCJ#1;M#\+/]_9ZOU)O/AW>*>$[;-FHVW$P_?((EJ
M-5WC1>?\\RK--Y@6[^>;I_Q[F)WAQ*/B3)).7*S]]"/+$#4:8+5[EL1BM&SB
M[;=FK).@89@5T!4*.G 2-A;A?).Z7H)\OGF]Q#\V_VDU06E(V)Y<["QI_](^
MU%'G"ER13F-0L?@F=1Z[D=>)TSF@C1Y6(_WB;+-FOC'EK.$DMT1,B5HB4T]^
M)$5BQBJM@S3,-W05'J.NN[:S#5!VA#XZ -F-P\0-*\\2&>UE->2K]=]P_6&1
M)UG0.M&.>%)U.HD.&AP+=3 ;&I%#]HK9%AC;A;CNFM0> ['!M=%KXSM,F6G)
M!&"J529"<A*2R&!8TBX4RVV;!J'[-[X[9<'V,= Y7+Y=I% T:P@3B@I.H06G
M8YV^[05X3N8Y!ZZ9CX&3>]D"::/V 3IET?<QH.U"ZQWLPO>=@462(3,D5L_)
MA5!JTXBP^JZ.)<E-S%QA"_ ><^YXROKP%N>.^\C\R).:7^;#M(8?Z(S*EJ"R
MJL.!I'+DNC)6!^[6%D@L61?0.]_H2N1DIXXG;6/;P;'C/BH=%,PGZW(05A]^
MG2W^6#4I?-SR],:]#!YAIV5AX]6[KRK:HO0^IF) 1D< )CA3I*$CE."#$YCI
MP;N-Q]KYE0.7,<J4,)BD@5M#%MPF<@,T&2!.,5+2J82DFCA_W9<Q'J?K1ZH7
M]Y%Z!\[7PZ40ECG&E/+5";#D#F@.9#,S,<.4,9$):UU3"!U<='2JZL:]U+U7
MT=$^LN\ 2-M3_81WCE'P#:S&(TJF #6_$TKD);OH@M=-;-"3*SK:2]L[%1WM
M(_JQ*V6W%H3ZX(7=M#L+O+IO%,'2#TC\2+0*E6)REWERC<NH3U7=>(BA&4:V
M8X/CWOI>2VX68Q13%(NF7IU&<'5X>+369Y*+%;A+R/9]E5'OI=F=RJCW$7,'
M&]&66#1X\NL2A7_"UW[&%)'2VJDSPK4): 2&J-LV]/AMKW3'4R54#^*['";E
M#G#R$M<U$'B]7'R>4E#YT]??5YA?S*]&M3ZKS1+/SUHOPP3NK%.>)Y":(@3%
M"VVI-ED@*9H@K<;8)J+:G]1.7)T#P7'W=J>EIOK XK7[JR2BX_0:D%:0Y^:E
M!*>D)Z\P&IT8*H=-DF<.&(S5"D&M5?[@_>$^\N]@;M:-%+6:7S9/TQG>8.G=
M8E]IBF1#+KXV0:CKU3!:KZ'*0*/5PB)WJDFWYQ;,C.O'GQC*HZ.A W/Z,]*;
M:\]$4C']/,.-KN?YV<=Z>_#?F\\GR*04*CE:Y2&<9Y)X5S(43EM2S)RYU,0I
MW(6X<8WO^!"Z,Q1S8'UV@-'+B7LWDX8GPBC&M4Z0C4RUZ7>&X"CVTEF[$H6Q
MLM&)ZU9RQK6<W>%P )UU@+SKJ^95^74Z#R37^?N:9+>J;9&GJ[0X(YE/DO2.
MZ83DLRL*_!.3$(2B2)%Y(4)R4ODV/L".!(X;3'>'SB9Z[0"OER.1[YN%7$26
M1DL&KNA:*Q<2!!412E1*QR*U:9/D]@A=XQ89=(?.(;4X=NOUFI#W:GX^5^/E
M8GZQU,+L8K*&SRP*R4R=H%LH?C2TOI10@,0/YMKC8L>Y!P^_9]SZ@FX -K1&
M^LD:WQ#_;330<_(^WN-JHK3D!!,%J6@$57L0T)J)Y.TJY1RS4:LF<].WDS-N
M"4(W*!Q09QULN22]6HR!/^/Y]VORNJAYO!*692JH8"40AY)$1&Z%-RB@8!'1
M6&\C:[+[[D[BN)4.W2&TD6Z[1.VS=.[RDMQQ^GESZ87<>ZE3AI)I_2DI$6(P
M"KCT6=(V0+M$DW*N78@;]]BG%3 >Q=^16NIGP[[+VHOY9Y+\8CFMQ9'<9H-(
MX/"U#R>W=3J+B""<M,9*^L^VR;7.@U2->\(S&N0.U4O/6'N]1'([\F6@=3G^
M:G[></'"$ZXQ%F<L5A8SQ?XQ@HN%D2Q-%E:Q8&23BNG#R!WWA&<T= ZNR9YA
MN^'IF[-SSEQ&E:VS=49N'4Y9;(3@?%V=B)$;87DZE5>YA;QQCW9&@^71FNH9
MAI=.R.OPM7H@]78II>49$3@-<3K;^-\3PYG65AGP)=69J=R#4]G15H'D?W.)
MRC9IA788N>,>$(WN3@ZFR2Y#F\O-X0V2)W.&$R4XLNPH&M2UZ!T-0K#D.VL1
M?"@ZB.B;5,L^2MFX!T2CH? 8_70 N-VS5B;*"(99<D!6V:NNLR?+3=Y(9I'\
M$O)#FB12[$[BN&[DZ7/96FBN@T2W>SBKL=SJ'D$J9G*R,D$NF7R2K#($;04M
M;%U83,B(RQ-B\P%2.RDV^:UEQNY0FNK /I)S<=D4\+Q)$?%**VS]]?4LS-?D
M<]2BK,ULZ4EMG*#%)A.)(7G(68%#M*"C\")EX639I8YI;PSN3F*7N;Z#@65Q
M$LT=&]L,@\KE(B'FU:\DY//+4/HDGU4!XD6\9GC.)=9I+DP*^F("5#9JE6#4
MDEP?99OTN7B<M"[3=)NA<%A-]6@1ST6W^6SB0BCT/UH_B9%#HXV&&#V'5)02
MV<80]&ELX#6BNO0*3V;U#M5.EW;N;V%=^V)])>O]?#&;8:I:7+TJUYE4D4>9
M#3$IHJY#(")$*R/PD&Q)WBD9FYS='$#KN.>+(UO"H779@6G<7:*3D%QQJA"*
MBJI+43J(+G/(0DEC/-8NJN,&+..>*IX8G(TTUV\P?94VO$60.8? 8U2$(47N
ML'<<G.$1BD3I=> :VR3:[D]J)V7638/IH335@7V\=$Y^72S?X*>S9?H05N01
M7VM2.'$Y.VY-!L]KFWS+ P1! F361V.$$]PUJ8MYG+0N@^?!P'&/&SF0IKIP
M)HF1"ZY>E=\6\_?O</GQ9XSKB?5HDK4&@O(%E'#$">,*K),I9W1.AB:'A_<1
MU&6 W II@VBE"WSM+KA)LL(D+3B0,\&!_ 8&KA[(,Q&\D$$XAZ>\2ME"8I=!
M<RL,-M)<!]Y?9:L&6/2M'G=^IKBKWIAO>IG>OLN<E*AB4LF#T[8>@\9(#K3P
M(,F98<R95'23O7<?(KL;Z7*,Q]=,.]TB[QDMM.7R*ZVI\ZE(Y"QHS]" Y9ON
MTQC!)6V@:-2Z.$8+JLW,P5VHZVZPR_!8.T8?W4QPVXTUM%%))(8$JT,_$Z]=
ML*R&S+30KB!YL4TR8H>#VBD'O+2'VC[ZZ*4%_=FG3[.-H,+LLKGPBWE9+#^>
MJ^K2%PD<6<D\ 9,HR'6M[D)F$J3B@5DMC4AMQE7M1E]W(V&. 5L+G71P5'+9
MW+X.("3W=)+) KOHB?R OF8*U7:/FP%O/.=$$;=JTV#W%ATC]YMKH>L[&7Z'
M"W[L>O5KB:_/5JNSCS64H7CZ+2X#!2YUKH>@G3W5)I"1U6-K5,"B\]XA^G*[
M(.2>8O4'7C)R;E-#= PJW@[,RVYC_H+AEMGB(-M,P:YG!KSG->)-*2:3HHA-
M#L:&&[O8[NS_!*9H>"5U@+QO-?.ORAL,LU]6U1^8>">EKOV+B\Z,N,@>HHT>
MK*'@-B2M4PY-]K>MY'0W?^P8#VD B7> F]KY8U6KZ''U:O[+EWHI>S9=?3AG
M:W-@K)TS1='6;+ .]RA9TAHP&0QW3JL8C<]-SA(>I:R[B6+'H&E8/0Q=*3;T
M1*:W9Q\_AN7717D[?3^?EFFJJ:/G=4>;(56S:2)OX.5B3?O1#99V&\FTS^.'
MF<ET,$-##&6Z>/FKAU]^M7>:D)0JJEXI;@IU2H3(ZI!#VM*4T^2*"[63R[K?
M>X_VK1YZR3N2XT^S>G^:/1-:1 ZH:F 1Z"=:E D<MP69SXJX;.)<[43>B..<
M&J+DCH<UO*H&VRK',667W]M9LZLWG-*@;6=K!)O&$8URV0$C&(%R-7_"Q@C9
M9<)8S*C9;CWC3FO3OHU8(PUM'O[UV_+PVF!TM.XHLJD'(X:6!\8"0006+&:?
M<A-+]A!13\=^[8.(N^-=!U)+!P[^[S7!B&*3*470%-82$2SQD"!6]U0I:R$F
M<BJ%\,XKYK333;SYFV2,<Z)U:A@=(?H.@'//+?JMU6!5[< 7)&16NU;XP"'X
M)(%+*3QB4)PU2;G9B;IQSK).;JT&5U0'Z'NW#/E;RYX['<[.N9LPA^28J@ )
M>:PQ<8:HM :6$T-!ZRR%U )].U$W3D[-J=$WO*(Z0-]E?[.OMU>1I-"G.%H[
MFIF:/6D+N(0!:K3",P^,3'F;^\+M!(V32W-JC VBC@Y@==',I+8Q)9%M<RZ-
MYI%;E8BAS2&?=1!*0#!.A,*DEAB:M*%YE+)Q,FE.#;1A%=0!XNKT A(<N01W
M' )CC#>J%G)I3IQ8IL$;$2%E5$H4C\ZW2=RZEZ1Q$FA.'UP.HI(.P/6&%$0$
M5.?S9UHXL\6F[<-%N\6+C5_%$KWU2,ZF$*"2HY^BX)"UU$KE'*UOTB]X!]K&
MN8T\O4D;5DD=X&[['*%7GR[&6KV8)^)P^AEK1Y*+-3;)6087DJD]H&(=VL(@
MBA! :FMK@2FR-K>8!] ZSKWFJ7'96HD=X/27L)R3V&KEP8;;.R&Y]BID1]%X
MV+2@M0F\XAJBU$X8PZSPH@4F'Z%KMS->]M0!.*1VGOCM5#TV6G^]6G+/_@C+
MO-H,N6YX8?702T]YA[4S\X-<:Z4/F,]F2#15S,5J_RZ*@C<OWN2FG1O!54U(
M.U]V-2OR_+-O=7FZSK#0%IRU'A2& F03!7T)CAN=G+/E,3T-2M'1F_H%':_*
MW7:S&VU<6YG&RB(+^<4NJYJ:YR%H=)"2%HY1..9MDVY(NY,XYC79& B[L[FW
M468'>_HWSKXY,/N(]Q;W2@OAF;(4YSD#JF@'/KE:&,9<,9:+W*;M\+!LC'F=
MUQ?<3PZ*3I?$=9_^.O<7)=]?;W&</ O,DA'(WM:KT6(A&J$A()?2,.9XFSZS
MQY,^YA5CK]!OJ/RNX/YRL>EC59N4DR2GB7[:L/O[?+J^C]EL@G8,$;3G%%7$
M7-/=/(),1C(CDU"QS8#J8Z@>\R:S+Y"W5OD3#R2O+NI^QG68SAI&CW?>=,J0
M\6$VAX@3K]YPA=]8,*7:%T4JZ4"Y4D=@,@LY*QL2YUB8V"G@N_/HP2[+GY\M
MZWK>P'\B$V>^("=O/C!R8J2!P&,":15Y]J&2W6C6RQ9J1HS'CM/DO3?A!\NZ
M@QWT]5FD=?3[^B(@_":A+]/51/!8#&8/6E3I%);!US->1A\:X0)W;3IX/D34
MV(,EC];Y[39T0RF@8S"]HW__\^)CF,XGUD8T4M"VJTNJ+?4\!$'QE!;)H<U.
M)=XD2^QQTL8%UG PV!%?!^JD Y1=L?#;5;5?LD*J* L@%YMY1Q*\5QK09\U#
MR2S:1JTC;I,R]A#2H<W3D<+N"2YOPA]_"_3<:9C1DD+'?$WJX,Q2()"C@<@"
M!0*%43S 2BZRK4MTG9I.]K0#57P?8@Z6=T^@^74ZGZXHXOSK8I%7$Y_0RU 0
MA'-UF$4A0QPH?&3%ZQ""9-C&(=I.3B>V9F#8'"[QGG#S'XOEW^OTVT7"U6J"
MR)+T10)CF;C(A2QPS;O&*)3)EM<;[::XN4'.V*.(V^#F<(EW@)MG'Q?+]?2_
MS_-NR@M2Q_S]M$[\/)^?HT)DW$@)NHZG58K37FY8A"B=]=GD;%*3JZF'R1I[
M=O"@.!I0 T_\X'!SB!IO7QY<'>@V/T[<\?VG/&0\1"0C5%YK[9*VED)$D6JN
ME*= +M>:_D);:"I62]5CY?5C]U;/EDM:C)L&+ZN?OFZ_UCV/='+193-')R$M
M557/^"GF49"1)U>,,L*VZ4HY% =/IZ9['ZSM>U'91N$=;/,U@?9E^(B;4YU
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M0Y;@/:XF3DCC72:+'7*AJ$:1I\#KF!">R*0KJ[-OTNIG.SGC)ALWPM, DN_
M1]NR*E[,;Z\*=,Q;7QSDNC24D13(.!U!TGH(*=I42I.^-+L0-VZ^Y>ELU7%:
MZ=8_>X,);S@GR\6<?DSGN1>_U=,^_G*QQH-\L=T?/HS?=2 S0U2G/OSJ*U"&
M8G3$6--5:B]T5L@P,58W.28XAJC5[19P]YPH[O:^8ZW32_SCOE=LUMO7\Z_O
M2((_T;_[^\1F&4NB8$BQ.IDGDN%U/!B03!:-W'$KFIQ_[4OHB ?U#9!RVWPU
M5=L3-65'A)2[/?@4)JQ%B+@/*+4HL3 > 4NM^Q,B0Q"T TJTFC98%G-A@YNO
MH7&RV=+?AAD>O*_=>L(PFG^(K*%. >HKWN!ZNMS(^56<3=]O2/UYNDJSQ>IL
MB5>JCMHDQX0'%^HH=^LYQ)1JQD!(-F%0EC>IL]B#QJ-N *ND7Y67B_FOTWF8
MIVF8G;MZWXRB"+45BS$UHY/\.U;;^&7I0697O"C!R;#;7OWHJT:.]QNAXL9E
MX+#B[G8/NEK$1VPW=YXQL'UI>LZX!Y:X,27I5,!J@Z <H2KDJ"%Z4[(WAH?;
MJ7U/R\+\-4SGK^;W 7\B%/J8*&C$6DVEI/'$N<Y@BN09B^/"B9W,R\/O>3JV
M91\\W+ M PJZ@Q,A<H428E[]2L(\YXD^R6=I/?U\<1HQ4:B4S8J!SK5_L[8(
M :V"K(6)(EDRPKO4*>W?VN)1TD8^:6R,MD8J&CL9ZATNW^(R_"U\F7X\^W@M
MP^L-OC^;U7_Y]=F\YO%\K*.GPNQOTQFNUHLYKFK.5U&"MFIN(@>5I*#MVTF0
MPANDH)6'E'8R8H?3,/(!Y"D,W(D4-#8._Q.7'XFSUTMR4+Z\Q/5OB]5J$J3C
M7@0-DBE/"XE"3B>8 R%M=MDRH_EN?=RV/7W<BMV38.=HH7:P);[%VHARGO#Y
M8K5>\8F7 57.C'9TORDTC10J^$2R$<%[,JW%MFEM=Y..<6LH3[79'2/\#K#S
M,\;UMZZGYYGT4@I7HA50$J-0$V7U"$VM6^;:*9&]-4T*Z;;0LA.&FC5\/Q6&
MCE5"!SCZY4L]ISR;KCYL)%4J2YLZ'5V,8CEYXD,Y4)$5" 41,BT(SJ)"IYL<
ME-U'T+@!W]&:7C00>Z?PJ:VA+DJSHLO<Z-J1RI(I5<DZ<)Q$Y ,QEG6V)C?9
MT1XF:UPH#:/Z'?!TH![&=I=_FBY>;\[X+MIO2.36!FL@F61!60HY(Z-]FNLZ
M]-!XB@,>/7O<]N#^4'"HPA8#26_DEC57K9_>)IR'Y72Q6171*.T2*@A2E%HO
M6L>L&PW&6V<R\2/#+GF<.S6OV4K!N&<_0VT\PPAX;(1<T/W[?/4)T[1,,5^L
M%Z$#D]YS\!@"*!,D17XR@$8RJ$7(PO,N'6MV0\E]5(S7\&@ S2Z&%G,G6/EU
ML<045NL+>R@L,RIP,J>L5A]D&R&B(/T&$Y*)UMWIGW\\4&Z2,")*AM'K%J0<
M(>0.G-@W6.UK6I\M:4NNQP'/YIO:X.7G\R9BO&2!N@XVL8Z3O<T(/G$RO\%Q
MKRU2 -DDZ_D1NL8](1XZ(AI2"1U@JOIRK\H-IB[6&E&*.K%ZO)3JF!RN(9:<
MP*1LO9>)1VQR2G,O1>,ZPH/J?=%""6,'1&]^OGE6>6%DE2JAU#)-GS39;.TR
M.)TEV!P\=VC0Z]WZ26U__KBH&$ASBV'%.#82WO[UV58>>+9.2R> 9&!H^V:6
M D6L9>$^&%LLEK ;%.YYP;@A4 ,L#"'(#C:9FWOP;]^J>+/1.BM/6X!VM66)
M I=\!!.S%TDQF[!)8<T]](Q['3FTHS*$T#O 3LTN6M5;4UR]FF\[C9IHS>J0
M9P4Y9$;A(P]D(U4"SC0/OJCB0I/V#(]2UM-5P('Z7[141@?HNGV[:KGU0:A"
M7ER]9?-DKIV@4%/4A@,R"IYC$Z?WD*OM$YWE#8.<8P3=;;KQ\[#Z$.:Y?JOS
M/3^'62V?H$]>S#^3&[ IIC@D!7FGYPZ3EKP_"T/4N]37/;OSUF<WWOIMO)\T
M10B?P;/$:K:,@)"< RUMD9EL#4JSD]>XSUN/'IVQ]5W?[O6_)=ZSDF3V)@$M
M)0H< ZT$'XT"S:1/C 7O9)-."#M3.&*Q7C.<W!F\T41=3]IP;3S09N;KXNFG
M,V+;V#FY*4L"630.*6I'1>")%H+/'K3RO'BGC4J[95.>TI1]FQ907W?WE6\_
M+);K=[C\>%O:WQ9-XCX&'R5$%00HR1U$*2)8'A C,<X:C:DZFO2G8OSV0=;]
M,W!/HN G;14OJK=X*[MX]?S36<;M+)W<-AIFM!3% \HZ B?6D5DN(B!CACYW
M/MRN>.W*-MY>&Q,5BT:5 @19SVZ$=^ 1/<1LF>6<V])F .[])#T56[8/$NZW
M94<II(.CB6_T7\W1S)(\3%T2&%/G:$I9QU8*1R!@F9=@BFL#J;ND]#*L^S@E
MWVD[=)3$N\/,\[#&]XOE]+\WBKFX.D!N,M<U:O&A@$(TM%-;#3RSZ*+&K&XW
M9F^!H6VDC8NI8Y7_():.UD0'V*JV^X)R9XTI&)!B8$&"R68SB5R YQ08^UR2
MD4U:UGXCH2>L'*_<+8<1!TBZ XS\_O;=$L/J;/GU+::SY::Y[@4G7F8AHG8@
MD.("I4L=GR$XL$)&61C/DFX2 MY/TKB'[(TQ-) F.L#4MNCS4D#*.W(*!22C
M:A=HF\'7G$"1H[+,!:U<$SMT/TGCYKHUQM1 FN@ 4W<9X!BTI"]U7$HMR:68
M(SC-(=!2L8HEY]K4)!Z&H&9)"(T1=)S<.P#.\\7RTV))8JEWI'<LJ\@:4R 6
M6$@<E'&B"DF $"+HG(S/MDE+G0>I&K=,NK6K-)@^.@#7KV&Z_/<P.\.?PJQ>
ME;_]@+C^ZW)Q]FDZ?W_55N?;Y/GPJ4KQVE0$F;C3@6<HM,>#"I;7,)A!$MH4
M[@*SN@G^CB5\7$^LT6G"2;79 7J??0[3697:KXME[<KS;34^^TA^P_2_ZRRJ
MU7H2//*BI8/,ZW(W2D,4M/IU41&Y$R$IVP*D.](W;F1Y6M#<;NG>0(-] S.E
MLX^U@P]FDO%J]?N<8J99Y;,FNOV$9;'$=^'+1)?@4%"(A/2U#DG;[",>0O(>
ME<-@39.&7T=3/JYA[17,#;3^1&%>4SF_,2Q\<=(8"4[Q "J1X&,I#+@5+.?
MR!=K<D1S-.7C1MU/#N:':WU_F/MSF,_Q?27DW0G0?CDMCO$LF50UI535UFN:
MW#:I,S@I9&'%.2]/[&>,.KBO<[0>HK7O(9'D5LN"P1-)Q.D326ZQ=/)$$JD]
M$YG5MOC&@>(YU]Z?&H+CTJ(KPI;=JLPZ223)*C%9)]OXY!BHNAJ"B74HE^&L
M")UB:%(E]?032?9!PAZ))/LHI(LI:>^6H8Y.>E8[Y$[77W_Z>G7%+4J)R1H#
M65=6% O@9;*0',:@';K(FF#K7HJZ32S92^FWZ[L'D7\',<961BY[<Z A!Y)Y
M,(K$HB)MWS&2<Z!U3%IS$WS!DT&IAXX! VE]%RP=H((.T+1UM7US-+4)9*A%
MHOB;M*X8+Q!%M& T<QR-1J[+R?:]_L^JCS%0 VJB UR]N8ASO_%RK6YU8I7T
MFGD!OBA3JQ@%!&TE)$6_<Y-]3DUFI#U(58?;WH'JO],N9RA==!OM7474?]LD
MW.#!99_;'S1,_+8#D4,$:EM?<^6/B\2PL%3K4[0$19L@.%(3A?G9NQ"CDF*W
MF2L/OF:P:]AK#W\Q_W2VO1X0L]2"%P;"%T&<) $.,R%:1.^]MD[>;OLY\)WK
M+E2.&+ -AXA[+U@'U]/3,C6'%VH^]+B&9J=5*>;#4+.6)U<[#@1;9YMKJR&F
M6.<%*Y$%YF28Z\CX_/1UVP'M-SQSZ3S3'"'S3,LG>P;!H=_,:V<\(\NQR?'V
MK@1V:W+VP<'].1T#:N=I69MC"B ??F!#B].NQ/$1K$FN;70%>"Z;5&M-,1DF
MH$A-:HW%J^#[MSGGJ5 ^,B[JZ")+NZ:*I8#W4D'")(TVUF<<Q=Z,?!X]G/[W
MM35[:Z6#R/P:3U<__N\I+HFH#U\W ^(WYV,4]C%7BH3H0^W+ZQ&\S!Z*3S&'
M8'7@N_12/P9K#Y#72X;84+"X'W=#Z:@GY%U?IW?YNSA(U<X'E"%!4,6#4DAL
M%A/ \& 2BA)=8^=J%RJ[P>%@,-DAP!M&9ST!\CQDW4B,7^2MQQ12441[XL)0
M:,P%A-KVT0N9E&'"86A2U_0 39V ;7@DW(>Y(]72*<+$!2O)<*6*#B!BL:!*
MG4 8= )ELF+"Y&A$DRKP!VCJ)%=U%(0=HI9.$28OJWJ$4A[YIK<CN;Y%.:"0
MN$[@59%EIY0H)T.8[*$X<UR$':*6GA!V:+:BYE;G+*N1CN+<_W!,&0K#F/=&
M>8ZBR4R,IUT2=<(@XP1Z[0#'V]/6KJ3P[<)BPE1!862&5._R%=IZ:(@&2,9"
M\FB%22=L![J%PDX\P9, 9Z<NH<=JL0-XWI^7/6'2H\QUVI(V55Z!0<PR (]*
M1T4>B2M->D[=3U(OIG$$  ZDIPX0=RW19-OZT3;[E+0B'@('9;DB-R5DT%$;
M8XU&)YKD?CU,5B<.Y!C(&U!?W=YWU1X"WV9P'W2C?OL1P]QI/4C8$+=8MUYP
M=7^A4\$@$"%P<5'IZXA72#6)0O,H<LZ/B>2A%PPQ6&9;LD=!78'HP1M1Q]+*
M3923H:3">2I"!MO$?-Q#SXCW4T-H=MMDF6.E_E2,P.')-=L?U,0@/)A0\^-0
MHKBX1!] %I=/:B*,K62V-)+HN"!>(X1D&"TEVOMB/)\BZM *890I8QO)VX.E
M<J:E6HP"7@S%)S(R\-;6G!A,UNO";6ERP;6%E@Z-XSX:?7CLUO[2[L W?WL6
M5_A?9T3^+Y_Q6C]4H6IM;M%@+447B@PZ>*\1DF2TG90D6&I3B+B=GI[&:QV@
MY]LE& ,(O4_L7)QH)UYB<JA!;8J3@@WD)Y!WP(LJ]!PMM&XRINU>BD:NN1A"
MWX]CZ #A]X>BB[N+P'04-:FR*$D^*V>U%TLAA<M(#F>),?DV[3ZW4=,=>@[1
M],/X.4#L'6#GM\7\/3WM8S705ZL*DXJLR R:-F]0(M16WER U<58493UI4EG
MO&W$]#3<[_A]ZVAQ=PB9BZ7D0_;"UAG+SF=03B<(46J0*3*!UG*5FMP=;B=G
M7(-SO)H?P<T!,N\ .3=7TT8HU@G#30R@(DHRE^8BYS=&ZU(R)EO=9)>Z2\JX
MQ]5#&YHC1=T=6%Z&CY>@+RA%KN,EG&:U%"Y3Y,F*!5M2=D*HZ@^VA\PW@GJ*
MK/97](.X.5#JW:'GVZV.DDE+6E604R+WC*&%J)0 ;AD%"\H&F9MT+G\R0]2'
M,SJ'";T+[)R_]OR6\'P&\Z8IX"03%]HS32+AGH3#-GT ->A@M14A*(5-TDWN
MI:@GVW.@ON]@: CA=X"BU\M%0LRK7TELSQ?SS[A<3VF!;>:^&Z\=+SX!T]:2
MF;;DMSEGB16O!=,ZV]2D1>X#-/449PV#I*$4,"*6SINX$>TWY?-B3H_&U?I-
M6.,F@R&_QF6J^GJ/DX"J.)L]9%6SHNMN75/N@259LK?$MMIQ,N1>[^W)?3X.
M/ZV%WH%MNLG9M<5Q_N.*M/:FZHY/3&+9N=I2M#!#1M<E\)&"5JXX.8-D<F.;
MU**=*>S)@QIJ!VRAG*>!NM?+:4(^B:XD'72A]8/E/#<B%F[ ^1A-;:@K1)/]
M<6<*QQT3,Q+J#E!.!ZA[';Y6CEZ5BZ2_^?LZI'N]2']_L5J=7?F8DR2RS>@"
MF&AKIV:'$#-R2-GS4+))T30Y5MB1OIT09YX2XEHHI@.\_3X/E_,_-E*[X.67
M+Y]POL*)-(R+FDJFBV4D,<W!)_)!$T\I(SK);),0\F&R=D*7?4KH&E -'8#J
MIH2N<HHG0J.P7GD0WB(H]?]7=VV];=Q*^/W\%P*\7UX.X#0M$""M@Z3%Z9O
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MR_?X8.\.=5'6Z@!D///&NE7X".HXKE??,1K9*F]#I\&K\FC( ],6-/ZHR'Q
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MY@Q$4VT%&WJ);0^:Y4"OEH?(I'2P3/W?KSW\!?VDN(3__N?_4$L! A0#%
M  @ :81>45V4Q+0:EP  MO\# !H              ( !     &5X:#$Q;W!E
M;FUA<FME='-A;&5A9W(N:'1M4$L! A0#%     @ :81>47#?=33:!P  9R4
M !H              ( !4I<  &5X:#,Q,6-E<G1I9FEC871I;VYO9G N:'1M
M4$L! A0#%     @ :81>408'B[;;!P  YB0  !H              ( !9)\
M &5X:#,Q,F-E<G1I9FEC871I;VYO9G N:'1M4$L! A0#%     @ :81>4>)I
MZ(Q !0  RQ@  !H              ( !=Z<  &5X:#,R,6-E<G1I9FEC871I
M;VYO9G N:'1M4$L! A0#%     @ :81>497.-Y6>"   O"D  !H
M     ( ![ZP  &5X:#4Q=F5O<&EN:6]N,3 M,S!X,C N:'1M4$L! A0#%
M  @ :81>45XSQ0SEB0$ @J$1 !$              ( !Q;4  &QX<G@M,C R
M,# Y,S N:'1M4$L! A0#%     @ :81>44P6.VKC#0  )9D  !$
M     ( !V3\" &QX<G@M,C R,# Y,S N>'-D4$L! A0#%     @ :81>45)#
M>^4:$P  /+P  !4              ( !ZTT" &QX<G@M,C R,# Y,S!?8V%L
M+GAM;%!+ 0(4 Q0    ( &F$7E'A-I*Y?$8  &H0 P 5              "
M 3AA @!L>')X+3(P,C P.3,P7V1E9BYX;6Q02P$"% ,4    " !IA%Y1\_48
MX'ZA  #8J08 %0              @ 'GIP( ;'AR>"TR,#(P,#DS,%]L86(N
M>&UL4$L! A0#%     @ :81>406X#;.@7   RA\$ !4              ( !
MF$D# &QX<G@M,C R,# Y,S!?<')E+GAM;%!+!08     "P + /("  !KI@,
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
